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THESIS ABSTRACT
Background
The development of childhood atopy is postulated to be influenced by perinatal 
microbial exposure. Inadequate numbers of probiotic organisms forming the intestinal 
microbiota, is an early pre-symptomatic feature linked to the expression of allergy. 
Perinatal probiotic supplementation is therefore hypothesized to contribute to the 
microbiota mediated immunomodulatory response determining immune hypo- 
responsiveness to allergens.
Aims
This thesis examined the anti-allergy immunomodulatory effects of probiotic bacteria in 
vitro in the context of the pathophysiology of atopy, as a preamble to perinatal probiotic 
supplementation.
Methods
Cytokine responses were measured after umbilical cord blood mononuclear cells 
(CBMCs) were co-cultured in the presence of a consortium of probiotic organisms 
consisting of two strains of lactobacilli and two strains of bifidobacteria. Additionally 
pregnant women with a familial history of allergic disease from 36 weeks gestation and 
their infants to age 6 months, were supplemented with probiotics or a placebo daily. The 
immunomodulatory effects of probiotics on immune function in vivo was then analysed 
within the peripheral blood of the supplemented neonates.
Results
CBMCs co-cultured in the presence of the probiotic consortium generated a dose 
dependent, monocyte mediated release of the pro-inflammatory cytokines TNF-a, IL- 
12p70, IFN-y and the immunosuppressive cytokines IL-10 and TGF-pi. The consortium 
down regulated PH A and SEB induced IL-13 (a key allergy orchestrating cytokine) 
while potentiating IFN-y (a key Thl driving cytokine) responses from CBMCs. 
Interestingly in the probiotic supplemented group the cord blood eosinophil count was 
significantly reduced. Additionally the IL-12p70 concentrations in microbial stimulated 
venous blood at age 6 months was significantly elevated in comparison to the placebo 
supplemented group.
Conclusion
The immunomodulatory effect of probiotic bacteria is marked by a capacity to promote 
a Thl orientation of the immune system. Probiotics administered during pregnancy and 
early infancy may therefore be effective in the prevention of Th2 mediated atopic 
disorder.
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Chapter 1: Introduction
1.1 History of the Probiotic concept
The word probiotic originates from the Greek words pro and bios meaning “for life” 
to describe a family of commensal bacterial that:
(1) Colonise the mammalian gastrointestinal tract (GIT).
(2) Improve the microbial balance
(3) Impart a health benefit surpassing that of general nutrition alone.
In their active state probiotic bacteria are recognised as antonyms of antibiotics due 
to their growth stimulatory effects on other bacterial microorganisms (Guamer and 
Schaafsma 1998). They are non-pathogenic, and thrive symbiotically in the presence 
of the mammalian cellular immune system, imparting an immunomodulatory 
influence on the host immune equilibrium.
The diverse array of probiotic bacteria within the GIT occurs in a niche specific 
manner determined by their metabolic and survival needs and their immunogenicity 
renders them far from immunologically inert. This allows an inadvertent contribution 
to the microbiota-immune axis impacting upon both immunologic and non- 
immunologic facets of human immunity and shaping both local and systemic 
immunomodulatory responses.
Although no legal definition for the term “probiotic” exists the minimum criteria for 
classification suggests a probiotic must be:
(1) Viable.
(2) Delivered in optimal dosages with minimal batch to batch variation
through shelf life.
(3) Specified at genus and strain level
(4) Efficacious when administered in specific doses in controlled studies.
Probiotic supplementation is therefore expected to contribute to gastrointestinal 
steady state homeostasis:
The rationale behind perinatal probiotic supplementation of the newborn stems from 
observations that probiotic bacteria colonise the neonate immediately after birth [See 
1.5.4]. Subsequently the immunomodulatory effects of probiotic bacteria is now a 
key area of interest in contemporary immunology, an interest compounded by the
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premise that a probiotic optimised GIT is widely connected with the resistance of the 
allergic phenotype [See 1.5.1].
The earliest reported reference to probiotic bacteria occurs in a Persian version of the 
book of Genesis 18:8 emphasising that Abraham owed his longevity to the 
consumption of fermented “soured milk” (Schrezenmeir and de Vrese 2001; Crane 
2002). The notions that ingestion of large inoculums of probiotic bacteria, of lactic 
acid bacteria (LAB) and bifidobacteria origin, improves gastrointestinal and immune 
health have been prevalent since the 1900s. This era witnessed the advent of dietary 
intervention methods employing probiotic bacteria enriched dairy products to 
improve health and increase longevity of human life (Gill 1998).
Bifidobacteria were first described and isolated by French paediatrician, Dr Henry 
Tissier in the 1900s as the predominant organism in the stools of breast-fed infants 
and named B. bifidus (Tissier 1900). Rapid colonisation of the newborns’ GIT with 
lactic acid producing bifidobacteria and lactobacilli strains under the influence of 
breast milk is now a widely accepted paradigm (Crane 2002). Tissier (1990) 
hypothesised that bifidobacteria are crucial in preventing the outgrowth of 
pathogenic diarrhoea inducing bacteria by abrogating their ability to grow via a 
phenomenon known as competitive exclusion.
In 1908 Metchnikoff hypothesized that ingestion of large quantities of LAB 
(probiotic supplementation) with intrinsic fermentative capacity increased human 
longevity, and that consumption of foods initially fermented with probiotic bacteria 
conferred a desirable health benefit via regulation of the intestinal autointoxication 
process. Anticipated health benefits were attributable to improvements to the GIT 
microbiota balance due to replacement of proteolytic putrefying organisms, such as 
Clostridium (potent producers of toxic substances like ammonia from protein 
metabolism), with more useful fermentative lactic acid producing bacteria that 
exponentially outgrow the growth of pathogenic organisms and restricting the growth 
of toxin-producing bacteria due to direct competition for nutrients vital for survival 
within the GIT niche (Metchnikoff 1908).
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In 1920 Rettger and colleagues highlighted that Lactobacillus bulgaricus had a poor 
survival rate upon transit through the GIT and hypothesised that organisms isolated 
from human stools were superior probiotics, being more amenable to GIT transit and 
exponential growth and colonisation during transit (Rettger et al. 1935). In 1930 a 
human faecal isolate of Lactobacillus acidophilus was used in a commercial milk 
fermented product named acidophilus milk (Rettger et al. 1935) and similarly in 
1935 the Japanese food company, Yakult Honsha, commercialised the sale of live 
bacteria in a fermented milk drink. This arose from the discovery of Lactobacillus 
casei Shirota capable of transiting the acidic environment of the stomach and 
colonising the intestine. This organism was subsequently introduced into a fermented 
milk drink named Yakult which is now sold worldwide (Yalkult 2010).
1.1.1 Lactic acid bacteria (LAB) and bifidobacteria in health and immunity
Probiotic bacteria belonging to the genera Lactobacillus and Bifidobacterium 
represent major bacterial taxa utilised for probiotics (See Table 1.1). Lactobacilli are 
Gram-positive, catalase-negative bacteria capable of producing lactic acid as a 
primary end-product of the fermentation of carbohydrates. The genus 
Bifidobacterium is only poorly phylogenetically related to genuine LAB, and its 
species employ a metabolic pathway for the degradation of hexoses different from 
those described for LAB (Felis and Dellaglio 2007).
Bifidobacterium are Gram-positive, curved, and often bifid rods. In bottle-fed 
infants, however, Gram-positive, straight, unbranched rods were the predominant 
organisms and were identified as B. acidophilus. The predominance of bifidobacteria 
in the GIT of healthy infants during the first weeks of life was noted by Bullen 
(1976). Interestingly bifidobacterial numbers are fewer in the stools of bottle-fed 
versus breast-fed infants and once weaned these infants harbour bifidobacteria only 
in small numbers compared to their breast fed counterparts (Poupard et al. 1973). 
Infants fed bottle or supplementary cow’s milk, commonly harboured Escherichia 
coli, Streptococcus faecium, Pseudomonas aeruginosa strains along with clostridia 
and proteus species. (Bullen 1976). These bacterial colonisation differences are 
postulated to reflect the different pH of stools from breast- versus bottle-fed infants: 
pH 8-9 of bottle fed infant faeces compared with the pH 5-6 of breast fed infants.
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Table 1.1: Commonly employed probiotic strains of the human GIT.
L.casei B. infantis
L.acidophilus B. bifidus
L.crispatus B.angulatum
L. brevis B. breve
L.delbrueckii group B. longum
L.fermentum B.adolescentis
L.gasseri B. catenulatum
L.paracasei B.pseudocatenulatus
L.plantarum group
L.rhamnosus
L.ruminis
L.sakei
L.salivarius
L.vaginalis
L. cun’at us
L.fructivorans
Pediococcus pentosaceous
Leuconostoc argentinum
Leuconostoc mesenteroides
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1.1.2 Toll like receptor (TLR) -  mediated immunomodulatory effect of 
probiotic bacteria
Despite the rise to prominence of probiotic bacteria as health promoting supplements, 
a paucity of research data exists characterising their interactivity with the immune 
system and their immunomodulatory contribution to immune integrity in health and 
disease. This has led to heightened research interest into the immunomodulatory roles 
of probiotic bacteria in IgE mediated atopic disorder, an interest that forms the central 
theme of this thesis.
Probiotics are postulated to directly or indirectly influence immunity via uptake by 
the GIT M cells and subsequent transfer to antigen presenting cells. The emerging 
paradigm implies that probiotic bacteria can modulate the Thl/Th2 balance 
culminating in increased IgA producing B cells, concomitant with reduction in IgE 
producing cells in turn leading to a reduced allergic response (Ouwehand et a l 
2002).
Since TLR mediated immune recognition of probiotic bacteria by innate and/or 
adaptive cells of immunity culminates in upregulation of immune response shaping 
cytokines this interaction is referred to as the immunomodulatory effect of probiotic 
bacteria, to define improvements in intestinal microbial balance, that impact upon 
host immunity both locally at the gastrointestinal associated lymphoid tissue (GALT) 
and systemically (Isolauri et a l 2001). Probiotics have therefore gained recognition 
as powerful inductors of the immune response (Schrezenmeir and de Vrese 2001).
Pattern recognition receptors (PPRs) e.g. TLRs expressed on the surface of APCs
recognise micro-organism associated molecular patterns (MAMPs) typically bacterial
cell wall components expressed on Gram-positive probiotic bacteria culminating in a
downstream signalling cascade that activates transcription factors involved in
cytokine signalling. The TLR system is an immune-surveillance system whose
archetypal role is to recognise distinct microbial patterns of both non-pathogenic and
pathogenic micro-organisms. Probiotic bacteria are recognised as non-pathogenic by 
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the immune system and impose a profound non-pathological immunomodulatory 
influence on newborn immunity that ultimately shapes the cellular architecture of the 
gastrointestinal associated lymphoid tissue (GALT) and the functionality of both the 
peripheral and systemic immune system.
Despite the premise that the overall number of genes in the microbiota is 
approximately two orders of magnitude greater than the gene number in host’s DNA, 
microbiota-associated clinical pathology in healthy individuals does not ensue (Berg, 
1996). This highlights an intrinsic evolutionary requirement for peaceful coexistence 
between the host and probiotic bacteria, representing a classic example of mutualism 
existing irrespective of the plethora of bacterial MAMPS engaged by innate and 
adaptive immune mechanisms (McCracken and Lorenz 2001).
Since a relationship between the qualities of probiotic bacteria colonising the 
neonatal microbiota and the development of atopy exists; the strain specific 
immunomodulatory activity of probiotic bacteria has been utilised in numerous 
perinatal dietary supplemental studies to treat symptoms and/or prevent disorders of 
an atopic derivation (See Table 1.6.1). Kalliomaki’s ground breaking study in 
Scandinavia demonstrating that the rate of atopy was reduced by almost half in a 
probiotic group compared to the placebo group increased interest in the application of 
perinatal probiotic supplementation for the prevention of IgE-mediated allergy. This 
rationale is now supported by well documented studies reporting immunomodulatory 
benefits in both prevention (Kalliomaki et a l 2001) and treatment (Isolauri et a l 
2000; Bjorksten 2004) of allergic disease. Probiotic strains of lactobacilli and 
bifidobacteria origin in particular have been distinguished for their anti-allergy 
properties (Kalliomaki and Isolauri 2004).
1.1.3 The PROBAT trial
The PROBAT trial was a randomised double blind placebo controlled study involving 
probiotic supplementation of expectant lactating woman from 36 weeks of gestation 
until their newborn was 6 months of age. Mothers of newborn recruits with a familial 
history of allergy from the South Wales region were preferentially selected for the 
trial based upon answers on the study recruitment questionnaire to assess for familial 
history of allergy. The trial was conducted employing a study consortium inclusive of
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four probiotic strains Lactobacillus paracasei, Lactobacillus salivarius,
Bifidobacteria bifidum and Bifidobacteria lactis susp. animalis prepared by the 
industrial sponsor administered daily as a probiotic supplement to both mother and 
newborn.
1.1.4 Aim of study and thesis hypothesis
The principal goal of this thesis was to characterise the in vitro and in vivo 
immunomodulatory role of a subset of probiotic bacteria emerging from the 
lactobacillus and bifidobacteria family in protecting against the onset/and or 
symptoms of IgE mediated atopic disorder). Another major goal was to contribute to 
our current understanding of the impact of probiotic supplementation on immune 
function in both in vitro and in vivo scenarios, and to characterise the 
immunomodulatory mechanisms employed by probiotics during development of a 
functionally mature immune system in the neonate. We hypothesised that perinatal 
probiotic supplementation would contribute to both pre and post-natal factors 
programming normal development of neonatal immunity during and after pregnancy 
marked by enhanced development of neonatal cellular immunity underlying 
resistance to development of childhood atopy.
1.2 Epidemiology and immunology of allergy
Current epidemiological data indicate that the prevalence of allergic diseases has 
risen dramatically in many parts of the developed world with approximately one in 
five children in industrialized countries debilitated with allergic diseases ranging from 
asthma, allergic rhinitis or atopic dermatitis (Jarvis and Burney 1998). This ratio is 
steadily increasing (Masoli et a l 2004) with the prevalence of diagnosed asthma and 
associated symptoms strongly in children increasing at a rate of about 5% a year in 
the United Kingdom, the Scandinavian regions, Switzerland, the United States, 
Australia, New Zealand, and Taipei (Jarvis and Burney 1998).
To provide further insight into the worldwide allergic epidemic, the International 
Study of Asthma and Allergies in Childhood (ISAAC), formed in 1991 to facilitate 
research into the potential causes of the rise in asthma, allergic rhinitis and eczema 
investigated variations in the prevalence of these conditions at the population level.
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Although familial associations of allergic disease indicates a genetic element as a 
principal causative factor, other evidence implicates a role for environmental factors. 
Furthermore probiotic intervention studies reveal an important immunomodulatory 
role for probiotic bacteria in shaping the development of the immune system and 
modulating pathways of immunity that impact on normal regulation of the allergic 
immune response (See Table 1.6).
Allergy was established as a clinically relevant ailment in 1906 by Viennese 
paediatrician Clemens Von Pirquet who distinguished a subset of patients who were 
abnormally hypersensitive to normally innocuous environmental allergens like dust, 
pollen or food antigens. Pirquet coined the phenomenon "allergy" to describe a 
rapidly developing immune reaction mounted against harmless ubiquitously 
occurring allergens. In the modem era allergy is regarded as a type I hypersensitivity 
reaction representing an instantaneous allergic response towards allergens to which 
individuals are atopically sensitised.
The concept of atopy, derived from the Greek meaning idiosyncratic, was applied by 
Coca in 1923. Atopic disorders encompass an archetypal spectrum of allergic 
diseases including eczema, allergic rhinitis and asthma occurring when the immune 
system is dysregulated. A standardised nomenclature of allergy was proposed by the 
European Academy of Allergy and Immunology in 2001 in which atopy is to be 
defined as a familial tendency to produce IgE antibodies in response to low doses of 
allergens, culminating in symptoms such as asthma, rhinoconjunctivitis, or 
eczema/dermatitis (Johansson and Lundahl 2001; Johansson et a l 2004). Therefore 
atopy is reserved for describing clinical traits and a genetic predisposition to become 
IgE-sensitised to environmental allergens, and is applied exclusively if IgE- 
sensitisation has been documented by a positive skin prick test or by IgE antibodies 
in semm. In contemporary immunology atopy is classified as an inherited 
hypersensitivity immune reaction of T helper 2 (Th2) exuberance (See T cell subsets 
in allergy 1.2.1) orchestrated by a limited number of allergens, mediated by 
excessive production of IgE antibodies towards environmental allergens (Peisong 
2001). The understanding of T cell responses in allergy highlighted the critical 
importance of Th2 cells in helping B cells toward IgE expression. Th2 cells interact 
with eosinophils via IL-5; smooth muscle cells via IL-9; and epithelial cells and 
keratinocytes via IL-13 (Dillon et a l 2005; Chattopadhyay et a l 2007).
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1.2.1 T cell subsets in allergy
Originally two T helper (Th) T cell subsets originating from the naive T cell 
compartment were first identified based on their cytokine secretion profile. These 
were termed the Thl and Th2 T cells. The Th2- IL-3, IL-4, IL-5, IL-9 and IL-13 
secreting T cells are responsible for orchestrating expression of humoral/antibody 
responses such as IgG or IL-4 mediated IgE induction. (Schmidt-Weber et al. 2007). 
While the T h l: IFN-y secreting cells are crucial in inflammatory delayed type 
hypersensitivity responses, macrophage activation and induction of MHC class II 
molecules.
The Th2 cytokines IL-4, 5, 9 and 13 are important during initiation, maintenance and 
amplification of allergic inflammation in allergy afflicted organs (Romagnani 2000; 
Spergel and Paller 2003; Romagnani 2004). The discovery of further T cell subsets 
such as the regulatory T cells (Tregs) and Thl 7 has modified perceptions of atopic 
immunopathology and the bivalent concept of the Thl/Th2 paradigm. (Schmidt- 
Weber et al. 2007). Key observations leading to this reappraisal include the bi-phasic 
nature of the Thl/Th2 contribution during the pathogenesis of eczematous lesions 
(Grewe et al. 1998; Miraglia del Giudice et al. 2006; Ong and Leung 2006), and the 
inverse association between IgE mediated helminth infection and Th2 mediated 
allergic disease (Smits et al. 2010).
Thl 7 cells produce pro-inflammatory cytokines such as IL-17, IL-6, TNF-a, IL-1 p 
and IL-22 (Harrington et al. 2005; Park et al. 2005; Chung et al. 2006; Mangan et 
al. 2006) and induce expression of inflammatory mediators, like granulocyte colony 
stimulating factor, acute phase proteins, and TNF-a (McAllister et al. 2005; 
Komiyama et al. 2006; Harrington et al. 2005). Thus, IL-17 production provides a 
means by which the adaptive immune system communicates with the innate immune 
system to promote inflammation (Harrington et al. 2005, 2006). The role of Thl 7 
cells in allergy still requires clarification, with experimental models implicating a 
role for Thl 7 cells in mediating neutrophilic inflammation in acute airway 
inflammation and acute asthma attacks (Hoshino et al. 2000; Hellings et al. 2003; 
Nakae et al. 2003; Prause et al. 2004; Hashimoto et al. 2005). Interestingly, IL-17 
expression is increased in the lungs, sputum, bronchoalveolar lavage fluids, or sera of
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asthmatic patients, and the severity of airway hypersensitivity in patients has been 
demonstrated to correlate with IL-17 expression level (Molet et a l 2001; Chakir et 
al 2003). IL-17 mediated neutrophilia has also been observed in bronchoalveolar 
lavage fluids. Interestingly sputum IL-17 mRNA was demonstrated to correlate with 
CXCL8 and neutrophil counts (Bullens et a l 2006). Furthermore anti-IL-17 has been 
demonstrated to reduce neutrophil infiltration in models of experimental asthma 
while increasing eosinophil infiltration (Hellings et al. 2003; Sergejeva et a l 2005). 
Conversely, exogenously administered IL-17 reduced pulmonary eosinophil 
recruitment and bronchial hyperactivity. Taken together, these studies suggest a 
regulatory role for IL-17 during allergic inflammation (Schnyder-Candrian et a l 
2006). However, few studies assessing the impact of perinatal probiotic 
supplementation on maturation of the Thl, Th2 and Thl7 arms of newborn immunity 
exist during this critical preventative window for interventions against allergic 
disease (Kalliomaki et a l 2001; Kalliomaki et a l 2003).
1.3 Immunology of atopy with special reference to the immunomodulatory 
role of probiotic bacteria in shaping current and emerging T helper paradigms
Neonatal differentiation of haematopoietic cells into lymphocyte subsets of the T cell 
lineage is in part controlled by alterations affecting the epigenetic status of immature 
thymocytes during maturation. This process is influenced by microbiota-induced 
cytokine responses that shape the cytokine immune microenvironment during 
immune homeostasis. These mechanisms coalesce to determine the type and or 
intensity of Thl, Th2, Thl 7 and T regulatory immune pathways engaged by the 
maturing fetus in response to microbial stimuli. For instance, newborns are prone to 
intracellular infections since the IFN-a promoter in the neonate is hyper-methylated 
to circumvent toxic and deleterious Thl immune response. Immune mechanisms 
pertaining to efficient resolution of intracellular infection develop much later in 
infant life. Therefore specific cytokine responses are developmental stage dependent 
and will determine how newborns respond to perinatal probiotic supplementation 
with age.
At a time when the newborn is solely reliant on maternal Ig antibodies and regulatory 
cytokines present in human breast milk to maintain immunity (Chirico 2005); 
probiotic bacteria provide a strong immunomodulatory influence (Strachan 2000;
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Prescott 2003) during activation of immune pathways shaping post-natal immunity.
A probiotic optimised newborn intestinal tract is postulated to play an important role 
in attenuating the risk of Th2-mediated atopic disorder (Martinez 1994; Holt et a l 
1999)
1.3.1 Immunology of atopy
To reverse the allergic potential of an individual two avenues have been undertaken; 
one method attempts to prevent the immune response from becoming Th2 skewed 
via perinatal intervention studies employing the use of probiotics, prebiotics or 
synbiotics Furrie (2005). The other method attempts to manage the individual who is 
already atopic (Helin et a l 2002; Rosenfeldt et a l 2003; Wang et a l 2004). To 
determine the potential efficacy of any such treatments, knowledge of the target 
cells and molecules of the immune response which need to be under the 
immunomodulatory influence of probiotic bacteria is required (Furrie 2005).
The rationale behind probiotic supplementation of the newborn stems from a 
hypothesis that atopic disorder is the result of a fundamental failure of immune 
regulation involving inadequate induction and/or activation of regulatory signalling 
pathways occurring via the TLR system of innate immunity. This failure is postulated 
to be due to a lack of early life non-pathogenic microbial stimulation from intestinal 
probiotic bacteria engaging TLR-mediated immune responses (See 1.1.2). This 
phenomenon is coined under the umbrella of the Hygiene Hypothesis introduced by 
Strachan (1989).
Atopic sensitisation is a fundamental feature underlying allergic dysregulation 
defined by positive skin prick tests involving specific IgE directed against common 
allergens (Kurukulaaratchy et a l 2005). The highest risk of childhood atopy has been 
associated with familial history and early life sensitisation to allergen in early life (Illi 
et a l 2001b). Development of sensitisation requires allergen exposure and repeated 
allergen exposure is likely to trigger symptoms (Sporik et a l 1990). The presence of 
allergen-specific IgE underlies the allergic reaction and clinical symptoms of disease. 
Secreted IgE circulates in the blood and binds FcsRI expressed on the surface of mast 
cells and basophils. Later re-exposure to the same allergen results in the allergen 
binding to IgE molecules on the surface of the mast cells or basophils inducing cross­
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linking FceRI and activation of the cells. Activated mast cells and basophils undergo 
a process called degranulation culminating in the release of pharmacologically active 
inflammatory mediators for e.g. cytokines, from their granules into the surrounding 
tissue mediators that cause the classic systemic symptoms of atopy such as 
vasodilatation, mucous secretion, and smooth muscle contraction and itchiness (Gold 
and Kemp 2005). Atopic sensitization commonly occurs early in life, if epithelial 
barrier integrity is compromised, and the epithelium becomes aberrantly activated. 
This may occur through a complex interplay of environmental insults and host factors 
(Cookson 2004). Barrier dysfunction in the lung and skin allows allergens to activate 
the epithelium and produce cytokines that are permissive for the induction and 
development of Th2 responses (Fort et a l 2001; Prefontaine et a l 2009; Paul and Zhu 
2010). A dysfunctional epithelial barrier also allows antigen-sampling dendritic cells 
to become directly activated by allergens and undergo maturation in a Th2-permissive 
milieu such that they subsequently prime allergen-specific Th2 responses (Cookson 
2004; Paul and Zhu 2010; Islam and Luster 2012). Key hematopoietic effector cells in 
allergy include T lymphocytes, B lymphocytes, dendritic cells, and eosinophils.
Signature immunological features of atopic disorder include elevated production of 
the Th2 cytokines IL-4, 5, 9 and 13 accompanied by a decrease or similar production 
of the Thl cytokine IFN-y (Bottcher et a l 2006). While attenuated IFN-y production 
at birth is considered a hallmark of the immune response of those who develop atopy, 
older allergically sensitised children present with hyper-production of IFN-y while 
others may have mixed Thl/Th2 responses variations of which can be related to 
different patterns of allergic disease (Macaubas et a l 1999; Smart and Kemp 2002; 
Heaton et a l 2005). Therefore, a detailed understanding of the kinetics of T cell 
immunity underlying atopic sensitisation is necessary before one can decide how best 
to employ perinatal probiotic supplemental strategies to manipulate the immune 
response in clinically predisposed atopic individuals (Prescott et a l 1999).
1.3.2 Role of allergens
Allergens are diverse antigens capable of triggering allergic reactions and IgE 
sensitisation within breached tissues. They can be presented to the immune system in 
minute doses across the epitheliums of the respiratory and gastrointestinal tracts and
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also the skin. Some allergens (e.g. house dust mite proteins) exhibit protease activity 
demonstrated to be inhibited by probiotic bacteria (Ichikawa et a l 2009).
1.3.3 Immunoglobulin E and the allergic reaction
The discovery of the immunoglobulin E (IgE) antibody class served as a major 
breakthrough in the understanding of the pathogenesis of allergy (Ishizaka et al 
1966). Granulocytes, particularly the mast cells initiate the allergic response via 
signal transduction through their high-affinity (IgE) receptors (FceRl) together with 
membrane-bound surface IgE when directly engaged with allergens of the external 
environment. Signals initiated by IgE-mediated allergenic interactions are transduced 
via the intrinsic expression of FceRl on the granulocytes cell surface (Oettgen and 
Geha, 2012).
The evolutionary role of IgE in humans is to provide protective immunity against 
parasitic worms once endemic in the economically developed world; however in the 
absence of a parasitic burden in affluent societies, IgE mediated immunity to 
allergens has seemingly taken precedence (Bell 1996). Early immunological 
mechanisms predisposing an individual towards IgE mediated atopy are complex and 
instrumental to development of allergic disease.
1.3.4 Role of the granulocytes in allergy and innate immunity
Th2 cytokines are instrumental to the allergic response which concludes in 
recruitment of granulocytic effector cells (See Figure 1.1) such as the eosinophils, 
basophils and mast cells which migrate to sites of allergic tissue inflammation either 
alone or in combination with cytophilic or IgE antibodies promoting the clinical 
manifestations of atopy (Cross et a l 2001).
Upon recruitment from the circulation the granulocytes localise to sites susceptible to 
allergic challenge such as the epithelial surfaces of the intestinal and respiratory tracts 
and the skin (Furrie 2005). This process requires upregulation of adhesion molecules 
on the endothelium of blood vessels and granulocytes, and the subsequent 
granulocyte migration through the vessel wall towards the inflammatory site along a 
chemokine and/or cytokine concentration gradient (Lampinen et a l 2004).
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Human granulocytes respond to a variety of adaptive- and innate- immune stimuli 
that regulates de novo generation of inflammatory cytokines pivotal in allergic 
disease, they do not just contribute to symptoms of allergic disease but also 
orchestrate events leading to them (Gibbs 2005). For example, despite the basophilic 
granulocytes representing approximately 1% of the total nucleated peripheral blood 
pool (Macfarlane et a l 2000), basophils are not only recruited to sites of allergic 
inflammation but their mediators are released in sufficient quantities to contribute to 
allergic symptoms (Gibbs 2005). Their cellular expression of CD40 ligand synergises 
with IL-4 and IL-13 cytokines to induce B-cell proliferation and class switching to 
IgE and IgG4 (Macfarlane et a l  2000).
The combined application of granulocytic-specific monoclonal antibodies together 
with techniques to purify granulocytes to homogeneity from peripheral blood, led to 
the observation that key granulocyte populations interactive with T and B cells are a 
common occurrence in allergy afflicted tissues (Falcone et a l 2000; Voehringer et 
al 2004; Gibbs 2005). For example examination of lesional skin from atopic 
dermatitis subjects revealed increased eosinophils counts (Oyoshi et a l 2009). 
Whereas basophils form a major infiltrate in bronchial biopsies and airway tissues of 
asthma patients (Koshino et a l 1996; Gauvreau et a l 2000; Macfarlane et a l 2000; 
Nouri-Aria et a l 2001). Furthermore basophils are the major infiltrate in nasal lavage 
fluids after allergen provocation from patients with allergic rhinitis (Iliopoulos et a l 
1992) and also occur in skin biopsies from patients with atopic dermatitis 
(Macfarlane et a l 2000). This has shed light on the immune role of the granulocytes 
during propagation of the allergic response and immunity to pathogens.
Interestingly, granulocyte cytokine release without the need for prior IgE-mediated 
allergen sensitisation can occur pointing to granulocytic involvement in directing 
Th2 immune responses from initial pathogen or TLR agonist interaction. Bacterial 
peptidoglycans can similarly activate basophils by stimulating TLR2 receptors 
culminating in IL-4 and IL-13 release, further potentiating an IgE mediated allergic 
response (Oettgen and Geha 1999; Turner and Kinet 1999; Gould et a l 2003; 
Bieneman et a l 2005; Galli et a l 2005). For example, TLR2 expressing basophils 
upon interaction with TLR2 ligands such as (e.g., Peptidoglycan) can directly 
activate basophils for mediator/cytokine secretion as well as augment FcsRI-
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dependent responses thus highlighting the potential of a TLR2 ligand such as 
peptidogoglycan expressed on probiotic bacteria to influence the innate immune 
response (Grangette et al. 2012).
With these observations in mind one major goal of this thesis was to determine 
whether perinatal probiotic supplementation could have any effect on circulating 
peripheral blood granulocyte levels. The immune role of the granulocytes during the 
initiation and maintenance of the allergic response is summarised in the diagram 
below
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Figure 1.1 Schematic overview of the key hematopoietic effector granulocytes 
involved in allergy.
1.3.5 Role of the lymphocyte subsets of adaptive immunity in allergy
Lymphocyte populations form a vital cellular constituent o f the adaptive immune 
system and disease states tend to be marked by clearly defined lymphocyte 
populations. Lymphocyte compositional analysis therefore serves as a useful 
diagnostic tool in understanding the pathogenesis o f allergic disease. According to the 
expression levels o f cell type specific, cluster o f differentiation (CD) proteins, 
lymphocyte populations are divided into three main subgroups: The (CD3 ) T cells, 
the (CD19+) B cells and the (CD3'/CD16+ CD56+), natural killer cells.
Mature T cells in peripheral blood are further sub-divided into (CD4 ) helper T cells 
that release cytokines and growth factors regulating the differentiation o f other 
immune cells and (CD8+) cytotoxic T cells that exhibit suppressor activity that lyse 
tumorous or virally infected cells (Supramac 2008). Optimal functioning o f the 
immune system can be influenced by imbalances resulting from abnormalities in the 
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number of lymphocytes in either the CD4 or CD8 lymphocyte compartments.
The CD4/CD8 ratio is therefore used as a parameter to assess immune system health 
(Calder 2007).
The expression of alternatively spliced mRNA isoforms of CD45 a trans-membrane 
protein tyrosine phosphatase expressed on haematopoietic nucleated cells (Ten Dam 
et a l 2000) renders CD4+ and CD8+ T cells either naive (CD45RA+) or memory 
(CD45RO+) T cells (Akbar et a l 1988; Sanders et a l 1988; Hermiston et a l 2003). 
This definition is based on the ability of CD45RO+ T cells, to respond exclusively to 
recall antigen in vitro, but not CD45RA+ (Akbar et a l 1988; Sanders et a l 1988; 
Plebanski et a l 1992), and the distinction that the majority of CD4+ T cells in cord 
blood express the CD45RA antigen (Depaoli et a l 1988).
Naive T-cell generation by the thymus and proliferation and differentiation within the 
periphery provide the developing newborn with a naive T cell repertoire to mount 
neonatal adaptive immune response (van Gent et a l 2009). Although the influence of 
perinatal probiotic supplementation on naive and memory T cell pools has not been 
typically studied, a consequence of naive T cell priming at epithelial sites is the 
generation of memory T cells persisting throughout the lifespan of the host after 
resolution of inflammation (Sheridan and Leffancois 2011). In the context of atopic 
diseases, sensitization to environmental allergens at the epithelial surfaces generates 
long-lived allergen-specific memory T cells programmed to home to the mucosal and 
epithelial surfaces for immune surveillance. Re-exposure to antigen or allergen can 
also increase the size of the tissue resident memory T cell pool (Vezys et a l 2009). 
These programmed homing pathways increase the likelihood that tissue-patrolling 
memory T cells will encounter activated dendritic cells presenting a cognate allergen 
in the tissue as well as in the draining lymph nodes. After T cell receptor activation, 
naive T cells differentiate into effector T cells, some of which are maintained as 
memory T cells expressing an altered profile of trafficking receptors; after 
inflammation is resolved. Low levels of the ligands for these receptors are 
constitutively expressed in the steady state to facilitate tissue-specific memory T cell 
homing and immune surveillance (Schaerli et a l 2004).
Tissue-specific trafficking within the circulatory system via adhesion molecules 
involving lymphoid organs and peripheral tissues is a fundamental prerequisite for 
effector T cell function and lymphocyte extravasation into target peripheral tissues
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(Luster et al. 2005). During inflammation, ligands for selectins, integrins and 
chemoattractant receptors are upregulated in tissues and provide directional cues for 
inflammatory T cells (on which the corresponding receptors are upregulated) for 
entry into inflamed tissue via the circulatory system. Allergy-prone organs such as 
the skin and intestinal tract provide an additional level of specificity in organ-specific 
T cell trafficking via a process known as ‘imprinting’ (Luster et al. 2005; Agace 
2006; Bromley et al. 2008) best characterized in the skin and small intestine (Cahill 
et al. 1977; Picker et al. 1990; Berlin et al. 1995). Since micro-organisms are tissue 
tropic in virulence during initial priming of naive T cells, allergy-prone organs 
exposed to the environment imprint, preferential tissue-specific inflammatory 
effector T cell and memory T cell entry from the circulation to streamline immune 
surveillance (Cahill et al. 1977; Agace 2006; Sigmundsdottir and Butcher 2008). T 
cells programmed to home to the small intestine are programmed during initial 
antigen priming and typically express integrin a4p7+.
Regulatory T cells (Tregs) maintain peripheral T-cell self-tolerance to innocuous 
self and or environmental proteins and exert immunological control over excessive 
inflammatory responses (Sakaguchi 2004). Tregs mediate immunomodulatory or 
immunosuppressive capacity to inhibit inappropriate and potentially deleterious 
immune responses.
Impairment of pathways affecting Treg populations and function are cited as central 
in driving the immunology of clinical atopic disease (Campbell et al. 2001).
Pivotally, Treg dependent production of the immunomodulatory cytokines IL-10 and 
TGF-p plays a key role in controlling allergic inflammatory responses (Joetham et al. 
2007; Sohn et al. 2007; Provoost et al. 2009). This is exemplified by studies 
demonstrating that allergen-specific immunotherapy with house dust mite antigen 
decreased symptoms in asthmatic children in an IL-10 dependent manner, 
culminating in the expansion of Treg cells (Seddiki et al. 2006).
In this respect, one goal of perinatal probiotic supplementation is to enhance the 
neonatal Treg repertoire postulated to be protective against an allergic outcome. 
Substantiating these observations studies in germ free (GF) mice highlighted a causal 
link between the intestinal microbiota and the development of gut derived Treg cells
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(McLoughlin and Mills 2011). Interestingly GF mice express lower numbers of 
CD4+CD25+FoxP3 cells with attenuated IL-10 production kinetics in the mesenteric 
and peripheral lymph nodes compared with conventionally reared mice (Ostman et 
a l 2006). Furthermore, oral tolerance could not be established in GF mice because of 
the impaired suppressive function of their CD4+CD25+FoxP3 cells and attenuated 
production of TGF-0 and IL-10 (Ishikawa et a l 2008). In vitro experimental 
evidence also exists for the direct effects of Bifidobacterium infantis and 
Lactobacillus salivarius (employed as constituents of the PROBAT study 
consortium) as inducers of increased Treg cell development (de Roock et a l 2010).
Elevated CD4+CD25+FoxP3 Treg cells in the mice spleen were associated with 
Bifidobacterium infantis supplementation in mice (Ishikawa et a l 2008).
Furthermore a recent phase II trial demonstrated that daily administration of 
Lactobacillus salivarius for 4 weeks in healthy adults enhanced systemic 
concentrations of Treg produced IL-10 (Sierra et a l 2010). Another study 
highlighted the potent effects of the intestinal microbiota on Treg cell development 
in human subjects and a positive correlation was found between the numbers of 
Gram-positive anaerobes (lactobacilli and bifidobacteria) in maternal stool and IL-10 
secretion by naive cord blood mononuclear cells. Notably gram-negative anaerobes 
(Bacteroides and Prevotella species) were also involved in this positive correlation 
(Karlsson et a l 2002) highlighting that the immunomodulatory probiotic effect is not 
exclusively restricted to Gram positive anaerobes.
The role of dendritic cells (DCs) is considered particularly in this thesis due to their 
dendrite mediated capacity to directly interact with probiotic bacteria and mediate 
tolerogenic immunomodulatory cytokines responses. (DCs) originate from the bone 
marrow and occur either as conventional plasmacytoid DCs (pDC) or myeloid DCs 
(mDC). DCs are potent antigen presenting cells characterised by a high capacity for 
antigen uptake. They are widely distributed in the gastrointestinal tract, lymph nodes 
and occur in low frequencies in peripheral blood to regulate naive T cell maturation 
into effector T cell populations and subsequent polarization of the T cell response. 
Their intrinsic cell surface expression of pathogen recognition receptors (PRRs) such 
as TLRs renders them (1) responsive to probiotic bacteria specific MAMPs, and (2) 
able to present non-probiotic bacteria derived antigens to naive T cells upon (PRR)- 
mediated (Kalinski et a l 1999).
20
DCs are central to the initiation of immunological reactivity to allergens and their 
contiguous dendritic networks are present in the epithelium of the gut, skin and 
airways where they mediate antigen surveillance. Interestingly cross-sectional studies 
in older children and adults with atopic disorder have described changes in DC 
subsets in patients with asthma (Uchida et al. 2001; Matsuda et al. 2002;
Hagendorens et al. 2003). Animal models highlight the importance of mDCs during 
pathogenesis of allergic airway inflammation,(Constant et al. 2002; van Rijt et al. 
2005), and a role for pDCs in immune tolerance (Colonna et al. 2004), and host 
defence against viral infections at mucosal surfaces (Lund et al. 2006).
Gut DCs are constantly exposed to intestinal probiotic bacteria and bridge the gap 
between innate and adaptive gastrointestinal immunity by continually sampling gut 
luminal content. When immature state DCs capture antigen in the presence of 
appropriate inflammatory stimuli, they migrate to secondary lymphoid organs and 
undergo maturation via upregulation of major histocompatibility molecules required 
for (1) antigenic peptide presentation, (2) upregulation of co-stimulatory molecules 
required for T-cell stimulation (3) de novo cytokine induction necessary for 
orchestrating stimulus-specific enhancement of T, B and NK cell responses. At the 
lymph nodes DCs mediate differentiation of naive T cell into effector T cell 
populations critically involved in driving gut Treg differentiation and tolerogenic B- 
and T-cell responses (Borchers et al. 2009).
At the cytokine level IL-12p70 production by dendritic cells is pivotal during 
induction of probiotic mediated Thl response. Whereas DCs that produce IL-10 or 
TGF-(3 promote induction of Treg cells and tolerogenic responses (Tang 2009). At the 
immunoglobulin level, DCs facilitate IgA secretion by B cells to maintain intestinal 
epithelial barrier function to commensal organisms (Macpherson et al. 2005).
Interestingly, DCs found in the intestinal mucosa preferentially induce differentiation 
of resident T cells into Th2 (Iwasaki and Kelsall 1999) and Treg (Kelsall and Leon 
2005) subsets promoting a tolerogenic state in the GIT. This observation was 
supported by in vitro findings that DCs can be conditioned towards a tolerogenic 
phenotype by intestinal epithelial cells stimulated with Lactobacillus spp. gut 
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microbiota isolates. Interestingly Gram-negative E. coli were less effective in 
mediating this tolerogenic conditioning property (Zeuthen et a l 2008).
DCs from GF mice are reduced in numbers and are impaired in their ability to 
activate T cells (Walton et a l 2006). The ability of the microbiota to influence 
antigen presenting cell function in the gut is supported by studies indicating that bone 
marrow derived DCs incubated with Lactobacillus species had enhanced ability to 
promote Treg cell differentiation in vitro and prevent intestinal inflammation after 
adoptive transfer in vivo (Foligne et a l 2007). Furthermore lactobacilli spp. have 
been demonstrated to differentially regulate DCs, with consequent influence on the 
Thl/Th2
cytokine balance at the intestinal mucosa (Christensen et a l 2002) as well as on the 
activation of NK cells (Fink et a l 2007). Interestingly, exposure to non-viable heat- 
killed probiotic Lactobacillus species induced the upregulation of DC maturation 
markers, such as MHC class II and CD86, in murine DCs confirming that probiotic 
bacteria do not need to be viable to be immunogenic (Christensen et a l 2002).
Gut homing Lymphocytes involved in the intestinal immune response are localised 
to organized immune inductive sites of the GALT such as Peyer's patches (PP), 
mesenteric lymph nodes (MLN) and diffuse effector sites of the gut epithelium and 
lamina propria (LP). B7 integrins are responsible for trafficking and retention of these 
lymphocytes at these sites. a4 integrin (CD49d) subunit combines with the p7 
integrin to form the a4 p7 integrin responsible for homing of naive and gut tropic a4 
P7+ memory effector lymphocytes via extravasation from blood to gut mucosal 
tissues of GALT, MLN and LP (Pabst 1991; Briskin et a l 1997; Williams and 
Butcher 1997). These inductive sites are responsible for priming of naive B and T 
lymphocytes that later seed to mucosal effector sites like the gut lamina propria 
(Farstad et a l 1996; Williams and Butcher 1997; Gorfu et a l 2009). Thus, 
lymphocyte populations are retained in steady state in the lamina propria or in the 
epithelium of various tissues. The ability of lymphocytes to be mobile and survey on 
the one hand, and to localize and accumulate in tissues on the other hand are critical 
for host defence. T cells in nearly all mucosal epithelial sites express a4 p7 integrin 
demonstrated to mediate lymphocyte binding to epithelial cell E-cadherin. These
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interactions are key in directing lymphocyte traffic and retention in mucosal organs 
(McCracken and Lorenz 2001).
B cells whose principal effector molecules are the IgE antibodies, have a pivotal role 
to play during development of allergic disease. Variable diverse and joining 
segments for the immature IgE immunoglobulin transcripts (VDJCe) are detectable 
in the umbilical cord blood from the third trimester becoming more prevalent after 9 
months of age (Miller et a l 1973; Lima et al. 2000; Thornton et a l  2003) Sterile Ie 
transcripts can be detected as early as 8 weeks of gestation indicating that many 
foetuses are primed for isotype switching to IgE production by the end of the first 
trimester of pregnancy. Post-natal maturation of circulating and tissue B cells in 
relation to allergic disease outcomes is not extensively studied, but it will be 
interesting to note whether probiotics influence on development of post-natal B cell 
populations. This is considered in chapter 5 of the thesis.
B cell development occurs in the bone marrow where sIgM+SIgD+ B cells exit as 
immature transitional B cells. Circulating B cells at birth have an immature 
phenotype with the majority of cells expressing IgM and CDlc (Sims et a l 2005; 
Cuss et a l 2006). Immediately after birth there is an increase in recent bone marrow 
emigrant cells which differentiate into naive B cells. Consequently, B cells are 
present in ample amounts in cord blood. Naive B cells constitute the largest 
peripheral B cell subset throughout childhood and peak during the first 6-12 month of 
life decreasing gradually during early childhood (van Gent et a l 2009; Comans-Bitter 
et a l 1997; de Vries et a l 1998).
Naive B cells can differentiate into plasma or memory B cells following binding of 
antigen by specific immunoglobulin receptors (Pascual et a l 1994; Liu et a l 1996)
1.3.6 Key cytokines regulating allergic responses
TNF-a and IL-12p70 are inflammatory cytokine that provide differentiative signals 
for polarization of naive T cell inflammatory responses towards a Thl immune 
pathway. The Thl response is antagonistic to the Th2 response (Miettinen 1996; 
Hehlgans and Pfeffer 2005; Uings et a l 2005; Kekkonen et a l 2008). Interestingly 
during allergic responses TNF-a is an important inflammatory inductor of eosinophil 
activation and survival (Levi-Schaffer et a l 1998). In vitro studies have 
23
demonstrated that several Lactobacillus strains interact with mononuclear cell 
cultures via engagement of the NF-kB pathway, thus elevating TNF-a concentrations 
in cell culture supernatants (Matsuguchi et a l 2003; Viljanen et al. 2005). IL-12p70 
further potentiates the Thl immune response by stimulating NK and T cell IFN-y 
production and promoting peripheral blood lymphocyte proliferation and 
differentiation into Thl lymphocytes (Trinchieri 1995; Szabo et a l 2003; Kekkonen 
et a l 2008).
IFN-y produced predominantly by effector lymphocyte subsets is also a Thl 
cytokine involved in nearly all phases of the inflammatory response, including 
activation, growth and differentiation of macrophages, T, B and NK cells and is 
crucial for resolution of allergic-related immunopathologies (e.g. severe asthma). 
Suppressive effects of IFN-y on allergic diseases are postulated to be mediated by 
mechanisms involving: (1) Regulation of allergen presentation to T lymphocytes. (2) 
Differentiation of naive T cells toward Thl phenotype and/or inhibition of Th2 cell 
recruitment/differentiation. (3) Suppression of Th2 cytokine release from activated T 
cells. (4) Inhibition of effector cell recruitment to the site of inflammation. (5) 
Induction of apoptosis in T cells and eosinophils and (6) and blockage of IgE isotype 
switch in B cells (Teixeira et a l 2005). Interestingly, (Prescott et a l 2005) 
demonstrated that administration of probiotics was associated with significant 
increases in IFN-y responses to PHA and SEB. The increase in IFN-y responses to 
SEB was directly proportional to the decrease in the severity of atopic dermatitis.
IL-lp and IL-6 exert both pro- and anti-inflammatory activity on monocytes, B cells 
and T cell, and acute phase reactions (Fitzgerald et a l 2001). IL-1P induces 
neutrophilia in vivo and drives the early phase of the inflammatory response and 
resultant changes in airway smooth muscle responsiveness in asthma patients 
(Whelan et a l 2004). Elevated levels of IL-1 P protein have been detected in the 
airways of patients with asthma (Pujol et a l 1990; Borish et a l 1992) and IL-ip 
modulates airway constrictor and smooth muscle relaxation responses (Hakonarson 
et a l 1997; Shore and Moore 2002). However, the role of probiotic bacteria as an 
inductor of the IL-lp response has not been studied.
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IL-6 induces expansion of Th2 effector cells involved in allergic responses; when 
released by dendritic cells and inhibits the suppressive function of CD4+CD25+ Tregs 
thus inhibiting peripheral tolerance (Teta 2006). In the context of the progression of 
allergy, IL-6 binds the soluble IL-6 receptor (IL-6R), increased after allergen 
challenge in asthmatic patients. Conversely via membrane-bound IL-6R, IL-6 
controls CD4+CD25+ survival, and initial stages of Th2 cell development in the lung. 
Currently, there is a paucity of studies modelling interactions with probiotic bacteria 
and IL-6R but it is postulated that IL-6 may exert anti-inflammatory and protective 
effects in intestinal mucosa and enterocytes. (Viljanen et a l 2005) studied in vivo the 
immunologic effects of Lactobacillus rhamnosus (LGG), probiotic supplementation 
in infants with atopic eczema-dermatitis syndrome and cow's milk allergy for 4 
weeks and discovered that plasma IL-6 levels increased significantly after treatment 
with LGG.
1.3.7 Role of the classical Th2 cytokines
IL-4 is a mast and T cell derived Th2 cytokine that plays a critical role in IgE 
regulation and stimulation of activated B and T-cell proliferation differentiation of 
naive helper T cells into Th2 cells (Sokol et al. 2008). IL-4 exerts its biological roles 
through the IL-4 receptor expressed on B cells, T cells, and monocytes. The IL-4- 
dependent production of IgE due to IL-4 induced isotype class switching of IgM to 
IgE (Isidoro-Garcia et a l 2005). Overproduction of IL-4 is associated with allergies 
(Sokol et a l 2008) and differentiation to the Th2 allergic phenotype which plays a 
crucial role during induction and maintenance of allergy. Asthma and atopy have 
been linked to the IL-4 gene mapped to chromosome 5q31 (Marsh et a l 1994;
Palmer et a l 1998) and IL-4 polymorphisms are associated with increased total IgE 
levels and allergic phenotypes (Basehore et a l 2004). The IL-4RA gene is located on 
chromosome 16p(16pl2.1) (Pritchard et a l 1991), a region implicated in linkage 
with atopy in diverse populations (Deichmann et a l 1998; Ober et a l 2000). Several 
single-nucleotide polymorphisms have also been identified in the coding region of 
the IL-4RA gene, many of them resulting in amino acid substitutions (Deichmann et 
al 1997; Deichmann et a l 1998). Polymorphism of IL-4RA gene plays central role 
of the IL-4/IL-4RA pathway in atopy and association of the 576Q>R polymorphism 
with the atopic phenotype has been described (Hershey et a l 1997; Kruse et al 
25
1999; Sandford et al. 2000; Shirakawa et al. 2000; Kauppi et al. 2001; Bottini et al. 
2002; Wjst et al. 2002; Hytonen et al. 2004; Lee et al. 2004).
IL-13 is an immunoregulatory Th2 cytokine produced by activated T cells that 
regulates immunological processes that underpin the pathophysiology of allergic 
disorders. IL-13 enhances expression of CD23 on monocytes and B-cells and also 
promotes IgE mediated allergic inflammation while inhibiting microbial driven 
inflammation. IL-13, like IL-4, contributes to isotype switching in B cells to 
promote IgE production and modulates inflammation by attenuating expression of 
IL-1 and TNF-a (Foster 2003). Investigations on over-expression of IL-13 in the 
lung and in acute models of asthma in mice have defined important roles for IL-13 in 
eosinophil accumulation and the promotion of enhanced airways hyperreactivity to 
cholinergic stimuli (Kumar et al. 2003; Yang et al. 2003; Leigh et al. 2004).
1.3.8 Role of the regulatory cytokines
TGF-fil is a potent immunoregulatory cytokine instrumental in tissue remodelling, 
wound repair, haematopoiesis (Fitzgerald et al. 2001; Marie 2006), prevention of 
intestinal inflammation, upregulation of IgA synthesis (Yang et al. 1999) and 
inhibition of inflammatory T and B cells, dendritic cells, mast cells and eosinophils 
(Wahl 1992; Holgate 2000; Solway and Irvin 2007). The onset of allergy has been 
attributed to a lack or decreased number of suppressive, Tregs. TGF-p has been 
demonstrated to induce Tregs and participate directly in suppression of effector T 
cells thereby facilitating the return of reactivity to allergens to normal sub 
symptomatic activity (Schmidt-Weber and Blaser 2004). Interestingly perinatal 
probiotic supplementation has been associated with altering the concentrations of 
TGF-B1 and TGF-B2 in human breast milk, thus increasing the immune quality of 
human breast milk.
IL-10 is an anti-inflammatory cytokine produced by monocytes, activated B cells, 
macrophages, mast cells, keratinocytes, dendritic cells and T cells (Moore et al.
2001; Asadullah et al. 2003). IL-10 antagonises synthesis of IL-12, TNF-a and IFN-y 
(Pessi et al. 2000) and IL-10 stimulates proliferation and antibody production by B 
cells; including cooperation with TGF-P to stimulate IgA production by human B
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cells and down-regulates IgE synthesis by enhancing class switching to IgG4 
synthesis (Moore et a l .1993; Pessi et al. 2000). Also, IL-10 targets various cells 
involved in the allergic response and is a powerful inhibitor of pro-inflammatory 
cytokine production. IL-10 downregulates eosinophil survival and inhibits IgE- 
mediated activation of mast cells. IL-10 impairs DC maturation reducing their 
stimulatory capacity for induction of Thl and Th2 cells. Furthermore, IL-10 also 
promotes IgG4 production in B cells, leading to a favourable ratio of IgG4 to IgE 
(Hawrylowicz and O'Garra 2005).
T-cell production of IL-10 is triggered at the time and site of allergen exposure (Urry 
et a l 2006). In humans, allergic individuals have a propensity for lower proportions 
of allergen-responsive IL-10-secreting CD4+T cells and more IL-4 secreting cells in 
their peripheral blood compared with their healthy non- allergic counterparts (Akdis 
et a l 2004). This suggests that a high IL-10 to IL-4 secreting T-cell ratio is important 
in the maintenance of immune homeostasis and prevention of inappropriate 
responses to allergens in healthy individuals. Interestingly alveolar macrophages 
from asthmatic patients secrete lower levels of IL-10 than normal non-asthmatic 
subjects (Urry et a l 2006). In addition, an inverse correlation between IL-10 levels 
and the severity of asthmatic disease has been described (Borish et a l 1996; Lim et 
a l 1998; Heaton et a l 2005).
1.4 Newborn immunity and the Thl/Th2 paradigm refined
Before one can accurately interpret the results of any intervention study assessing the 
immunomodulatory effects of perinatal probiotic supplementation on immunity; an 
appreciation for the progression of early neonatal immune development is 
warranted (Prescott and Nowak-Wegrzyn 2011). Neonatal organs undergo a dramatic 
transition at birth, from a sheltered intra-uterine existence to an environment where 
antigens are ubiquitous. This transition is countered by a gradual, age-dependent 
maturation of immunity in the post-utero environment. Given the limited exposure to 
antigens in utero, newborns rely strongly on innate immunity to maintain immune 
integrity and counter deleterious antigenic threats (Krishnan et a l 2003; Kenzel and 
Henneke 2006; Belderbos et a l 2009). Neonatal adaptive immunity is initially 
distinguished by a strong bias against production of Thl-polarizing cytokines and up­
regulation of immune responses favouring the production of Th2 polarising 
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cytokines upon antigen recognition (Adkins et a l 2004; Chaouat et a l 2004). 
Although this Thl/Th2 bias renders the newborn prone to persistent Th2 mediated 
allergic responses and susceptible to microbial infection, the attenuation of Thl 
immune responses in early life has been cited numerously as an evolutionary 
conserved precautionary mechanism originating in utero and extending to the post- 
utero environment to circumvent potentially harmful Thl immune responses in early 
neonatal life. This phenomenon is supported by evidence that infection-induced 
production of the Thl pro-inflammatory cytokines is associated with premature and 
pre-term delivery; and aberrant TNF-a production is a hallmark of miscarriage via 
apoptosis induction in placental and foetal cells (Vitoratos et a l 2006).
However, after birth there is an age-dependent maturation of the immune response 
and a gradual attenuation of the initial biased Th2 predisposition. This is concomitant 
with an increasing affinity towards maturation of antigen and/or microbial mediated 
Thl immune responses and is influenced by prenatal and postnatal exposure to 
environmental microbial products that can activate innate immunity that might 
accelerate this maturation process (Bach 2002; Liu and Leung 2006; Ng et a l 2006). 
Therefore it is postulated that Th2-dominated immune responses reminiscent of the 
in utero environment undergo microbially-driven post-natal maturation, to 
circumvent development of Th2 mediate atopic disorder.
To provide a mechanistic insight into the immunomodulatory potential of probiotic 
bacteria in neonatal immunity; an appreciation for the threefold demands of neonatal 
immunity are paramount. These demands encompass:
(1) Protection against infection at the maternal-foetal interface (Barton 1984; 
McDonagh et a l 2004).
(2) Immune adaptation during the transition between the sterile intra-uterine 
environment to the antigen-rich post-utero environment due to microbial 
colonization of the skin and GIT (Karlsson et a l 2002; Marchini et a l 
2005), and
(3) Avoidance of harmful alloimmune reactions between mother and foetus 
by inhibition of Thl immune responses at the maternal-foetal interface 
(Makhseed et a l 2001).
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1.4.1 Correlation between underlying cytokine predisposition and the onset of 
allergic disorder in infancy.
In newborns that develop the atopic phenotype clear developmental and early pre- 
symptomatic differences manifesting post-utero are already evident (See Table 1.4) 
when compared to healthy neonates at the same developmental stage. Early pre- 
symptomatic immunological imbalances in effector cytokine function are 
consistently reported and these are associated with imbalances in the quality and/or 
quantity of colonising intestinal probiotic bacteria. Key immunological features 
contributing to the increased neonatal risk of atopic disease include lower 
proliferative newborn T cell responses reduced cytotoxic T cell responses and 
dysregulated or attenuated cytokine production in response to microbial stimuli 
(Miles et a l 1996; Lewis 1998; Hartel et a l 2005). These symptoms are postulated 
to have a profound impact on the pathophysiology of atopic disorder. Epigenetic 
differences in immune function disrupting normal gene activation or silencing 
patterns required for an optimally functioning immune system are evident at birth 
between healthy and atopic neonates (Kuriakose and Miller 2010). Interestingly Thl 
function is actively regulated by the foetus through epigenetic mechanisms that alter 
methylation patterns and gene expression of the IFN-y promoter in effector CD4+ T 
cells (Pfefferle et a l 2010).
The development of allergic disease is hypothesised to manifest with early pre- 
symptomatic differences in allergen-specific cytokine production (Beasley et a l 
1998; Prescott et a l 1998; Prescott et a l 1999). Studies employing the stimulation of 
human mononuclear cells with the cytokine inducing lymphocyte mitogens 
phytohaemagluttin (PHA) and Staphylococcal enteroxin B (SEB) have provided 
invaluable insight into the immunology of atopic disorder. These studies have 
revealed that early pre-symptomatic differences exist in cytokine production ability 
by mitogen stimulated mononuclear cells isolated from neonates in whom atopy was 
and was not developing. PHA stimulated mononuclear cells isolated from atopic 
children, consolidate IL-4, IL-5 and IL-13 responses; and insufficiently upregulate 
IFN-y responses between 6 months and one year of age compared to non-atopic 
counterparts (Tang et a l 1994; Prescott et a l 1999; Herberth et al 2010). Numerous 
authors have demonstrated that infants who eventually express the atopic phenotype
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by 12 months of age already present with significantly stronger Th2 T cell responses 
to allergens and mitogens by 6 months of age (Prescott et a l 1999). This 
immunological predisposition is concomitant with impaired Thl IFN-a responses 
during the first months of life and persists in children who develop inhalant 
sensitisation by 6 years of age (Sudo et a l 1997). Furthermore, attenuated IFN-y 
production is a hallmark of the immune response at birth in children with an 
increased risk of atopic sensitisation (Wilson 1991; Tang et a l 1994; Warner et al 
1994; Nurse et a l 1997; Campbell et a l 1999; Smart and Kemp 2001), concomitant 
with a failure to efficiently upregulate IFN-y during infancy (Prescott 2003; Schaub 
et a l 2008; Smith et a l 2008; Tulic et a l 2011). These observations have been 
attributed to an underlying impairment of IL-12 production by neonatal T cells 
necessary for development of Thl biased cells (Nilsson et a l 2004). Additionally a 
reduced capacity to produce IL-12 at birth is associated with a reduced number of 
IFN-y producing cells associated with weaker allergen-specific Thl responses and 
development of skin prick reactivity and atopic dermatitis during the first 2 years of 
life (Upham et a l 1999).
The postulate that the capacity to produce Thl (typically IFN-y), Th2 (typically IL- 
13) and regulatory cytokines IL-10 is diminished at birth in children at genetic risk 
of developing childhood allergic disease is now widely accepted (Holt et a l 1992; 
Tang et a l 1994; Warner et a l 1994; Prescott etal. 1998).
Lower proliferative responses and dysregulated or attenuated microbal mediated 
cytokine production by newborn T cells are key signature features contributing to the 
increased risk of atopic disease during infancy. These observations have been linked 
to imbalances in the quality and/or quantity of colonising GIT probiotic bacteria and 
are postulated to have a profound impact in the pathophysiology of childhood IgE- 
mediated atopic disorder (Hartel et a l 2005).
Cytokine production abnormalities seen in the atopic newborn support an arena for 
an increased propensity for the differentiation of Th2 biased T cell responses 
mediating increased peripheral blood IgE levels and eosinophilia during infancy 
(Prescott et a l 1999; van der Velden et a l 2001; Neaville et a l 2003). This suggests
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that events regulating the expression of atopic disorder and allergen-specific T cell 
memory are operational pre- and/or post-natally when the antigen inexperienced 
immune system initially encounters innocuous allergens (Prescott et a l 1999;
Baraldo et a l 2007). In summary cytokine imbalance marked by reduced Thl 
secretion predispose an individual to the development of clinical atopic disease 
(Smart and Kemp 2002). This observation reinforces the rationale behind perinatal 
probiotic supplementation with Thl inducing probiotics bacteria at the neonatal stage 
to circumvent the onset of allergy in clinically predisposed individuals.
Table 1.4 Pre-symptomatic differences manifesting post-utero in allergy-prone 
neonates
Innate Immunity Adaptive immunity
The IL-12 p40-p35 heterodimer 
activates cell mediated Thl immunity 
responses. Newborns display 
attenuated capacity to produce IL-12 
due to a neonatal defect in p35 
promoter nucleosome remodelling 
(Goriely et a l 2004).
Reduced overall capacity to produced 
cytokines due to reduced antigen 
presentation exhibited by neonatal dendritic 
cells and a high proportion of immature T 
cells with limited cytokine induction 
potential compared to low proportion of 
mature T cells with a greater cytokine 
induction potential.
Neonatal monocytes have reduced Diminished capacity of infantile T cells to
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expression of the MyD88 adaptor 
protein and are less responsive to 
LPS and bacterial lipopeptides 
signalling through TLR2 and TLR4 
consequently an impaired capacity to 
produce TNF-a ensues.
produce IFN-y due to selective attenuation of 
post-natal IFN-y gene expression in T cells 
due to hypermethylation of CpG sites in the 
proximal promoter and reduced capacity to 
transcribe IFN-y.
Neonatal dendritic cells exhibit 
reduced antigen presentation and lack 
the capacity to deliver polarising 
signals to T cells
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Figure 1.2. A schematic overview of T cell phenotypes in allergic disease and 
their role in orchestrating allergy development. Diagram adapted with 
permission from (Schmidt-Weber et a l 2007).
T h l, Th2, T h l7, and Treg cells are characterized by cytokines, which mediate 
specific functions in different tissue cells such as the dendritic cells (DC), 
keratinocytes (Ker), epithelial cells (Epit), B cells (B), eosinophils (Eos), mast cells 
(Mas), fibroblasts (Fib), and neutrophils (Neut) (Schmidt-W eber et al. 2007). The 
continuous balance o f  T-cell subsets at the onset and during the course o f  disease 
determines the immunological features o f the disorder.
The newborns inability to deviate from the in utero Th2 scheme o f immunity is 
hypothesised to contribute towards atopic susceptibility. Additionally lower IFN-y 
and IL-13 responses at birth are considered as indicators o f  a functionally immature 
immune system. The failure to efficiently upregulate IFN-y and IL-12 is also critical
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to the development of atopic sensitisation during infancy and this is associated with 
reduced number of IFN-y producing cells (Upham et a l 2002; White et a l 2002; 
Prescott et a l 2003; Nilsson et a l 2004).
1.4.2 Atopic allergic march
The principal environmental risk factors for allergy development during the post natal 
period are early exposure to food allergens. This is associated with IgE-mediated 
allergic manifestations in the skin, GIT and respiratory tract (von Berg 2009). The 
manifestation of allergic disease in childhood generally follows a characteristic 
evolution known as the atopic allergic march, relating to the gradual development of 
the archetypal spectrum of atopic disorders persisting initially from early infancy to 
adolescence with atopic dermatitis representing the first clinical manifestation, 
followed by allergic symptoms of the upper or lower airways and IgE responses to 
alimentary or environmental allergens. IgE responses to cow's milk and hen's egg are 
usually primary immunological markers of atopy often substituted by IgE responses 
to indoor or outdoor allergens. Eczema and food allergy caused by food allergen 
sensitisation is often followed by aeroallergen sensitization, then a shift in disease 
burden to that of asthma and allergic rhinitis. However, the extent to which early life 
atopic sensitization sentences a child to a clinical history of allergic disease in later 
life is unclear (Kurukulaaratchy et a l 2005).
One of the key questions regarding the early life origins of allergic disease relates to 
the environmental factors that underlie the epidemic of allergy that has afflicted the 
developed world over recent decades.
1.5. The microfloral hypothesis and the role of the GIT microbiota in allergy 
pathogenesis
Since alterations in microbial exposure alone do not sufficiently explain the observed 
increase in allergic disease, attention has now focussed on the importance of the 
immunomodulatory role of commensal probiotic bacteria during gastrointestinal 
immune homeostasis.
The microbiota hypothesis states that perturbations in the gastrointestinal microbiota 
alter the symbiotic relationship between commensals and human immunity with 
disruptive effects on evolutionary conserved regulatory mechanisms necessary to 
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impart microbiota-mediated immunological tolerance towards allergens in the 
mucosa (Brandtzaeg 2009).
1.5.1 Differences in gastrointestinal commensal flora in atopic and non-atopic 
subjects
Variations in early intestinal colonization patterns have been implicated in the 
predisposition to allergic disease through effects on mucosal and systemic immune 
function. Recent studies comparing the microbial composition of the GIT microbiota 
in infants in whom atopy was and was not developing demonstrated that differences 
occurred: with anaerobic lactobacillus and bifidobacteria strains amongst the earliest 
and most predominant colonisers of the GIT in children showing resistance to the 
development of allergic disorder. Interestingly, infants manifesting with the allergic 
phenotype presented with more clostridia and staphylococci preceding the 
development of allergic disease concomitant with a reduced diversity of early faecal 
microbiota (Kalliomaki et al. 2001; Tang 2009). These studies linked postnatal 
differences in probiotic bacteria colonisation patterns in infancy (Aim et a l 1999) 
with pre-symptomatic immune dysregulatory differences pertaining to the 
development of clinical allergic disease (Bottcher et al. 2000; Kalliomaki et al. 2001; 
Prescott 2003) and logically led to the experimental application of probiotic bacteria 
to optimise the immunomodulatory potential of the intestinal microbiota. The 
principal goal of probiotic and allergy research is to, therefore, promote a favourable 
arena for enhanced development of innate, adaptive and oral tolerance immune 
mechanisms and to induce a probiotic mediated immunological equilibrium that is 
protective against the manifestation of IgE mediated atopic disorder in clinically 
predisposed atopic neonates (Prescott and Bjorksten 2007).
Interest in variations in the intestinal microbiota composition in relation to allergic 
disease during infancy was initiated by comparison of the faecal microbiota of 
Estonian versus Swedish 1 year old children. The intestinal microbiota of Estonian 
children had more lactobacilli and eubacteria but fewer clostridia; a microbiota 
reminiscent of that prevailing in infants of Western Europe in the 1960s. Changes in 
the intestinal microflora of infants in western industrialised countries were suggested 
(Sepp et al. 1997). This group then went onto compare the faecal microflora of 
allergic and non-allergic children from Estonia and Sweden. Allergic children from 
both countries had a similar microbiota which differed in composition to non-atopic 
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children: increased levels of aerobic microbes, particularly coliforms and 
Staphylococcal aureus, and decreased levels of anaerobic microbes, particularly 
lactobacilli, and bacteroides (Bjorksten et al. 1999). This group then undertook a 
prospective study, collecting faecal samples at 5 to 6 days and at 1, 3, 6 and 12 
months and monitoring development of allergic disease until 2 years of age. Faecal 
samples were analysed using traditional microbial culture techniques. In comparison 
with infants who did not develop allergy (by skin prick test or clinical history), those 
who developed allergy were less often colonized with enterococci during the first 
month of life, and less often colonised with bifidobacteria during the first year of life 
and had higher counts of clostridia at 3 months of age (Bjorksten et a l 2001). The 
authors concluded that differences in the GIT microbial composition in infants who 
do and do not develop allergy are operational before the clinical manifestation of 
allergic disease. Prospective follow-up until 5 years of age has now been reported and 
allergy development remained associated with being less frequently colonised during 
the first 2 months of life with lactobacilli, bifidobacteria but also Clostridium difficile 
(Sjogren et a l 2009). Colonisation with bifidobacterium species was associated with 
exposure to higher levels of endotoxin and coming from a larger family.
Other analytical approaches frequently demonstrate similar differences in microbial
flora composition in the GIT and allergic outcomes in early childhood irrespective of
country: faecal levels of C. difficile-derived caproic acid was higher in Swedish
allergic than in non-allergic children (Bottcher et a l 2000); gas liquid
chromatography of bacterial cellular fatty acids and quantitative fluorescence in situ
hybridization of bacterial cells demonstrated that as early as 3 weeks of age, Finnish
children who developed atopic sensitisation had more clostridia and less
bifidobacteria than children who remained non-atopic (Kalliomaki et a l 2001). A
similar intestinal microbiota profile was also established in Japanese children
presenting with atopic dermatitis (Watanabe, Narisawa et a l 2003). These studies
highlighted the need for adopting methodologies beyond conventional bacterial
cultivation techniques on Agar plates. An anthroposophic lifestyle inclusive of
consumption of fermented vegetables, restricted use of antibiotics and vaccinations
was also associated a more desirable intestinal microbiota composition and a lower
incidence of allergic disease (Aim et a l 2002; Shreiner et a l 2008). Taken together,
these studies highlight a relationship between subclinical intestinal microbial 
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exposure and allergic outcomes in later life. Antibiotic use in early life would clearly 
impact on this.
1.5.2. Antibiotic use
The attractiveness of the link between antibiotic use and allergic disease, lies in the 
data on national trends of antibiotic use versus the incidence of allergic disease, and 
in the impact of oral antibiotic use on the gastrointestinal microbiota (Shreiner et a l 
2008). As discussed above, the intestinal microbial environment in infancy clearly 
has a pivotal role in the aetiology of atopic disorder. The use of antibiotics in the first 
year of life has been associated with increased risk of developing asthma, hayfever 
and eczema and allergic sensitisation in childhood, but the association with 
wheezing/asthma outcomes is the most robust relationship. Interestingly the 
likelihood of developing asthma was greater for antibiotic use in the first year of life 
than after the first year of life, or if never used (Wickens et a l 1999). Consequently 
early and repeated antibiotic usage has been implicated as a surrogate to identify 
infants who are most susceptible to development of atopic disorder in later life 
(Mullooly et a l 2007). However studies in which antibiotic use for lower respiratory 
tract infection was excluded showed no detrimental effect of antibiotic use in the first 
year of life on the development of a spectrum of atopic disorders including: asthma, 
allergic rhinitis or eczema (Illi et a l 2001; Celedon et a l 2002).
1.5.3 The Hygiene Hypothesis
The expression of the atopic phenotype appears to be synonymous with the 
industrialized environments of the affluent world. The hygiene hypothesis links a 
marked reduction in the level of microbial exposure and childhood infections, 
compared to that prevailing in less affluent regions as a causal factor in the rise in 
allergic disorders (Von Hertzen and Haahtela 2004). Increased use of antimicrobial 
medication, consumption of sterile food, reduced family size and improved or 
exaggerated hygiene and health care practices (See Table 1.5.3), typical of the 
western lifestyle during early childhood, is postulated to favour an arena for lower 
infection rates during childhood. This is concomitant with biased immune 
polarization toward a Th2 phenotype during postnatal immune maturation., and has 
led to a relative lack of microbial stimulation of the infant GALT (Rosalind and 
Bloomfield 2004).
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At the immunological level the hygiene hypothesis proposes that the microbial 
environment interfaces with the innate immune system and modulates its ability to 
impart instructions to adaptive immune responses, most critically in utero and/or in 
early life (Vercelli 2006). The microbiota hypothesis substantiates notions introduced 
in the hygiene hypothesis and proposes that signals generated following microbial 
exposure modulate immunity towards ubiquitously occurring environmental 
allergens (Pan et a l 2010). The intestinal microbiota composition provides an 
important immunomodulatory inoculum for postnatal maturation of the immune 
system via induction of innate and adaptive immune mechanisms for programming 
Treg cells responses and non-inflammatory IgA responses. This is most relevant in 
infancy when postnatal immune programming is initiated (Prescott and Bjorksten 
2007; Prescott et a l 2010)
The rationale behind the application of probiotics as a therapeutic strategy against 
IgE-mediated atopy stems from observations that prolonged prenatal and postnatal 
exposure to environmental microbes activates innate immunity in accord with the 
hygiene hypothesis (Strachan 1989). This regulates the Th2 bias of neonatal 
immunity by enhancing Thl-cell polarization, thus attenuating immune responses 
that support IgE mediated atopy (Bach 2002; Liu and Leung 2006).
However efforts to manipulate the Th2/Thl equilibrium with probiotic bacteria 
should be conducted with caution, with the penultimate goal to induce a T regulatory 
cell response with low grade inflammation (Marschan et a l 2008); as opposed to an 
excessive Thl immune response linked to the development of autoimmune disease. 
The introduction of artificial newborn feeding regimens and contemporary hygiene 
practices is postulated to encourage undesirable colonisation of the GIT. This is 
marked by immunological priming and IgE mediated clonal expansion of allergen 
specific Th2 lymphocytes and over excessive immunology towards allergens 
(Romagnani 2004). Aberrant Treg cell function in infants who subsequently develop 
allergic disease has been reported, along with the conjecture that immaturity of both 
Thl and Treg compartments increase the risk of inappropriate persistence of a Th2 
immunity in atopic individuals (Bousquet et a l 2004; Miller and Ho 2008; Smith et 
al 2008; Martino and Prescott 2010).
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Although the initial interpretation of the hygiene hypothesis was rather simplistic, its 
immunological basis has foundations in epidemiological and socio-economic data 
implying a causal link between changes in microbial load and allergic disease 
(Rosalind and Bloomfield 2004). Epidemiologic support for the hygiene hypothesis 
linked to the effects of intestinal microbiota microbial imbalances on immune 
development and the pathology that ensues in the absence of probiotic organisms of 
lactobacilli and bifidobacteria origin flourishing in the GIT (Bjorksten 2004). These 
strains are hypothesised to affect the quality of immune stimuli required for normal 
maturation of post-natal immunity to allergens, pathogens and non-pathogenic 
commensals (Strachan 1989; Vaarala 2003; Watanabe et a l 2003; Kabesch and 
Lauener 2004).
An alternative arm of the hygiene hypothesis suggests that the lower microbial 
burden has served to decrease activity of Treg cells. This notion arose from 
epidemiological observations highlighting that expression of the allergic phenotype 
is lower in prevalence and far less severe in regions of the world debilitated with a 
chronic persistence of helminth infections known to induce strong and persistent Th2 
responses in concert with high production of suppressive cytokines (Romagnani 
2004). Furthermore demonstration that exposure of a pregnant mother and newborn 
during the first year of life to microbial products released by farm animals, exerts an 
important protective effect against the development of allergy. This observation was 
attributed to the chronic stimulation of the TLRs, yielding further support for the 
hygiene hypothesis (Braun-Fahrlander et a l 2002). Microbial colonisation of the 
GIT is also linked with lifestyle and/or geographic factors, postulated to be an 
important determinant in the worldwide rise in allergic disorder as summarised in 
table below (Bjorksten 2005).
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Table 1.5.3: Environmental risk factors for the development of food allergy
Purification of 
household water 
supplies via 
chlorination.
Pregnancy, early 
childhood and during 
adult life
Reduces mycobacteria 
and other pathogenic 
microorganisms present 
in untreated water.
Cleaner home 
environments marked 
by better personal 
hygiene, increased use 
of household 
detergents and proper 
disposal of sewage 
waste water.
As above Exposure to household 
pathogens and enteric 
organisms in sewage 
reduced.
Improved access to 
modem medicinal 
practices e.g. 
antibiotic therapy for 
infectious disease.
As above Indiscriminate 
destructive action of 
antibiotics eradicates 
both probiotic 
microorganisms and 
infective microorganism.
Increased use of 
processed foods.
As above Increases the growth of 
putrefying bacteria like 
clostridia in the intestinal 
tract.
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Table 1.5.3.1: Incidental reductions in microbial exposure imposed by lifestyle
Lack o f rural 
exposure or 
increasing urban 
dwelling
Early childhood Reduction in 
exposure to 
environmental 
mycobacteria and 
enterobacteria
Less outdoor 
exposure to sunlight 
or fresh air
Early childhood Less exposure to 
airborne microbes in 
the natural 
environment
1.5.4 The commensal microbiota and its establishment during infancy
Microbial communities are specified by the term “microbiota'’, defining a unique 
array o f host specific micro-organisms that colonise distinct niches within the host 
according to their metabolic and survival needs. Processes involved in the 
establishment o f the microbiota from neonate to adulthood are intricate and depend 
on bacterial succession as well as cross talk between bacteria and TLR-mediated 
immune recognition implemented by the host (Mackie et al. 1999). Approximately 
100 billion to 1,000 billion beneficial bacteria per millilitre literally consume harmful 
bacteria and other pathogens (Barron 1999). Probiotics, in particular, form part o f the 
resident commensal microflora community and have been implicated as enhancers o f 
the immunomodulatory capacity o f the intestinal microbiota (Crane 2002).
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The newborn is rapidly colonised initially by bacteria from the surrounding 
environment of maternal origin following passage through the birth canal. Further 
colonisation commences immediately after birth (Adlerberth 1999), with aerobic and 
facultative anaerobic bacteria encompassing the coliforms, enterobacteria, 
lactobacilli, staphylococci and streptococci strains forming the principal colonising 
organisms (Kuhn et a l  1986; Cooperstock et a l 1983). These strains are postulated to 
lower the oxidation reduction potential in the intestine allowing establishment of 
anaerobes such as bacteroides and bifidobacteria. The most common anaerobic 
genera in terms of concentration within the GIT are the strict anaerobes, forming the 
majority bacterial stakeholder residing at approximately 97% of the total inoculum 
and encompassing strains from the Bifidobacterium, Lactobacillus, Bacteroides, 
Clostridium, Fusobacterium, and Eubacterium genres. The (facultative anaerobes) 
form a minority bacterial population at only 3% with principal strains emerging from 
the corynebacteria and propionibacteria families, the Gram-negative enteric bacterial 
families including E. coli, Veillonella and Salmonella spp, the Gram-positive cocci 
including Peptostreptococcus, Peptococcus, Enterococcus, Micrococcus, 
Staphylococcus and Streptococcus and the fungal species Candida albicans are chief 
coloniser of the GIT (Noverr and Huffiiagel 2004).
During infancy, the GIT develops a complex ecosystem stabilizing at approximately 
1014 organisms with approximately 30-40 species believed to flourish. The
12composition gradually alters to resemble that of the adult, reaching densities of 10 
organisms per ml of luminal contents consisting of approximately 100 trillion 
microorganisms, from some 400 to 1000 different species (Simon and Gorbach 
1984).
The GIT microbiota composition differs both cross-sectionally and longitudinally 
(Shreiner et a l 2008) with approximately 60% of the composition non-culturable 
employing contemporary techniques and only around 300-500 species currently 
culturable in vitro (Isolauri et a l 2001). Improvements to PCR and genome 
sequencing techniques permit further characterisation of the intestinal microbiota and 
discovery of strains with potential probiotic effects.
The development of the microbial community plays a pivotal role in regulating the 
maturation of the newborn immune system. Gastrointestinal microbial imbalances
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occurring early in life are postulated to lead to the induction of insufficient tolergenic 
mechanism supporting the development of immune dysregulated disorders.
Therefore the rationale behind perinatal administration of probiotic bacteria is to 
influence favourable colonisation of the newborn GIT.
From culture based data, the mouth harbours a complex microbiota consisting of 
facultative and strict anaerobes, including streptococci, bacteroides, lactobacilli, and 
yeasts (Sekirov et a l 2010). The mammalian lower intestine contains an extremely 
diverse and dense flora of commensal bacteria not normally pathogenic in an 
immunocompetent host (Noverr and Huffnagel 2004).
Table 1.5.4 Distribution of the microflora within the GIT
Stomach and Duodenum Principally lactobacilli and streptococci 
colonise this region. Harbours relatively 
low bacterial numbers: < 105 bacterial 
cells per gram of contents. Phasic 
propulsive motor activity in synergy with 
the actions of acid, bile and pancreatic 
secretions impedes stable colonisation of 
the lumen,
Jejunum and ileum Bacterial numbers progressively increase 
from approximately 104 cells in the 
Jejunum to 107 cells per gram of contents 
in the distal ileum.
Large intestine 19Heavily populated by anaerobes 10 cells 
per gram of luminal contents.
Infant feeding regimens play a crucial role in establishing the commensal microbiota
of the GIT immediately after birth. Major changes in gut microbiota composition 
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occur during breast feeding, weaning, and the transition to solid foods (Cooperstock 
et a l 1983). Penders et a l (2006) evaluated a broad range of external influences on 
acquisition and composition of the gut microbiota in infancy.
After analysis of 1032 faecal samples from babies aged 1 month of age the most 
important determinants of infantile gut microbiota composition was proposed to be:
1. Mode of delivery.
2. Birth environment.
3. Gestational age.
4. Mode of feeding, early life antimicrobials and other medicinal usage.
5. Early life exposure to infection.
6. Infant hospitalization.
Thus, the establishment and maintenance of a probiotic optimised GIT is determined 
by factors affecting early microbial populations a complex process influenced by 
microbe-microbe and microbe-host interactions (Mackie et a l 1999).
The first observations that significant differences existed in the microbiota 
composition in breast-fed versus bottle-fed infants were made a century ago. The 
microbiota of breast-fed infants was dominated by LAB and bifidobacteria species, 
while formula-fed infants harboured a more complex and diverse adult-like 
microbiota characterised by a mixture of anaerobic and aerobic bacteria with 
enterobacteria, lactobacilli, bacteroides, clostridia, E. coli, C. difficile, bifidobacteria 
and streptococci predominating (Penders et a l 2006). The predominance of
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bifidobacteria associated with exclusive breast feeding is postulated to offer 
protection against gastroenteritis. Scientific interest in bifidobacteria was promoted 
by the observation that breast-fed infants were less susceptible to infections and the 
allergic phenotype in later life than bottle-fed babies. It was postulated that 
bifidobacteria in the colon might play a role in the newborns resistance to infection 
(Yasui et a l 1989). More recent studies of infant GIT microbiota have failed to 
confirm exuberant colonisation with bifidobacteria in exclusively breast fed infants, a 
change attributed to changes in maternal diet or obstetric practices (Lundequist et al. 
1985; Hall et a l 1990).
Breast milk is rich in biogenic prebiotics oligosaccharides (growth substrate for 
probiotics), probiotic micro-organisms such as bifidobacteria are postulated to be 
present in human breast milk (Martin et a l2003; Gueimonde et a l 2007). An intrinsic 
evolutionarily conserved mechanism operating in human breast-milk appears to 
support and drive the colonisation of an infant gut microbiota rich in a diverse array 
of beneficial probiotic microorganisms. The occurrence of oligosaccharides, like 
fructo-oligosaccharide (FOS) and galacto-oligosaccharide (GOS) renowned for their 
ability to influence and support growth and survival of LAB and bifidobacteria 
populations (Newburg 2009), underscores this premise. Upon introduction of solid 
food, the intestinal microbiota increasingly resembles that of adults, reaching a stable 
microbial ecosystem in which anaerobes predominate.
Mode of delivery also impacts on the composition of the infant microbiota. Numerous 
studies of microbiota development have shown major differences in culturable 
microbiota in vaginally versus caesarean section delivered newborns. Infants bom by 
caesarean section harboured a paucity of bifidobacteria and bacteroides, concomitant 
with frequent colonisation by C. difficile, compared with vaginally delivered infants. 
Hospitalisation and prematurity was also associated with elevated C. difficile counts. 
In preterm infants, treatment with antibiotics or being nursed in an incubator 
significantly reduced early colonisation with lactobacilli and bifidobacteria (Hall et 
al 1990). Improved maturation of humoral immune mechanisms such as elevated 
circulating IgA and IgM-secreting cells have been observed at 6 month of age in 
vaginally delivered infants who tended to harbour more Bacteroides firagilis and 
Bifidobacterium species than caesarean delivered infants. Term infants bom vaginally
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at home who were breastfed exclusively also seemed to have the most "beneficial" 
gut microbiota (Gronlund et a l 2000).
1.5.5 The intestinal microbiota and the immune system
The gut microbiota is exposed to host physiological systems and coexists peacefully 
within the host, irrespective of immunogenicity. This symbiotic host-microbe 
relationship has co-evolved in the presence of the intestinal microbiota and the 
gastrointestinal immune system (Sekirov et a l 2010) and is key during establishment 
of normal gut barrier functions, regulation of systemic and local immune 
responsiveness and hyporesponsiveness (oral tolerance) to food and microorganism 
derived antigens (Cebra 1999; Nagler-Anderson 2001; Noverr and Huffnagle 2004; 
Brandtzaeg 2009; Chung and Kasper 2010). The gut microbiota is postulated to 
stimulate the immune system via induction of a subtle mode of intestinal 
inflammation regulated by TLR-mediated immune recognition of probiotic bacteria. 
This contrasts to clinical mucosal inflammatory response mediated upon immune 
recognition of pathogenic organisms (O'Farrelly 1998; Viljanen et al. 2005; Marschan 
et al. 2008).
Intestinal commensals play key roles in gastrointestinal health (See Table 1.5.5) by 
assimilating indigestible nutrients of human metabolism, competitively excluding 
harmful bacteria from gaining a foothold and facilitating processes of digestion, 
absorption and B vitamin and enzymes synthesis (Barron 1999; Isolauri et a l 2001).
TLR-mediated interactions between the immune system and the gut microbiota 
occurring at the GALT do not cause overt inflammation in healthy individuals (von 
Hertzen and Haahtela 2006). Normal development of the immune system depends on 
tolerogenic symbiosis with the microbial ecosystem, and is important in mediating 
memory mechanisms of systemic immunity (Guamer and Malagelada 2003a; Guamer 
and Malagelada 2003b). Probiotic bacteria, in particular are noted for their 
immunomodulatory influence on innate and adaptive immune mechanism that 
contribute to an immune microenvironment in which non-pathogenic tolerogenic 
responses to food antigens and allergens occur (Hooper and Macpherson 2010).
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A diverse range of haematopoietic cells are found within the GIT including 
lymphocytes, macrophages and DCs. These cells participate in the overall immune 
response and the number of intraepithelial lymphocytes (IELs) is approximated to be 
more than half the T cell repertoire estimated for peripheral lymphoid organs (Noverr 
and Huffnagel 2004). Greater than 70% of all haematopoietic cells of the host are 
located in the intestine to combat the challenge presented by environmental antigenic 
load. Undeveloped mucosal immunity is cited as the reason for higher vulnerability to 
post-natal infections and sensitisation to dietary antigens during infancy (Kalliomaki 
et a l 2003). Although mucosal protection marked by locally produced secretory IgA 
is quantitatively and functionally defective for a variable period after birth; probiotic 
lactobacilli and bifidobacteria of intestinal origin have been demonstrated to enhance 
IgA responses (Kalliomaki et a l 2003).
Stimuli provided by commensal bacteria are crucial for the development of a fully 
functional and balanced immune system, including homing of B and T cells to the 
lamina propria and expansion and maturation of IgA plasmocytes and IgA production 
(Isolauri et a l 2001). During infancy, principal components of the gut barrier are 
immature rendering the intestinal surface relatively permeable, thus enhancing 
proneness to inflammatory responses. Disturbed microbiota succession is linked to 
the risk of developing infectious, inflammatory and allergic diseases in later life. 
Experimental and clinical follow-up studies suggest that constant stimulation by the 
intestinal microbiota strongly outweighs the importance of occasional infections in 
providing the essential immunological provocation necessary for maturation of gut 
barrier functions and innate and adaptive immunity (Isolauri et a l 2009).
1.5.6 The effect of probiotics on the allergy-associated immune response and 
T cell responses
An impressive body of in vitro data evidence exists detailing the role of probiotics in 
favourably modulating the intrinsic Th2 skewed nature of allergen specific T cell 
responses in a Thl dependent manner (Cross et a l 2001; Niers et al 2005;
Flinterman et a l 2007). Nonetheless mechanisms by which probiotics regulate 
allergic responses in vivo remain to be fully characterised.
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The anti-allergy strain specific function of bifidobacteria and lactobacilli is well 
documented both in vitro and in vivo and is postulated to occur via the 
immunomodulatory action of Thl cytokines, (Isolauri et al. 2000; Paganelli et al. 
2002) TGF-P and intestinal IgA upon induced immune recognition during the Th2 
allergy driving phase of the disorder (K ailas  a l 1992; Kaila et al. 1995; Isolauri et 
al. 1995; Miettinen et al. 1998; Fukushima et al. 1999; Kiijavainen et al. 1999; 
Phuapradit et al. 1999; Hessle et a l 1999; Christensen et al. 2002; Ichikawa et al. 
2009). Numerous authors have demonstrated that stimulation of human mononuclear 
cells with probiotic strains can induce a strain specific production of a range of 
inflammatory cytokines (Isolauri et al. 2001). Interestingly probiotic induced IL-12 
and IFN-y production by mononuclear cells has been demonstrated to not only 
induce Thl differentiation, but also shift in vitro allergen-specific Th2 responses 
towards a Thl-polarised phenotype. This effect has been replicated in vitro with 
microbial CpG-containing oligodeoxynucleotides mixed to, or conjugated with 
allergens, resulting in production of high quantities of Thl-polarising cytokines by 
intestinal macrophages (Parronchi et al. 1999; Tighe et al. 2000)
The Thl cytokine inductive capacities of probiotic bacteria is postulated to 
antagonise Th2 cytokine release from mitogen stimulated peripheral blood 
mononuclear cells (PBMCs), a property with anticipated benefits for the 
management of atopy in vivo (Pochard et al. 2002). In support of this induction of 
Th2 cytokines by PBMCs stimulated with the superantigen e.g. SEB is inhibited by 
prior exposure to a four strain mix of Lactobacillus plantarum, Lactococcus lactis, 
Lactobacillus casei and Lactobacillus rhamnosus. This inhibitory effect was not 
observed in the presence of the Gram-negative bacterium E. coli TGI and was dose 
dependent with higher strain doses leading to more pronounced reduction of IL-4 and 
IL-5. Interestingly bacterial viability did not impact upon cytokine induction ability 
as heat killed bacteria performed equally as well as exponentially growing strains 
(Pierre 2002).
In another study, production of IL-4, IL-5 and IL-13 by PBMCs from allergic patients 
sensitised to aeroallergens was attenuated significantly when PBMCs from these 
patients were incubated with LAB and the relevant aeroallergen in vitro (Pierre 
2002). This study further highlighted the role of probiotic bacteria in limiting allergic
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responses, and modulating Thl/Th2 activity in vitro. This has encouraged support for 
the application of perinatal probiotic supplementation as a strategy to circumvent 
atopic disorder later in life (Cross et al. 2001). The net effect of probiotic-mediated 
inflammatory cytokine production in vivo is postulated to be the inhibition of IgE 
secretion from plasma cells orchestrated by the inhibitory effect of inflammatory 
cytokines on Th2 responses (Sudo 1997; Heller 2003; Osbourne 2008; Ichikawa et a l 
2009).
1.5.7 Effects of probiotics on T cell responses
The TLR-mediated recognition of Thl cytokine inducing probiotic bacteria is 
postulated to alter the cytokine microenvironment induced during a Th2 atopic 
response and attenuate upregulation of a Th2 mediated allergic response (Prescott and 
Dunstan 2005). Some probiotic strains have a greater in vitro capacity to stimulate 
Thl cytokine production; while others induce Th2 or mixed, Thl/Th2 responses 
(Tang 2009). (Christensen et al. 2002) highlighted the specific immunomodulatory 
qualities of probiotic bacteria. Lactobacillus casei for instance is a strong inducer of 
TNF-a, IL-12, and IL-6 whereas Lactobacillus reuteri is a poor IL-12 inducer. 
Interestingly, some bifidobacteria and lactobacilli strains have inhibitory or opposing 
effects on regulatory function and differentially modify each other’s effects. For 
instance (Christensen et al. 2002) demonstrated that Lactobacillus reuteri 
specifically inhibits Lactobacillus casei-induced DC cytokine production, and up­
regulation of co-stimulatory markers; and Bifidobacterium lactis downregulates TGF- 
p-production.
Bifidobacteria and lactobacilli have been postulated to promote regulatory responses 
but mechanisms for doing so are variable. Bifidobacteria induce production of the 
regulatory cytokine, IL-10 by both myeloid and plasmacytoid DCs and down regulate 
expression of co-stimulatory molecules CD80 and CD40 on DCs. Down-regulation of 
IFN-y appears to be IL-10-dependent. Contrastingly, specific Lactobacillus species 
induce Treg cells by generating semi-mature DCs with increased expression of co­
stimulatory molecules and lower levels of pro-inflammatory cytokines concomitant 
with a down regulation or negligible effects upon IL-10 production (Hart et al. 2004).
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In another study, Lactobacillus paracasei, strongly inhibited CD4+ T cell 
proliferation and production of the IFN-y and IL-4, IL-5, but produced the 
regulatory cytokines IL-10 and TGF-0 in a dose-dependent manner (von der Weid et 
al. 2001). Similarly Lactobacillus rhamnosus induced T-cell hyporesponsiveness to 
CD3/CD28 stimulation and reduced production of IL-2, IL-4 and IL-10 both in vitro 
and following in vivo administration (Braat et a l 2004). Probiotic bacteria 
predominantly modulate DC and T-regulatory cell activity, although effects on Thl or 
Th2 immune pathways (Tang 2009).
In vitro and clinical studies with probiotics suggest that Lactobacillus rhamnosus GG 
(LGG) attenuates Th2 immune responses by promoting Thl responses. The cytokine 
profile induced by LGG-stimulated PBMCs is characterised by increased IFN-y and 
IL-12 production, no change in IL-4 production and a modest increase in IL-10 
production (Miettinen et al. 1998).
Comparable Thl-promoting effects have been demonstrated in vivo with increased 
production of IFN-y in infants with cow’s milk allergy and eczema given an LGG- 
containing dietary supplement (Pohjavuori et al. 2004). The increase in IFN-y levels 
from mononuclear cells in response to probiotics could offer a mechanistic 
explanation for the possible clinical benefits of probiotics in controlling the 
manifestation of atopic diseases (Vaarala 2003). However, a cautionary note is 
proffered by the cow’s milk allergy study as in a parallel study group, a consortium 
of four probiotics that included LGG had no effect on IFN-y production and 
increased IL-4 production indicating that different and potentially antagonistic 
immune responses can be mediated by individual or mixtures of probiotic strains. In 
support of this premise, in animal models of Thl mediated autoimmune arthritis, 
some probiotics strains inhibited Thl immune responses providing alleviating effects 
on disease progression whilst others exacerbated arthritic pathology by potentiating 
Thl immune responses within the already Thl biased disease state (Lamacchia et al. 
2010).
The observations that elevated levels of the transcription factors NF-kB and STAT6
occurred subsequent to stimulation of human monocytes with Lactobacillus
rhamnosus cell wall components (Miettinen et al. 2000) has allowed researchers to
deduce the signalling pathways employed by probiotic bacteria to induce a cytokine
response. Toll-like receptor signalling in small intestinal epithelium promotes B-cell 
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recruitment and IgA production in the lamina propria (Guamer and Khan 2008). 
Interestingly, in a mouse model constant activation of TLR4 in the intestinal 
epithelium did not lead to unbalanced inflammation but rather elevated production of 
secretory IgA, highlighting an increase in gut barrier function in response to constant 
TLR4 stimulation (Shang et al. 2008).
Table 1.5.5: Summary of the immunologic and non-immunologic health benefits 
of a probiotically optimized GIT in terms of probiotic host interaction and 
symbiosis between microbiota. As reviewed by (Guamer and Khan 2008).
Immunological benefits Non-immunological benefits
Activation of local macrophages to 
increase antigen presentation to B 
lymphocytes and increase secretory 
(IgA) production locally and 
systemically
Digest food, fecal matter and compete 
for nutrients with pathogens.
Modulation of Thl/Th2 and Th3 
cytokine profiles
Alter local pH exerting an unfavourable 
local environment for pathogens
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Induction of hyporesponsiveness to food 
antigens
Produce bacteriocins to inhibit pathogens
Scavenge superoxide radicals
Enhance intestinal barrier function and 
integrity and compete for adhesion sites 
with pathogens.
Stimulate epithelial mucin production
Exhibit enzymatic activity e.g. (p- 
glucosidae)
1.5.8 The immunomodulatory effects of probiotic bacteria in germ free mice
The importance of probiotic bacteria in immunity has been demonstrated by studying 
the pathology that ensues in GF mice, in the absence of the immunomodulatory 
presence of probiotics bacteria. In GF mice the establishment of the lymphocyte 
repertoire is impaired and mice present with multiple maturational defects linked to 
the absence of immunomodulatory signals provided by the intestinal microbiota, such 
as an inadequately colonized GIT, and reduced size of extra-intestinal lymphoid 
organs like the spleen, and thymus.
Interestingly studies in animal models indicate that the induction of IL-12 in vivo 
might reduce baseline serum IgE levels thereby improving the severity of allergic 
responses. From a mouse model using in situ analysis of Peyer’s patches following 
oral administration of FITC-labelled Lactobacillus paracasei it was reported that (i) 
IgE production was reduced in vivo; (ii) Lactobacillus paracasei interacted with 
CD1 lb-positive cells and induced IL-12 mRNA expression in the Peyer’s patch; and 
(ii) blood IL-12 levels increased transiently 10 hours after administration (Ichikawa et 
a l 2009).
In the absence of immunomodulatory signals provided upon recognition of MAMPS; 
cellular development of the lymphocyte compartment is severely compromised in GF 
animals, with impaired expansion of the CD4 T-cell repertoire representing a 
signature immunodeficiency. This phenomenon is postulated to occur in a cytokine 
dependent manner, with GF animals exhibiting systemic skewing towards an allergy 
supporting IL-4 mediated Th2 cytokine profile compared with conventionally 
colonized mice, which up-regulate a more balanced Thl/Th2 profile (Sekirov et al.
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2010; McLoughlin and Mills 2011). Interestingly (Mazmanian et al. 2005) 
demonstrated that colonization o f GF mice with the commensal organism Bacteroides 
fragilis alone was sufficient to promote a Thl response and correct the T hl/T h2 
imbalance seen in GF mice; in a signal transducer and activator o f transcription 6 
signalling (STAT-6) dependent manner in DCs that promoted IL-12-dependent 
expansion o f  Thl cells, proliferation o f CD4+ T cells, and restoration o f lymphocyte 
development (Falk et al. 1998). These observations in GF animals lend support for 
the rationale behind perinatal probiotic supplementation o f the neonate. The 
maturational defects observed in germ free mice are summarised in Table 1.5.8
Table 1.5.8: Immunological defects in germ free mice due to a lack of an 
intestinal microbiota
Impaired macrophage chemotaxis and phagocytic activity.
Fewer spleen-derived macrophage precursors with reduced expression o f MHC class 
II (Starling and Balish 1981; Nicaise et al. 1998).
Decreased size o f  Peyer's patches and mesenteric lymph nodes lack o f germinal 
centres, the site o f  B-cell proliferation and affinity maturation plasma cells 
production (Shroff et al. 1995)
Imunoglobulin class profile greatly altered with IgG concentrations much lower than 
in conventionally reared mice, with little or no production o f IgA or antibody 
diversification (Wostmann 1981).
Fewer intestinal T cell and cytotoxic T cell populations (Umesaki et al. 1999)
1.6. Probiotics
1.6.1 Probiotics and health
Currently numerous strains o f probiotic origin are commonly employed in the 
nutrition industry by virtue o f their desirable metabolic and immunomodulatory 
properties that impact positively upon the integrity and functionality o f the 
gastrointestinal and immune systems.
The existence o f mutualism between probiotic bacteria and the host has long been 
appreciated with probiotics colonising a nutrient rich habitat, with a stable
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temperature and pH to salvage energy from assimilation of otherwise indigestible 
GIT dietary constituents such as cellulose. This symbiotic benefit is postulated to 
have lasting longevity from foetus to adulthood. From a non-immunologic 
perspective, the dense intestinal microbiota concentration hinders pathogenic bacteria 
from adopting a facultative intracellular existence. Numerous studies have indicated 
that probiotics are capable of modulating the composition and/or activity of the 
intestinal microbiota, which in turn is expected to influence immune responses. The 
most commonly employed probiotic bacteria are bifidobacteria and lactobacilli 
(Isolauri etal. 2001).
Probiotics are typically employed as dietary supplements and have been used 
extensively for preservation of food via fermentation (Guamer and Khan 2008). The 
most common forms for probiotics are dairy products and probiotic-fortified foods 
containing the bacteria in freeze-dried form. Although many over-the-counter 
products deliver in the range of 1-10x109 colony forming units (CFU)/dose, some 
strains appear to be efficacious at lower levels, while some require substantially 
more. For instance, Bifidobacterium in f antis has been demonstrated to be effective 
in alleviating the symptoms of inflammatory bowel disease at 1 x 109 CFU/day 
(Whorwell et a l 2006), whereas studies with VSL#3 (a cocktail of eight LAB 
strains including mixture of 1 strain of Streptococcus thermophilus, four 
Lactobacillus spp, and three Bifidobacterium spp. Strains) have used sachets with 3- 
4.5xlO9 CFU (Huynh et a l 2009). Therefore the general dose required for 
probiotics dosage is variable and should be based on human studies showing a 
health benefit (Guamer and Khan 2008).
Despite the influx of probiotics products to the supermarket shelves and increasing 
inclusion in dairy products, a cloud of mystery surrounds the potential of their 
immunomodulatory attributes and the mode by which they enhance immune integrity. 
A probiotic optimised GIT in healthy newborns is associated with maturation of 
humoral immune mechanisms, particularly of circulating IgA and IgM secreting cells, 
reflecting the dependency of the regulation of the mucosal immune response on the 
normal gut microbiota (Gronlund et al 2000).
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From an immunological and gastroenterological standpoint there are valid reasons 
for anticipating health benefits of probiotic supplementation. However there is a 
paucity of convincing scientific evidence recommending probiotics as part of a 
standard therapy in the setting of allergy disorder (Prescott and Bjorksten 2007). 
Furthermore, despite several studies indicating immunomodulatory benefits of 
probiotic supplementation during prevention of allergic disorder, a recent Cochrane 
systematic review concluded that, “upon pooling results for different probiotic strains 
used in clinical trials probiotics are not effective for the treatment of allergic disorder 
or atopic sensitization” (Osborn and Sinn 2007).
1.6.2 Perinatal supplementation with probiotics and prevention of allergic 
disease: clinical outcomes
In utero persistence of the Th2 mediated immune microenvironment is important for 
successful pregnancy to antagonise upregulation of toxic autoimmune Thl responses 
deleterious to placental integrity (Makhseed et a l 2001). In healthy newborns the 
probiotic rich microbiota is postulated to act on regulatory T cells to shift the 
balance of immunity from over reliance upon the default in utero Th2 pathway; 
towards maturation of Thl, Thl 7, tolerogenic and non-inflammatory IgA mediated 
pathways. This shift occurs independently of the neonatal propensity to support 
immune responses of a Th2 mediated discourse in health neonates but is impaired in 
children presenting with atopy (Prescott et a l 1999).
The optimal timing, be it during pregnancy, postnatally or perinatally at which 
probiotic supplementation is most efficacious, and the mechanisms underlying their 
role in preventing atopy remains to be resolved. Nonetheless a window of 
opportunity for perinatal probiotic supplementation is postulated to exist both pre and 
postnatally when the newborn is most amenable to a favourable immunomodulatory 
contribution provided by intestinal probiotic bacteria Furrie (2005).This contribution 
is necessary to circumvent over reliance upon Th2 dominated neonatal immunity, a 
driver of atopic immune responses. Thus the quality of immune education provided 
by intestinal microbiota during infancy is vital for normal immune development 
(Bjorksten et a l 2001).
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There are now numerous prenatal, perinatal and post-natal probiotic intervention 
studies: Features common to all perinatal probiotic intervention studies for the 
prevention of allergy were twofold: (1) All included participants with at least one 
family member expressing a phenotype of atopic disease i.e. at least one first-degree 
relative (or partner) with atopic eczema, allergic rhinitis, or asthma; and (2) At least 
one principal measurement of allergic outcome (for example allergen specific IgE 
data measured in plasma or by skin prick test (SPT) (See Table 1.6.1).
The landmark study by the Finnish group led by Professor Erika Isolauri, evaluated 
the allergy preventive effect of Lactobacillus GG supplementation on atopic disease 
among infants at high risk for atopic disorder using a perinatal double-blind, 
randomised placebo-controlled trial (Kalliomaki et a l 2001). Lactobacillus GG was 
administered to mothers daily for 2 to 4 weeks before expected delivery, and to their 
infants from birth to 6 months of age, and breastfeeding mothers. Of the 83% of 
neonates who completed the study to two years of age, 46% in placebo group had 
eczema but only 23% had eczema in the probiotic group. Probiotics had no effect on 
severity of atopic dermatitis. No differences appeared in specific IgE levels or SPT 
results (Kalliomaki et a l 2001). In the follow up study assessing the persistence of 
‘atopic’ eczema protection, the difference in atopic eczema prevalence between the 
two groups was retained (Kalliomaki et a l 2003). However the probiotic group 
tended to have a greater proportion of children with symptoms of rhinitis/wheezing. 
Similarly to the previous study, no difference in atopic sensitisation was observed as 
determined by SPT positivity, since IgE-sensitisation did not differ between probiotic 
and placebo groups. In the most recent follow up study from this group, the 
cumulative risk for developing eczema in the first 7 years was significantly lower in 
the probiotic versus the placebo group but more children in the probiotic group had 
rhinitis (Kalliomaki et a l 2007).
In another study of LGG supplementation (1 x 1010 CFU/day to the pregnant women 
from 4 - 6  weeks before delivery and after birth to breast feeding mothers for 3 
months and then to infants for another 3 months) there was no difference in the 
cumulative incidence to eczema to 2 years or the severity of disease. This was 
concomitant with no difference in total IgE concentrations or frequency of 
sensitisation observed in the placebo versus probiotic group. Worryingly probiotic
56
supplementation exacerbated incidences of childhood recurrent episodes of wheezing 
bronchitis (Kopp et a l 2008).
Interestingly, (Abrahamsson et a l 2007) discovered perinatal supplementation with
Q
Lactobacillus reuteri ( 1x 1 0  CFU/daily) or placebo from 36 weeks of pregnancy 
until delivery and then to neonate until 12 months of age was associated with less 
IgE-associated eczema at age 2 years. Although the results were only significant at 2 
years of age, the expression of eczema was consistently lower in prevalence in the 
probiotic group. In contrast to the (Kopp et a l 2008) study, the cumulative incidence 
of wheeze was similar at 2 years.
In a randomised double blind placebo controlled (RDBPC) perinatal study involving 
n =1223 recruits (Kukkonen et a l 2007) studied the effects of a consortium of 
probiotic strains: Lactobacillus rhamnosus GG (5 x 109 CFU); Lactobacillus 
rhamnosus LC705 (5 x 109 CFU); B. breve (2 x 108 CFU); Propionibacterium 
freudenreichii (2 x 109 CFU) strains on the cumulative incidence of food allergy, 
eczema, asthma and allergic rhinitis and IgE-associated disease over the first 2 years 
of life. Pregnant women took 2 capsules per day from 2 to 4 weeks before delivery 
and then the baby was administered strains from 1 capsule per day from birth to 6 
months of age. Infants were also administered prebiotic galacto-oligosaccharides 
daily with (n =461) probiotic and (n=464) placebo completing the study to 2 years of 
age. No effect on the cumulative incidence of any allergic disease was discovered, 
but IgE associated disease tended to be less frequent in probiotic group with eczema 
and atopic eczema less likely in probiotic group. Similar to previous studies no effect 
on sensitisation at 6 or 24 months was observed. After adjustment for confounders, 
IgE-associated disease, eczema and atopic eczema was significantly lower in 
probiotic group.
In the follow up study Kuitunen et a l (2009) assessed the cumulative incidence of
allergic and IgE-mediated allergic disease until 5 years of age. Again no difference in
allergic or IgE-associated allergic disease, frequency of eczema, IgE-associated
eczema, asthma, allergic rhinitis or atopic sensitisation was discovered. Despite
caesarean-section deliveries being associated with a less favourable microbial
colonisation of the newborn GIT (Biasucci et a l 2008), it was interesting to note that 
y/
caesarean-delivered children supplemented with probiotics in this study had 
significantly fewer IgE-associated allergic diseases, particularly eczema, and less IgE 
sensitisation.
In another RDBPC study, (Kim et a l 2009), employed a consortium of 
Bifidobacterium bifidum, Bifidobacterium lactis and Lactobacillus acidophilus and 
daily administered 1.6 x 109 CFU of the consortium to pregnant women, 8 weeks 
before expected delivery until 3 months after delivery. They also administered the 
consortium to the newborns either breast-fed or formula. Interestingly the prevalence 
of eczema in the probiotic group was significantly reduced in infants at 12 months of 
age, despite total IgE levels and frequency of atopic sensitisation being comparable 
between their consortium and placebo groups.
(Niers et a l 2009) studied maternal supplementation during the last 6 weeks of 
pregnancy and then postnatally to the baby for 12 months with 3 x 109 CFU/day of a 
consortium of Bifidobacterium bifidum, Bifidobacterium lactis, Lactobacillus lactis 
(1 x 109of each organism). Interestingly, supplementation was associated with 
reduced prevalence in parentally reported eczema reduced in the probiotic group; 
subsequently confirmed following GP consultation. No differences in the groups for 
wheezing, cough, rhinitis and total IgE were found.
A study undertaken in New Zealand used a strategy of supplementation with 6 x 109 
CFU/day of Lactobacillus rhamnosus HN001 (n= 34) or 9 x 109 CFU/day 
Bifidobacterium lactis HN019 (n = 35) or a placebo (n = 36) to the mother from 35 
weeks of pregnancy to 6 months after delivery in lactating women. Their offspring 
received the same from around birth to 2 years of age (Wickens et a l 2008). 
Supplementation with Lactobacillus rhamnosus but not B. lactis was associated with 
significantly reduced risk of eczema by 2 years of age and reduction SCORAD. 
Neither probiotic affected likelihood of having a positive SPT but those taking 
Lactobacillus rhamnosus presented with significantly reduced IgE-associated 
eczema.
In a Prenatal study (Boyle et a l 2008) investigated the role of probiotic 
supplementation in protection against the development of eczema. The authors
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administered 1.8 xlO10 CFU of the probiotic Lactobacillus rhamnosus strain (LGG) 
daily for 7 days in a randomized controlled trial, and measured foetal immune 
responses ex vivo. CBMC samples were harvested from infants of 73 women with a 
history of doctor-diagnosed asthma, allergic rhinitis, food allergy or atopic eczema in 
themselves, their partner or a previous child, and cultured them with heat-killed 
LGG, ovalbumin (OVA) or without stimulus. Interestingly LGG pre-treatment of 
pregnant women did not influence CD4 T cell proliferation, forkhead box P3 
expression, DC phenotype or cytokine secretion in CBMCs cultured with heat-killed 
LGG or OVA suggesting that prenatal probiotic supplementation failed to influence 
fetal antigen-specific immunity in a way that could be protective against eczema 
development.
In a postnatal probiotic supplementation study in which Lactobacillus acidophilus 
probiotic strain administered for the first 6 months (Taylor et a l 2007) worryingly 
reported that increased risk of allergen sensitization at 1 year of age was synonymous 
with supplementation. The follow up study assessed effects on subsequent allergic 
outcomes in 153 children from the initial prevention cohort at 2.5 years of age, and 
discovered that postnatal probiotic supplementation did not attenuate the risk of 
dermatitis at 2.5 years compared with that in placebo group. There was no significant 
reduction other allergic diseases or allergen sensitization. Interestingly children in the 
probiotic group had fewer gastrointestinal infections in the preceding 18 months.
In another study (Taylor et a l 2006a) recruited 231 pregnant women with a history of 
allergic disease as indicated by a positive allergen (SPT) into a RDBPC study. The 
probiotic (3><109 CFU/day Lactobacillus acidophilus) or placebo (maltodextrin 
alone) was perinatally administered daily for the first 6 months of life independent of 
maternal feeding regimens. The authors assessed mononuclear cell samples from 118 
infants recruited to the study, for TLR-mediated cytokine responses to TLR-agonists, 
e.g. peptidoglycan (PGN), for TLR2, and lipopolysaccharide (LPS) for TLR4 in 
mononuclear cell supernatant. The TLR-agonist induced response was utilized as a 
surrogate of innate immune function in response to probiotic supplementation. 
Interestingly no differences were observed in the probiotic or placebo groups when 
cytokine responses were examined following stimulation with PGN or LPS.
Similarly, no differences were seen in the antigen-presenting capacity of these
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infants. The mean fluorescence intensities of human leucocyte antigen-DR on 
monocytes, B cells and dendritic cells subsets were not affected, nor were the 
percentage of circulating DC subsets affected by a 6-month supplementation with 
Lactobacillus acidophilus. The authors concluded that probiotic supplementation 
with Lactobacillus acidophilus did not alter early innate immune responses in this 
population at high risk of developing allergic disease. In the same cohort, (Taylor et 
a l 2006b) studied whether probiotic supplementation could modify allergen specific 
immune responses. Interestingly mononuclear cells of children who received the 
probiotics showed significantly reduced production of IL-5 and TGF-p in response to 
SEB stimulation. There were no significant effects of probiotics on either (Thl) or 
(Th2) responses to allergens or other stimuli. The only other effects observed were 
for reduced TNF-a and IL-10 responsiveness to HDM allergens in children receiving 
probiotics.
(Tang et al. 2009) studied the effects of probiotic administration on infant intestinal 
microbiota composition in infants at high risk of developing allergic disease. By 
randomising 122 pregnant women to receive either Lactobacillius rhamnosus LGG 
or placebo, from 36 weeks gestation until delivery, the authors determined the infant 
and maternal fecal bifidobacterium composition by terminal restriction fragment 
length polymorphism at birth and during the first 90 days of life. Interestingly at 90 
days, infants in the LGG group were more frequently colonized with Bifidobacterium 
longum, and harboured a bifidobacterium fecal composition closely resembling that 
typically observed in healthy breast-fed infants. However the authors did not clearly 
assess how the increase in Bifidobacterium longum was attributable to prenatal LGG 
supplementation.
(Martino et a l 2008) studied colonization patterns and mucosal IgA production at 6 
months of age in relation to early probiotic exposures, systemic immune 
development and childhood allergic outcomes in a cohort (n = 189) receiving either 
Lactobacillus acidophilus or a placebo since birth. Interestingly, in this study 
children who developed sensitization to one or more allergens by 12 months of age 
had significantly higher total IgA levels at 6 months, irrespective of probiotic 
treatment, implying no connection between colonization patterns and total or 
secretory IgA levels on atopic sensitization, atopic dermatitis or food allergy.
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Breastfeeding and the use of yoghurt or probiotic supplements were independently 
associated with significantly higher proportions of ‘favourable’ gut microbiota 
lactobacilli and bifidobacteria species, attenuated cytokine production and increased 
expression of regulatory cell cytokines such as TGF-p.
In a RDBPC study involving 253 Asian infants at high risk for developing allergic 
disease, (Soh et a l 2009) assessed the effect of probiotic supplementation during the 
first 6 months of life on eczema and allergic sensitization by age 1. Infants received 
at least 60 mL of commercially available cow’s milk formula with or without
7  7(Bifidobacterium longum 1x10 CFU)/g and Lactobacillus rhamnosus 2x10 CFU/g) 
daily for the first 6 months. Clinical evaluation was performed at 1, 3, 6 and 12 
months of age, with serum total IgE measurement and SPTs conducted at the 12- 
month visit. Un-informatively the incidence of eczema in the probiotic group at 22% 
was similar to that in the placebo group at 25% and the prevalence of allergen 
sensitization showed no difference. Total IgE levels were also similar in both groups. 
Atopic eczema (with sensitization) in the probiotic (7.3%) group was comparable to 
the placebo group (5.8 %.), indicating that post-natal probiotic supplementation had 
no effect on eczema or allergen sensitization in infants at risk of allergic disease.
In summary data in support of the application of perinatal supplementation of the 
neonate presenting with a familial history of atopic disorder to attenuate the risk of 
the atopic disorder are mixed. Some studies highlight a protective effect of probiotic 
supplementation on the development of atopic dermatitis, some imply that there is no 
significant effect of probiotic supplementation on atopic disorder and some 
supplemental studies even exacerbating the risk of atopic or respiratory disorder 
(Taylor et al. 2007) (See Table 1.6.1). To add further complexity to the rationale of 
probiotic supplementation for the protection against allergic disorder; probiotic 
effects in supplemental trials appear to be strain and consortium specific. It is 
currently not clear whether one specific probiotic strain or a group of strains are 
important in protecting against atopic disorder or whether probiotic supplementation 
will be dependent on the disease specific immune signature of a particular atopic 
disorder.
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1.6.3 Perinatal supplementation with probiotics and prevention of allergic 
disease: laboratory measures
Different groups have complemented their clinical studies with attempts to 
understand the immunological mechanisms that underlie anticipated 
immunomodulatory effects of probiotics on measures of allergy. These include 
immunological analysis of breast milk, umbilical cord and infant blood. Studies of 
blood from infants participating in probiotic studies generally investigate levels of 
candidate mediators in plasma/serum such as IgE, the inflammatory marker C- 
reactive protein CRP, eosinophilic cationic proteins or cellular immune activity 
whole blood or mononuclear cell cultures at the cytokine level. For example the 
response of maternal and umbilical cord blood MNCs to IL-2, P-lactoglobulin (PLG) 
or inactivated LGG was examined in an LGG supplementation cohort (Kopp et al.
2008). Interestingly, LGG induced release of IL-10 and IFN-y but not IL-13 by cord 
and maternal MNCs, with no significant differences between the study groups for 
any of the other responses measured.
In the study by (Niers et al. 2009), employing a consortium of Bifidobacterium 
bifidum, Bifidobacterium lactis, Lactobacillus lactis, whole blood culture responses 
to the T cell stimuli anti-CD3/CD28 or PHA were assessed at 3 months of age. Anti- 
CD3/CD28-stimulated IL-5 was significantly reduced in the probiotic group 
compared to the placebo group. This is noteworthy as IL-5 is involved in the 
differentiation of eosinophils and supports prolonged eosinophil survival. However 
the authors did not measure the extent of eosinophila in the study groups. There 
were no differences in IL-10 or with any PHA-stimulated responses.
Analysis of cord blood plasma from newborns in a New Zealand cohort revealed that 
neonates of mothers receiving probiotic had significantly enhanced cord blood IFN-y 
and a significantly higher proportion had detectable cord blood IFN-y levels, 
compared with the placebo group (Prescott et al. 2008). This pattern was evident for 
Lactobacillus rhamnosus and cord sCD14 was lower for Bifidobacterium lactis. 
Development of atopic eczema in the first 2 years of life was associated with 
elevated cord plasma IL-13 and IL-10 regardless of probiotic supplementation.
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Perinatal probiotic supplementation has also been associated with increased 
circulating levels of the CRP, along with increases in total IgA, total IgE and IL-10 
at 6 months of age but no differences in IL-2, IL-4, IL-6, TNF-a or IFN-y (Marschan 
et a l 2008). Elevated CRP at 6 months was associated with decreased risk of eczema 
and allergic disease at 2 years of age.
A study by (Taylor et a l 2007) supplemented neonates post-natally with 
Lactobacillus acidophilus, and then examined early markers of allergic disorder. 
Interestingly, inhalant sensitization and childhood dermatitis at the 2.5 year follow up 
phase was associated with higher proportions of circulating CD4+CD25+ regulatory 
T-cell populations and higher allergen-induced FOXP3 levels at 6 months. However 
the authors did not attribute this observation to a cytokine mediated 
immunomodulatory effect of Lactobacillus acidophilus influencing regulatory T cell 
development, but rather to the chronic inflammatory immune landscape of inhalant 
sensitization and childhood dermatitis, associated with increased early expression of 
regulatory T-cell markers. Furthermore, children with dermatitis were reported to 
have lower PHA induced IFN-a, IL-10 and IL-6 responses. However, it was not 
apparent in this study, whether Lactobacillus acidophilus influenced PHA induced 
responses.
In studies utilising breast milk, analysis of either TGF-pi or TGF-p2 often forms the 
focus. LGG supplementation pre-natally and post-natally was associated with 
significantly elevated TGF-p2 but not TGF-pl levels in breast milk of probiotic but 
not placebo taking mothers. Interestingly, the presence of cord blood IgE correlated 
with elevated TGF-P2 in breast milk (Rautava et a l 2002). Elevated TGF-P2 was 
also found in colostrum from a group of women who had been taking a consortium 
of LGG and Bifidobacterium lactis from the first trimester. This difference did not 
persist at 1 month post-partum, and there were no differences in any of the other 
mediators measured- sCD14, IFN-y, TNF-a, IL-10, IL-6, IL-4, and IL-2 (Huurre et 
a l 2008). In contrast lower TGF-P2 and elevated IL-10 were found in colostrum but 
not milk collected one month postpartum in a study of supplementation with 
Lactobacillus reuteri (Bottcher et a l 2008). The effect on TGF-P2 was most 
pronounced in mothers with L. reuteri recovered in their faeces. Total and secretory
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IgA, TNF-a, and sCD14 were also measured, and no differences between probiotic 
and placebo groups were observed. Breast milk samples from the New Zealand 
cohort in which two different species of probiotic were compared (Lactobacillus 
rhamnosus HN001 or Bifidobacterium lactis HN019) were analysed for total IgA, 
IL-13, IFN-y, IL-6, TNF-a, IL-10, TGF-01 and sCD14 (Prescott et a l 2008). In this 
cohort TGF-pi levels were higher in milk collected 1 week postpartum for both 
probiotic groups but this was significant for the B. lactis group only. Probiotic fed 
mothers were more likely to have total IgA and IL-6 detectable in their breast milk 
confirming the strain specific immunomodulatory effects of probiotic 
supplementation on the immunological composition of human breast milk.
These studies indicate that investigators can successfully demonstrate that 
supplementation with probiotics in pregnancy has the potential to influence fetal 
immune parameters as well as immunomodulatory factors in breast milk.
Determining how this relates mechanistically to clinical effects of probiotics is now 
the challenge. Recent studies challenging the general view of a sterile intrauterine 
existence in which microbial colonisation of the gut begins after delivery might 
contribute to these effects (Satokari et al. 2009). For instance, DNA transcripts of 
Bifidobacterium and Lactobacillus have been detected in the human placenta, 
irrespective of mode of delivery: of 34 placentae studied bifidobacterial DNA was 
detected in 33 and L. rhamnosus DNA in 31 (Satokari et a l 2009). This was 
interpreted as horizontal transfer of bacterial DNA from mother to foetus via the 
placenta. This observation is significant because bacterial DNA contains 
unmethylated CpG oligodeoxynucleotide motifs capable of inducing immune 
responses. Exposure to bacterial DNA may programme the infant's immune 
development during foetal life, earlier than previously considered (Satokari et a l
2009). These observations also reinforce the notion of the existence of evolutionary 
conserved mechanisms favouring microbial development of a probiotic rich intestinal 
tract. Given the findings of (Satokari et a l 2009) it is interesting that the work of 
(Patni et a l 2009) demonstrated that whilst transcripts for TLR9, a receptor involved 
in the innate immune response to unmethylated DNA, were detectable in the term 
and preterm placenta, a functional cytokine output could not.
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Table 1.6.1: Table of pre-natal, perinatal and post-natal probiotic studies
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Author Study Age at 
enrollment, 
health 
status and 
length of 
study
Variables measured Effects of probiotics
(Kalliomaki 
et al. 2001)
(RDBPC withN 
=159 participants); 
2 arms:
(1) Placebo: capsule 
of
microcrystalized
cellulose
(2) Experimental: 
capsule of LGG lx  
,0CFU/
Capsule (2 capsules 
per day)
0-6
Months 
Family 
history of 
atopic 
disease
6 months 
(2 year 
follow-up)
1. Atopic eczema 
presence
2. Serum total IgE
3. Serum specific 
IgE
4. Skin prick test
1. LGG supplementation 
significantly reduced the 
frequency of atopic 
disease to half of that of 
the placebo-group
(Rautava et 
al. 2002)
(RDBPC); 2 arms:
1. Control/placebo: 
microcrystalline 
cellulose
2. Experimental 
probiotic LGG 
capsules 2 x l0 10 
CFU/d
N = 62 mother 
infant pairs
Mother age 
(n/a) 
Infants 1 
day of life 
Family 
history of 
atopy
(4 weeks 
prior to 
birth until 
infant 
reached 3 
months)
1. Serum total IgE 
measured from cord 
blood
2.TGF-P1 and 
TGF-P2 measured 
from breast milk at 3 
months
3. Risk of atopic 
eczema
2. TGF-|32 higher in 
probiotics group
3. Risk significantly 
reduced in probiotics 
group compared to placebo
(Kalliomaki 
et al. 2003)
(RDBPC); 2 arms:
1. Control: capsule 
of
microcrystalized
cellulose
2. Experimental- 
capsule of LGG lx  
1010
CFU/capsule 
2 capsules per day
N =  159
0-6 months 
Family 
history of 
atopic 
disease
4 year 
follow-up
1. Atopic eczema 
presence
2. Bronchial 
inflammation via 
exhaled nitric oxide 
4. Skin prick test
1. LGG supplementation 
significantly
reduced the relative risk of
atopic eczema
to 0.57 frequency of atopic
disease to half
of that of the placebo-
group
(Kalliomaki 
et al. 2007)
Supplementation 
protocol: as above 
116/132 of those 
who completed at 2 
years of age studied 
at 7 years of age
Assessing persistence of 
potential to prevent 
eczema at 7 years.
2. rhinitis; asthma; SPT
1 .Cumulative risk for 
developing eczema in first 
7 years significantly lower 
in probiotic group 
3.More children in 
probiotic group had 
rhinitis
6 6
(Rinne et al. 
2005)
Microbiology and 
laboratory data - faecal, 
infant blood and breast 
milk analysis
1. Fecal Bifidobacterium 
and
Lactobacillus/Enterococcus 
counts significantly higher 
in breastfed than formula- 
fed infants at 6 months.
2. At 3 months, total numbei 
of IgG-secreting cells in 
breastfed infants 
supplemented with 
probiotics exceeded those in 
breastfed infants receiving 
placebo correlating with 
concentration of sCD14 in 
colostrum. Total numbers of 
IgM-, IgA-, and IgG- 
secreting cells at 12 months 
were significantly higher in 
infants breastfed exclusively 
for at least for 3 months and 
supplemented with 
probiotics as compared with 
breastfed infants receiving 
placebo._________________
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health status and 
length of study
measured probiotics
(Huurre et 
al. 2008)
Lactobacillus 
rhamnosus strain 
GG and
Bifidobacterium
lactis
Study group:
N= 171 mother- 
baby pairs 
Supplementation 
protocol: 1 x 1010 
CFU/day or 
placebo
(microcrystalline 
cellulose and 
dextrose 
anhydrate)
Women with atopic 
disease
First trimester to 
end of exclusive 
breast feeding.
Primary
outcomes: Breast 
milk cytokines & 
atopic
sensitisation of 
infants at 6 and 
12 months of age 
Other outcomes: 
Breast milk 
immediately after 
birth and at 1 
month from 140 
(probiotic -  72; 
placebo -  68).
1. TGF02 elevated 
in colostrum of 
probiotic group 
but not significant 
and not at 1 
month.
(Niers et 
al. 2009)
Bifidobacterium
bifidum,
Bifidobacterium
lactis,
Lactobacillus
lactis
Study group 
Supplementation 
protocol: 3 x 109 
CFU/day (1 x 109 
of each organism)
> 1 family member 
with atopic disease
Last 6 weeks of 
pregnancy and 
postnatally for 12 
months to offspring.
1. Impact on 
allergic disease at 
2 years of age, 
with
questionnaire and 
visit at 3, 12 and 
24 months.
2.Weekly diaries, 
SPT at 24 
months, total IgE 
at 3, 12 and 24 
months, faecal 
analysis, whole 
blood culture 
(with anti- 
CD2/CD28;
PHA) at 3 months 
of age
Parentally 
reported eczema 
reduced in 
probiotic group (p 
= 0.035); in those 
who consulted GP
Significantly 
lower anti- 
CD2/CD28 
induced IL-5 at 72 
hours.
(Kim et al. 
2009)
Bifidobacterium
bifidum,
Bifidobacterium
lactis,
Lactobacillus 
acidophilus 
Supplementation 
protocol: 1.6 x 
109 CFU of each 
in
maltodextran/com 
oil once daily 
Exclusive breast 
feeding to 3 months 
of age and then 
breast/formula.
> 1 family member 
with atopic disease
8 weeks before the 
expected delivery 
until 3 months after 
delivery and to 
baby from 4 to 6 
months of age.
1. Eczema 
outcomes at 12 
months of age; 
assessed at 3, 6 
and 12 months.
2. Total and 
specific IgE at 12 
months of age.
At 3 months fewer 
in probiotic group 
had eczema but 
not significant (p 
= 0.086).
At 6 months half 
as many in 
probiotic group 
had eczema (p = 
0.053). By 12 
months probiotic 
< placebo, p = 
0.048. Total IgE 
level and 
frequency of 
sensitisation 
comparable 
between the 
groups.
Prevalence of 
atopic eczema 
halved in 
probiotics but p = 
0.223.
6 8
(Wicken et 
al. 2008)
Lactobacillus 
rhamnosis or 
Bifidobacterium 
lactis
Supplementation 
protocol: 6 x 
109CFU/day of L. 
rhamnosus or 9 x 
109CFU/day of B. 
lactis to mother 
from 35 weeks of 
pregnancy to 6 
months after 
delivery if breast 
feeding. Baby 
received same 
from around birth 
to 2 years of age
> 1 family member 
with atopic disease
1. Cumulative 
prevalence of 
eczema and point 
prevalence of 
atopy (by SPT) at 
2 years of age.
2.Faecal analysis
Those receiving L. 
rhamnosus had 
significantly 
reduced risk of 
eczema by 2 years 
of age and 
reduction in risk 
of high SCORAD 
note that those 
taking L. 
rhamnosus had 
significantly 
reduced IgE- 
associated eczema 
(p = 0.04).
(Prescott 
et al. 
2008)
Organisms: as 
above
Study group: as 
above
Supplementation 
protocol: as above 
Primary outcomes
Cord blood and 
breast milk 
cytokines ( 3 - 7  
days, 3 months 
and 6 months 
postpartum) from 
n = 30 -  40 in 
groups from 
above clinical 
study.
Measured IL-13, 
IFN-y, IL-6, TNF- 
a, IL-10, TGF-pi 
and sCD14 in cord 
blood and breast 
milk as well as 
total IgA in breast 
milk.
If mother received 
probiotic cord 
blood IFN-y 
increased and 
more subjects had 
detectable cord 
blood -  same 
pattern for both 
organisms but 
significant for L. 
rhamnosus
Cord sCD14 lower 
in B. lactis group.
TGF-pi higher in 
1 week milk 
samples in both 
probiotic groups 
but significant for 
B. lactis.
Probiotic fed 
mothers more 
likely to have total 
IgA and IL-6 
detectable in their 
breast milk.
Author Study Age at 
enrollment, 
health 
status and 
length of 
study
Variables measured Effects of 
probiotics
(Abrahamsson 
et al. 2007)
Organisms:
Lactobacillus
reuteri
Supplementation 
protocol: 1 x 108 
CFU/daily or 
placebo from 36 
weeks of pregnancy 
until delivery and 
then same to baby 
to 12 months of 
age.
Study 
group: > 1 
family 
member 
with atopic 
disease
Primary outcomes: 
Allergic disease to 
2 years of age with 
SPT/specific IgE to 
food.
Probiotic group 
has less IgE- 
associated eczema 
in 2nd year (8% 
vs. 20%, p = 0 
.02) -  only 
significant at 2 
years of age but 
consistently lower 
prevalence in 
probiotic group.
Egg white 
specific IgE less 
often detectable in 
probiotic group 
only significant at 
two years of age.
Infants in 
probiotic group 
less likely to be 
SPT+, this was 
significant in 
those with allergic 
mothers. 
Cumulative 
incidence of 
wheeze similar at 
2 years
(Bottcher, et al. 
2008)
Organisms: as 
above
Study group: as 
above
Supplementation 
protocol: as above
Colostrum (day 3) 
and mature milk (1 
month) from above 
-  total and 
secretory IgA, 
TGFpl, TGF|32, IL- 
10, TNF, sCD14 
and Na/K ratios
n = 109;54 
probiotic, 55 
placebo. Probiotic 
group had 
significantly 
lower TGFP2 and 
significantly 
higher IL-10 in 
colostrum (but not 
mature milk). 
Infants receiving 
breast milk with 
lower TGFp2 less 
likely to become 
sensitised during 
first 2 years.
(Kopp, et al. 
2008)
Organism(s): 
Lactobacillus 
rhamnosus strain 
GG
Supplementation 
protocol: 1 x 1010 
CFU/day to mother 
from 4 - 6  weeks 
before delivery and 
after birth to breast 
feeding mothers for 
3 months and then 
to neonates for 
another 3 months; 
otherwise to infant 
for 6 months.
Study 
group: > 1 
family 
member 
with atopic 
disease
Atopic dermatitis at 
2 years of age 
Other outcomes: 
Severity of AD, 
wheezing bronchitis 
and allergic 
sensitisation.
Children with 
recurrent episodes 
of wheezing 
bronchitis more 
frequently in 
probiotic group
No effect on
eczema but
increased
recurrent
wheezing
bronchitis.
(Kopp et al. 
2008)
Organism(s): as 
above
Study group: as 
above
Supplementation 
protocol: as above 
Other outcomes:
Performed in vitro 
studies using cord 
blood and maternal 
peripheral blood 
MNCs from those 
taking probiotic or 
placebo and 
exposed to IL-2, 0- 
lactoglobulin (PLG) 
or inactivated (70% 
ethanol) LGG. 
Cytokine responses 
by mononuclear 
cells (MNCs) -  in 
vitro and in vivo
LGG induced 
release of IL-10 
and IFN-y but not 
IL-13 by cord and 
maternal MNCs
(Kukkonen, et 
al. 2007)
Helsinki and 
Tampere,
Organism(s): L. 
rhamnosus GG (5 x 
109 CFU); L. 
rhamnosus LC705 
(5 x 109 CFU); B. 
breve (2 x 108 
CFU);
Propionibacterium 
freudenreichii (2 x 
109CFU)
Supplementation 
protocol: Mother 
took 2 capsules/day 
from 2 - 4  weeks 
before delivery and 
then baby 1 
capsule/day from 
birth to 6 months of 
age -  babies also 
given galacto- 
oligosaccharides 
daily
Study 
group: > 1 
family 
member 
with atopic 
disease
Cumulative 
incidence of any 
allergic disease 
(food allergy, 
eczema, asthma and 
allergic rhinitis) and 
IgE-associated 
disease over first 2 
years
Eczema and IgE 
sensitisation (SPT 
at 6 and 24 months, 
specific IgE at 24 
months); faeces at 
meconium, 3, 6 and 
24 months
Eczema and 
atopic eczema 
less likely in 
probiotic group.
After adjustment 
for confounders 
anyIgE- 
associated 
disease, eczema 
and atopic eczema 
significantly 
lower in probiotic 
group.
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1.7 Need for the study
A vast body of evidence has accumulated linking consumption of probiotic rich 
fermented foods, with enhanced immune tolerance mechanisms. Probiotics are 
therefore postulated to have a therapeutic role in pathologies with a dysregulated 
immune component. Despite unprecedented research efforts to determine the impact 
of probiotic organisms in health and disease; commonly accepted paradigms for their 
immunomodulatory mechanisms are unclear. To date, research into the role of 
probiotic bacteria in allergic disorder, is based primarily upon in vitro data suggesting 
an intrinsic capacity of probiotics to attenuate experimentally induced Th2 immune 
responses by enhancing Thl inflammatory and regulatory mechanisms (Cross et a l 
2001) .
However, due to the vast diversity and quantity of probiotic micro-organisms 
existing within the GIT, attempts to determine the immunomodulatory capacity of a 
probiotic optimised diet in vivo remain inconsistent and highly controversial with 
results ranging from beneficial to inconclusive health benefits. Additionally, the 
premise that many potentially probiotic micro-organisms are currently un-culturable 
using available techniques adds further complexity to the field. Observations that 
probiotics exhibit strain specific effects, have inspired researchers to ascertain 
favourable cocktails of probiotics necessary to mediate beneficial 
immunomodulatory effects in immune dysregulated disease settings such as IgE 
mediated atopic disease and gastrointestinal disorders where probiotic imbalances 
are implicated (Cross et al. 2001).
Although there is a sound theoretical basis for anticipating benefits of probiotic 
supplementation; existing data are insufficient to support recommendation of 
probiotics as a part of standard therapy for allergic conditions. Furthermore, 
although several studies appear to show a benefit in prevention of atopic eczema this 
literature review has indicated that some studies refute these observations, showing 
no clear preventive effect on sensitization, nor any allergic disease other than 
eczema.
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The term “ probiotic”  has therefore been loosely applied to include bacterial strains 
with little documented immunomodulatory capacity or controlled studies to support 
health benefit claims. Moreover it is not known whether effects in experimental 
systems have any clinical relevance. Explanations for the varied results between 
studies include host factors (including genetic differences in microbial responses and 
allergic predisposition) and other environmental factors, such as general microbial 
burden, individual microbiota, diet (including consumption of prebiotic substances), 
and treatment with antibiotics. As more studies are completed, these factors are 
likely to make robust meta analyses problematic to perform (Prescott and Bjorksten 
2007).
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Chapter 2: General Materials & methods
Methodologies employed in this thesis can be divided into two broad strategies with 
a common goal: to characterise the immunomodulatory effects of a study 
consortium of probiotic bacteria (Lactobacillus salivarius, Lactobacillus paracasei, 
Bifidobacteria bifidum and Bifidobacteria infantis) to model how indigenous 
gastrointestinal tract bacteria might benefit immunity. The in vitro arm of this study 
employed a cross-sectional population of healthy neonates, healthy pregnant and 
non-pregnant women, and healthy men (section 2.1). The in vivo arm focused on 
discerning the immunomodulatory effects of probiotic supplementation using a 
cohort of newborns (n = 438 section 2.2).
2.1 Materials & methods for in vitro analysis
2.1.1 Optimising culture conditions for use of probiotic bacteria in 
mammalian cell culture systems.
In the laboratories of the industrial partner (Cultech Ltd), an assessment of how well 
strains of the study consortium tolerated conditions typically used for culture of 
mammalian cells was first determined. The experimental co-culture conditions for 
assessing the immunomodulatory effects of the study consortium, upon interaction 
with mononuclear cells, were then analysed in vitro.
The consortium consisted of the bacterial micro-organisms:
- Lactobacillus salivarius CUL61 (national collection of industrial, food and 
marine bacteria (NCIMB) 302111);
- Lactobacillus paracasei CUL08 (NCIMB 30154);
- Bifidobacteria animalis subsp. lactis CUL34 (NCIMB 30172); and
- Bifidobacteria bifidum CUL20 (NCIMB 30153).
2.1.2 Assessing the viability of the study consortium in mammalian cell
culture systems.
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The ability o f bacterial organisms o f  the study consortium to survive and proliferate 
in standard cell culture media commonly used to culture human mononuclear cells 
was assessed. Survival o f  probiotic strains in both the absence and presence o f 
mononuclear cells was quantified by total viable counts (TVC) on agar plates.
1 x 1 0 ll) CFUs o f the study consortium was added to culture medium and then serially 
diluted down to 1 x 107 CFU in 4.5 ml o f culture medium. The culture media used 
were: RPMI1640 with Glutamax and phenol red pH indicator, and A1M/V (both 
Invitrogen, UK). At time 0 (T0), and after 6  (T6) , 24 (T2 4) and 48 hours (T48), 500 pi 
from the 1 xlO 7 CFU dilution was serially diluted in maximum recovery diluent 
(MRD, Oxoid, UK) to concentrations ranging from 1 * 1O6 to 1 x 102 and used for the 
TVC (Figure 2.1).
PR O BIO TIC CAPSl'LF.
At T0 T6 and T^a 500ul from the UK)6 CFU
dilution was serially diluted in maximum 
recovery diluent ( M R D )  used for maintaining 
viability of bacterial strains dunng numeration 
procedures. J
4.5ml 4.5ml 4.5ml 4.5ml
V / \  / V
l x l O 'C F U / m l
Probiotic concentrations ranging from 104 to 102 CFU /ml 
were selected for total viable counts (TVCs) on agar 
plates.
Figure 2.1: Dilution procedure for lx lO 1 CFUs of the study consortium for 
enumeration purposes.
Total viable counts (TVCs) were determined by adding selected dilutions o f the 
study consortium onto MRS or MRSx agar plates (provided by the industrial 
partner) using a modified Miles and Misra (Miles et al. 1938) plate count technique. 
Agar plates where then transferred to a 37°C anaerobic incubator for 2-3 days to 
allow viable organisms to grow. Members o f the genera Lactobacillus and 
Bifidobacteria can be selected on solid culture media that have an acidic pH such as 
MRS under anaerobic conditions (Tannock 1999). MRSX agar plates select for 
bifidobacteria species whereas MRS agar plates support abundant growth o f 
Lactobacillus species exclusively.
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To determine the total number o f viable colonies present at each time point the 
number o f bifidobacteria and lactobacillus species were summed. The following 
formula was used to obtain the TVC:
TVC = (total number o f colonies x 10) x 10 x dilution factor
2.1.3 Viability of study consortium in mammalian cell culture medium during 
co-culture with mononuclear cells
Adult peripheral blood mononuclear cells (PBMCs) were isolated by density 
gradient centrifugation as described below. PBMCs (5x 105) were co-cultured with 
concentrations o f  the study consortium ranging from 1 x 107 to 1x 104 CFU/ml. Doses 
were prepared by dilution o f 500mg o f a 1 x 10 10 CFUs freeze-dried active product in 
RPMI1640 with Glutamax and phenol red pH indicator supplemented with 5% fetal 
bovine serum (FBS; Invitrogen) and 0.5mM 2-mercaptoethanol (Invitrogen)(Figure 
2 .2 ).
RPMII640
Figure 2.2: Illustration of the dilution process of the study consortium in 
RPMI1640
At each time point (To, T6, T 2 4 , and T48) the co-culture was transferred to a 
microfuge tube and centrifuged for 7 minutes at 3200 x g to obtain a pellet 
containing a mixture o f PBMCs and the study consortium. The pellet was re­
suspended in 1 ml MRS agar broth (a liquid phase growth media for lactobacillus
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and bifidobacteria species) and then serially diluted in MRD for total viable counts 
on each sample dilution as described in 2.1.2.1 (Figure 2.3).
i.5ml 0.5ml 0.5ml 0.5ml0.5ml
re-suspend 
pellet in 1ml 
MRS
4.5ml
M R D
4.5ml
M R D
4.5ml
M R D
4.5ml
M R D
4.5ml
M R D
Neat 1 2 3 4 5
Maximum recovery diluent 
(MRD) is an isotonic diluent 
containing a low level of 
peptone used for maintaining 
the viability of bacterial 
organisms for at least 1 hr 
during dilution procedures
Five 10pl drops of each dilution were added unto MRS and MRSx agar plates and left to 
incubate for 3days in an anaerobic incubator. The number of CFUs present at each time 
point during the co-culture with PBMCs was calculated as previously described in this 
section.
Figure 2.3: Illustration of the dilution process of the PBMCs-consortium pellet 
in maximum recovery diluent.
2.1.4 Flow cytometric analysis of the interaction between probiotic 
microorganisms and mononuclear cells
This part o f the study investigated the application o f flow cytometry for determining 
the viability o f the study consortium, especially after the effects o f co-culture with 
mammalian cells. The study consortium was labelled with carboxyfluorescein 
diacetate succinimidyl ester (CSFE). CFSE is a colourless non-fluorescent 
compound which passively diffuses into cells. Intracellular esterases encountered 
during diffusion cleave acetate groups present within the CFSE molecule yielding a 
highly fluorescent carboxyfluorescein succinimidyl ester which reacts with 
intracellular amines forming florescent conjugates well retained in viable cells.
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Excess un-conjugated reagent and by-products passively diffuse back into the 
culture medium.
CellTrace™ CFSE cell proliferation kit (Invitrogen) was used to label the 
consortium bacteria. Briefly, CFSE was prepared according to the manufacturer’s 
guidelines: the recommended working concentration was 50 pM and was prepared 
by using 18 pi of dimethyl sulphoxide (DMSO; Sigma) to dissolve the contents of a 
vial containing CellTrace™ CFSE to create a 5 mM stock solution. This underwent 
a further 1 in 50 dilution (12 pi of the 5mM stock in 588 pi sterile PBS) to yield a 
0.1 mM solution of which 100 pi was added to a 100 pi preparation of the study 
consortium containing 1 xlO8 CFUs/ml (final CFSE concentration of 50 pM). The 
mixture was left to incubate in ice for 10 minutes; cold RPMI1640 was added prior 
to a further 5 minute incubation and then centrifugation at 4000 x g for 10 minutes. 
This washing step was repeated twice. Finally the pellet containing 1 x 107 CFUs of 
CFSE labelled bacteria was re-suspended in 100 pi of RPMI1640/Glutamax 
supplemented with 5% FBS and 0.5Mm 2- Mercaptoethanol (2-ME) and co-cultured 
with 0.5 x 105 mononuclear cells (MNCs; prepared as described in section 2.1.3) in a 
total of 500pl/well of a 48 well plate.
At To and T2 4  the contents of the co-culture was transferred to a microfuge tube and 
spun at 510 x g  for 7 minutes at 4°C, supernatants were removed and the pellet was 
re-suspended in 50 pi of FACS buffer. Where necessary, relevant antibodies were 
added to each tube and left to incubate on ice for 30 minutes. The antibodies used 
were: anti-CD45: APC, anti-CD14: PE-Cy5.5 or anti-CD3: PE-Cy5.5 (Caltag; 
Invitrogen). After incubation, 3 ml of FACS buffer was added to each tube and 
tubes were spun at 510 x g  for 7 minutes at 4°C. The supernatant was poured away 
with care taken to not disturb the cell/bacteria pellet which was re-suspended in 2 0 0  
pi of FACSFix (BD CellFIX diluted 1 in 10 with distilled water; BD Biosciences). 
Cells/bacteria were acquired and analysed within 24 hr of fixing using a FACSAria 
flow cytometer and CellDiva software (version 5.0.3; both BD Biosciences).
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2.1.5 Density gradient centrifugation of umbilical cord or adult peripheral 
blood for the isolation of mononuclear cells
Mononuclear cells o f the haematopoietic system are a critical component o f  the 
immune system involved in both innate and adaptive immune responses. 
Mononuclear cells are distinguished from other leukocytes in that they do not 
contain granules and hence are called collectively agranulocytes, encompassing 
predominantly lymphocytes and monocytes. M ononuclear cells used in this thesis 
were extracted from whole blood using ficoll, a hydrophilic polysaccharide that 
separates layers o f blood yielding mononuclear cells depleted o f red blood cells and 
most granulocytes located under a layer o f plasma (Delves et al. 2006) (Figure 2.4). 
The resulting cell population is termed adult peripheral blood mononuclear cells 
(PBMCs) if  the blood sample is from an adult donor or cord blood mononuclear 
cells (CBMCs) if  from the umbilical cord.
B l o o d  s a m p l e  is 
l a y e r e d  u n t o  —  
H i s t o p a q u e  a n d  
u n d e r g o e s  
d e n s i t y
c e n t r i f u g a t i o n .
H i s t o p a q u e
I Plasmalymphocyte and 
monocyte band
Erthrocytes 
and neutrophils
Figure 2.4: Illustration of the separation of mononuclear cells, plasma and 
erythrocytes and granulocytes by density gradient centrifugation method.
All handling o f umbilical cord blood and adult peripheral blood took place in a 
Class II tissue culture cabinet to limit contamination. Undiluted heparinised blood 
was layered onto an equal volume o f HistopaqueR- 1077 (Sigma, USA) in a 50 ml 
Falcon tube (Greiner Bio-one, Germany) and centrifuged at 805 x g for 20 minutes 
at room temperature (brake off). The plasma was then removed, filtered (0.2 pm
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polyethersulfone filter; Millipore, MA, USA), aliquoted into well-labelled tubes and 
stored at -20°C until later analysis. The layer of cells at the interface was removed 
into a 30 ml Universal (Greiner Bio-one, Germany), the tube topped up with RPMI 
1640/Glutamax (Invitrogen, UK) and centrifuged at 515 x g  for 10 minutes at room 
temperature. Following centrifugation the supernatant was discarded and the cell 
pellet resuspended in RPMI 1640/Glutamax, prior to another centrifugation at 515 x 
g  for 7 minutes at 4°C. The supernatant was discarded and cells were gently 
resuspended in an appropriate volume of RPMI 1640/Glutamax supplemented with
0.5 mM 2-mercaptoethanol and 5% FBS (both Invitrogen, UK) before being 
manually counted on a haemocytometer. This approach is summarised in Figure 2.5.
10 to 20 ml of a venous adult peripheral blood or an umbilical cord blood 
sample was applied gently using a sterile syringe, employing an aseptic 
technique under sterile conditions in a fumigated culture hood to a 50 ml 
centrifuge tube containing an equal volume of Ficoll Histopaque solution.
_____________________________________________ I __________________________________
Contents were transferred to a 2°C centrifuge and spun at 2000 rotations 
per minute (RPM) with the break off for approximately 30 minutes._________
_____________________________________________ I __________________________________
The plasma layer was collected and discarded using a sterile Pasteur 
pipette. The mononuclear cell layer was transferred to a 50 ml universal 
tube.__________________________________________________________________
I
Mononuclear cells (PBMCs or CBMCs) were then topped up with fresh 
RPM11640 medium and spun in a 5°C centrifuge at 515g for 10 minutes.
The supernatant was poured away and the pellet re-suspended in fresh 
RPM11640 515g for 7 minutes.__________________________________________
_____________________________________________ I __________________________________
The supernatant was removed and mononuclear cells were re-suspended in 
up to 10 ml of RPM11640 supplemented with 2-ME and 5% Foetal calf 
serum.
Figure 2.5: Flow chart for isolation of mononuclear cells from heparinised 
whole blood using density gradients centrifugation.
Following re-suspension, a 10 pi sample of mononuclear cells was transferred to a 
C-Chip haemocytometer (Digital-Bio, Korea) for enumeration. Note that a cell 
viability dye was not included as extensive experience in the research group has 
found that with freshly prepared mononuclear cells the number of non-viable cells is
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negligible. Five squares were counted (See Figure 2.6) and then cell numbers werte 
calculated: (number o f mononuclear cells counted x 5) x 104 per ml. Based on this; 
count MNCs were diluted in accordance with experimental requirements: typicalb/, 
MNCs were used at 1 x l0 6/ml o f cell culture media unless otherwise stated.
Overtlo* well Loading groove
Gna system
° = Mononuclear cells
Figure 2.6: Diagrammatic view of haemocytometer adapted from
http://www.pathology.washington.edu/research/labs/rabinovitch/flowroom/protocols/
RabLabManual_files/image002.jpg
2.1.6 In vitro dose response studies.
Mononuclear cells were co-cultured with varying doses o f the study consortium to 
model haematopoietic cell and probiotic interactions in terms o f the spectrum of 
cytokines released from mononuclear cells upon exposure to potentially probiotic 
microorganisms. Purified mononuclear cells (MNCs) at lx l 0 6/ml in 
RPMI 1640/Glutamax supplemented with 5% FBS and 0.5 mM 2-mercaptoethanol
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(referred to as ‘complete medium’ [CM] from here on; all Invitrogen as before) were 
prepared from umbilical cord and adult peripheral blood by density gradient 
centrifugation and co-cultured in duplicate in a 48 well plate (Greiner Bio-one) in 
the presence of varying of doses of the study consortium. MNCs were co-cultured in 
the presence of 106, 105, 104, 103 or 102 CFU/ml of the consortium of potential 
probiotic microorganisms prepared from the study capsules as described in 2 .1 .2 . 
The 48 well plates (500pl/well) were then transferred to an incubator at 37°C in 5% 
C0 2 -in-air for culture. After the first 6 hr, 250 pi of media was removed and replaced 
with an equal volume of fresh CM. After further 18 hr incubation at 37°C in 5% 
C0 2 -in-air, cell free culture supernatants were harvested: the contents of the wells 
were transferred to microfuge tubes which were centrifuged at 515g for 7 minutes to 
yield cell/bacteria free supernatants that were stored at -20°C until analysis. The 
cytokines measured using specific ELIS As (See section 2.1.12 and figure 2.9) were: 
TNF-a, IL-10, IL-6 , IL-12p70, IL-ip, and TGF-pi.
For more detailed investigation of the mechanism of the responses observed in the 
above investigation the following approaches were taken:
2.1.7 Transwell studies
The requirement for contact between the study consortium bacteria and MNCs was 
assessed using transwells to separate the consortium and MNCs into distinct 
compartments during co-culture (Figure 2.7). Since the base of the transwell chosen 
is perforated with pores measuring 0.4pM in diameter and lactobacilli and 
bifidobacteria strains are approximately 1-2 pM in diameter contact between 
mononuclear cell and the consortium was fully restricted. CBMCs or PBMCs at 
1 x l06/ml in complete medium were added to the wells of a 24 well plate (Greiner 
Bio-one). A transwell with 0.4 pM pores in the membrane (ThinCerts™ -  tissue 
culture inserts, transparent; Greiner Bio-one) was placed into the well and the study 
consortium at 106 CFU/ml placed into the transwell. The plates were cultured at 
37°C in 5% CC>2 -in-air for 24 hours. Cell free supernatants were harvested as before 
from the MNC side of the transwell.
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Figure 2.7: Illustration of the separation of mononuclear cells and potential 
probiotic bacteria of the study consortium using a transwell.
2.1.8 The interaction of CD14+ monocytes with study consortium
Monocytes play crucial roles during immune defence, inflammation and tissue 
remodelling via their ability to phagocytise, process and present antigen, and by 
cytokine production. Therefore to explore the contribution o f monocytes to the 
cytokine response to the study consortium, the ability o f monocyte-depleted MNCs 
versus purified monocytes was compared. CD 14" monocytes and CD 14 depleted 
MNCs were prepared using magnetic microbeads and an autoMACS (both Miltenyi 
Biotec, Germany).
2.1.8.1 Principles of AutoMACS technology
MACS* technology is based on MACS magnetic microbeads, automated or manual 
MACS separators, and a MACS column matrix. When placed within a MACS 
separator, the MACS column matrix provides a magnetic field strong enough to 
retain specific magnetically labelled cell types within a cell sample.
MACS microbeads are small biodegradable superparamagnetic particles coupled to 
highly specific antibodies antibodies against proteins such as CD (cluster o f 
differentiation) proteins. They have no known reported effects on the structure, 
function, or activity status o f  various cells types including mononuclear cells and 
therefore do not impact negatively on the overall experimental procedure. Cells can
be prepared by positive selection -  the target cell is labelled with magnetic
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microbeads -  or negative selection -  the unwanted cells are labelled with magnetic 
microbeads to yield the target population that is not labelled. Once the total cell 
population o f interest (e.g. MNCs) is labelled with magnetic microbeads, the cell 
suspension is place on a MACS column in a MACS separator. Cells labelled with 
magnetic microbeads will be retained in the column, while unlabelled cells will pass 
through the column to be collected as the unlabelled fraction. Retained/labelled cells 
can then be eluted from the MACS column after removal from the magnetic MACS 
separator.
Figure 2.8: Picture o f an AutoMACS cell separation machine as used in this study -  
(source o f picture home.ncifcrf.gov/ccr/flowcore/automacs.jpg).
2.1.8.2 Isolation of CD14+ monocytes and CD14' depleted MNCs
MNCs were first isolated from adult peripheral blood or umbilical cord blood 
samples by density gradient centrifugation over H istopaqueR- 1077 as described 
above (2.1.3). Contaminating red blood cells (RBCs) were then removed by 
magnetically separating Glycophorin (a sialoglycoprotein marker for RBCs) 
positive RBCs from the CBMC buffy coat. Due to the lighter density o f RBCs in 
CBMC preparations compared to PBMCs preparations, this step was particularly 
critical for umbilical cord blood samples since the CBMC buffy coat preparation is 
always contaminated with RBCs. MNCs were labelled with glycophorin magnetic 
microbeads (Miltenyi Biotec) in accordance with the manufacturer’s guidelines with 
one exception: 30 pi microbeads/107 CBMCs and 10 pi microbeads/107 PBMCs to 
allow for different levels o f RBC contamination in the samples. Labelled MNCs
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were then applied to the autoMACS and programme ‘ depletes ’ used to deplete the 
MNC preparations of RBCs. RBC-depleted MNCs eluted from the magnetic column 
were then used for preparation of CD14+ monocytes and CD 14' depleted MNCs.
MNCs were counted and then labelled with CD 14 magnetic microbeads in 
accordance with the manufacturer’s guidelines (Miltenyi Biotec). Labelled MNCs 
were then applied to the autoMACS and collected as positively selected CD14+ 
monocytes as one fraction, and negatively selected CD 14' depeleted MNCs as the 
other fraction. To ensure complete depletion of CD14+ monocytes from the CD 14' 
depelted fraction, the cells in this fraction were pelleted by centrifugation, 
resuspended in MACS buffer (Miltenyi Biotec) and re-applied to the autoMACS. 
This time the programme ‘depleteS’ was used and only the negatively selected 
fraction was retained for further analysis. Cells in the two fractions of interest -  
CD14+ monocytes and CD14-depleted MNCs - were then used for further analysis.
2.1.8.3 Co-culture of CD14+ monocytes and CD14' depleted MNCs with study 
consortium
CD14+ monocytes and CD 14' depleted CBMC or PBMCs were counted using a 
haemocytometer and resuspended in completed medium at 1 x 106 cells/ml. These 
cell fractions were then co-cultured in duplicate with study consortium bacteria at 
106 CFU/ml in a total volume of 500pl/well of a 48 well plate as before. After 24hr, 
cell free supernatants were harvested and stored at -20°C until analysis of TNF-a.
2.1.8.4 Flow cytometric evaluation of cells prepared using magnetic 
microbeads.
The AutoMACS protocol is compatible with downstream applications such as flow 
cytometry which was used to assess the purity of each fraction obtained via the 
purification procedure. In initial experiments, depletion of RBCs was determined 
using flow cytometry with anti-CD235a: PE (Caltag, Invitrogen). The purity of the 
CD 14+monocyte fraction and the success of depletion of these cells from the CD 14' 
depleted MNC fraction was monitored in every experiment using anti-CD 14: FITC 
(Caltag). After counting, 5 x 105 cells were transferred to a FACS tube and FACS 
buffer added to give a total volume of 100 pi. Antibodies were added at pre­
optimised titrations and the samples incubated on ice for 30 minutes in the dark.
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After the addition of 3ml FACS buffer, cells were pelleted by centrifugation (510 x 
g, 7 minutes, 4°C) and then resuspended in 200 pi FACSFIX. Cells were acquired 
and analysed on a FACSAria flow cytometer using CellDiva software within 24hr as 
before.
2.1.9 Toll-like receptor (TLR) blocking experiments
The effect of blocking either TLR2 or TLR4 on the response by MNCs to the study 
consortium was determined. Functional grade antibodies (no azide, low endotoxin) 
known to neutralise the receptors of interest were used. MNCs (106/ml in complete 
medium) in a total volume of 500pl/well of a 48 well plate were pre-incubated with 
anti-TLR2 (clone TL2.1, mIgG2a), anti-TLR4 (clone HTA125, mIgG2a) or mouse 
IgG2a isotype control antibodies (all at final concentration of 20pg/ml; all 
eBioscience, San Diego, CA, USA). After lhr, 106or 105 CFU/ml of the study 
consortium was added at the outset of the culture. As a control MNCs exposed to a 
TLR4 ligand - lipopolysaccharide (LPS; lOng/ml; Invivogen) - or a TLR2 ligand - 
peptidoglycan (PGN; 3pg/ml; Invivogen) -  were used to control for success of TLR 
blocking. Cells/bacteria/antibodies were incubated for 24hr at 37°C in 5% CC>2 -in- 
air prior to harvesting of cell free supernatants which were stored at -20°C until 
analysis using cytokine specific ELISAs.
2.1.10 Effects of the study consortium on stimulated mononuclear cell cytokine 
responses
The effects of the study consortium on cytokine production from MNCs following 
additional stimulation with the mitogen phytohaemagglutinin (PHA) or the 
superantigen staphylococcal enterotoxin B (SEB) was determined. This approach 
was chosen to model the effects of the study consortium on the Thl/Th2/Treg 
cytokine balance. PHA is a plant lectin that can be used in immunological assays to 
trigger proliferation and cytokine production by T lymphocytes. SEB is an 
exoprotein belonging to a family of structurally related proteins known as bacterial 
superantigens. These are a distinct class of antigens capable of stimulating a primary 
T cell response similar in magnitude to that in response to allogeneic MHC 
molecules. Superantigens can bind to both MHC and T cell receptor molecules and 
thereby stimulate proliferation and cytokine production by very large numbers of T 
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cells. Superantigens are unique to other protein antigens in that they are recognised 
by T cells without being processed into peptides that are captured by MHC 
molecules (Janeway 2003).
PBMCs or CBMCs were initially stimulated in the presence or absence of 106 CFUs 
of the study consortium for 24 hr as described above. PHA (lpg/ml, Sigma) or SEB 
(200ng/ml, Sigma) was then added to appropriate wells and the cultures left for a 
further 24 hr at 37°C in 5% C0 2 -in-air before harvesting of cell/bacteria free culture 
supernatants. Supernatants were stored at -20°C until cytokine analysis using 
specific ELIS As. The cytokines selected for analysis were IFN-y, IL-13, IL-4 and 
IL-17.
For more detailed investigation of the mechanism of the responses observed in the 
above investigation the following approaches were taken:
2.1.11 Studies using MNCs from pregnant women
To establish if pregnant women might differ to non-pregnant women in their 
response to the study consortium, MNCs were prepared from healthy term (>37 
weeks of gestation) pregnant women and non-pregnant women as described in 2.1.3. 
Dose response experiments as per 2.1.4 and the effect of pre-exposure to the study 
consortium on the response to PHA and SEB as per 2.1.9 were conducted.
2.1.12 Enzyme linked immunosorbent assay (ELISA)
2.1.12.1 Principles of ELISA
The enzyme linked immunosorbent assay (ELISA) is a biochemical technique used 
to detect the presence of an antibody or an antigen in a sample. An unknown amount 
of antigen binds to a surface or an optimised amount of capture antibody affixed to a 
surface, and then a second specific antibody is washed over the surface so that it can 
bind to the antigen. This antibody is linked to an enzyme, and in the final step a 
substrate is added so that the enzyme can convert to some detectable signal which is 
then measured, usually, as the optical density (Lequin 2005).
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Figure 2.9: Diagrammatic representation of a sandwich ELISA.
An ELISA plate is coated with a capture antibody which binds or adsorbs to the plate 
in the solid phase. Blocking buffer is added to block nonspecific binding sites on 
the plastic. Cell culture supernatants containing unknown quantities o f the analyte of 
interest are added along with the standards o f known quantities. The analyte o f 
interest then binds to the capture antibody. The plate is then washed and the detection 
complex composed o f an enzyme linked to a detection (or secondary) antibody 
applied to the plate. After further washing to ensure that unbound antibody-enzyme 
conjugates are removed an enzyme substrate is added. The enzyme converts a 
typically colourless substrate to a coloured one that can be detected as an optical 
density reading. A standard curve yields an optical density for a known amount o f 
analyte and the concentrations in the samples can be calculated from the optical 
density.
Diagram adapted with permission from Beckman Coulter products 
(www.microscopesblog.com/.../ELISA-710650.jpg)
2.1.12.2 ELISA methodology
Cytokine concentrations in supernatants from study consortium and MNC co­
cultures were determined using commercially available ELISA kits according to the
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manufacturers’ instructions. The methodology for all assays was essentially the same 
with minor variations mainly in sample dilutions and depending on the manufacturer 
of the kit. Briefly, half area 96 well plates (Greiner Bio-one, Germany) were coated 
with 50pl of capture antibody prepared in coating buffer (PBS, Invitrogen; or 0.05M 
carbonate-bicarbonate buffer, pH 9.6, Sigma) and incubated overnight at 4°C. After 
discarding excess coating antibody, non-specific reactivity was blocked by 
incubation for 1 hour at room temperature with 1% bovine serum albumin (BSA; 
Sigma) in PBS (150pl/well). ELISA plates were then washed three times with wash 
buffer (1% BSA in PBS with 0.05% Tween-20 (Sigma); 200pl/well) before the 
sample or standard was applied in duplicate (50pl/well). After 2 hour incubation at 
room temperature, the plates were washed four times with the wash buffer as before 
and then the biotinylated detecting antibody was added (50pl/well) and incubated at 
room temperature for 1 or 2 hours, depending on the assay. Following this the plates 
were washed four times and avidin-horseradish peroxidase was added (50pl/well) 
and incubated for 20 or 30 minutes at room temperature (timings were assay 
dependent). Upon completion of the incubation with avidin-horseradish peroxidase 
the contents of the wells were discarded and the plates washed six times with wash 
buffer as before. Substrate chromogen (tetramethylbenzidine, BD Biosciences; 
50pl/well; prepared according to the manufacturer’s instructions) was then added and 
the blue colour allowed to develop (variable times for each assay). The reaction was 
stopped with 1 M H2 SO4  and the subsequent colour intensity (yellow) was recorded 
as the optical density at 450nm using a POLARstar Omega plate reader (BMG 
Labtech, Germany).
For the assay to be quantitative, a standard curve must be prepared for each assay as 
this enables cytokine concentrations in the samples to be calculated (Excel,
Microsoft Office 2007). Standard curves were prepared by plotting concentration on 
the y-axis against optical density at 450nm (OD450nm) on the x-axis using Excel 
(Version 2007). An example is shown (Figure 2.10). Cytokine concentrations in the 
samples were calculated from the standard curve and corrected for any dilution 
made. Calculations were made using the equation of the line generated in Excel 
(Figure 2.10) as a value for x, i.e. the optical density value obtained, was available 
for all samples enabling calculation of the unknown, y, i.e. concentration of the 
cytokine of interest.
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Figure 2.10: Example of a standard curve prepared during analyses used in this 
thesis.
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Table 2.1: Details of ELISA kits used for the specific cytokines analysed for this 
study.
Cytokine Sensitivity Company
IL-12p70 15.6 pg/ml OptEIA, BD Biosciences
IL-6 4.8 pg/ml OptELA, BD Biosciences
IL-lp 15.6 pg/ml OptEIA, BD Biosciences
IL-10 7.8 pg/ml OptEIA, BD Biosciences
IL-13 0.5 pg/ml Pelikine Compact™ Sanquin, Amsterdam.
TNF-a 15.6 pg/ml OptEIA, BD Biosciences
IFN-y 4.7 pg/ml OptEIA, BD Biosciences
TGF-pl 5.9 pg/ml Opt ELA, BD Biosciences
IL-17 15.6 pg/ml Duoset, R&D Systems
2.1.13 Statistical analysis
The student’s t-test was used for the statistical analysis to determine whether 
cytokine responses to the study consortium could be deemed statistically significant. 
P < 0.05 was considered statistically significant. All data was expressed as mean ± 
SEM. Further details of the statistical analysis can be found in the relevant chapters.
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2.2 Materials and methods for in vivo analysis - The PROBAT trial: probiotics 
for the prevention of allergic disease
2.2.1 Background to the study
The PROBAT trial is a randomised-double blind placebo controlled study conducted 
in South Wales that has been underway since 2004. The principal aim of this study 
was to investigate the immunomodulatory effects of a consortium of potential 
probiotic strains of Lactobacillus and Bifidobacterium species. The potential role of 
these commensal organisms in regulating immunity involved in the attenuation of 
the onset of IgE-mediated allergic disorder was the main focus of the study. The 
experimental approach adopted was one of probiotic supplementation to pregnant 
women from 36 weeks of pregnancy until the birth of the baby and the newborn 
from birth until 6 months of age. Infants were to be predominantly at high risk for 
the development of allergic disease. High risk was classified as those bom into a 
family with a history of atopic disease: mother and/or mother’s existing children 
and/or the father of current pregnancy have one or more of the following medically 
diagnosed IgE-mediated allergic diseases: asthma, atopic eczema or allergic rhinitis.
Consideration of the impact of probiotics on immune function in this age group was 
made by extensive laboratory based analysis of samples collected at the birth of the 
baby (umbilical cord blood and placenta), breast milk at 2 weeks and 6 weeks 
postpartum and blood from the infant at 6 months of age. Faecal samples were 
collected throughout to monitor colonisation with the species present in the study 
capsule. The potential impact of the probiotic consortium used on immune function 
was further explored by the inclusion of infants from low risk families; defined as 
those who had no first degree relatives with an atopic disorder.
The principal outcomes of the PROBAT trial were four fold. Can perinatal 
administration of the potential probiotic consortium of choice (see 2.1.1):
1. Reduce the incidence of IgE-mediated atopic disease during infancy and 
childhood?
2. Reduce the prevalence of eczema during the first year of life?
3. Reduce the prevalence of asthma at 5 years of age?
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4. Regulate key immune parameters which could potentially attenuate the risk of 
IgE-mediated allergy in later life?
2.2.2 Power analysis
The PROBAT trial follows on from an innovative study conducted in Finland 
demonstrating that nearly half of the infants perinatally exposed to probiotics 
developed eczema in the first two years of life compared with those exposed to a 
placebo (Kalliomaki et a l Lancet 2001 and 2003). The frequency of atopic eczema 
in the probiotic group was half that of the placebo group: 23% versus 46%. For the 
power calculation of the study in Swansea, it was assumed that forty percent of 
infants in the placebo group would develop eczema by age 6 months. A total of 236 
infants would allow the detection of a reduction of eczema in the probiotic group to 
20% with 90% power at the 5% level of statistical significance.
Demographics and size of the study population
We enrolled 454 allergic women delivering in the South Wales, Swansea city area 
between Month 2005 and Month 2009 from a total of 1419 pregnant women 
approached and assessed for eligibility. Of these, 220 were randomized to receive the 
study consortium and 234 to receive the placebo. Allergic women were preferentially 
recruited to the PROBAT trial as their unborn children were considered to be at high 
risk of developing atopic disorder in 91% (n = 413) of recruited women.
The study was powered to evaluate probiotics in the prevention of asthma and we 
expected 21% in the placebo group to develop asthma by age 5 years. A total of 540 
infants (270 in each arm) would have allowed the detection of a reduction of the 
frequency of asthma of 50% in the intervention group with 90% power at the 5% 
significance level. We expected that 40% of infants in the placebo group would have 
eczema by age 2 years (Kaur et a l 1998; Wadonda-Kabondo et a l 2003).Therefore, 
a total of 308 infants (154 in each group) would be sufficient to detect a 50% 
reduction in eczema frequency (20%) in the probiotic group with 90% power at the 
1 % significance level. Recruitment began in May 2005 but, because of funding 
constraints, was terminated early. At that point, 402 mothers had been recruited and 
the last infant was reviewed at the 2 year follow-up visit in November 2009. A 
statistical power analysis to determine the number of subjects needed to offset the 
expected heterogeneity of the immune response in the birth cohort was conducted.
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Based on previous studies by Kalliomaki et a l (2001) the numbers recruited in the 
study allow for detection of differences in immunological responses between the 
groups at a statically power of over 95% for all cytokines).
Maternal allergy was defined as a doctor-diagnosed clinical history of asthma, 
allergic rhinitis or eczema and a positive skin prick test (SPT) to one or more 
common allergens (HDM; grass, pollens, cat pelt, dog hair, feathers, moulds, and 
cockroach extracts). A weal size of 3mm above the negative control was considered 
positive. Additionally there were no statistically significant differences between the 
probiotic and placebo groups with respect to gender, gestational age, birth weight, 
older siblings, day care attendance, or exposure to smoking at home.
Immune response in a large birth-cohort will show marked heterogeneity attributed 
to factors such as health status, genetic variability, diet, maternal smoking, level of 
physical activity, or cognitive status .
Confounding variables that could affect the integrity of the current study are briefly 
described below based on the findings of (Gardner and Murasko 2002).
Health Status of the Subjects
Since subjects recruited on the PROBAT trial were specifically selected on the basis 
of an increased genetic predisposition to developing atopy in later life. To delineate 
changes in immune function due to age, expression of atopic disease or a specific 
effect of the study consortium during the supplementation period all adverse events 
effecting immune status that could potentially skew experimentally analysed ex vivo 
immune responses were recorded in (Allen et a l 2010). This step was of 
considerable importance since it is widely reported that application of antibiotics to 
resolve early childhood infection is linked with expression of atopic disorder in later 
life (Almqvist et a l 2012).
Supplementation Group allocation occurred by block randomization, with 
stratification according to maternal allergy (asthma vs. other allergy), parity (first 
child vs. two or more children) and paternal allergy (allergic vs. non-allergic). Infants
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allocated to the study consortium received 1 x 1010 of the bacteria strains in 
maltodextrin (Cultech) daily, while those in the control group received maltodextrin 
alone. The products were matched in taste and appearance. Supplements were 
supplied in capsules administered daily to lactating mothers for 36 weeks gestation 
and then to their newborns for the first 6 months of life, independent of feeding 
methods. The consortium conformed to the FAO/WHO expert panel guidelines for 
probiotics (resistance to acid and bile; adherence to cells of the intestinal epithelium 
and colonization in the intestinal tract; antagonistic activity towards enteric 
pathogens and maintenance of strain identity and viability throughout shelf-life).
2.2.3 Ethical approval
Ethical approval was obtained from the local research ethics committee, LREC for 
Bridgend, Neath Port Talbot and Swansea in February 2004 (International standard 
randomized controlled trial, ISRCTN 26287422). Informed written consent was 
obtained from all pregnant women recruited to the study (Appendix 2 for patient 
information sheet and consent form). Ethical approval was granted and the reference 
number for this study is 2004.02
2.2.4 Study participants
Women aged 16yr or older with a normal singleton pregnancy attending antenatal 
clinics in hospitals or general practice surgeries in the greater Swansea area were 
eligible to join the study. The majority of women recruited to the study were 
carrying a fetus at increased risk of atopy, defined as a fetus with a first-degree 
relative with a familial history of atopy: mother, father or sibling with either asthma 
or eczema diagnosed by a health professional or allergic rhinitis treated by a doctor. 
A group of women pregnant with a fetus at low risk of atopy and atopic disease by 
virtue of an absence of a first degree relative with asthma, eczema or allergic rhinitis 
as defined above were also recruited
2.2.5 Recruitment to the PROBAT trial
Pregnant women were invited to join the study before 35-36 weeks gestation during
the booking visit (usually around 10 to 16 weeks of pregnancy) or at subsequent
routine antenatal clinic visits with the local NHS trust. Women were initially given
information explaining the aims and designs of the study and verbal consent was 
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sought to confirm willingness to further consider participation in the study. The 
women were provided with more information about the study and if they were 
willing to progress with the study, informed written consent was obtained. At 
approximately 36 weeks of pregnancy women who had consented were visited at 
their homes or in hospital clinics by a member of the research team. During the visit 
the aims and design of the PROBAT study were reviewed and the inclusion and 
exclusion criteria were explained. Women were invited to provide a blood sample at 
the 36 week routine antenatal clinic visit.
2.2.5.1 Inclusion criteria
Mother aged >16 years.
Scheduled to give birth at Swansea Singleton Hospital.
Gestation at delivery >36 weeks.
Freely given, signed, informed consent to participate in the randomised-blind 
placebo controlled trial.
2.2.5.2 Exclusion criteria
Any adverse medical condition likely to affect the outcome of the pregnancy.
Any adverse medical condition affecting the mother or newborn.
Member of the household or infant’s sibship already recruited on the study. 
Women unwilling to discontinue use of other bacterial dietary supplements.
2.2.6 Random allocation and blinding
As a randomised double blind placebo controlled study, neither the mother nor any 
member of the research team knew which preparation a particular mother and baby 
was taking throughout the study until at least the time of writing this thesis. This 
was a requirement that has been adhered strictly to, ensuring that a comprehensive, 
unbiased and fair assessment could be made as to whether or not the probiotics have 
been effective in preventing the development of atopy/atopic disease. A computer­
generated, random allocation sequence was generated by the independent statistician 
(Duolao Wang) to enable apportioning of each mother-infant dyad to either the 
study consortium or placebo arm of the study on a 1:1 basis.
Probiotic and placebo powders were prepared by Cultech Ltd and the random
allocation sequence for the probiotic and placebo vials was maintained by the 
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company: a series of cards bearing the randomised study identification numbers in 
opaque envelopes were prepared. Following informed consent, mothers were 
allocated the next card in the series and thereby allocated randomly to either the 
probiotic or placebo group. Probiotic and placebo preparations were identical in 
appearance therefore neither the participants nor the study team were able to 
distinguish probiotic from placebo. Cultech Ltd ensured that the release of the 
probiotic or placebo allocation code was made available to the academic research 
staff only after the compilation of the 2 year clinical data and immunological 
information generated from cord samples collected around the birth of the baby and 
at 6 months of age. Access to the randomisation code was provided to the local NHS 
Trust so that it was available if any mother or baby on the study presented to one of 
the local hospitals in an emergency.
2.2.7 Intervention
The probiotic and placebo products used in the PROBAT study were prepared 
according to stringent manufacturing processes. The raw materials and final 
products were subject to robust microbial quality control testing to ensure that each 
of the component micro-organisms met the standard required specification and 
identity and that no contaminating organisms were present in the probiotic capsule. 
Women during the last month of pregnancy and their infants from birth to age 6 
months received daily vegetarian capsules composed of hydroxypropyl 
methylcellulose containing either the probiotic supplement or the placebo.
2.2.7.1 Constituents of the probiotic supplement
Probiotics were manufactured as a freeze-dried powder, in a vegetarian capsule and 
contained in vacuum sealed bottles. Each lOOmg of powder contained a diverse 
consortium of potentially probiotic organisms. The probiotic preparation contains 
live bacteria and the bacterial strains and numbers of organisms taken per day were: 
2 live strains of Lactobacillus and 2 live strains of Bifidobacterium. In total 1 xlO10 
CFUs of probiotic bacteria (See 2.1.1) was administered each day to study 
participants.
2.2.7.2 Constituents of the placebo
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The placebo comprised an equal volume of inert maltodextrin powder identical in 
appearance to the probiotic preparation.
2.2.8 Method of probiotic administration
To maximise probiotic colonisation within the intestinal tract of the newborn, 
participating mothers were required to take the study preparation once a day from 36 
weeks gestation until delivery of the baby. From the day of delivery until age 6 
months, mothers were expected to administer the same dosage of the preparation to 
their infants. Mothers were visited every 6 weeks by a member of the research team 
to ensure a fresh supply of the preparations if required and to answer any pertinent 
questions regarding the study and also to retrieve the empty vials as a measure of 
compliance.
2.2.8.1 Administration to the pregnant woman
Participating women were randomly allocated to take either the active probiotic 
preparation or an identical placebo (See 2.2.6). The expectant woman was expected 
to take one capsule per day of the freeze dried powder as a food supplement 
sprinkled onto meals from 36 weeks of pregnancy until delivery.
2.2.8.2 Administration to the infant
Participating women were expected to administer the contents of one capsule per 
day of the trial supplement as soon as possible following the birth of their child 
every day from birth to 6 months of age. The trial capsule was to be split open and 
administered to their newborns via one of the following methods:
Sprinkling the freeze dried powder directly onto the mother’s nipple; 
Sprinkling powder directly into the newborns mouth;
- Mixing the powder in a cup with a small amount of expressed breast milk or 
clean water prior to administering to the newborn;
For bottle fed babies, the powder could be added directly to the milk or 
water.
Mothers were strongly urged to breastfeed in accordance with accepted postnatal 
ward practice and were encouraged to breast feed during the course of 
supplementation due to the well-known and widely reported health benefits of 
breastfeeding for both mother and child.
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2.2.9 Arrival of expectant woman onto antenatal and labour wards and 
collection of samples
Expectant women participating on the PROBAT trial could be identified by a trial 
label on the front of their patient notes. Midwives employed by the trial ensured that 
participating women were carrying a supply of the trial supplement for themselves 
and their soon to be newborn as part of their personal belongings. At delivery, 
umbilical cord blood and the placenta/attached membranes was collected for use as 
described in section 2.3. Delivery suite staff then contacted the study team to notify 
them of samples for collections.
2.2.10 Out of office hours
To cater for babies being delivered out of office hours, an on-call system was 
utilised - each member of the research team was allocated a weekend on the on-call 
rota and carried the study mobile phone to ensure that samples collected during the 
weekend could be collected and processed in the laboratory.
2.2.11 Clinical outcomes
All participants were visited at home every 6 weeks until the baby was 6 months old 
to provide supplies of the study preparations and to monitor compliance.
Assessment of the trial clinical outcomes was performed by a trained member of the 
research team at 6 months and 2 years of age (to date; further follow-up is planned). 
At 6 months of age, the assessment involved:
(i) a detailed examination of the child to assess the severity of atopic eczema defined 
according to the presence of specific symptomatic manifestations including itchy, 
inflamed rash affecting the face, scalp or extensor surfaces/flexures of the limbs;
(ii) Parents were asked to complete a questionnaire regarding symptoms of allergy 
and general wellbeing;
(iii) Skin prick testing (See 2.2.10.2);
(iv) Peripheral blood sample collected for laboratory analysis (See section 2.3.6).
The infant’s health records held by the general practitioner also were assessed by 
health professionals to identify clinical diagnoses of atopy. Blood collection from 
the infant was subject to parental consent.
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2.2.11.1 Procedure for allergy assessment in newborns
A trained member of the research team was designated to ask questions regarding 
the general health of the participating mother in terms of the prevalence of allergic 
disorders in the family and also about the families exposure to environmental factors 
linked with allergy such as keeping domesticated pets and use of antibiotics. 
Newborns were visited every 6 weeks to the age of 6 months and every year to the 
age of 2 years to collate information assessing the current atopic status.
2.2.11.2 Skin prick tests
Skin prick tests (SPTs) were performed at the ages of 6 months and 2 years and 
involved placing on the skin a drop of fluid containing one of a number of common 
allergens including p-lactoglobulin, ovalbumin, Dermatophagoides pteronyssinus, 
cat dander, and grass pollen. The skin is then gently scratched through the drop and 
the subject observed to determine whether a local skin reaction ensues. The allergic 
skin reaction usually reflects atopic sensitisation to a specific allergen in the fluid 
and is represented as flare and wheel. A positive (histamine) and negative (diluent) 
control is always included.
2.2.12 Additional information
In order to interpret the findings of the PROBAT trial, additional information 
regarding possible risk factors for IgE-mediated allergy where collected from all 
participants and analyzed by virtue of a questionnaire:
Brief details of atopic diseases in first degree relatives 
Number of older siblings 
Household pets
Maternal smoking during pregnancy and exposure to cigarette smoke in the 
home
Mode of delivery 
Method of feeding 
Attendance at nursery
Drugs received during pregnancy, labour, infancy and childhood, especially 
antibiotics
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2.2.13 Potential side effects of probiotic supplementation in the newborn
Probiotics are food supplements “generally regarded as safe” according to the 
recommended classification by the Food Standards Agency. A recent publication 
form our research group indicates that dietary supplementation with lactobacilli and 
bifidobacteria is well tolerated and not associated with adverse events during late 
pregnancy and early infancy (Allen et al. 2010).
2.3. Procedures for PROBAT trial sample collection
Additional ex vivo laboratory-based analyses were conducted using samples 
collected during the PROBAT study to elucidate the potential immunomodulatory 
effect of the study consortium. The following describes the samples collected and 
what they were used for.
2.3.1 Maternal blood sample at 36 weeks of gestation
At the time of performing this study, pregnant women under the care of the local 
trust routinely had blood taken at around 36 weeks of pregnancy as part of their 
clinical obstetric care. Women who consented to be involved in the PROBAT study 
and had this routine sample take also provided a peripheral blood sample for this 
study: 9ml into sodium heparin (Vacutainer, Greiner Bio-One); 4ml into gel and clot 
activator tubes (Vacutainer).
2.3.2 Umbilical cord blood at birth of the baby
Umbilical cord blood samples were collected routinely immediately following the 
birth of the newborn child and preceding the cutting of the umbilical cord. Blood 
was collected into sodium heparin and gel and clot activator tubes as for maternal 
sample.
2.3.3 Placenta at birth of the baby
Placentas were collected from the hospital and the time elapsed between delivery 
and arrival in the laboratory recorded. The placenta was weighed and if not longer 
than 2hr had passed since delivery it was processed as described below.
2.3.4 Breast milk
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Breast milk samples from breast feeding mothers at 2 weeks and 2 months after the 
baby’s birth where collected. Samples were aliquoted in a Class II tissue culture 
cabinet to limit contamination. Up to 5 aliquots of approximately 1ml breast milk 
were transferred to microfuge tubes using a sterile pastette and immediately stored 
at -80°C.
2.3.5 Faeces
Faecal samples were obtained from the infants on this study to determine whether 
probiotic bacteria could be recovered more frequently in the stools. Stool samples 
were collected from infants to assess the faecal microbiota to determine differences 
in probiotic colonisation between the placebo group and intervention group.
Samples were collected just after birth and at 3 months, 6 months and at regular 
intervals thereafter to trace the duration of colonisation after stopping 
administration. These samples were analysed by Cultech Ltd to avoid unmasking of 
the research clinicians regarding the allocation sequence. An aliquot of these stool 
samples were frozen and stored for future measurement of non-invasive markers of 
gut inflammation and permeability.
2.3.6 Blood from infant at 6 months of age
Blood samples (up to 5ml venous blood into sodium heparin) were obtained by 
trained paediatricians from veins in the back of the hand or antecubital fossa using an 
aseptic technique and 23 gauge butterfly needles after applying a topical anaesthetic 
cream.
2.4. Procedures for PROBAT trial sample analysis
2.4.1 Analysis of umbilical cord blood samples
Umbilical cord blood was used as follows:
Heparinised sample: automated haematology analysis (n = 100); whole blood 
culture (n = 108); whole blood flow cytometry (n = 63); sample for DNA analysis (n 
= 212); preparation and culture of MNCs (n = 102); plasma (n = 197). Clotted 
sample was used for the preparation of serum (n = 226).
2.4.1.1 Automated haematology analysis
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Total blood counts and differential were measured using a CellDyn® 3200 analyser 
(Abbott Diagnostics, Germany). CellDyn® is a multi-parameter automated 
haematology analyser designed for in vitro diagnostic use in clinical laboratories. 
Further details are provided in Chapter 6.
2.4.1.2 Whole blood culture
Whole blood cultures were used to study key pro- and anti-inflammatory cytokine 
responses in the presence of the inflammatory stimuli such as lipopolysaccharide 
(LPS) and peptidoglycan (PGN). Umbilical cord blood (UCB; 200 pi) was diluted 1 
in 4 with 600 pi of culture media (RPMI1640/Glutamax with 0.5 mM 2- 
mercaptoethanol, all Invitrogen) in 4.5 ml culture tubes (Greiner Bio-one). 
Duplicates were prepared. The following stimuli were used: unstimulated, LPS 
(lOng/ml; Invivogen), PGN (3pg/ml; Invivogen), IFN-y (lOng/ml; Invitrogen), LPS 
+ IFN-y, PGN + IFN-y. IFN-y was added to appropriate tubes and all tubes were left 
to incubate for 90 minutes at 37°C and then LPS or PGN added as appropriate. All 
tubes were then left to incubate at 37°C in 5% CC>2 -in-air for 20 -  22 hours. Cell free 
culture supernatants were harvested by centrifugation and then supernatants were 
transferred to labelled microrack tubes (Greiner) and stored at -80°C until analysis 
using ELISA.
2.4.1.3 Mononuclear cell culture
Isolated mononuclear cells (See section 2.1.3) were placed into 4.5ml culture tubes 
(Greiner Bio-one, Germany) containing 500pl media (AIMV serum free medium 
supplemented with 0.5mM 2-mercaptoethanol; all Invitrogen) in aliquots of 0.5x106 
cells/500pl. Once the cultures were prepared, two tubes were left un-stimulated, two 
were treated with the PHA (1 pg/ml; Sigma) or, if cell numbers permitted, SEB 
(200ng/ml; Sigma) or anti-CD3/CD28 T cell expansion beads (5pl/500pl; Dynal, 
Invitrogen). All tubes were incubated at 37°C in 5% C02-in-air for 48 hours. Cell 
free culture supernatants were collected by centrifugation and stored at -20°C until 
analysis using ELISA.
2.4.1.4 Whole blood flow cytometry
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Multi-parameter flow cytometry was used to assess various leukocyte cell 
subpopulations. Cord blood collected into sodium heparin was used and 
immunophenotyping done using a whole blood lysis method (Perez et a l 2005; 
Schwonzen et al. 2007). Principally whole blood was incubated with monoclonal 
antibodies; the stained sample was treated with a lysing solution to remove red 
blood cells while preserving the leukocytes for flow cytometric analysis. 
Predetermined concentrations of antibodies were added to FACS tubes and then 
50pi of cord blood was added to each tube, vortexed and incubated for 30 minutes 
on ice in the dark. Lysis of red blood cells was then performed - 3mls of FACS Lyse 
(BD Biosciences) was added to each tube which was then vortexed and incubated 
for 10 minutes in the dark at room temperature. Tubes were then centrifuged at 4°C, 
510 x g  for 7 minutes, supernatant discarded, and 3mls of FACS buffer (PBS/0.2% 
BSA/0.05% sodium azide) added. Following repeat centrifugation and discarding 
the supernatant, 400pl of FACS fix (BD Cell Fix, BD Biosciences) was added. 
Samples were covered and then stored in the fridge before acquisition within 24 
hours using the BD FACS Aria™ flow cytometer and CellDiva Software (BD 
Biosciences, San Jose, CA). The panel of monoclonal antibodies and fluorochromes 
used are listed in Table 2.2.
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2.4.2 Placental explant culture
Placental explants cultures (0.2g of wet tissue/ml of media) were prepared as 
described (Hanna et al. 2000). Briefly, the overlaying deciduas basalis on the 
maternal side of the placenta was removed and 1 cm pieces of placental tissue were 
taken from different sites across the placenta and placed into sterile PBS. 
Disturbance of the chorioamnion was avoided. Placental tissue was washed 
repeatedly with PBS to remove contaminating blood, and fresh PBS was used for 
washing steps. The tissue was then minced into smaller pieces (approximately 1 -2 
mm ) and washed further with PBS. Pieces of placental tissue (0.5g) were 
transferred into each well of a standard tissue culture 6-well plate (Greiner Bio-one, 
Germany) containing 2.5ml of Ultraculture medium (Cambrex, Belgium) 
supplemented with 2mM Glutamax (Invitrogen, UK) and lOOU/ml penicillin G,
1 OOpg/ml streptomycin sulphate and 0.25pg/ml amphotericin B (PSF; Invitrogen, 
UK). Care was taken to avoid any blood clots or fibrous tissue. Four wells of a 6- 
well plate were left unstimulated and two were stimulated with LPS (lOng/ml) 
wells. Plates were then incubated at 37°C in 5%C02-in-air for 24 hours. Tissue free 
culture supernatants were collected by centrifugation and stored at -20°C until 
analysis by ELISA. Extreme care was taken to limit LPS/endotoxin contamination 
during explant preparation, including the use of disposable plastic-ware and other 
consumables (e.g. scissors) whenever possible (Jones et al. 1997). All 
media/reagents were tested by the manufacturers and found to be endotoxin free.
2.4.3 Analysis of blood from 6 month infant
Infant blood was used as follows:
Heparinised sample: automated haematology analysis (n = 158); whole blood 
culture (n = 107); whole blood flow cytometry (n = 80); preparation and culture of 
MNCs (n = 96); red blood cell pellet (n = 152); plasma (n = 181).
2.4.3.1 Automated haematology analysis
As for umbilical cord blood with the exception that the sample could be diluted in 
PBS prior to analysis if samples size was limiting. Values used in analysis were 
corrected for this dilution.
2.4.3.2 Whole blood culture
As for umbilical cord blood.
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2.4.3.3 Mononuclear cell culture
As for umbilical cord blood.
2.4.4.4 Whole blood flow cytometry
As for umbilical cord blood.
2.4.4 ELISA analysis of supernatants from whole blood and MNC cultures
Whole blood culture supernatants were analysed for: TNF-a and IL-10 for 
unstimulated and LPS- and PGN-treated samples; IL-12p70 for unstimulated and 
LPS- and PGN-treated samples in the presence and absence of IFN-y. Mononuclear 
cell supernatants were analysed for: IL-4, IL-10, IL-13 and IFN-y. These methods are 
described in further detail in (4.2.1 to 4.2.2)
2.5 Samples archived for future work
Samples stored for future work at a later stage are described below.
2.5.1 Placental biopsies for RNA analysis
Additional placental tissue (3 pieces) was removed and washed several times in cold 
PBS to remove contaminating blood. A fixed amount of tissue (0.2-0.26g) was 
transferred into 1.3ml of RNAlater™ (Sigma, USA). Biopsies in RNA later were 
stored at 4°C for 48 hours and then transferred to -80°C for long term storage.
2.5.2 Sample collection for DNA analysis.
Aliquots (200pl) of whole anti-coagulated umbilical cord blood were placed in 
labelled tubes and stored at -80°C.
2.5.3 Preparation of plasma
Plasma was kept following the density gradient centrifugation process (as previously 
described 2.1.3) and transferred to a bijou. The plasma sample was sterile filtered 
(0.22pm; low protein binding polyesthersulfone filter; Millipore, Bedford, MA,
USA) and aliquoted into well-labelled tubes for storage at -80°C until needed.
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2.5.4 Preparation of serum.
Umbilical cord blood collected into the yellow-top tube (gel and clot activator tube; 
Vacutainer, Greiner Bio-one) was used for the preparation of serum. The sample 
was left at room temperature for at 60 -  90 minutes to clot, centrifuged at 1800 x g 
at room temperature for ten minutes, and stored in labelled aliquots at -80°C until 
needed.
2.6 Statistical analysis
Principle outcomes measured by the PROBAT trial directly concerned with this 
thesis were: the impact of maternal probiotic consumption during the last few weeks 
of pregnancy on immune function at birth; and the impact of infant probiotic 
consumption for the first 6 months of life on immune function at 6 months of age. 
Due to the varied and/or detailed nature of the statistical approaches used for 
analysis of in vitro and ex vivo experiments these are detailed in the relevant 
chapters.
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Chapter 3: Effects of study consortium on cytokine production from 
umbilical cord blood (CBMCs) and adult peripheral blood 
mononuclear (PBMCs) cells in vitro
3.1 Background
Perinatal probiotic supplementation of newborns with a familial history of allergy has 
become a rationale of increasing research interest to prevent or attenuate the 
symptoms of IgE mediated atopic disorder. This rationale is in part due to the well 
documented immunomodulatory effects of probiotic bacteria in human immunity, 
and has generated an avenue for development of clearly defined in vitro models 
representing the newborn immune response to probiotic bacteria. Since data 
modelling the immunomodulatory impact of probiotic bacteria upon the cellular 
constituents of newborn immunity in vitro is scarce, the use of mononuclear cells 
prepared from umbilical cord blood (CBMCs) isolated by density gradient 
centrifugation (See Chapter 2) was at the heart of the in vitro model employed in this 
thesis. The principle focus of chapter 3 was to therefore provide in vitro 
immunological data supporting the application of probiotic bacteria in the PROBAT 
trial, and to provide the clinical framework for experimentally driven hypotheses into 
how perinatal probiotic supplementation might positively modulate early newborn 
immunity at the cytokine level, particularly in clinically predisposed atopic 
individuals. The general thesis hypothesis is that, immunomodulation mediated by 
the consortium might positively influence and divert the deleterious immune 
equilibrium rendering a child atopic in later life, (See Chapter 1) towards a more 
balanced scheme of immunity as seen in non-atopic individuals.
Information gathered from this in vitro study was required to support an assessment 
on whether perinatal probiotic supplementation using the consortium could be 
efficacious against the onset and/or progression of IgE-mediated atopy in later life. 
Furthermore, in vitro data produced at the cytokine level essentially provided the
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foundation for experimentally driven hypotheses into how the consortium may 
function in vivo during development of early newborn immune mechanisms 
necessary to counter the onset of IgE mediated atopy in later life (See chapters 4, 5 
and 6).
Since perinatal supplementation to prevent allergic disease development is a field of 
increasing interest, the use of cord blood mononuclear cells (CBMCs) in these 
models is essential. There is a paucity of research considering the immunomodulatory 
effects of probiotic microorganisms using CBMCs to model the neonatal immune 
response. A perinatal supplementation study employing the study consortium on 
infants at birth and 6 months of was initiated in Swansea in 2005. This offered the 
opportunity to concurrently study the effects of the same four micro-organisms on 
immunological phenotypes measurable ex vivo using CBMCs and peripheral blood at 
6 months of age versus those generated in an in vitro model using CBMCs.
The strains of probiotic used are postulated to orchestrate key immunomodulatory 
actions upon host immunity characterised by generation and maintenance of 
important activities of mucosal immunity such as: anti-microbial and pro- 
inflammatory actions mediated by Thl type cytokines (IL-12, TNF-a and IFN-y); 
anti-inflammatory and oral tolerance activities, induced and maintained by 
immunoregulatory cytokines (IL-10 and TGF-p); stimulation of adaptive immune 
responses marked by local and systemic IgA and IgG determined by the Th2 type 
cytokines (IL-4 and IL-5) (Brandtzaeg 2002; Brandtzaeg 2009). Cytokine synthesis 
patterns from haematopoietic cells induced by LAB in vitro and in vivo are strain 
specific (See Chapter 1 section 1.7.2).
In order to interpret how CBMCs might respond to a consortium of potential 
probiotic microorganisms it is imperative to gain an appreciation of the nature of 
newborn immunity in terms of the maturational stage of the developing immune 
system and how it differs from adult immunity. After delivery, the immune system of 
the neonate is immature and undergoes rapid development strongly influenced by the 
quality of immune education provided by antigenic stimuli encountered during the 
initial years of life. The immune system of the growing fetus fundamentally develops 
towards a Th2-skewed in healthy infants in which Th2 cells predominate (Prescott et 
al. 1998). However, newborns generally have a reduced ability to produce many
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cytokines and growth factors compared to the adult. Passive transfer of maternal 
antibodies across the placenta from mother to child facilitates this fetal predisposition 
in favour of Th2 humoral immunity as opposed to Thl cell mediated immunity. 
Newborns are initially protected by these maternal antibodies for the first two to three 
months of life, and are relatively free of bacterial infections during this time (as 
reviewed by (Jordan et a l 2008). Antibody production does not reach adult levels 
until age four years. NK and cytotoxic T cells have an attenuated function in the 
neonate to limit exuberant and potentially toxic Thl immune responses.
Consequently newborns are somewhat vulnerable to viral and intra-cellular infections 
(Jordan et al. 2008).
3.1.1 Cytokines to be studied
The ideal cytokines to be studied are the Th2 cytokines postulated to have a 
mechanistic role in atopic disorder and/or those demonstrated to be modulated by 
probiotics from previous studies such as the Thl cytokines. There is considerable 
overlap between the cytokines of interest in both development and maintenance of 
allergic disease and those demonstrated by other investigators to be up or down- 
regulated in the presence of probiotic bacteria. An overview of each cytokine chosen 
for inclusion in this investigation was provided in terms of their induction by 
probiotic bacteria and their role in allergy (See 1.3.6 to 1.3.8).
3.1.2 Need for the study
The in vitro immunomodulatory attributes of a consortium of potentially probiotic 
lactobacilli and bifidobacteria strains were characterised within a traditionally 
employed in vitro model used to determine how potentially probiotic strains 
indigenous to the intestinal microbiota influence innate and adaptive immunity. The 
conglomerate of strains employed are more accurately classified as potentially 
probiotic since they have not yet been confirmed in any therapeutic, clinical or 
supplemental study to have a beneficial effect on human health; therefore for ease 
and clarity the strains will be referred to as the study consortium.
3.1.3 Aim of study
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The aim of this study was to gain an insight into the immunomodulatory mechanisms 
of action of the probiotic study consortium employed in the PROBAT trial by 
studying their interactions with mononuclear cells. The initial goal was to screen for 
cytokines produced by mononuclear cells prepared from umbilical cord blood 
(CBMCs) and adult peripheral blood (PBMCs) in response to the study consortium in 
vitro. The capacity of the study consortium to modulate newborn immunity at the 
cytokine level, and any differences in responses between CBMCs and PBMCs was 
also examined. Bearing in mind that newborns have a diminished functional immune 
capacity compared to the adult (See Chapter 1), we aimed to determine whether this 
is apparent in responses of CBMCs to the consortium and elucidate possible 
mechanism for any differences. Mechanisms by which the consortium generated 
interpretable signals to the immune system were also analyzed by defining the key 
cell types involved in cytokine production and whether this production is dependent 
on direct contact between mononuclear cells and the consortium.
3.2 Rationale and Methodology behind study
3.2.1 Viability of the study consortium
Since our proposed in vitro model was dependent on interactions between the 
consortium and mononuclear cells it was imperative that a viability assessment of the 
consortium in typical laboratory culture systems used for mammalian cells was first 
analysed. The lactic acid and bifidobacteria strains present in the study consortium 
are Gram-positive bacteria encapsulated in a freeze dried form. Since the focus of the 
present thesis was to analyse the immunomodulatory effects of probiotics on 
neonatal immunity, it was imperative that the viability of the probiotics strains in 
typical laboratory culture systems used for mammalian cells was first analysed. The 
present study sought to determine whether the study consortium remains viable in 
cell culture media used for culture of umbilical cord and peripheral blood 
mononuclear cells in ours and others research laboratories: serum free AIMV 
supplemented with 2-mercaptoethanol (complete AIMV) or RPMI1640/Glutamax 
supplemented with 5% FBS and 2-mercaptoethanol (complete RPMI all Invitrogen). 
Probiotic strains of the study consortium employed in the PROBAT trial were 
incubated in the presence of complete RPMI or complete AIMV over a 24hr period. 
The viability of organisms was assessed by monitoring total viable counts (TVCs; 
section 2.1.2).
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3.2.2 Study consortium-mononuclear cells in vitro co-culture model
Although a system of studying direct interactions between cells of the mucosal 
immune system and the commensal bacteria in their natural GIT environment is 
laborious to replicate in laboratory practice, the use of mononuclear 
cell/haematopoietic cell-probiotic co-culture studies to model microbial host cell 
interactions in vitro offers a commonly acceptable alternative. The reliability of the in 
vitro model is supported by the fact that interactions between commensal bacteria and 
leukocytes during real time gastrointestinal physiology occurs via bacterial 
translocation through the epithelial barrier (Deitch et a l 1991; Sedman et a l 1994). It 
has been postulated that increases in non-specific (phagocytosis, NK cell activities) 
and specific (antibody synthesis) immune activities observed in mammalians can be 
attributed to increased translocation of probiotic bacteria through the epithelial barrier 
due to ingestion of probiotic strains of LAB origin (Miettinen 1996).
Mononuclear cells were prepared from anti-coagulated umbilical cord and adult 
peripheral blood by density gradient centrifugation (section 2.1.3). CBMCs or 
PBMCs were incubated with: (i) a dose course of study consortium for 24hr prior to 
harvesting of cell/bacteria free supernatants for later analysis using specific ELISAs 
for TNFa, IL-10, IL-lp, IL-6 and IL-12p70; (ii) 106 CFUs/ml of study consortium 
for 24hr prior addition of PH A (lpg/ml) or SEB (200ng/ml) for a further 24hr 
incubation at which time cell/bacteria free supernatants were harvested for later 
analysis using specific ELISAs for IFNy, IL-4, IL-13 and IL-17.
3.2.3 Determining the principle cellular responders to the consortium
CD14+ monocytes and CD 14' depleted mononuclear cells were prepared using 
magnetic microbeads (Miltenyi Biotec) with purity/depletion monitored using flow 
cytometry. Contact between mononuclear cells and bacteria was abrogated by the use 
of trans-wells (section 2.1.5) and the cytokine response to 106 CFU/ml of the study 
consortium determined. For this part of the study only TNF-a was measured as an 
output.
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3.3 Results
3.3.1 Optimising viability of probiotic strains present in cell culture medium 
using traditional microbiological techniques
Optical density measurements (OD) were initially undertaken as a qualitative 
measure to determine the turbidity o f  liquid cultures containing lactobacilli and 
bifidobacteria strains o f  the study consortium maintained in either com plete RPMI or 
complete AIMV. Changes in turbidity were used as a qualitative measure o f  bacterial 
proliferation. M easurement o f  turbidity in MRS broth served as a positive control as 
it is well documented that lactobacilli and bifidobacteria grow well in this media 
(Tannock 1999). This was confinned in our study as strains proliferated in MRS; 
much more so than in either complete RPMI or complete AIMV (Figure 3.1). Figure
3.2 shows the growth in complete RPMI or complete AIMV with a different scale on 
the y-axis. From this it can be seen that a gradual increase in turbidity o f  a liquid 
culture occurs in complete RPMI with OD increasing from 0.046 to 0.056 and 
peaking at approximately 6 hours before declining slightly to 0.053 by 24 hours. 
Conversely, the turbidity change in complete AIMV was minimal with OD increasing 
from 0.046 to 0.047 by 6 hours before declining to 0.045 by 24 hours im plying a lack 
o f bacterial growth in this media.
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Figure 3.1 Changes in optical density at a wavelength of 600nm (OD) of a liquid 
culture of the study consortium at starting level o f approximately 1 xlO6 CFU/ml 
grown in MRS broth (n=3), com plete AIMV (n=3) or complete RPMI (n=3). 
Comparisons with MRS are provided in (a) and use o f different y-axis scale in (b)
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AIM'V
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allows the differences in growth in com plete RPMI versus com plete AIM V to be 
visualised.
Viability o f  the study consortium in com plete RPMI 1640 or com plete AIMV was 
then assessed using the conventional m icrobiological technique o f  total viable count 
(TVC). Results o f  TVC show that bacteria numbers did not increase in com plete 
AIMV, in fact viable bacteria could not be recovered even im mediately upon 
preparing the bacteria in this media at time 0 (Figure 3.2). In compete RPMI there 
was an initial increase 1 x 106 - 5x 106 CFU/ml in TVC from 0 - 6  hours but then from 
6 - 2 4  hours numbers declined to approxim ately the initial starting level (Figure 3.2). 
In bacterial terms, since the log numbers have not changed these fluctuations in 
CFUs/ml over the 24 hours reported herein actually represent only a small increase. 
However the key inference from these results is that the study consortium was stable 
in complete RPMI 1640, a medium com monly used to culture m ononuclear cells, but 
not complete AIMV. Results are consistent with the previous OD measurements. 
Therefore all further work was undertaken in com plete RPMI.
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Figure 3.2 Comparison of the growth of the study consortium in complete RPMI 
or complete AIMV.
Survival of probiotic strains in RPMI1640 or AIM/V culture media was quantified 
by total viable counts (TVC) on agar plates. Briefly, the contents of a capsule 
containing 500 mg of the study consortium at 1 x 1010 CFUs was added to each 
culture medium and then serially diluted down to 1 xlO7 CFU in 4.5 ml of culture 
medium. At time 0 (To), and after 6 (T6 ), 24 (T2 4 ) and 48 hours (T4 8 ), 500pl from the 
1 xlO7 CFU dilution was serially diluted in maximum recovery diluent (MRD) to
f \  9concentrations ranging from 1x10 t o l x 10 and added dropwise to MRSx and MRS 
agar plates. Plates were transferred to an anaerobic incubator for 2-3 days prior to 
enumeration of colonies via total viable counts.
3.3.2 Optimising culture of bacteria with mammalian cells by assessing the 
viability of the study consortium in cell culture medium during co-culture with 
PBMCs
Since the foundation of the in vitro model was the co-culture of mononuclear cells 
with live study consortium bacteria, having determined above that the bacteria 
remained viable in complete RPMI it was imperative to determine the viability during
n
co-culture with mammalian cells. Different starting concentrations of bacteria (10 ,
106 and 104 CFUs/ml) were co-cultured with PBMCs at 106/ml. Current results
n
indicated that organisms at an initial starting concentration of 1 x 10 CFU/ml 
generally proliferated better alone than in co-culture with PBMCs. At To 
approximately 7.5x106 CFU/ml were present reducing markedly within 6 hours to 
approximately 4.5xlO6. In sharp contrast, growth rates increased when organisms
n
were cultured in the absence of PBMCs reaching 1x10 CFU/ml at the same time 
point. By 24 hours although there was a general depletion in the number of viable 
organisms remaining; approximately twice as many viable organisms were present 
when strains were cultured exclusively in supplemented RPMI 1640 compared to 
when strains were cultured simultaneously with PBMCs; values were approximately 
4.0x106 and 2.0x106, respectively, at 24 hours (Figure 3.3 (a)). At an initial value of 
1 x 106 CFU/ml strains generally proliferated better in the presence of the PBMCs than 
in the absence with values reaching approximately 9.75x 106 and 4.0x 106 CFU/ml 
respectively at To and gradually decreasing at T6. However, the rate of decrement was 
greater when strains were cultured in media alone than in the presence of PBMCs 
approximate values were 7.4x105 and 6.03xlO5 CFU/ml respectively. By 24 hours the
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trend was repeated approximate values were 3.8><104 and 3.2><104 (Figure 3.3 (b)). 
Conversely at an initial value o f  approximately 1 xlO4 CFU/ml growth rates were 
similar regardless o f prior culture conditions. At To approximately 1x 104 CFUs/ml 
viable strains were recovered alone and in co-culture with PBMCs values increased 
markedly and doubled within 6hrs to approximately 4.0X 104 By 24 hours although 
there was a general depletion in the number o f viable strains to just above the initial 
starting value at approximately 2 x 104 (Figure 3.3 (c)).
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Figure 3.3. Growth rate of a co-culture of the study consortium bacteria in the
presence of PBMCs cultured in complete RPM11640 (± SEM).
Study consortium bacteria at different starting CFUs/ml (a) lx lO 7, (b) lx l  06, and (c) 
lx l0 4 were co-cultured with (n=2) or without PBMCs (106/ml) over 24 hours and 
total viable counts o f bacteria monitored to (Ohr), t6 (6 hours) and t24 (24 hours). 
Results are an average o f two experiments.
3.3.3 Effects of the study consortium on cytokine production from PBMCs and 
CBMCs in vitro.
The results presented above set the tone for the experimental conditions required for 
cytokine analysis. The immunomodulatory effects o f the study consortium on 
cytokine responses from mononuclear cells (PBMCs or CBMCs) co-cultured with a 
dose course o f the consortium over 24hr was determined. Mononuclear cells cultured 
alone served as an internal experimental control. The cytokines measured where 
TN F-a, IL-12p70, IL-10, IL-6 and IL -1 (3 (Figure 3.4a -  f). Generally PBMCs or 
CBMCs cultured alone (control) generated negligible baseline cytokine production. 
Conversely, mononuclear cells from both groups responded to the consortium in a 
dose dependent manner. Other than at the lowest dose o f 102 CFUs/ml for IL -1 p, IL- 
6 and IL-12p70 the study consortium induced a statistically significant increase in all 
the studied cytokines for both CBMCs and PBMCs when compared to the untreated 
controls. The effect o f  the consortium on TG Fpi was also considered. Since TG Fpi 
typically occurs in a latent form not readily detectable by ELISA, cell/bacteria free 
supernatants were also acidified then neutralised to release active T G F p i. The 
capacity o f the consortium to induce TGF-pi responses after activation by CBMCs 
and PBMCs occurred in a dose independent manner. These responses when 
compared to the controls where not statistically significant at any dose. Interestingly 
the difference in TGF-pl production between PBMCs and CBMCs measured after 
activation followed a similar trend as all the other cytokines measured with PBMC
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again upregulating stronger TGF-(31 immune responses to the presence o f  the 
consortium compared to CBMCs, these difference were however only statistically 
significant at low consortium doses o f 103 (P < 0.019) and 102 (P < 0.048) CFUs/ml.
The cytokine response made by adults versus neonates was also compared and 
although there were no statistical differences in TN F-a, IL-6 and IL-1 p production 
between PBMCs and CBMCs in response to the study consortium, IL-12p70 and IL- 
10 production was significantly impaired in the neonate compared to the adult (Table 
3.2.).
The results presented herein serve to highlight the distinct developmental differences 
between neonatal and adult immunity as represented by differences in cytokine 
kinetics between PBMCs and CBMCs co-cultured in the presence o f the consortium. 
Generally CBMCs demonstrated an attenuated ability to induce a cytokine response 
in response to co-culture with the consortium at the strongest doses in comparison to 
adult PBMCs. PBMCs always produced the strongest cytokine responses compared 
to CBMCs at the highest consortium dose for all cytokines measured. The most 
striking difference was the reduced capacity for IL-12p70 production by CBMCs in 
response to the consortium (Figure 3.4b). Overall the ability o f the consortium to 
induce cytokines responses in CBMCs versus PBMCs samples varied with each of 
the cytokines selected for analysis.
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Figure 3.4 (i) The effect of a dose course of a study consortium of probiotics on 
cytokine production in pg/ml (± SEM) by n = 25 adult peripheral blood mononuclear 
cells (PBMCs dark grey bars) and n = 25 umbilical cord blood mononuclear cells 
(CBMCs white bars) in comparison to the unstimulated control. P-values < 0.05 are 
denoted on the graphs with an. * PBMCs or CBMCs at 106/ml were co-cultured with 
doses of the study consortium (ranging from 106 to 102 CFUs/ml indicated on the x- 
axis) for 24hr. Cell/bacteria free culture supernatants were harvested for later analysis of 
(a) TNF-a and (b) IL-12p70 using specific ELISAs in accordance with the 
manufacturer’s instructions.
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Figure 3.4 (ii) The effect of a dose course of a study consortium of probiotics on 
cytokine production in pg/ml (± SEM) by n = 25 adult peripheral blood 
mononuclear cells (PBMCs dark grey bars) and n = 25 umbilical cord blood 
m ononuclear cells (CBMCs white bars) in comparison to the unstimulated control. P- 
values < 0.05 are denoted on the graphs with an. * PBMCs or CBMCs at 106/ml were 
co-cultured with doses o f the study consortium (ranging from 10 to 10 CFUs/ml 
indicated on the x-axis) for 24hr. Cell/bacteria free culture supernatants were 
harvested for later analysis o f (c) IL -1 p and (d) IL-6 using specific ELISAs in 
accordance with the m anufacturer's instructions.
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Figure 3.4 (iii) The effect of a dose course of a study consortium of probiotics on 
cytokine production in pg/ml (± SEM) by n = 25 adult peripheral blood 
mononuclear cells (PBMCs dark grey bars) and n = 25 umbilical cord blood 
mononuclear cells (CBMCs white bars) in comparison to the unstimulated control. P-
values < 0.05 are denoted on the graphs with an. * PBMCs or CBMCs at 106/ml were
6 2co-cultured with doses o f the study consortium (ranging from 10 to 10“ CFUs/ml 
indicated on the x-axis) for 24hr. Cell/bacteria free culture supernatants were 
harvested for later analysis o f (e) IL -10 and (f) TG F-pi using specific ELISAs in 
accordance with the m anufacturer’s instructions.
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Table 3.2. Results of statistical analysis of effect of each dose (CFUs/ml) of the 
study consortium on production of IL-12p70 and IL-10 by CBMCs compared
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u h
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Comparisons 
between 
PBMCs and 
CBMCs cytokine 
responses at each 
dose
IL-12p70 IL-10 TG F-pl
106 0.001 0.001 No significance
105 0.002 0.088 No significance
104 0.022 0.057 No significance
103 0.015 0.006 0.019
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102 No significance 0.057 0.048
Interestingly statistical significance was not reached at any dose when the effect of 
study consortium on production of other classical pro-inflammatory cytokines such as 
TNF-a IL-1 p and IL-6 was compared between CBMCs and PBMCs.
3.3.4 Effects of the study consortium on cytokine production from mitogen- 
and superantigen-stimulated CBMCs and PBMCs.
The study consortium was co-cultured in the presence of CBMCs or PBMCs for 24 
hour followed by stimulation with phytohaemagluttinin (PHA) or staphylococcal 
enterotoxin B (SEB) for a further 24 hour. The dose course experiments conducted 
above indicated that 1 xlO6 CFUs/ml stimulated a significant cytokine response so 
only this dose was used for these experiments. By culturing bacteria at this dose with 
MNCs at 1 x 106/ml a 1:1 ratio of MNC to consortium was achieved. For all 
figures/tables the presence of consortium bacteria is represented with (+).
In figure 3.7 it can be seen that SEB and PHA alone induced significant increases in 
IL-13, IFN-y and IL-17 by CBMCs and PBMCs. In the presence of the study 
consortium, the IL-13 response to both SEB and PHA was significantly decreased in 
PBMCs (P = 0.011 and 0.007) respectively but not by CBMCs. The converse was 
seen for IFN-y, with SEB- and PHA-induced IFN-y responses potentiated in the 
presence of study consortium by PBMCs (P = 0.036 and 0.018), respectively. This 
trend was also observed for SEB induced IFNy by CBMCs (P = 0.017) but not PHA 
induced IFN-y production by CBMCs. Notably, in the absence of any stimuli the
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study consortium induced IL-13 by CBMCs but IFN-y by PBMCs. PHA and SEB 
induced significant increases in IL-17 from PBMCs (P = 0.0007 and 0.00001) 
respectively but not for CBMCs. Interestingly, the study consortium significantly 
decreased SEB-induced IL-17 by PBMCs (p=0.003). In marked contrast the presence 
of the consortium appeared to potentiate PHA- and SEB- induced IL-17 by CBMCs 
however this did not reach statistical significance (p = 0.099 and 0.066 respectively). 
The SEB (P=0.026) and PHA (p=0.032) induced IFN-y responses in the presence of 
the study consortium were significantly greater by PBMCs than CBMCs. The SEB 
(P=0.034) induced IL-17 response in the presence of the consortium was also 
significantly greater by PBMCs than CBMCs.
The current results also indicated that the consortium was able to significantly induce 
IL-17 (P=0.03), IFN-y (P=0.02), but not IL-13 (P=0.704), compared to the untreated 
control, independent of T-cell mitogen stimulation (provided by SEB) or lymphocyte 
mitogen stimulation (provided by PHA) suggesting that these cytokines can also be 
induced by the consortium from a non-lymphocyte source. These data indirectly 
correlate with the results showing that CD 14 and CD 14 negative mononuclear cells 
fractions are able to respond to the consortium via cytokine production (See 3.3.6).
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Figure 3.5 Effects of consortium on SEB and PHA induced cytokine production
Employing n = 15 umbilical cord blood mononuclear cells (white bars) and n = 15 
adult peripheral blood mononuclear cells (grey bars). Mononuclear cells from 
umbilical cord and adult peripheral blood were cultured for 24 hours in the presence 
o f 106 CFUs/ml o f the consortium denoted by (+) and then a further 24 hours in the 
presence o f SEB (200ng/ml) or PHA (1 pg/ml). Cell-free culture supernatants were 
prepared and then (a) IL-13, (b) IFN-y, and (c) IL-17 (pg/ml ± SEM) measured using 
specific ELISAs. The student t test was employed to determine whether there was a 
statistically significant difference in mononuclear cell response between (1) 
consortium and the control. (2) SEB or PHA stimulated mononuclear cells versus the 
control and (3) SEB or PHA stimulated mononuclear cells alone versus SEB or PHA 
stimulated mononuclear cells in the presence o f the consortium. Details o f  p-values < 
0.05 are denoted on the graphs with an *
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3.3.4.1 Effects of the study consortium on IFNy/IL-13 ratio.
The PHA and SEB induced IFN-y/IL-13 ratio (Fig 3.6) was significantly enhanced in 
the presence o f the study consortium by both PBMCs and CBMCs, highlighting the 
potential o f the consortium to influence T hl/Th2 polarisation in favour o f  Thl 
responses. This polarizing effect is consistent with emerging research by (Ghadimi et 
al. 2010) indicating that LAB enhance autophagic ability o f mononuclear phagocytes 
by increasing Thl autophagy-promoting cytokine IFN-y levels and reducing Th2 
autophagy-restraining cytokines IL-4 and IL-13. Regulation o f  the onset 
and/progression o f  potential IgE-mediated allergy responses requires an appropriate 
ratio o f  T h l/T h2 /T h l7  cytokines to exert control over physiologically, and 
immunologically regulated processes involved during the onset and progression of 
allergy. The study consortium has been able to induce both Thl promoting cytokines, 
such as IFN-y, and immunosuppressive Th2 cytokines like IL-13.
14000
PBMCs □  CBMCs
12000
10000
ro 6000
Control (+)
■ y ~ h  ,
SEB SEB(+) PHA PHA (+)
Figure 3.6 Ratio of IFNy/IL-13 levels in supernatants
CBMCs (n = 15) or PBMCs (n = 15) were cultured for 24 hours in the presence o f 
106 CFUs/ml o f the consortium denoted by (+) and then a further 24 hours in the 
presence o f SEB (200ng/ml) or PHA (1 pg/ml). Cell free culture supernatants were 
prepared and then IL-13 and IFN-y measured prior to calculation o f the ratio o f these 
two cytokines. The student t test was employed to determine whether there was a 
statistically significant difference in mononuclear cell response between (1) 
consortium and the control. (2) SEB or PHA stimulated mononuclear cells versus the 
control and (3) SEB or PHA stimulated mononuclear cells alone versus SEB or PHA 
stimulated mononuclear cells in the presence o f the consortium. Details o f p-values < 
0.05 are denoted on the graphs with an *
126
3.3.4.2 Effects of the study consortium on IL-17/IL-13 ratio
To further investigate the potential role of the consortium upon novel pro- 
inflammatory cytokines also involved in the pathogenesis of IgE mediated allergy, 
the IL-17/IL-l3 ratio induced by the consortium was also monitored (Fig 3.7). IL-17, 
a novel pro-inflammatory Thl cytokine produced by activated T helper cells (Aarvak 
et al. 1999), plays an upstream role in T cell-triggered inflammation and 
haematopoiesis by stimulating stromal cells to secrete other cytokines and growth 
factors. IL-17 is capable of stimulating production of the pro-inflammatory cytokine 
IL-6 (also analysed in this study), proliferation of T cells as well as growth and 
differentiation of CD34+ human progenitors into neutrophils (Fossiez et a l 1996; 
Onishi and Gaffen 2010). Current results indicated that the IL-17/IL-l3 ratio was not 
significantly altered by the consortium in both PBMCs and CBMCs under any of the 
treatment conditions, and there were no significant difference in the ratio between 
PBMCs and CBMCs. Although the IL-17/IL-l 3 ratio appeared to increase when 
CBMCs where exclusively treated with SEB or when SEB stimulated PBMCs were 
treated with the consortium, neither of these conditions reached statistical 
significance (P=0.06 and 0.064 respectively. However this could be attributed to the 
small sample size employed for analysis.
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Figure 3.7 Ratio of IL-17/IL-13 levels in supernatants
CBMCs (n = 15) or PBMCs (n = 15) were cultured for 24 hours in the presence of 
10A CFUs/ml o f the consortium denoted by (+) and then a further 24 hours in the 
presence o f SEB (200ng/ml) or PHA (1 pg/ml). Cell free culture supernatants were 
prepared and then IL-17 and IL-13 measured prior to calculation o f the ratio o f these 
two cytokines. The student t test was employed to determine whether there was a 
statistically significant difference in mononuclear cell response between (1) 
consortium and the control. (2) SEB or PHA stimulated mononuclear cells versus the 
control and (3) SEB or PHA stimulated mononuclear cells alone versus SEB or PHA 
stimulated mononuclear cells in the presence o f the consortium. Details o f p-values < 
0.05 are denoted on the graphs with an *
3.3.5 Requirement for contact between study consortium bacteria and 
mononuclear cells.
The effect o f study consortium bacteria on MNCs could reflect secreted bacterial 
products or require direct contact between the bacteria and the mammalian cells. This 
was investigated using transwells with a pore size o f 0.4pm to prohibit contact 
between the bacteria and the MNCs. The presence o f a transwell separating 
mononuclear cells and study consortium into distinct compartments abolished the 
cytokine-inducing effect o f the bacteria (Figure 3.9). This was seen for all the 
cytokines included for analysis: T N F-a (Figure 3.9(a)), IL-10 (Figure 3.9 (b)) and IL- 
1 p (Figure 3.9 (c)). An additional dose response curve o f the study consortium was
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performed with IL-12p70 as the o u tp u t, and this confirmed that contact was required 
between bacteria and PBMCs or CBMCs at all doses o f bacteria studied (Figure
3.10).
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Figure 3.8. Requirement for contact between study consortium and 
mononuclear cells for cytokine responses.
Mononuclear cells from umbilical cord (CBMCs) and adult peripheral blood 
(PBMCs) were cultured for 24 hours in the presence o f  106 CFUs o f the consortium 
and remained in contact or were separated by a 0.4pm transwell. Cell free culture 
supernatants were prepared and (a) TNF-a, (b) IL -1 (3 (c) IL-10, measured using 
specific ELISAs. Significant differences (p < 0.05) between the response by CBMCs 
and PBMCs in response to the consortium in the presence and the absence o f a 
transwell are denoted by *
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Figure 3.9 Requirement for contact between study consortium and mononuclear 
cells for IL-12p70 response.
Mononuclear cells from umbilical cord (n = 3) and adult peripheral blood (n = 3) were 
cultured for 24 hours in the presence of different doses of the study consortium and were 
allowed to remain in contact or were separated by a 0.4pm transwell. Cell free culture 
supernatants were prepared and then IL-12p70 measured using specific ELISAs.
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Significant differences (p < 0.05) between the response by CBMCs and PBMCs in
response to the consortium in the presence and the absence of a transwell are denoted by 
*
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3.3.6 CD14+ monocytes are required for the response by MNCs to the study 
consortium
Having confirmed the requirement for contact between MNCs and study consortium 
bacteria, a candidate group o f responsive cells within the MNC preparation were 
studied. M onocytes were purified from total MNC preparations by positive selection 
with anti-CD 14 magnetic microbeads. MNCs were first isolated from adult peripheral 
blood or umbilical cord blood samples by density gradient centrifugation over 
HistopaqueCR-1077 as in (2.1.3). Contaminating glycophorin positive red blood cells 
(RBCs) were first removed from the mononuclear cell preparation by labelling 
MNCs with glycophorin magnetic microbeads (Miltenyi Biotec), in accordance with 
the m anufacturer’s guidelines. Labelled MNCs were then applied to the autoMACS 
and programme ‘depleteS’ used to deplete the MNC preparations o f RBCs. RBC- 
depleted M NCs eluted from the magnetic column were then used for preparation o f 
CD144 monocytes and CD 14' depleted MNCs. MNCs were counted and then 
labelled with CD 14 magnetic microbeads. The CD 14 depleted fraction was used as a 
source o f MNCs virtually devoid o f  monocytes so that comparison o f glycophorin 
depleted MNCs, CD14+ monocytes and CD 14 'depleted MNCs could be made. All 
preparations were monitored using flow cytometry with anti-CD 14 antibody (Figure
3.10).
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Figure 3.10 Flow cytometry was used to monitor preparation of CD14+ monocytes.
The relative abundance of CD 14 cells in (a) positively selected CD 14 monocytes, and 
(b) CD 14' depleted MNCs is shown. Reactivity to anti-human CD 14: FITC antibody is 
shown on the x-axis and SSC was used as the y-axis parameter. Total MNCs, CD 14 
monocytes and CD 14'depleted MNCs (all at 106/ml) were exposed to 106 CFUs/ml of the
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study consortium for 24hr. TNF-a was measured in the cell/bacteria free culture 
supernatants.
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Figure 3.11 Contribution of CD14+ monocytes to cytokine response to study 
consortium bacteria.
A single dose o f  study consortium bacteria (106 CFUs/ml) were co-cultured with 
glycophorin depleted MNCs (n=3), CD14+ monocytes (n=3) or CD 14 depleted 
MNCs (n=3) (106 cells/ml) for 24 hours with later analysis o f  TN F-a.
3.4 Discussion
This in vitro study analysed the immunomodulatory attributes o f a study consortium 
o f probiotic strains hypothesised to impact positively on immune development and 
impart anti-allergic immune function. These immunostimulatory properties were 
assessed by testing interactions o f the consortium with mononuclear cells prepared 
from human adult peripheral blood and umbilical cord blood, and responses were 
measured in terms o f cytokine production by mononuclear cells in our in vitro model 
system.
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Due to the need to co-culture bacteria with mononuclear cells in this model system it 
was imperative to establish the effects of standard mammalian cell culture systems on 
the study consortium viability. The present results indicate that the study consortium 
maintained viability in cell culture media RPMI1640/Glutamax supplemented with 
5% FBS and 2-ME for at least 24 hours, in comparison to growth rates in the serum 
free medium AIMV media, as indicated by the total viable counts. Comparable 
results were obtained using optical density measurements where turbidity was applied 
as a proxy for bacterial proliferation. Bacteria viability was retained in the presence 
of mononuclear cells in RPMI/FBS/2-ME so this media was used for the remainder 
of the in vitro experiments. Although these steps ensured robustness of the study, 
research has demonstrated that viability of probiotic bacteria is not an absolute pre­
requisite for cytokine induction in response to interaction with haematopoietic cells, 
with heat killed probiotic bacteria also displaying immunogenicity (Sashihara et a l
2006).
3.4.1 Immunomodulatory effect of the study consortium on production of 
inflammatory cytokines by umbilical cord blood and adult peripheral blood 
mononuclear cells
In previous studies, lactobacilli and bifidobacteria strains have been demonstrated to 
have a strong cytokine inductive capacity on PBMCs in vitro. IFN-y, TNF-a, IL-1 p, 
IL-6 , IL-12 and IL-10 have all been induced experimentally upon interaction with 
probiotic bacterial strains (Miettinen 1998; Haller 2000; Lammers et a l 2003; Niers 
2005; Shida 2006; Helwig et a l 2006; Foligne et a l 2007; Drouault-Holowacz et a l
2006). Similarly, the current study demonstrated a similar capacity for consortium 
strains to induce TNF-a, IL-12p70, IL-10, IL-6 and IL-1 p in a dose dependent 
fashion by CBMCs and PBMCs. The most notable differences were the dramatically 
reduced response by CBMCs for production of IL-12p70 at all doses and IL-10 at 
high doses of the study consortium. This may in part be reflective of the immature 
developmental stage of newborn immunity (Nilsson 2004; Gabrielssons 2001). 
However, interpretation must take into account that kinetics of TNF-a, IL-6 and IL- 
1 p production were comparable between adults and neonates. Although at the highest 
consortium dose production of these 3 key pro-inflammatory cytokines was 
attenuated in CBMCs. These observations are in line with numerous studies
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indicating that newborns are deficient in their ability to produce the important Thl 
cytokine IL-12p70 (Nilsson et a l 2004; Tube et a l 2011) a predilection that supports 
the framework for atopic sensitisation in infancy in genetically predisposed 
individuals (Upham et a l 2002; Prescott et a l 2003; Holt et a l 2005). Additionally 
post-natal vulnerability to mount stronger Th2 immune responses concomitant with 
weaker allergen-specific Thl response and variation in antigen presenting cell 
function in early life supports the postulate of the intrinsically Th2 skewed nature of 
newborn immunity. Fortunately, this scenario improves post-natally upon 
immunological maturity, shaped by the quality of immune education received ex 
utero; of which, interactions with immunomodulatory probiotic strains of the 
microbiota is crucial. This is one of few studies considering the impact of probiotics 
on cytokine production by umbilical cord blood mononuclear cells in vitro and 
provides an insight into how newborn immunity might be shaped at an 
immunological level according to early interactions with probiotic bacteria.
3.4.2 Immunomodulatory effect of the study consortium on production of anti­
inflammatory cytokines by umbilical cord blood and adult peripheral blood 
mononuclear cells
This in vitro studied demonstrated that the consortium was directly capable of 
inducing the anti-inflammatory cytokine IL-10 without the need of additional 
mononuclear cell mitogenic stimulation and was in line with data from a clinical 
study demonstrating that ingestion of Lactobacillus rhamnosus is associated with 
high serum levels of IL-10, which is preceded by a rise in mitogen-induced IL-10 
from PBMCs (Pessi et a l 2000). Current results are also in keeping with a study 
demonstrating that in vitro addition of probiotics to PBMC cultures resulted in 
enhanced proliferation and production of IFN-y, IL-10, and TNF-a (Flinterman et a l
2007).
The effect of the study consortium on another anti-inflammatory cytokine TGF-pi 
from CBMCs and PBMCs was also considered. Since TGF-pi typically occurs in a 
latent form not readily detectable in most ELISAs utilising monoclonal antibodies, 
samples were acidified to release detectable TGF-pl. Levels of TGF-pi detectable in 
culture supernatants were higher for PBMCs than CBMCs. The study consortium 
potentiated TGF-pi levels in PBMCs but not CBMCs. The ability of another
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probiotic strain, Lactobacillus johnsonii, to induce TGF-pl has been demonstrated 
using the intestinal epithelial cells line Caco-2 and PBMCs (Haller et al. 2000).
Results of the current study supports observations that the anti-inflammatory IL-10 
and TGF-pi mediated responses can be induced by probiotic bacteria. For instance 
Lactobacillus paracasei a constituent of the current study consortium induced the 
development of a population of CD4+ T lymphocytes with low proliferative capacity 
and high TGF-/? and IL-10 production, reminiscent of Trl cells implicated in oral 
tolerance and gut homeostasis (von der Weid et a l 2001). Since it is known that 
probiotics stimulate dendritic cells to enhance IL-10 production (Drakes et al. 2004) 
and that IL-10 is essential for Trl expansion (Wakkach et a l 2003), probiotics may 
induce the development of Trl through dendritic cells stimulation. Since IL-10 and 
TGF-P are the archetypal cytokines involved in differentiation of Treg populations 
the effects of perinatal supplementation in enhancing peripheral blood levels of 
putative Tregs was considered in chapter 6.
3.4.3 Effects of the consortium on PHA and SEB induced responses
This part of the study considered the immunomodulatory impact of the study 
consortium on production of the prototypic Thl (IFN-y), Th2 (IL-13) and Thl7 (IL- 
17) cytokines. These responses were first monitored by separately priming CBMCs 
and PBMCs with either (PHA) or (SEB) alone; or separately priming CBMCs and 
PBMCs with either (PHA and IFN-y) or (SEB and IFN-y).
Interestingly, the study consortium potentiated IFN-y responses by both SEB and 
PHA stimulated PBMCs but only SEB stimulated CBMCs. The opposite effect was 
seen for IL-13 production. PHA and SEB were both able to significantly stimulate 
IL-13 production by CBMCs and PBMCs but this response was attenuated in the 
presence of the study consortium for both PHA and SEB for PBMCs but, only SEB 
for CBMCs. Overall; these results indicate that the study consortium favours Thl 
responses to the detriment of a Th2 response. This is consistent with previous studies 
indicating that lactobacilli and bifidobacteria indicating increased in vitro production 
of Thl cytokines from probiotic treated PBMCs or CBMCs (Cross et a l 2001) 
Moreover NK cell IFN-y production has also been demonstrated to increase in 
response to probiotics (Ogawa et a l 2006).
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Generally the IFN-y response by CBMCs was significantly reduced when compared 
to PBMCs under all treatment conditions, an observation that supports the attenuated 
CBMC IL-12p70 response was compared to the PBMC IL-12p70 in response to the 
consortium. The current data is in keeping with all published studies highlighting 
immunological difference between adults and newborns in inducing Thl immunity in 
response to stimuli by micro-organisms (White et a l 2002).
IL-12p70 is a key cytokine in the initiation of IFN-y production by human PBMCs, 
as well as monocytes (Bekeredjian-Ding et a l 2006). Given the synergy between IL- 
12p70 and IFN-y in maintaining Thl responses, the previously observed lack of IL- 
12p70 production by CBMCs, in response to the study consortium in part, explains 
the lack of IFN-y produced by activated CBMCs. Induction of IL-12p70 in response 
to the consortium is important for subsequent generation of IFN-y and potentiating 
Thl immune responses (Hessle et a l 1999; Kato et a l 1999). Current results were in 
line with in vitro experiments by other authors, demonstrating that the stimulation of 
PBMCs from healthy donors with lactobacilli and bifidobacteria species enhanced 
secretion of IL-12 (Cross et a l 2001). Taken together the current results indicate that 
the Th2-inhibitory effects of IFN-y and IL-12p70 produced by the consortium if 
replicated in vivo via a course of perinatal probiotic supplementation, may be 
restricted to the early phase of polarisation of immature ThO cells. Experiments were 
initiated to explore this by considering the effects of exogenous IL-12p70 on the 
CBMC response or neutralising IL-12p70 on the PBMC response.
Current results indicate that synergy between IFN-y and IL-12p70 is vitally
important for the imposition of Thl cytokine responses induced by the consortium.
Furthermore, intrinsic immunomodulatory mechanisms operating to limit Thl type
responses during the neonatal stage appear to be operating, and highlight a
reasonable explanation for the limited consortium-mediated Thl response by
CBMCs. These observations are in line with the documented literature that Thl
responses are toxic to the placenta and are inhibited by trophoblast-derived IL-10 and
progesterone (Krishnan et a l 1996; Roth et a l 1996; SzekeresBartho et a l 1996). At
birth, Thl responses are of a lower magnitude than later in life and newborn CD4+ T
cells produce lower IFN-y levels than adult naive T cells due to hypermethylation at
CpG and non-CpG sites within the IFN-y promoter (White et a l 2002). In the
presence of suboptimal CD28 co-stimulation, IL-12 stimulates the production of both
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IL-4 and IFN-y by neonatal CD4+ T lymphocytes, whereas adult cells do not produce 
IL-4 under similar conditions (Ohshima and Delespesse 1997). Although the current 
study did not assess the effects of probiotic bacteria on other prominent Th2 
cytokines like IL-4 and IL-5, these effects have been studied by others, and despite 
experimental differences probiotic bacteria have been demonstrated to inhibit IL-4 
and IL-5 production by mitogen stimulated PBMC (Pochard et al. 2002; Pierre 
2002).
The role of the relatively novel pro-inflammatory cytokine IL-17 produced by 
activated T helper cells (Aarvak et al. 1999) has generated much interest in studies of 
allergic disease and asthma. Therefore the effect of the study consortium on IL-17 
production by CBMCs and PBMCs was also considered. Both PHA and SEB 
significantly induced IL-17 from PBMCs than CBMCs. Interestingly the study 
consortium potentiated the effects of SEB and PHA for CBMCs but had negligible 
effect on the response by PBMCs.
3.4.4 Requirement for contact between bacteria and mononuclear cells
Probiotic bacteria may mediate their effects via direct cellular contact or by release of 
soluble antimicrobial factors that interact with the host immune system. Since the 
process of probiotic bacterial translocation via the M cell through the gut epithelial 
barrier is well characterized; transwell experiments were conducted to determine 
whether cytokine responses induced by the consortium were dependent on direct 
contact with mononuclear cells and not a secreted immunogenic product of probiotic 
metabolism. As a result of M cell mediated translocation in vivo, probiotic bacteria 
may encounter macrophages or DCs to stimulate GALT mucosal immunity via 
induction of suppressive pro-inflammatory immune responses
The current in vitro study indicated that direct interaction of the consortium with 
mononuclear cells was necessary to initiate immunomodulatory signals. A generally 
accepted paradigm is that dietary consumption of probiotic rich food culminates in 
interaction of immunoregulatory LAB with cells of the GALT system supported by 
evidence demonstrating direct interaction of LAB with intra-intestinal lymphoid foci 
(Cross et al. 2001).
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Since TNF-a, IL-12p70, IL-lp and IL-10 cytokine production by CBMCs and 
PBMCs was essentially abolished in the presence of a transwell prohibiting contact 
between bacteria and mononuclear cell; the current in vitro study indicated that direct 
interaction of the consortium with PBMCs or CBMCs is necessary to initiate 
immunoregulatory signals. Other studies have demonstrated that direct contact 
between LAB and intestinal cells is necessary induce expression of cytokine 
receptors on interferon activated human intestinal cells (Delneste et al. 1998).
3.4.5 Evaluation of the principal cellular source of cytokine production from 
mononuclear cells in response to the consortium
This aspect of the in vitro study sought to determine the cellular source of cytokines 
produced in response to the consortium. A comparison was made of total MNCs 
preparations that retained their monocyte population, MNC preparations virtually 
devoid of monocytes and a preparation of cells comprised only of CD14+ monocytes. 
TNF-a was selected as the cytokine for this part of the study chiefly because it is a 
marker of heightened immunological activity and a mediator of both Thl and Th2 
cytokine pathways. From these studies, it is clear that monocytes are the main 
contributors to inflammatory cytokine response to the study consortium. However, 
whether they are the actual source of the cytokines or are essential to the response 
made by other non-monocyte cells remains to be determined. There was some 
cytokine production in the CD 14 depleted preparation suggesting that other cell 
types, in all likelihood dendritic cells, might also contribute to the total cytokine 
output in response to the study consortium bacteria. Unfortunately, the need for large 
volumes of umbilical cord blood for this experiment means that the role of neonatal 
monocytes was outwith the present thesis, but would be an interesting area of 
research for the future.
The induction of cytokine secretion in response to bacterial cell walls of the intestinal 
microbiota is serum-dependent, and both CD 14 dependent and CD 14 independent 
pathways are involved (Chen et a l 1999). It has been demonstrated that lactobacilli 
induce secretion of IFN-y by human NK cells (Haller et a l 2000). This could explain 
why the CD 14 depleted fraction was able to induce a TNF-a cytokine response to the 
consortium. Further purification of the CD 14 depleted fraction into component NK, T 
and B cell subpopulation might clarify the role of CD 14 independent responses to the 
consortium. This analysis should also be extended to other cytokines since IL-12p70,
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IL-10 secretion is produced by B cells and activated APCs, IL-6 is secreted by T 
cells, and IL-1 p are also secreted by T and B lymphocytes, and NK cells (Fitzgerald 
et a l 2001).
3.4.6 Limitations of the study
The present study employed simplified in vitro systems in which key players of the 
mucosal regulatory response are lacking, including the gastrointestinal epithelial cells 
that regulate interactions between the consortium and monocytes. In this study 
mononuclear cells offer only a simple model for studying cytokine production by 
haematopoietic cells in response to lactobacilli and bifidobacteria. In vivo, lactobacilli 
and bifidobacteria strains are not in direct contact with mononuclear cells but instead 
interact with the gastrointestinal epithelium, where strains can be taken up by 
macrophages, DCs or M cells at the Peyers patches potentially leading to activation 
of lymphocytes and monocytes residing in the Peyers patches (McCracken and 
Lorenz 2001). Mononuclear samples consist of a rich source of monocytes NK, T and 
B cells; this study offers an adequate model for study of the immunological 
properties of lactobacilli and bifidobacteria in the GALT. In vitro bacteria-host cell 
studies facilitate the selection of novel probiotics strains for clinical trials. But the 
role of the consortium on the gastrointestinal epithelium still remains to be elucidated 
and co-culture with the consortium with a suitable intestinal cell line such as the 
CaCo2 and HT-29 are suitable candidates for future direction.
Although this in vitro study cannot reflect the strain diversity of the microbial 
ecosystem, we postulated that employing a consortium of four different probiotic 
strains known to flourish post-natally in the newborn GIT would account for the 
strain specific immunomodulatory diversity.
The premise that a vast majority of the intestinal microbiota is currently unculturable 
employing conventional techniques adds further complexity to the probiotic concept, 
and further opens the door for research defining optimal probiotic consortiums for 
immunomodulatory purposes in atopic disorder.
3.4.7 Final summary
Post-natal colonisation of the neonatal GIT provides immunomodulatory activity 
during a critical period in life, when immunoregulatory aberrancies, due to
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inadequate microbial colonisation may induce IgE-mediated atopic clinical disease 
(Isolauri E 2004).
The consortium in the present study induced in vitro mononuclear cells to generate a 
monocyte dependent, dose dependent release of the pro-inflammatory cytokines 
TNF-a, IL-6, IL-ip, IL-17, IL-12p70, IFN-y, the anti-inflammatory cytokines IL-10 
and the regulatory cytokine TGF-pi. The observed cytokine responses were 
dependent on direct contact between the consortium and mononuclear cells.
Interestingly, CBMCs displayed distinctly attenuated cytokine induction kinetics in 
comparison to PBMCs, and were impaired in their ability to produce IL-12p70 and 
IL-10 following incubation with the consortium. These two observations are likely 
intimately linked and reinforce the notion of the under-developed Thl scheme of 
newborn immunity that renders newborns susceptible to intracellular infections, for 
which Thl-cell mediated immunity is protective (Siegrist 2001; Adkins et a l 2004; 
March ant and Goldman 2005).
This is one of few documented studies assessing the kinetics of cytokine production 
from CBMCs in response to a consortium of probiotic strains at a time when neonatal 
Thl immunity is underdeveloped. Newborns exhibit an inherent immunological 
naivety at mounting Thl immune responses, and a propensity to respond to antigenic 
stimuli with a Th2 biased scheme of immunity. Generally, superior Thl cytokine 
inducing kinetics in response to the consortium was observed in PBMC samples 
compared to CBMC samples with all cytokines measured. This can be in part 
explained by differences in developmental stages and maturational differences 
between newborn and adult immunity,
In summary, the immunomodulatory efficacy of the consortium is in line with 
numerous in vitro studies highlighting that Gram-positive probiotic bacteria of 
lactobacilli and bifidobacteria origin actively induced the expression of a range of 
potent pro-inflammatory and regulatory cytokines, while down-regulating Th2 
responses from mononuclear cells in vitro (Miettinen 1996; Miettinen 1998; Hessle 
1999; Haller 2000; Shida 2006; Helwig et a l 2006).
The pro-inflammatory cytokines TNF-a and IFN-y, mediate the inflammatory 
response, whereas anti-inflammatory cytokines such as IL-10, are negative regulators
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(Chen et al. 1999). The study consortium was able to engage both inflammatory and 
anti-inflammatory arms o f  the immune response albeit to a greater extent in adults. 
This discrepancy in newborn versus adult responses to the consortium implicates 
engagement o f immunological pathways leading to a more subtle attenuated 
inflammation in the newborn to probiotic bacteria compared to the adult. At the 
gastrointestinal mucosal level this mode o f inflammation is postulated to encourage a 
regulatory scheme o f immunity (Figure 3.12).
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Figure 3.12 Interaction of probiotic bacteria with intestinal epithelial cells and 
dendritic cells from GALT or MLN. Diagram hand-drawn and adapted from (Lebeer et 
al. 2010). Probiotic bacteria are interactive with intestinal epithelial cells (EECs) and 
dendritic cells (DCs), by virtue of a dynamic mucus layer where they indiscriminately 
encounter DCs through two routes: (1) DCs residing in the lamina propria which sample 
luminal bacterial antigens by passing their dendrite processed between IECs into the gut 
lumen, and (2) DCs interacting directly with probiotic bacteria that gained access to the 
GALT via a specialized epithelial cells, termed M cells. The interaction of DCs or 
enterocytes with MAMPs present on the surface macromolecules of probiotic bacteria 
induces a specific molecular cytokine response via signal transduction through the TLRs, 
which interpret probiotic signals via activation of cytokine transcriptional pathways. Other 
important responses of DCs against probiotics include the production of major 
histocompatibility complex molecules for antigen presentation, and co-stimulatory molecules 
that polarize T cells into T helper or CD4+CD25+ regulatory T cells in the mesenteric lymph 
nodes or sub epithelial dome of the GALT (Lebeer et al. 2010).
At present, the availability of comparative data on the ability of probiotic strains to 
induce cytokine production within a similar in vitro experimental system, especially 
models employing CBMCs, are limited (Nier 2005; Foligne et al. 2007). However 
further studies involving co-culturing probiotics with mononuclear cells are coming 
to the forefront with a view to: (1) Determine mechanisms of probiotic 
immunomodulatory action to regulate immune responses from allergen-stimulated 
mononuclear cells extracted from allergic patients, and (2) select probiotics by virtue 
of their in vitro capacity to produce anti-inflammatory cytokines such as IL-10, 
implicated for its regulatory role in dysregulated immune disorders (Cross et al. 
2001).
In light of the in vitro data, the present study demonstrates that the consortium can 
boost in vitro immune function in a way that can potentially lessen the symptoms of 
allergic disease in an in vivo scenario due to the ability of the consortium to down 
regulate PHA and SEB induced (Th2) IL-13 while up-regulating (Thl) IFN-y 
responses. Furthermore, the results were consistent with previous data by Pierre 
(2002), who noted that LAB were capable of potentiating mitogen induced Thl 
cytokine responses by mononuclear cells, while down regulating mitogen-induced 
Th2 responses from the same cells.
The question of the net effect of the consequences of immune stimulation provided 
by the consortium in vitro, and whether the consortium can potentially promote 
suppressive Th2 antagonising immunomodulatory effects in sufferers of IgE 
mediated allergies, remains unanswered on the basis of the in vitro data presented.
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However, the in vitro immunomodulatory characteristics of the consortium will be 
used to forecast potential mechanisms of immunomodulatory action in allergic 
disorder.
Characterisation of interactions between commensal bacteria and the GALT provides 
the basis for understanding the role of the gut microbiota in achieving a homeostatic 
disease-free state in the host. This in vitro study demonstrated that the consortium 
exerts an immunosuppressive function via induction of the suppressive cytokines IL- 
10 and TGF-pi likely produced by regulatory T cells and T helper cells, which 
contribute to the anti-inflammatory tone of the gastrointestinal immune system.
Chapter 4: Probiotics in the prevention of atopic disorder: A randomised 
controlled trial
4.1 Background
Atopic disorder encompasses a broad range of diseases including atopic eczema, 
allergic rhinitis and asthma. These disorders are marked by a genetic propensity to 
develop allergen specific immunoglobulin E antibodies following allergen exposure. 
Upon resolution of an allergic response, atopic sensitisation to a particular allergen 
may ensue, to this end eczema and asthma early in life has been associated with 
atopic sensitisation and persistent disease (Arshad et al. 2001; Wiithrich et a l 2003; 
Illi et al. 2006). Despite the heterogeneity in atopic disorders, as evidenced by 
differences in how they manifest clinically; atopic disorders share a commonality in 
that they arise from a complex interplay between environmental and genetic factors. 
This interplay is determined by microbial exposure during the perinatal period, and 
genetically determined differences in the immune response mounted by non-atopic 
and atopic individuals towards allergens (Bieber 2010). Factors that cause the 
initiation and progression of atopic disorder in early life remain poorly understood. 
However the hygiene hypothesis proposed by Strachan (1989) based on observations 
of increased atopy in smaller families postulates that reduced exposure to childhood 
infections causes aberrant immunological responses to allergens (Okada et al. 2010). 
Additionally the microfloral hypothesis posits that the intestinal microbiota provides
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a crucial source of post-natal immune stimulation regulating host genes of innate and 
adaptive immunity. Furthermore inadequate early gut colonisation has been 
associated with the development of atopic disease (Shreiner et al. 2008: Yoo et al.
2007) thus adding a further layer of complexity to ideas introduced in the hygiene 
hypothesis. The human microbiota therefore has a vital immunomodulatory influence 
upon optimal establishment of mucosal and skin barrier integrity against allergen 
threats (see 1.5). In support of this premise probiotic bacteria of the intestinal tract is 
postulated to confer a health benefit on the host when administered in adequate 
amounts as a food supplement. The immunomodulatory mechanisms by which 
perinatal probiotic supplementation might work in vivo to prevent atopic disorder 
remain largely unclear. However it is hypothesised that a two-fold mode of action 
might exist involving: (1) modulation of the developing immune system away from 
development of IgE sensitisation. And (2) reduced exposure to allergens through 
improved epithelial barrier function, a downstream immunological consequence 
mediated by the Thl, cytokine, activating potential of specific probiotic bacterial 
strains. It is the differentiative effects of the Thl cytokines that are implicated in 
inhibiting atopic sensitisation, due to their inhibitory effect on the Th2 cytokines 
involved in the differentiation IgE producing B lymphocytes (Flohr 2011).
4.1 Aim of the study
This part of the thesis evaluated the effect of the probiotic study consortium or an 
inert placebo, administered to mother-infant dyads during the perinatal period on 
clinical and laboratory manifestations of atopy at age 0—2 years.
4.2 Rationale and Methodology behind the study
4.2.1 Participants
Allen et al. (2014) recruited women aged 16 years or more intending to give birth at 
Singleton Hospital, with a normal singleton pregnancy. Women with known adverse 
conditions likely to affect them or the fetus, during the pregnancy were excluded 
from the study. Allen et al. (2014) preferentially intended to recruit newborns at a 
‘high-risk’ of developing atopy, but in practice the authors report that comprehensive 
details of a familial history atopy was at times difficult to obtain in 80 out of 454 
participants on the trial who were believed to be not at risk of developing atopy. 
Similarly to the works of Kalliomaki et al. (2001), newborns with a first degree
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relative with either asthma or eczema as diagnosed by a health care professional, or 
allergic rhinitis treated by a doctor were considered at ‘high-risk’ of developing 
atopy, and therefore preferentially selected for the study.
4.2.2 Randomisation
Allen et a l (2014) allocated pregnant women at 36 weeks gestation to either the 
probiotic or placebo arm of the study according to a computer-generated, random 
sequence generated by the industrial partner (Cultech). The random sequence was 
held independently of the research team. Study participants were provided with 
intervention packs corresponding to either the probiotic or placebo arm of the study 
(Allen et a l 2014).
4.2.3 Study consortium
The probiotic intervention comprised a vegetarian capsule containing Lactobacillus 
salivarius CUL61 (National Collection of Industrial, Food and Marine Bacteria 
(NCIMB) 30211) 6.25x109 colony forming units (CFUs), Lactobacillusparacasei 
CUL08 (NCIMB 30154) 1.25x109 CFUs, Bifidobacterium animalis subspecies lactis 
CUL34 (NCIMB 30172) 1.25x109 CFUs and Bifidobacterium bifidum CUL20 
(NCIMB 30153) 1.25x109 CFUs as a freeze-dried powder. Allen et a l (2014) 
confirmed organism identity at the species and strain levels by 16S rRNA gene 
sequencing, rep PCR fingerprinting and cluster analysis, and Random Amplified 
Polymorphic DNA typing. Furthermore no live bacteria were identified in the 
placebo capsules, conforming with the random allocation sequence.
During the supplemental study Allen et a l (2014) posit a rationale for the use of a 
multispecies probiotic preparation. It was viewed that a multispecies supplement 
might have a greater protective efficacy against atopic disease rather than either a 
single species, or single organism preparation (Timmerman et al. 2004). Further 
Allen et a l (2014) go on to describe that the strains in the trial supplement from the 
genus Lactobacillus have been intentionally selected; and previously evaluated in 
clinical trials by Kalliomaki et a l (2001) studying the role of probiotic bacteria in the 
prevention of eczema. Additionally organisms were also selected on the basis of their 
in vitro capacity to initiate Thl cytokine responses by mononuclear cells (personal
146
communication; Dr S. Plummer 2006). Such responses in vitro would be consistent 
with protection against an allergic immunological microenvironment if replicated in 
vivo due to the inhibitory nature of Thl cytokine responses on the Th2 cytokine 
responses that orchestrate the allergic response. The anti-allergy immunomodulatory 
effects of the study consortium were further corroborated in chapter 3 of this thesis 
which studied the immunomodulatory effects of the study consortium on cytokine 
production by umbilical cord blood and adult peripheral blood mononuclear cells in 
vitro. (See 3.4.1 for a comprehensive analysis).
4.2.4 Capsule administration
Women in the placebo arm received capsules of identical appearance containing 
maltodextrin powder. The dose in both arms was one capsule daily from 36 weeks 
gestation until delivery. Infants received the same capsules as their mother once daily 
from birth to age 6 months (Allen et a l 2014).
Women either administered the capsule by mouth or sprinkled the contents onto 
food. The contents of the capsule were sprinkled directly into the infant’s open 
mouth or mixed with expressed breast milk or formula feed. Additionally mothers 
were informed not to consume or give to their infants any commercially available 
products similar in nature to the study consortium. Other commercially available 
probiotics or live yoghurts were therefore prohibited for consumption by recruits on 
the trial (Allen et a l 2014). Viability of the bacteria in the active preparation was 
consistent with the storage conditions confirming no significant deterioration in the 
product (Allen et a l 2014).
4.2.5 Data collection and allergen testing
Allen et al (2014) collected demographic information and possible risk factors for 
atopy during the initial recruitment phase. Follow-up questionnaires were scheduled 
every 6 weeks to age 6 months, and also at 1 and 2 years of age (Allen et a l 2014). 
Questionnaires recorded any atopic disorders diagnosed by health care professionals, 
treatments received and the occurrence and duration of common skin, respiratory and 
gastrointestinal symptoms (Allen et a l 2014).
Infants were examined by either a clinician or a trained researcher at research clinics, 
and the severity of eczema was evaluated employing the scoring atopic dermatitis
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index (scorad) (Kunz et a l 1997). Skin prick tests (SPTs) using common food 
allergens (cow’s milk, hen’s egg), aeroallergens (house dust mite, cat dander, grass 
pollen) and positive (histamine) and negative controls were also performed, with the 
response to an allergen considered positive if there was a wheal diameter >3 mm 
(Allen et a l 2014).
4.2.6 Outcome measures
The primary outcome for the probiotic study was the cumulative frequency of 
diagnosed eczema at 2 year follow-up (Allen et al 2014). Eczema was defined as an 
itchy rash affecting the face, scalp or extensor surfaces of the limbs in infants and 
flexures in older children and of duration >4 weeks and with >1 exacerbation by age 
24 months (Leung et a l 2003). Based on the information from questionnaires Allen 
et al (2014) determined a set of secondary outcomes for the study, these included:
(1) Responses to SPTs.
(2) Atopic eczema defined as eczema with one or more positive SPTs.
(3) Eczema of any duration (whether or not diagnosed by a health professional).
(4) Severity of eczema.
(5) Extent of treatment with topical steroid preparations.
(6) Respiratory symptoms with asthma and allergic rhinitis and
(7) Reported food allergy.
4.2.7 Data management and analysis
Strict blinding of the clinical research teams and laboratory staff regarding 
participant allocation was maintained until after databases were locked following 
completion of data collection (Allen et a l 2014). The follow-up period was defined 
by the authors as the time from birth to the age of the last follow-up questionnaire, 
and was specifically calculated for each infant. Demographic variables, possible risk 
factors for atopy, and primary and secondary outcomes were also considered and 
analysed by treatment allocated. Findings for binary outcomes were expressed in 
odds ratios (ORs) with 95% confidence intervals (CIs). For a detailed description of 
statistical tests employed see Allen et al (2014).
4.2.8 Sample size
Allen et a l (2014) aimed to recruit sufficient mother/infant dyads to observe a 50% 
reduction in the frequency of asthma by age 5 years from 20% to 10% (Kaur et a l
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2004) the authors anticipated that 40% of infants at increased risk of atopy in the 
placebo arm would have developed eczema by age 2 years (Kalliomaki et al. 2001; 
Wadonda-Kabondo et al. 2003). And that a total of 154 infants in each arm of the 
study would be sufficient to detect a 50% reduction in eczema frequency from 40% 
in the placebo arm to 20% in the probiotic arm with 90% power at the 1% 
significance level.
4.3 Results
Allen et al. (2014) report that recruitment began in May 2005 with the last newborn 
recruited to the study becoming 2 years old in November 2009, for the last scheduled 
follow up visit at 2 years old. Of 1419 women attending antenatal clinics who had 
expressed an interest in the study, 454 were eventually recruited and randomised 
according to the study. Demographic variables and possible risk factors for atopy 
were similar in the 220 women randomised to the probiotic arm and 234 to the 
placebo arm. Maternal smoking during pregnancy, keeping pets and houses affected 
by damp or mould was common in both arms. 374 women were carrying an infant at 
high risk of developing atopy, while 80 women were carrying an infant not at risk of 
developing atopy. A similar proportion each category of woman was recruited to 
each study arm see table 4.1 by (Allen et al. 2014).
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Table 4.1 Demographic characteristics and possible risk factors for atopy at 
baseline
Variable Probiotic arm* Placebo arm*
Socioeconom ic s ta tu s (Tow nsend 220; 949  (33 3 -1 5 1 4 ) 234; 864 (3 3 0 -1 5 5 8 )
rank; N; m edian, IQR)
M other sm oked during 41/205 (20.0% ) 47/218  (21.6% )
pregnancy
Vaginal delivery 152 /216  (70 .4% ) 15 7/232 (67.7% )
House
Cat. dog. roden t or bird kept 112 /220  (50.9% ) 120/234 (51.3% )
indoors
D am p and /o r m ould  a s S9/217 (2 7.2% ) 56/232 (24.1% )
rep o rted  by partic ipan ts
No households w ith
1 adu lt 10/220 (4.6% ) 9/234 (3 .9% )
> 3  adu lts 20/220  (9.1% ) 25/234  (10.7% )
n o  o th er children 81/220  (36.8% ) 93/234  (39.7% )
> 3  o th er children 16/220 (7.3% ) 1 8/234 (7 .7% )
No. infants a t increased risk of 197 /220  (89 6% ) 205/234 (87.6% )
a to p y t
This table gives the number of participants (%) unless otherwise stated. 
‘ Denominator varies according to information provided by parents/carers and 
compliance with follow-up.
tDefined as first degree relative with either asthma or eczem a diagnosed by a health 
professional or alergic rhinitis treated by a doctor.
Allen et al (2014) also reported potential modifying factors for atopy during follow- 
up periods, such as feeding practice, exposure to other people and antibiotic usage 
was similar in both anus o f the study (table 4.3.2).
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Table 4.2 Modulating factors that could potentially influence the atopic 
status of study participants during follow-up
Variable Probiotic arm Placebo arm
Breast fed (full or partial)— any duration 49/191 (25.7% ) 47/205 (22.9% )
Age last breast fed in months (N; 
median, (IQR))
185; 1 [0-7] 190; 1 [0 -5 ]
Attended child-minder in first 12 months 10/163 (6.1% ) 16/172 (9.3% )
Attended nursery in first 12 months 65/162 (40.1%) 61/170 (35.9% )
Any oral/systemic antibiotics 155/214 ( 72.4%) 154 /22 5 (68 .4% )
This table gives tbe number of participants (%) unless otherwise stated.
The authors also report that completion o f questionnaires and attendance at research 
clinics was similar in the two arms (figure 4.1) with the median (IQR) age at follow- 
up being 2.11 years (2.01-2.28 years) in the probiotic arm and 2.09 years (2.01-2.24 
years) in the placebo arm (Allen et al. 2014).
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C om pleted follow  
up scheduled for
N u m b e r  (% )
6 n  ecks
12 w eeks 
18 weeks
24 w eeks
C lin ica l e x a m in a tio n
S k in  p rick  tes t 
l y r  
2 yr*
C lm icU  c.iajm naooo
S kin  p r ic k  te s t
161 (68.8)167 (75.9)
155 (70.5)
169 (76.8) 172 (73.5)
140 (59.8)
164 (74.5) 158 (67.5)
Probiotic
N - 2 2 0
Placebo
N-234
208 (94.6) 
170  (7 7  3) 
151 (6 8  6)
222 (94.9) 
164 (7 0  1) 
147 (6 2  8 )
187 (8 5 .0 )
130 (5 9 .1 )
131 (59  6)
191 (81.6) 
129 (5 5 .1 ) 
131 (56  0 )
454 women recruited at 36 weeks 
g e s ta t io n  u n d e rw e n t ra n d o m isa tio n
1419 p re g n a n t w o m e n  assessed  fo r 
e lig ib ility
2 2 3  fa ile d  to  m eet 
in c lu s io n  criteria* 
74 2  e lig ib le  b u t 
fa ile d  to  
p a r t ic ip a te '
Figure 4.1 Trial profile of Allen et a i (2014)
*Reasons for exclusion: pregnancy com plication (n= l 10); presented after 36 weeks 
gestation or at the end o f  the recruitm ent period and before 36 weeks gestation 
(n=83); m ultiple pregnancy (n=14); contacted again after recruitm ent term inated 
(n=9); previous infant participated in trial (n=6); unwilling to stop current probiotic 
(n= l). tR easons for failure to participate: lost contact with research team (n=288); 
not sufficiently interested or disliked tests (n=184); concern that trial was “too much 
to take on" (n=129); unw illingness to take the investigation products (n=85); not 
prepared to be allocated to the placebo arm (n=21); developed a m edical condition 
(n=16); language difficulties (10); not w illing for this child to be treated differently 
from previous child (n=7); bereavem ent (n=2). JFollow -up was often delayed; 
includes children seen up to, but not including, age 3 years (A llen et al. 2014).
4.3.1 Prim ary outcome measure
Allen et al. (2014) dem onstrated that the cum ulative frequency o f  diagnosed eczema 
at 2 years o f  age was sim ilar in the probiotic (73/214; 34.1% ) and placebo arms
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(72/222, 32.4%) of the study. Their result was further supported by observations that 
the cumulative frequency of parental reported eczema at 2 years of age, was also 
similar in the two arms. The severity of eczema and duration of rash tantamount with 
the use of alleviate topical steroids for eczema was also similar in the two arms 
(Allen et a l 2014).
4.3.2 Secondary outcome measures
Allen et al (2014) demonstrated that positive SPTs to one or more common 
allergens at either age 6 months or 2 years were significantly less frequent in the 
probiotic arm (OR 0.52; p=0.0360) in comparison to the placebo arm. The authors 
observed that reduced skin prick responses in the probiotic arm were mainly to food 
allergens (cow’s milk and egg proteins) and statistically significant differences were 
already apparent at age 6 months (Allen et a l 2014). Interestingly the authors 
discovered that sensitisation to aeroallergens (house dust mite, cat dander and grass 
pollen) occurred mainly after 6 months and was similar in the two arms. Interestingly 
the authors found that diagnosed atopic eczema at 2 years was significantly less 
frequent in the probiotic arm (OR 0.40; p=0.024) these results were consistent with 
comparisons of early diagnoses of atopic eczema at 6 months of age where infants 
recruited to the probiotic arm of the study presented less frequently (4/151) with 
atopic eczema when compared to infants in the placebo group (13/147). This 
observation reached statistical significance (P=0.021) (Allen et a l 2014). For a 
comprehensive summary of all secondary outcomes please refer to table 4.3.
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Table 4.3. Secondary Outcomes of the probiotic study
Variable Probiotic arm  P lacebo arm  OR (95%  Cl) p Value*
SPTt positive at 6 m 6/151 (3.97%) 16/147 (10.88%) 0.34 (0.13 to  0.89) 0.023
► cow's milk 0/148 (0.0%) 5/147 (3.40%) - 0.030*
► egg mm 14/147(9.5% ) 0.33 (0.11 to  0.95) 0.032
► house dust mite 1/151 (0.66%) 0/147(0.0% ) - 0.51*
► a t 0/151 (0.0%) 2/145(1,4% ) - 0.24*
► grass 1/150 (0.67%) 0/147(0.0% ) - 0.49*
SPTt positive at either 6 m or 2 yrs 18/171 (10.5%) 32/173 (18.5%) 0.52 (0.28 to  0.98) 0.036
► cow’s milk 1/171 (0.6%) 6/173 (3.5%) 0.16 (0.02 to  1.4) 0.12*
► egg 9/171 (5.3%) 19/173(11.0% ) 0.45 (0.2 to 1.0) 0.052
► house dust mite 9/171 (5.3%) 11/173(6.4% ) 0.82 (0.3 to 2.0) 0.66
► a t 3/171 (1.8%) 7/173(4.0% ) 0.42 (0.1 to 1.7) 0.20
► grass 2/171 (1.2%) 2/173(1.2% ) 1.0 (0.14 to 7.2) 0.99*
Skin
► Atopic eczema at 6 m 4/151 (2.7%) 13/147(8.8% ) 0.28 (0.089 to 0.88) 0.021
► S ew ity  of eczema at 6 m dinict; m ediaa (IQR) 14.3(7 .5-17 .9) 14.4(10.6-24.9) - 0.46
► Atopic eczema at 2 yrs 9/171 (5.3%) 21/173(12.1% ) 0.40 (0.18 to  0.91) 0.024
► Severity of eczema at 2 y rd in ic t; median (IQR) 11.1 (7.2-20.1) 14.2(7.2-14.2) - 0.85
► All reported eczem a§,! 119/214(55.6% ) 132/226 (58.4%) 0.90 (0.61 to  1.3) 0.55
► Received topical steroid preparation 30/214(14.0% ) 40/226 (17.7%) 0.76 (0.45 to  1.2) 0.29
Respiratory
► All reported asthm a! 23/171 (11.9%) 20/179 (10.0%) 1.2 (0.63 to 2.3) 0.57
► Night-time cough 156/214 (72.9%) 164/226 (72.6%) 1.0 (0.67 to 1.5) 0.93
► Night-time or daytime cough 178/214 (83.2%) 188/226 (83.2%) 1.0 (0.6 to 1.6) 0.99
► f e e z i n g  without symptoms of a virus infection 50/214 (23.4%) 55/171 (24.3%) 0,95 (0.61 to 1.47) 0.81
► Inhaled bronchodilator or steroid 26/214(12.1% ) 27/226 (11.9%) 1.0 (0.57 to 1.8) 0.94
► Allergic rhinhis! 10/190(5.3% ) 10/201 (5.0%) 1.1 (0.43 to 2.6) 0.90
► Sneezing and/or snuffling 207/214 (96.7%) 212/226 (93.8%) 1.95 (0.77 to  4.93) 0.15
Any reported food allergy 22/200(11.0% ) 31/204 (15.2%) 0.69 (0.38 to  1.2) 0.21
This table gives the number of participants (%) unless otherwise stated 
Y  test for contingency tables or fisher's exact test* where expected values in cells were <5.
tSPT valid if diameter of wheal for the positive control was >1 mm than diameter for the negative control; 5P1 positive if diameter of wheal for antigen was >3 mm than diameter for 
negative control. 
tSCORAD index” .
§0f any duration
f  Whether or not diagnosed by a health professional 
SCORAD, scoring atopic dermatitis; SPT, skin pndc test
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4.3.3 Compliance
Factors determining compliance within the probiotic trial were published and 
discussed thoroughly by Jordan et a l (2013). Unused capsules returned by 
participants from the probiotic and placebo arms for compliance monitoring were 
tested by an independent laboratory. Allen et a l (2014) discovered that the Median 
(IQR) compliance with the trial interventions in pregnant women was good, and was 
20 (12-28) days in the probiotic arm and 20 (12-28) days in the placebo arm. 
However in infants compliance was not so good, the corresponding values were 106 
(30-141) days in the probiotic arm and 103 (11-151) days in the placebo arm.
4.4 Discussion
Despite promise shown in vitro by strains of the study consortium to elicit Thl 
cytokines (TNF-a, IFN-y and IL-12p70) of a pro-inflammatory tone and thereby 
inhibit the production of the allergy accelerating cytokines involved in the 
manifestation of atopic disorders such as atopic eczema (Chapter 3). The findings of 
Allen et a l (2014) do not definitively support perinatal administration of a high-dose 
consortium of probiotic bacteria for the prevention of eczema in early childhood.
This result was unexpected, and contrasted with initial hypothesises introduced in 
chapter 3, suggesting that the in vitro potential for the study consortium to initiate 
pro-inflammatory cytokine responses, antagonistic to the development of allergy 
driving Th2 cytokines could occur in vivo as a downstream immunological effect 
perinatal probiotic supplementation. Interestingly Allen et a l (2014) discovered that 
perinatal probiotic administration was associated with a reduced frequency in IgE- 
mediated sensitivity to food antigens and atopic eczema. However the 
immunological mechanisms responsible for the observed reduction in IgE-mediated 
atopic sensitisation require further elucidation.
4.4.1 Limitations of the study
The findings of Allen et a l (2014) that the study probiotic did not affect the
frequency of eczema is inconsistent with a meta-analysis of 13 randomised, placebo-
controlled trials (3092 infants/children), where probiotic administration was
associated with modest reductions in the frequency of eczema (Pelucchi et a l 2012).
However Allen et a l (2014) do acknowledge several weakness of their study. For
instance the authors had intended to evaluate clinical outcomes in infants at increased
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risk of atopy, but in practice the atopy status was not always straightforward to 
accurately determine at recruitment. This meant that approximately 18% of the trial- 
cohort were non-atopic. However the frequency of atopy and effects of the probiotic 
were similar in infants with and without a first degree relative with atopy (Allen et al 
2014).
Allen et al (2014) also mention that they had expected that administering a novel 
intervention to healthy young infants would be laborious and although they cite that 
compliance with the trial interventions in mothers was good, compliance was far 
lower in infants. Mothers returning to work were also cited as a reason for missed or 
delayed follow-up questionnaires and study clinic attendances.
Another point of consideration is that there is a paucity of studies assessing how 
potential probiotic bacterial strains survive in the newborn GIT when employed as 
multi-species supplements. For instance the efficacy of GIT colonisation of each 
strain in a multi-species supplement is not often reported in a number of probiotic 
intervention studies. Furthermore it is not known whether strains of the multi-species 
supplement have to compete with each other in order to survive in the GIT, thereby 
reducing the overall effectiveness of the supplement.
Allen et a l (2014) observed that a reduced frequency of skin prick sensitivity to food 
allergens and eczema in children with demonstrated allergic sensitivity in the 
probiotic arm are consistent with those of a meta-analysis (20 cohorts; 4031 
participants, including our findings). In these meta-analyses probiotic administration 
during infancy and childhood was associated with reduced serum IgE and atopic 
sensitisation to food or inhalant allergens (Ealzab 2013). The main finding in the 
study of Allen et al. (2014) was that administration of probiotics in early life has a 
role in the prevention of atopic sensitisation. With the findings of the probiotic trial 
at the forefront the tone is now set to interpret the result of the study of Allen et a l 
(2014) in the context of the immunological outcomes of the study. These outcomes 
are concerned with understanding how the study consortium might impact upon the 
underlying immunological mechanisms involved in the establishment of atopic 
sensitization, this is explored in chapters 5 and 6.
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Chapter 5: Ex vivo effects of perinatal probiotic supplementation on 
cytokine responses by polyclonally stimulated umbilical cord blood 
mononuclear cells, and 6 month, infant peripheral blood 
mononuclear cells.
5.1 Background
Cytokine responses by lymphocytes form the cornerstone immune-transmission 
network of adaptive immunity and play essential roles in mediating tolerogenic 
immune responses, mediated against both the intestinal microbiota and ubiquitously 
occurring allergens (Paul and Seder 1994). By analysing ex vivo cytokine induction 
patterns of both mitogen stimulated newborn and infantile mononuclear cells isolated 
from recruits on the PROBAT trial (described in Chapter 2), this study assessed by 
ELISA the effects of perinatal probiotic supplementation on age-related maturational 
changes in cytokine production from birth and 6 months of age. In addition to 
assessing the impact of the consortium on infantile atopy and subsequent atopic 
disease, umbilical cord blood was collected at birth and peripheral blood from the 
infant to assess the immunomodulatory effects of the study consortium on immune 
function at birth and in early infancy. Results were assessed in relation to our current 
understanding of the development of immune function during infancy and immune 
parameters that related to the initiation and maintenance of atopic disease post- 
natally.
Cytokine responses by CBMCs in response to polyclonaly mitogenic stimuli are 
likely to be mediated by a population consisting of mainly immature and antigen 
inexperienced thymocytes. For instance the neonatal T cell repertoire is almost 
exclusively of the naive phenotype, accounting for 90% of neonatal CD4+ cells and 
displaying a reduced capacity for cytokine production compared to memory T cells 
which occur in greater amounts in PBMCs of 6 month old infants (Harris et a l
1992).
Data on the baseline cytokine production profiles upon mitogenic stimulation by 
mononuclear cells obtained in the neonatal period up until 6 months of age are 
limited (Hartel et a l 2005) for both atopic and non-atopic neonates and children. The 
principal observation arising in the late 70s was that infants and young children 
demonstrate an attenuated capacity for T cell responses when compared with older
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children (Hayward and Lawton 1977; Clerici et a l 1993) with neonatal T cell 
cytokine responses to polyclonal mitogens and superantigens, significantly reduced 
in early infancy, a discrepancy that extends even to neonatal T cell proliferative 
responses (Wilson, Westall et a l 1986; Lewis et a l 1991; Pirenne-Ansart et a l 1995; 
Smart and Kemp 2002). Such differences reinforce the notion of an age-related 
immune maturation over time and are reflected in changes in cytokine production 
from the anti-inflammatory, pro-inflammatory and regulatory cytokine families 
occurring with age.
Imbalances in effector cell responses are postulated to impact upon the 
pathophysiology of atopy and subsequent atopic disorder (Hartel et a l 2005). More 
specifically the balance of Thl (IFN-y), Th2 (IL-4 and IL-13) and regulatory T cell 
cytokines (IL-10) may determine the development of atopic disease in childhood and 
probiotics of the microbiota have been demonstrated to influence the levels of these 
cytokines in both in vitro and in vivo scenarios, thereby impacting upon the integrity 
of mucosal immunity (Gillingham and Lescheid 2009).
The manifestation of atopic disease changes throughout childhood, evolving from 
early infantile eczema to the development of asthma in a progression entitled ‘The 
Atopic March’(Smart and Kemp 2001). It is therefore of considerable interest to
(1) Appreciate differences between the ontogeny of age-related immunological 
changes in ex vivo cytokine production in response to antigen independent 
stimulation between healthy non-atopic children versus atopic children.
(2) Whether immunological changes giving rise to a scheme of immunity that 
supports atopic disorder in neonates showing immunological symptoms of 
atopy can be manipulated at the neonatal stage via a course of probiotic 
supplementation toward a non-atopic outcome.
Generally a diminished production of the T cell cytokines IL-13, IL-4, IL-10, IL-12 
and IFN-y in the neonate has been described (Wilson et a l 1986; Frenkel and Bryson 
1987; Vigano et a l 1999; Lewis et a l 1991; Pirenne-Ansart et a l 1995; Chipeta et 
al 1998; Gasparoni et a l 2003; Prescott et al 2003; Marchant and Goldman 2005). 
Despite the attenuated immune T cell capacity in the newborn, production of IFN-y
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has been demonstrated to increase rapidly throughout early infancy (Chipeta et a l 
1998), reaching adult levels by 1 year of age in one study Frenkel and Bryson (1987) 
or by 3 years of age in another study Miyawaki et a l (1985). To further support the 
notion of a limited Thl immune repertoire in the newborn compared to mature 
children, a recent study in healthy newborns, infants and young children aged 
between 1 and 96 months assessing mRNA cytokine and protein expression in 
response to phorbol 12-myristate 13-actate/ionomycin stimulation demonstrated that 
intracellular IFN-y expression increased significantly and progressively with age 
(Hartel et a l 2005). These observations were supported by works of Chipeta et a l 
(1998) and Gasparoni et a l (2003) who also noted that IFN-y-producing T cell 
populations increased progressively with age, and that a significant negative 
correlation exists between gestational age and IFN-y-CD4+ and IL-10- CD4+- 
producing cells with neonates having a substantially lower percentages of CD4+ and 
CD8+ IFN-y producing cells compared to older children. In a different study with 
infants aged 2-12 months, the number and percentage of T lymphocytes producing 
IFN-y and IL-4 was also shown to be increased over the first year of life, but 
remaining lower than in adults (Buck et a l 2002). Similarly (Tang and Kemp 1995) 
noted that IL-4 release was reduced in neonates versus adults and remained reduced 
in children under 10 years of age, but increased progressively with age.
Although a positive correlation is thought to exist between gestational age and IL-10- 
CD8+-producing cells (Gasparoni et a l 2003), IL-10 protein expression tended to be 
regulated on an individual basis during infancy and early childhood (Hartel, Adam et 
al 2005), while (PHA)-induced IL-13 release in neonates was similar to that of 
adults (Williams et a l 2000). Additionally (Gasparoni et a l 2003) measured T 
lymphocyte cytokine responses to Concanavalin A (ConA) by measuring 
intracellular IL-4, IFN-y and IL-10 in 12 very preterm, 12 preterm, 20 term neonates, 
10 children and 10 adults and discovered that immunoproliferation to ConA was 
significantly lower in cord blood than the blood from children or adults. Their 
observations were confirmed upon analysis of the percentages of lymphocytes 
occurring in the CD4 and CD8 compartments of which CD4+ lymphocytes was 
significantly higher in newborns while CD8+ cells were higher at older ages, with a 
resulting gradual decline of the CD4+/CD8+ ratio. While the percentage of IL-4- 
producing cells was higher for CD8+ and lower for CD4+ cells in cord blood than in 
children and adults reflecting a gradual development of immunity during gestation
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and highlighting a significant immaturity of the cellular immune response at birth 
(Gasparoni et al. 2003).
5.1.2 Newborn and infantile responses to experimental stimuli
In humans, IFN-y is a frequently measured cytokine for characterization of Thl 
cytokine responses, while IL-4 and 10 are often employed to characterize Type 2 
cytokine responses. The work presented herein utilised umbilical cord blood and 6 
month infant peripheral blood from recruits on the PROBAT trial.
Studies of T cell cytokine release have generally employed the lymphocyte mitogen 
PHA (Miyawaki et a l 1985; Frenkel and Bryson 1987; Pirenne-Ansart et a l 1995; 
Tang and Kemp 1995; Vigano et a l 1999) and the T cell mitogen/superantigens 
staphylococal enterotoxin B (SEB) (Wilson et a l 1986; Campbell and Kemp 1997), 
as an antigen-independent polyclonal stimulus to activate T cells by virtue of their 
non-specific binding to the variable chain of the T-cell receptor bearing the major 
histocompatibility complex class II chains outside the peptide-binding groove. This 
interaction has been utilised by numerous authors (Tang and Kemp 1995; Campbell, 
Fryga et a l 1999; Smart and Kemp 2001) to induce vigorous T-cell activation and 
cytokine release (Skov and Baadsgaard 2000).
To examine the age related ontogeny of cytokine release in the presence of prior 
probiotic supplementation, a global stimulus capable of activation of multiple T 
cells mimicking an antigenic interaction is beneficial as activation is not dependent 
on specific sensitivity to individual antigens (Smart and Kemp 2001). Furthermore, 
the use of SEB as a stimulus is postulated to be of particular relevance when studying 
cytokine release in atopic subjects since SEB is postulated to play an important role 
during development of the inflammatory response in atopic disorder (Hoeger et a l 
1992; Leung et a l 1993; Campbell and Kemp 1997; Hofer et a l 1999; Skov et a l 
2000).
The principle approach adopted in this ex vivo study was to determine the impact of 
probiotic supplementation on their contribution to cytokine release by both cord and 
6 month infant blood mononuclear cells stimulated with PHA or SEB to provide an 
insight into the underlying Thl/Th2 cytokine predisposition in response to antigen 
independent stimulus. Information on how this predisposition alters within a cohort
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of newborns who were susceptible to allergy and undergoing probiotic 
supplementation was also obtained.
This mitogen-lymphocyte interaction has been utilised to examine cytokine 
imbalances in childhood atopic disease (Rosenfeldt et ah 2003; West et ah 2009), 
and was employed in the PROBAT study to examine the effects of probiotic 
supplementation on ex vivo cytokine responses from mononuclear cells isolated from 
umbilical cord blood and venous blood of 6 month infants recruited to the PROBAT 
trial. IL-4, IL-10, IL-13 and IFN-y outputs at birth or at 6 month of age in 
supplemented individuals were analysed as exemplars of Thl, Th2 and 
immunoregulatory cytokine responses. The findings of the present study are likely to 
reflect cytokine release from both CD4+ and CD8+ T cells by SEB, since 
superantigens stimulate both CD4+ and CD8+ thymocytes from infants (Thulesen et 
ah 1999).
5.1.3 Aim of study
The principal aim of this study was to examine the effects of perinatal probiotic 
supplementation with the PROBAT consortium on maturation of age-related changes 
in newborn immune responses occurring from birth to early infancy. Whether or not 
perinatal probiotic intervention during a ‘critical window’ of immune development 
could attenuate the risk of allergen sensitization and associated disease in clinically 
predisposed allergic neonates was also assessed in terms of the effects of 
supplementation on ex vivo production of the prototypic Thl (IFN-y), Th2 (IL-4 and 
IL-13) and the regulatory cytokine (IL-10) by mononuclear samples isolated from the 
cord blood of newborn and 6 month old recruits on the PROBAT trial.
To delineate the immunological mechanisms of action by which probiotic 
supplementation could prove protective against atopic disorder the propensity of 
PROBAT trial mononuclear cells to mount ex vivo cytokine responses to mitogenic 
stimulation was characterized following induction of polyclonal proliferation of cord 
blood mononuclear cells and 6 month infant peripheral blood mononuclear cells in 
response to (SEB- T cell mitogen) or (PHA -Lymphocyte mitogen) or anti 
CD3/CD28 beads.
Ensuing immune responses as a result of prior mitogenic stimulation where 
measured in terms of cytokines synthesised from mitogenically stimulated cord
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blood mononuclear cell and 6 month blood mononuclear cells cultures. An 
assessment on whether probiotic supplementation can induce a T helper cytokine 
profile protective against allergic responses was then made in terms of how probiotic 
supplementation could affect the balance of the Thl/Th2/Thl7 immune axis.
5.2 Rationale and Methodology behind the study
The availability of detailed immunological phenotypes on newborns recruited on the 
PROBAT trial at birth and at 6 months of age, offered the opportunity to 
concurrently compare the effects of the consortium on immunological phenotypes 
measurable ex vivo using cord blood (CB) and 6 month peripheral blood (6Mth PB) 
versus those measurable in our in vitro model. Blood collected during the PROBAT 
trial provided the opportunity to: (i) compare responses at birth with those at 6 
months of age regardless of whether the child was on the placebo or probiotic arm of 
the study, and (ii) determine the impact of maternal/infant probiotic consumption on 
the cytokine response at birth and at 6 months of age.
5.2.1 Preparation and culture of mononuclear cells
Mononuclear cells were isolated from umbilical cord blood at birth and peripheral 
blood from 6 month old infants by density gradient centrifugation (See 2.1.3). Cells 
(0.5 x 106/500pl) were cultured for 48 hours at 37°C in 5% CC>2 -in-air in the 
presence/absence of PH A (1 pg/ml), anti-CD3/CD28 T cell expansion beads (5 
pl/500pl) or SEB (200 ng/ml). Cell free culture supernatants were harvested and 
stored at -80°C until analysis. Additional experiments utilized MNCs prepared from 
random umbilical cord blood samples collected after delivery by elective caesarean 
section as part of other studies in the group and from healthy adult volunteers. MNCs 
were prepared and treated in the same way.
5.2.2 Cytokine assays
Supernatants were thawed and analysed for IL-4, IL-10, IL-13 or IFN-y using 
specific ELIS As according to the manufacturer’s instructions as described (See 
2.1.4). Cytokine data were analysed as (a) continuous data and (b) dichotomous data 
(detected or non-detected).
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5.2.3 Statistical analysis for chapters 5 and 6
All data were log transformed before analysis. Statistical analyses were performed 
using SPSS software or Excel (Microsoft). A p-value < 0.05 was regarded as 
statistically significant. The student t test was employed as there were no pre-defined 
ideas about what might change. The ex vivo data of chapters 5 and 6 was an exercise 
in generating hypothesis, rather than testing them therefore p-values were not 
adjusted for multiple testing. We did not make formal adjustments for multiple 
testing for two reasons. First, many of the tests would be correlated; therefore an 
adjustment based on criteria such as Bonferonni would be highly conservative (and 
possibly lead to a high false negative rate). Second, we has little prior data on 
expected differences, hence we consider this an exercise in generating new 
hypotheses about how probiotics might affect a wide spectrum of immune 
parameters, rather than an exercise in testing pre-determined hypotheses (personal 
communication with Professor Gravenor 2010). As such, any significant trends that 
we detect will be confirmed by follow up studies. The difference in the mean level 
between the probiotic and control groups was investigated with two-sample t-tests. A 
significance level of 5% was used throughout. Data were presented as box-whisker 
plots, with mean, median, interquartile range, and (trimmed) maximum and 
minimum values.
5.3 Results
5.3.1 Age-related changes in cytokine responses from birth to 6 months of age
To determine age-related changes in cytokine responses at birth and at 6 months of
age in the presence of the study consortium or placebo, an initial comparison of
cytokines responses made to each stimuli employed was made for mononuclear cells
prepared from umbilical cord blood (CBMCs); and mononuclear cells prepared from
peripheral blood from 6 month old infants (6 month PBMCs) (Figure 4.1).Where
possible, age-related changes in cytokine responses to each stimuli were compared in
the same subject at birth, and at 6 months of age. Generally production of the Th2
cytokine IL-4 was significantly greater in 6 month PBMCs samples stimulated with
anti-CD3/CD28 beads or SEB (both p < 0.00001) but not PHA. For IL-10 the bead-
induced response was greater in the infants (p < 0.00001) but the PHA-induced
response was greater in the cord MNCs (p = 0.006), with no difference upon
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stimulation with SEB. For IL-13, the only difference was for PHA, with the response 
by CBMCs greater than that by (6 month PBMCs) (p < 0.00001). There were no 
significant differences for IFN-y.
As the cytokine response at birth and in early infancy is generally reduced compared 
to that o f adults, an alternative way o f analysing the data is to consider what 
proportion o f subjects made a detectable response for each cytokine and stimuli 
combination. This data is summarised in Table 4.1 detailing the proportion of 
samples up-regulating a cytokine response for each stimuli.
*
PHA beads SEB PHA beads SEB
 i------------------------------------------------ u  ------------------------- ------------------------- -------------------
PHA b e a d s  SEB PHA beads SEB
Figure 5.1. Cytokine responses by mononuclear cells from CBMCs (orange) or 6
month infant PBMCs (dark green). Mononuclear cells were prepared by density 
gradient centrifugation and cultured at 0.5 x 106/500pl in the presence o f PHA, anti- 
CD3/CD28 beads (beads) or SEB. Cell free supernatants were harvested and 
analysed for (a) IL-4, (b) IL-10, (c) IL-13, or (d) IFN-y using specific ELISAs.
Values obtained were corrected for levels in un-stimulated controls (which typically 
were not detectable) and mean ± SEM determined. * denotes significant difference (p 
< 0.05) between cord and infant.
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The IL-4 response to the stimuli was significantly different between the two age 
groups for all stimuli studied (p < 0.0001). There was a statistically significant 
increase in the proportion o f samples that returned a detectable cytokine output at 6 
months o f age compared to birth (Table 4.1). Other statistically significant 
differences were: fewer responsive infants for PHA-induced IL-10 (p < 0.00001), 
fewer responsive infants for IL-13 for all stimuli (PHA, p = 0.0017; beads, p = 
0.0455; SEB, p = 0.0032), and fewer responsive infants for SEB-stimulated IFN-y (p 
<0.00001) (Table 4.1).
Since this analysis was conducted on the whole cohort inclusive, o f some matched 
cord/infant samples, the IL-4 response was considered in more detail to ascertain 
whether the same pattern o f responders/non-responders was observed in samples 
from the same subject at the two different age points. For the response to beads 
(Figure 4.2b), there was a clear indication that the levels o f IL-4 increased between 
birth and 6 months o f age (n = 13); this is not as clear for PHA (Figure 4.2a). There 
were no matched pairs for SEB stimulation. Levels o f IL-4, IL-10, IL-13 and IFN-y 
in response to PHA, beads or SEB were determined and when the cytokine was 
detectable this was recorded as a ‘responder' whereas if  the cytokine was not- 
detectable this was recorded as a non-responder, statistically significant results were 
generated using Chi-square ( / 2). P < 0.05 was considered statistically significant
Table 5.1. Results o f statistical analysis o f proportion o f responders to each 
cytokine/stimuli combination.
IL-4
Cord infant p-value
IL-10
cord Infant p-value
PHA 42/97
(43%)
65/98
(66%)
<0.0001 84/98
(86%)
66/97
(68%)
<0.0001
Beads 16/84
(19%)
72/85
(84%)
<0.0001 58/84
(69%)
64/87
(74%)
0.2543
SEB 11/31
(36%)
31/34
(91%)
<0.0001 29/31
(94%)
32/35
(91%)
0.4846
165
IL-13
Cord infant p-vaiue
IFN-y
cord Infant p-value
PHA 87/96
(91%)
76/97
(78%)
<0.002 50/96
(52%)
48/97
(50%)
0.548
Beads 78/83
(88%)
67/84
(80%)
<0.046 59/83
(71%)
66/83
(80%)
0.05
SEB 30/30
(100%)
33/36
(92%)
<0.003 30/31
(97%)
22/27
(82%)
<0.0001
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Figure 5.2. IL-4 response by matched pairs of cord blood and 6 month infant 
peripheral blood MNCs.
MNCs were prepared as previously described and stimulated with (a) PHA or (b) 
anti-CD3/CD28 beads for 48hr prior to collection o f cell free supernatants for later 
batch analysis o f IL-4. Data from matched pairs are shown. PHA, (n = 25); beads, (n 
= 13).
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5.3.2 Cytokine responses by probiotic versus placebo
The number o f samples at each study point (birth -  umbilical cord blood; infant -  
peripheral blood at 6 months o f age) for which MNC cultures were available is 
summarised in Table 4.3. Figures 4.3 to 4.6 show the data for cytokines responses at 
birth and at 6 months o f age for each cytokine and stimuli combination. There were 
no statistically significant differences.
(a) (d)
(b) Placebo
co
+1
CuO
Q.
( C )
Placebo
Probiotic (e)
Probiotic (f)
Placebo Probiotic
Placebo Probiotic
Placebo Probiotic
Placebo Probiotic
F igure 5.3. IL-4 resp onse by m on on u clear  cells from  partic ip an ts in the P R O B A T  trial.
Mononuclear cells were prepared from (a, b, &  c) umbilical cord blood and (d, e, &  f) peripheral 
blood of 6 month infants and stimulated with (a &  d) PHA, (b &  e) anti-CD3/CD28 beads, and (c &  f) 
SEB. IL-4 levels in cell free culture supernatants harvested after 48 hours culture were measured using 
a specific ELISA. The box signifies the upper and lower quartiles (75% and 25% respectively), and
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the median is represented by the thick black line within the box. The whiskers represent the 5% and 
95% percentile. Outliers are represented b y . '' Statistically significant results (P < 0.05) were denoted 
by *
PlaceboPlacebo ProbioticProbiotic
LU 8
00
Placebo Placebo ProbioticProbiotic
Placebo Probiotic Placebo Probiotic
Figure 5.4. IL-10 response by mononuclear cells from participants in the PROBAT trial.
Mononuclear cells were prepared from (a, b, &  c) umbilical cord blood and (d, e, &  f) peripheral 
blood o f 6 month infants and stimulated with (a &  d) PHA, (b &  e) anti-CD3/CD28 beads, and (c &  f) 
SEB. IL-10 levels in cell free culture supernatants harvested after 48 hours culture were measured
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using a specific ELISA. The box signifies the upper and lower quartiles (75% and 25% respectively), 
and the median is represented by the thick black line within the box. The whiskers represent the 5% 
and 95% percentile. Outliers are represented by . ' ’ Statistically significant results (P < 0.05) were 
denoted by *
Placebo Probiotic Placebo Probiotic
Placebo Probiotic Placebo Probiotic
Placebo Probiotic Placebo Probiotic
Figure 5.5. IL-13 response by mononuclear cells from participants in the PROBAT trial.
Mononuclear cells were prepared from (a, b, &  c) umbilical cord blood and (d, e, &  f) peripheral 
blood of 6 month infants and stimulated with (a &  d) PHA, (b &  e) anti-CD3/CD28 beads, and (c &  f)
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SEB. IL-13 levels in cell free culture supernatants harvested after 48 hours culture were measured 
using a specific ELISA. The box signifies the upper and lower quartiles (75% and 25% respectively), 
and the median is represented by the thick black line within the box. The whiskers represent the 5% 
and 95% percentile. Outliers are represented by. 11 Statistically significant results (P < 0.05) were 
denoted by *
(a) (4)
(b)
Placebo f Probiotic
(e)
Placebo Probiotic
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Figure 5.6. IFN-y response by mononuclear cells from participants in the PROBAT trial.
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Mononuclear cells were prepared from (a, b, & c) umbilical cord blood and (d, e, & f) peripheral 
blood of 6 month infants and stimulated with (a & d) PHA, (b & e) anti-CD3/CD28 beads, and (c & f) 
SEB. IFN-y levels in cell free culture supernatants harvested after 48 hours culture were measured 
using a specific ELISA. The box signifies the upper and lower quartiles (75% and 25% respectively), 
and the median is represented by the thick black line within the box. The whiskers represent the 5% 
and 95% percentile. Outliers are represented by. ° Statistically significant results (P < 0.05) were 
denoted
5.3.3 IL-17 and IL-22 production in early infancy
Since completing the cytokine analyses shown above, there has been an increased 
interest in Thl 7 cells that have as their secreted prototypic cytokine, IL-17. These 
cells also secrete IL-22. Before determining whether analysis of MNCs from the 
PROBAT cohort should be extended to include these two cytokines, preliminary 
investigation of the capacity of CBMCs to produce these cytokines was considered. 
The same stimuli (PHA, beads and SEB) were used and the capacity of CBMCs and 
PBMCs to produce IL-17 and IL-22 was compared. As at least two-thirds of CBMC 
samples were expected to produce IL-10 (from Table 4.1), IL-10 production was 
employed as a control. The response by CBMCs for IL-17 and IL-22 for all stimuli 
was statistically significantly lower than that for PBMCs (Figure 4.7). For IL-10, the 
response by CMBCs was significantly reduced for anti-CD3/CD28 beads (p = 
0.0008) and SEB (p = 0.0024) but not for PHA. Because of the very low levels of IL- 
17 produced the analysis of IL-17 was not extended to the PROBAT cohort.
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Figure 5.7 Production of IL-10, IL-17 and IL-22 in response to various stimuli.
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CBMCs (n = 8 -  10) and PBMCs (n = 9) were left unstimulated (unst) or stimulated 
with phytohaemagglutinin (PHA), staphylococcal enterotoxin B (SEB) or anti- 
CD3/CD238 T cell expansion beads (aCD3/CD28) for 48hr. Cell free supernatants 
were harvested and levels of (a) IL-10, (b) IL-17, and (c) IL-22 ( ± SEM) measured 
using specific ELISAs. The response by CBMCs was significantly lower than 
PBMCs ** p < 0.01.
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5.4 Discussion
Despite promise in the application of perinatal probiotic supplementation as an 
intervention strategy to protect against IgE mediated atopy, optimal timings for 
supplementation and immunological mechanisms underlying protective effects are 
unresolved. In particular it is not known whether such treatments work (prenatally) 
or whether postnatal exposure to probiotic bacteria is more important (Boyle et a l 
2008). The focal point of chapter 5 was to therefore analyse whether perinatal 
probiotic supplementation had a positive effect on early newborn immune function, 
in a way that might prevent or attenuate the risk of allergic responses in later life. 
Before embarking on this experimental rationale, age-related changes in the 
polyclonal induction of key cytokines involved in the pathophysiology of allergy, by 
CBMCs or 6 month PBMCs from recruits on the PROBAT trial cohort was first 
determined. The principal finding emerging from this part of the ex vivo study was 
that there was no statistically significant effect on IL-4, IL-10, IL-13 and IFN-y 
production by mitogen stimulated mononuclear cells prepared from the blood of 
participants on the probiotic and placebo arms of the trial. This finding is discussed 
in further detail below.
5.4.1 Age related changes in Th2 cytokine induction by CBMCs and 6 month 
PBMCs prepared from a cohort of potentially atopic subjects in response to the 
polyclonal stimulation.
5.4.1.1 IL-4
As the cytokine response at birth and in early infancy is generally attenuated 
compared to that of adults; the proportion of subjects mounting a detectable response 
for each cytokine and stimuli combination was determined (Table 4.1). The IL-4 
response to the stimuli was significantly different between the two age groups for all 
stimuli studied and there was a statistically significant increase in the proportion of 
samples returning a detectable cytokine output at 6 months of age compared to birth.
The present study highlighted an age-related maturation of the IL-4 producing T cell 
compartment from birth to 6 months of age. On comparison of the age related 
cytokine responses by CBMCs versus 6 month PBMCs prepared from the PROBAT 
trial birth cohort (Figure 4.1) IL-4 production was higher by 6 month PBMCs 
samples stimulated with anti-CD3/CD28 beads or SEB. This observation can be
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accounted for by the fact that neonatal CD4+ T cells are predominantly of the naive 
phenotype representing 90% of the circulating T cells population. Since naive CD4+ 
T cells have a reduced capacity for cytokine production compared to memory T cells 
(Clement et a l 1988; Clement et a l 1990; Janeway 1992), it is plausible that the 
observed IL-4 increase could be attributable to an increase in the neonatal memory T 
cell pool at 6 months of age as the newborn matures under antigen experience. 
Furthermore, decreased cytokine release following ex vivo polyclonal stimulation of 
CBMCs may be reflective of a relative deficiency in post-natal memory T cells in 
early childhood.
Consistent with the current results Hartel et a l (2005) demonstrated that IL-4 mRNA 
expression levels increase with age in early infancy after PMA/ionomycin 
stimulation. These results were confirmed in the present study by extracellular 
detection of IL-4 protein by cytometric bead assay which also revealed an age related 
correlation of IL-4 protein response. In contrast to the present study, previous reports 
by Chipeta et a l (1998) and Gasparoni et a l (2003) noted a low-level intracellular 
IL-4 expression remaining unperturbed during infancy and childhood. Interestingly, 
in atopic subjects an expansion of IL-4-secreting cells is correlated to a progressive 
increase in serum IgE levels and there is a correlation between serum IgE levels and 
polyclonal IL-4 release in childhood (Tang et a l 1993). Further work is, however, 
necessary to delineate whether differences in the extent of IL-4 production with age 
can be attributed to age exclusively, or the expression of the early atopic phenotype. 
Additionally, the effect of probiotic supplementation on regulating the kinetics of IL- 
4 expression in atopy predisposed individuals still requires further characterisation.
Interestingly, PHA-induced IL-4 secretion has been demonstrated to increased only 
in highly atopic children and not in those with a lesser degree of atopy (Tang et a l
1993). The current study revealed no significant differences in PHA-induced IL-4 
production at birth and 6 months of age and contrasts with previous findings on the 
ontogeny of IL-4 production demonstrating that PHA-induced IL-4 production in 
healthy non-atopic children increased progressively throughout childhood until adult 
life (Tang and Kemp 1995).
It has been widely observed that when examining children for IFN-a, IL-4 and IL-5 
cytokines, particularly in the 0-2-year age-group, baseline up-regulation of these
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cytokines is strongly associated with age (Smart and Kemp 2001). Thus in our study 
where possible there was a necessity for age-matched controls. For this reason, the 
IL-4 response was considered in more detail to ascertain whether the same pattern of 
responders/non-responders was observed in matched cord/infant samples from the 
same subject at the two different age points. For the response to beads (Figure 4.2b), 
there was a clear indication IL-4 levels increased between birth and 6 months of age 
(n = 13). Since IL-4 is produced predominantly by the CD45RO memory T cell 
repertoire, current results were consistent with the widely accepted dogma that 
acquisition of infantile memory T cells increases with age, reflecting maturation of T 
cell immunity in the newborn linked to global increases in cytokine production by 
infantile mononuclear cells; seen from birth to 6 months in the present study.
5.4.1.2 IL-13
For IL-13, the only significant difference was seen for PHA with the response by 
CBMCs greater than that by 6 month PBMCs. These results were confirmed by the 
observations that there were fewer responsive infants for IL-13 for all stimuli. Since 
neonatal T cells are predominantly naive CD45RA+, and IL-13 is produced by both 
activated CD45RA+ naive T cells and CD45RO+ memory T cells, the likely source of 
ex vivo PHA induced IL-13 production by CBMCs would emerge from the naive 
CD45RA naive T cell population.
IL-13 is chiefly required by the fetus to maintain the pre-term in utero environment, 
which is immunologically Th2 skewed to prevent fetal rejection (Lin et a l 1993; 
Wegmann et a l 1993; Williams et a l 2000). Th2 immune responses antagonize Thl 
immune responses, which are toxic to placental structural integrity. Furthermore, 
intrinsic maternal regulatory T cell mechanisms limiting Thl responses may also be 
transferred to the fetus via the umbilical cord (Leber et a l 2010). This provides a 
logical explanation as to why post-natal PHA induced IL-13 responses by CBMCs 
were significantly greater than that by 6 month infant PBMCs. Conversely, lower 
infant PHA induced IL-13 responses concomitant with fewer responsive infants for 
IL-13 for all mitogenic stimuli employed can be in part explained by the accepted 
dogma that upon maturation of newborn immunity there is a move to enhance IgA 
responses for normal mucosal immunity with age as the developing newborn is 
introduced to a diverse variety of highly antigenic foods. IgA provides antibody 
mediated immunity towards food antigens as opposed to IgE up-regulated in atopic
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individuals to propagate the allergic response. Interestingly, in contrast to the present 
study Williams et a l (2000) demonstrated that polyclonally induced IL-13 
production by CBMCs did not differ from polyclonally induced IL-13 production by 
PBMCs. In the context of the expression of a clinical atopic disease, Prescott et a l 
(2008) observed that attenuated neonatal PHA induced cytokine responses were 
associated with atopic dermatitis along with elevated allergen-specific IL-13 at 6 
months associated with atopic dermatitis at 2.5 years. In the context of the study of 
Allen et a l (2014) who utilized a cohort of predominantly atopic predisposed 
individuals, it is of interest that the PHA induced ex vivo IL-13 response showed an 
inverse association with age, suggesting a reduction in a key allergy exacerbating 
cytokine in the PROBAT cohort with age. This is an interesting find when 
considered in the context of the secondary outcomes of the overarching trial and the 
role IL-13 plays in promoting IgE class switching, inhibiting inflammatory cytokine 
production and increasing the propensity of an individual towards an IgE sensitised 
state (Wynn 2003).
5.4.1.3 IL-10
IL-10 is a crucial anti-inflammatory cytokine relevant for T-cell regulation and 
suppression of the Thl cytokines, and several IL-10 single nucleotide polymorphisms 
exist in atopic disease settings (Raedler et a l 2012). IL-10 mediated immune 
responses are postulated to mature with age upon antigen experience, to maintain 
immune tolerance (Hadis et a l 2011; Renz et a l 2011). We therefore hypothesised 
that in response to the mitogenic stimuli the IL-10 response would increase with age. 
As hypothesised, the IL-10 bead induced T cell response was greater in the infants, 
but unexpectedly the PHA-induced response was greater by CBMCs.
5.4.1.4 IFN-y
Considering newborns recruited on the PROBAT trial were predominantly of an 
atopic status, it was unexpected that no differences for IFN-y production by CBMCs 
or 6 month PBMCs in responses to any of the stimuli were observed. There were 
fewer responsive infants for SEB-stimulated IFN-y. Numerous studies demonstrate 
that the IFN- y response to polyclonal stimuli is reduced in childhood atopic disorder. 
Paradoxically, some atopic children present with an increase in IFN- y secretion 
throughout childhood (Tang et a l 1993; Tang and Kemp 1994; Tang et a l 1995;
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Campbell and Kemp 1997; Nurse et al. 1997; Campbell et al. 1998). Since resolution 
of the symptoms of atopic dermatitis and food allergy occur later on in life (Smart 
and Kemp 2001); it is plausible that analysis of the mononuclear cell, mitogen 
induced, IFN-y response at a later age-point may correspond to an increase in IFN-y 
with age. This notion is supported by the observation that in adults, <50- 60% of 
circulating T cells are of the CD45RO memory-cell phenotype, and memory T cells 
have been demonstrated to produce < 10-fold more IFN-y than naive T cells (Wilson 
1991).
In summary, age-related changes in IL-4, IL-13, and IL-10 production highlighted in 
this study may reflect physiological maturation of the immune repertoire as maternal 
antibodies diminish within the first 6 months of life, and de novo synthesis of 
immunoglobulins becomes essential. Current results indicate that this is likely to be 
mediated in an IL-4 dependent manner and possibly to a lesser extent IL-13 since as 
ex vivo IL-4 production showed the strongest correlation with age. IL-4 and IL-13 
are regarded as key drivers for the induction of Th2 responses (Seder and Paul 1994) 
necessary for promoting humoral immune responses and maturation of adaptive 
immune responses in the newborn (Hartel et al. 2005). Current results were 
consistent with the findings of other birth cohort allergic disease prevention studies 
and reinforce observations by numerous authors highlighting the presence of an 
evolutionary conserved mechanism in the neonate to limit Thl responses from birth 
to early infancy even if the resulting immune equilibrium potentially encourages an 
immunological arena favourable for the development of allergic responses. Therefore 
avoidance of the up-regulation of the Thl inflammatory responses during infancy 
may be vital survival mechanism of the newborn.
5.4.1.5 IL-17 and IL-22 production in early infancy
Since the publication of perinatal supplementation studies, interest in the contribution 
of IL-17 to atopy and atopic disease has emerged. Initial investigations as part of this 
thesis of the capacity of newborns to produce IL-17 and IL-22 produced 
preferentially by Thl 7 cells found that similarly to other cytokines the production of 
these is attenuated in newborns versus adults. Therefore, the cytokine analysis for the 
PROBAT study was not extended to IL-17. This might be an oversight as differences 
might emerge that relate to probiotic versus placebo supplemented study participants.
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Since culture supernatants are still available analysis of IL-17 or other cytokines 
could be considered once the clinical effect of the study consortium is determined.
5.5 Cytokine responses by probiotic versus placebo
The present study examined the effects of probiotic supplementation on ex vivo 
cytokine responses by CBMCs and 6 month PBMC cultures stimulated with the 
polyclonal stimuli (PHA, SEB or anti-CD3/CD28 beads). There were no statistically 
significant differences between the placebo and probiotic group. The current results 
are in line with studies conducted by numerous authors documenting the effects of 
perinatal probiotic supplementation on maturation of immune function in potentially 
atopic newborns. In these studies newborns preferentially selected for probiotic 
prevention studies were those bom into families harbouring an increased genetic risk 
of atopy (i.e. > 1 family member with atopic disease). Studies assessing specific 
effects of probiotic supplementation on ex vivo immune responses from newborn 
hematopoietic cells and those studies adopting a similar perinatal supplementation 
strategy to the current study will be briefly discussed.
Since IL-4 and IL-13 are drivers of IgE antibody induction and the results of the 
current study revealed no significant difference in the levels of these cytokines 
within the probiotic and placebo groups it is reasonable to hypothesis that these 
results may provide insight into the clinical outcomes of the PROBAT trial and 
imply no significant differences in IgE mediated atopic sensitization between the 
placebo and probiotic groups. This hypothesis is in line with observations made by 
Kalliomaki et a l (2001) who administered 1 x 1010 Lactobacillus GG (LGG) CFU 
daily to lactating mothers 2 - 4  weeks before delivery and continued 
supplementation to their newborns until 6 months of age. Despite a statistically 
significant 50% reduction in the occurrence of atopic eczema occurring in the 
probiotic group compared to the placebo group, there was no recognizable 
immunological effect on atopy, no differences in the level of total IgE, or frequency 
of those with high total IgE or frequency of increased antigen-specific IgE and 
positive skin prick test results at 3, 12 and 24 month age-points.
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Further supporting the results of the current study Kopp et al. (2008) randomly 
assigned pregnant women with at least one first-degree relative or a partner with an 
atopic disease to receive either the probiotic LGG at 5 x 109 colony-forming units 
twice daily or placebo 4-6 weeks before expected delivery. Following a post-natal 
period of 6 months, ex vivo cytokine responses by newborn mononuclear cells 
CBMCs (n=68) from neonates taking probiotic or placebo exposed to either IL-2, P- 
lactoglobulin or inactivated (70% ethanol) it was demonstrated that although LGG 
induced release of IL-10 and IFN-y by CBMCs no differences between the study 
groups for either LGG- or PHA-stimulated cytokine responses were observed. 
Interestingly, these results were in contrast to their previous studies, indicating that in 
vitro stimulation with LGG resulted in significantly enhanced release of IL-10 and 
IFN-a by CBMCs, compared with cytokine release in un-stimulated controls. This 
suggested that the immunomodulatory potential of probiotic bacteria to preferentially 
regulate key cytokines of the Thl/Th2 immune axis in favour of an anti-allergy 
response in vitro does not necessarily translate to similar immunomodulatory effects 
in vivo in atopically predisposed individuals.
In a randomized double-blind study, Marschan et al. (2008) administered probiotic 
bacteria or placebo for 1 month before delivery to mothers, and for 6 months to their 
infants with a high genetic risk of allergy. In contrast to the current study, the effect 
of supplementation was measured in plasma samples for the presence of key 
inflammatory protein markers, immunoglobulin expression and influence on 
cytokines of the Thl/Th2 axis as the principal measurement. Interestingly, infants 
receiving probiotic bacteria had significantly higher plasma levels of C-reactive 
protein (P=0.008), total IgA (P=0.016), total IgE (P=0.047), and IL-10 (P=0.002) 
than infants in the placebo group. This result suggest that ex vivo plasma analysis 
may have served as a useful option to understand underlying immunological 
responses exhibited by the study consortium in vivo. Since plasma samples have been 
collected this type of analyses could form the basis of future work. Similarly to the 
results of the current study, probiotic supplementation had no effect on IL-4 and 
IFN-y levels albeit at the plasma level. CBMCs from neonates on the same study 
were also stimulated with (p-LG) and PHA prior to ex vivo monitoring of IL-4, IL-5, 
IL-10, IL-13 and IFN-a levels. Similar to the present study, PHA induced IFN-a, IL- 
4, IL-10, and IL-13 by CBMCs did not differ between probiotic and placebo groups,
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indicating that maternal probiotic supplementation had no effect on the cytokine 
profile.
Employing a rationale different to the current study, Boyle et a l (2008) in a pre-natal 
supplemental study measured fetal immune responses employing CBMCs prepared 
from cryopreserved cord blood from the newborns of (n = 73) study participants 
supplemented withl .8 x 1010 L. rhamnosus GG CFU daily from 36 weeks of 
pregnancy. Upon analysis of fetal response to heat-killed LGG no difference in 
cytokine (IL-10, IL-13, and TNF-a, IFN-y, TGF-pi, and IL-12p40) was observed. 
LGG treatment of pregnant women did not influence cytokine secretion in CBMCs 
cultured with heat-killed LGG.
Employing a similar methodology, West et a l (2009) supplemented infant cereals 
with (n =89) or without (n = 90) Lactobacillus F I9 (LF19) from 4 to 13 months. At 
the end of the study PBMCs were obtained and cytokine responses to the T cell 
mitogens anti-CD3 and anti-CD28 monoclonal antibodies determined. The ratio of 
IFN-y to IL-4 mRNA expression levels in polyclonally stimulated peripheral blood T 
cells from recruits was measured as a proxy for immune balance. Interestingly, the 
authors discovered that LF19 was associated with elevated IFN-y/IL-4 mRNA ratio 
in polyclonally activated T cells at 13 months of age and reduced cumulative 
incidence of eczema. The higher Thl/Th2 ratio in the probiotic compared with the 
placebo implicated an effect of LF19 on the T cell-mediated immune response. 
Suggesting that further analysis of the Thl/Th2 ratio in the probiotic versus placebo 
group in the PROBAT study may provide further insight into the effects of 
supplementation with the study consortium.
Reinforcing the results of West et a l (2009) in another disease treatment study, 4 
weeks supplementation with Lactobacillus rhamnosus GG was associated with 
enhanced IL-10 production by mitogen-stimulated PBMCs isolated from children 
with AD (Pessi et a l 2000) and in a comparable study in which LGG was given to 
infants and children with cow’s milk allergy and IgE-mediated eczema for 4 weeks, 
enhanced IFN-y responses to polyclonal T-cell activation was also observed in the 
probiotic compared with placebo group (Pohjavuori et a l 2004). Augmenting these 
results, eight weeks supplementation with Lactobacillus fermentum to very young 
children with eczema reduced the severity of disease and increased polyclonal IFN-y
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responses by T cells in probiotic-treated compared with placebo-treated children 
(Prescott et a l 2005).
In a study population comprising of infants participating in a clinical trial on the 
effects of probiotics on symptoms of atopic dermatitis, 132 infants were randomly 
selected by Marschan (2007) who employed a randomized, double-blind design 
concomitant with an elimination diet. Infants were under 12 months of age, had 
eczema, and were suspected to have cow's milk allergy. Lactobacillus rhamnosus 
GG (ATCC 53103) 5 x 109 cfu, or a mixture of four probiotic strains (MIX): LGG 5 
x 109 cfu, Lactobacillus rhamnosus LC705 5 x 109 cfu, Bifidobacterium breve Bbi99
8  92 x 1 0  cfu, and Propionibacterium freudenreichii ssp. shermanii JS 2 x 10 cfu, or 
placebo was administered for 4 weeks to the infants. Blood samples were collected 
before and after the treatment and infants and their breast-feeding mothers began a 
Cow’s milk-free diet. Infants were randomized to receive a probiotic (LGG or MIX) 
or placebo product and followed for up to 12 weeks by the study. Interestingly the 
authors demonstrated that in infants with Cow’s milk allergy, anti-CD28-stimulated 
IFN- y  secretion of PBMC increased significantly in LGG group (p = 0.023) 
suggesting an in vivo up-regulation of Thl immunity by LGG, but no changes 
occurred in follow-up samples in the MIX group (p = 0.239) or placebo groups (p = 
0.086). IFN- y  secretions appeared to potentiated more in the LGG group compared 
to the placebo group (p = 0.006), but in the MIX group, the IFN- y  level increase was 
not significant in comparison with the placebo group (p = 0.058). Consistent with the 
results of the current study no differences were detectable between IL-4 secretion in 
the LGG and placebo groups. Interestingly in infants with IgE-associated eczema, 
anti-CD28-stimulated IFN- y  secretion of PBMC was potentiated significantly in 
follow-up samples in the LGG group (p = 0.048), but no changes occurred in the 
MIX (p = 1.000) or placebo groups (p = 0.158). In comparison with the placebo, the 
level of IFN- y  secretion increased in the LGG group (p = 0.017), but no differences 
appeared in the MIX group in comparison with placebo (p = 0.319). Interestingly 
probiotic treatment had no significant effect on IL-4 secretion in infants with IgE- 
associated eczema. As in the present study probiotic treatment had no effect on ex 
vivo IL-4 or IFN- y  secretion in stimulated (CD28 antibodies) PBMCs.
The PROBAT trial did not have any effect on ex vivo IL-4, IL-10, IL-13 and IFN-y 
cytokine responses induced by mitogenic stimulation of mononuclear cells isolated
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from the study participants at birth or at 6 months of age. These results were 
comparable to findings from numerous studies adopting the same or similar rationale 
employing a probiotic consortium or exclusively administered probiotic strain, to 
assess the effects of supplementation on atopic disorder.
Interestingly, the results of probiotic treatment studies on neonates already presenting 
with atopic disorder generally indicate a positive effect on eczema which may occur 
via a pathway of improved maturation or recovery of Thl type immune responses in 
probiotic treated infants (Pohjavuori et al. 2004; Prescott et a l 2005; West et a l 
2009). Effects appeared to be greatest when a single probiotic strain was used in the 
intervention as opposed to a consortium as in the present study.
5.6 Limitations of the study
Evaluation of the effect of perinatal probiotic supplementation on age-related 
changes has been a focal point of the current study in which the immune response of 
both newborns and infants has been assessed concurrently. Despite the ontogeny of 
IL-4 production showing the strongest correlation with age in all reviewed studies, a 
comprehensive review of age-related changes in immune function has given rise to 
varied results. Reasons for these discrepancies can be attributed to heterogeneity in 
experimental conditions e.g. mitogenic stimulus employed, method of mononuclear 
cell preparation and age point for evaluation. Therefore, robust meta-analyses 
defining the ontogeny of cytokine production with age is needed so immune 
responses occurring with age that could potentially skew an immune effect of a 
probiotic supplementation study can be known beforehand. Additionally comparison 
of reports on age-related alterations in cytokine production is made more difficult by 
the various techniques used to quantitate cytokines. Most studies measure cytokines 
in supernatants employing ELISA or Radioimmunoassay, giving rise to high intra­
assay and inter-assay variation. Additionally, measurement of the effects of probiotic 
supplementation on immunological parameters in the context of ex vivo cytokine 
responses by CBMCs and 6 month PBMCs in responses to mitogenic stimuli are 
largely experimental as the stimulus employed in the current study are non-specific 
antigen independent stimuli. This could account for the reason why almost all 
probiotic intervention studies adopting this rationale have revealed no significant 
differences between probiotic and placebo groups. Some studies have evaluated 
cytokine mRNA produced by cells to avoid problems of measuring proteins in the
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supernatants of experimentally stimulated cells, to limit false positive results that can 
occur in artificially induced experimental scenarios in which immune parameters are 
explored. In the context of the current study it may have been better to ascertain the 
ex vivo effects of perinatal probiotic supplementation on the underlying Thl/Th2 
ratio, by extracting the RNA from the PROBAT mononuclear cell samples and 
conducting gene expression analysis of the relevant mRNA cytokine transcripts. This 
type of analysis would be independent of prior mitogenic stimulation and obviate 
variations in immunological responses that can ensue as a result of mitogenic 
stimulation.
While the levels of mRNA provide useful information regarding age associated 
alterations in transcription of cytokine genes, mRNA results do not always reflect the 
amount of protein produced and secreted. It is, therefore, difficult to resolve 
disparities among studies when different methods of cytokine analyses have been 
employed. Clearly, the combination of these variations in experimental design could 
significantly contribute to the varying outcomes, even when all other parameters of 
the study population are controlled. Interestingly despite differences in experimental 
design among perinatal probiotic intervention studies the current results are line with 
all the perinatal probiotic intervention studies demonstrating that there are no 
significant effects of probiotic supplementation on ex vivo immune responses 
produced by newborn or early infant mononuclear cells, however there are a paucity 
of studies to indicate whether this predisposition changes upon maturity beyond the 5 
year old age point.
Ethical considerations
The probiotic strains used in the study have well-documented safety properties 
(Allen et a l 2010). Previous studies of probiotic supplementation have demonstrated 
positive clinical effects on the prevention and treatment of atopic diseases (Majamaa 
and Isolauri 1997; Isolauri et a l 2000; Kalliomaki et a l 2001, 2003; Rosenfeldt et a l 
2003; Viljanen et a l 2005; Abrahamsson et a l 2007). Based on these findings, we 
assumed that infants would benefit from probiotic treatment.
5.7 Conclusions
Research employing the application of the polyclonal mitogens has considerably
enhanced understanding of immune responses during early infancy and clarified the
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mechanisms of allergic diseases and IgE sensitization. Although probiotic bacteria 
offer an attractive possibility for an immunomodulatory intervention in the treatment 
of atopic disorder, the underlying immunological mechanism imparted by probiotic 
bacteria to do so remain unresolved in the current study. Upon analysis of the effects 
of probiotic supplementation on ex vivo IFN-y, IL-10, IL-13 and IL-4 responses by 
umbilical cord blood and 6 month infant blood mononuclear cultures stimulated with 
the polyclonal stimuli (PHA, SEB or anti-CD3/CD28 beads) at each age point. There 
was no statistically significant immunomodulatory effect of perinatal probiotic 
supplementation when compared to the placebo. Although interest is growing in 
developing therapeutic applications and primary prevention strategies for allergic 
diseases, essential to this approach is a clear understanding of the immunological 
processes in early life which promote IgE-sensitization leading to allergic disease in 
terms of age related changes in the ontogeny of cytokine production from the 
neonatal stage to early infancy.
Chapter 6: Ex vivo effects of perinatal probiotic supplementation on 
the maturation of innate and adaptive immunity
6.1. Introduction
Profound haematopoietic differences in the cellular composition of human blood are 
apparent in the newborn and older infant. These differences are marked by an 
evolutionary conserved age related predisposition favouring granulopoesis, (the 
formation of granulocytes) in the neonate and lymphopoiesis, (the formation of 
lymphocytes) in the older infant (Christensen et al. 1989). It is widely accepted that 
lymphocyte subpopulations vary during the neonatal period (Comans-Bitter et a l 
1997) according to the balance of tolerogenic, allergenic and cellular immunity 
against pathogens. However, mechanisms by which probiotic bacteria might 
beneficially affect the cellular landscape of immunity in the atopy predisposed 
neonate are largely unknown. Furthermore, the effects of perinatal probiotic 
supplementation in preventing the proliferation of granulocyte and lymphocyte 
subsets pertinent to the expression of the atopic phenotype remained largely 
unexplored, particularly within a cohort of clinically predisposed atopic neonates. It is 
hypothesised that hematopoietic myeloid progenitors support recruitment of pro- 
inflammatory cells to tissue sites involved in the progression of atopic disease
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(Gauvreau et al. 2009). Elevated eosinophil counts at birth and/or at 3 months of age 
have been implicated in infantile eczema and early diagnosed aopic eczema in early 
life (Borres et al. 1995; Borres and Bjorksten 2004; Matsumoto et a l 2005). The 
clinical observation that hematopoietic progenitors from the cord blood of high risk 
infants give rise to elevated eosinophil and basophil progenitor levels is widely 
accepted. The hypothesis, in Chapter 6 was that the immunomodulatory effects of 
perinatal probiotic supplementation in vivo might occur via microbial stimulation of 
pattern recognition receptors, to curtail the differentiation of eosinophil and basophil 
progenitors (Reece et a l 2011). Defects in the cellular composition of human 
peripheral blood have been implicated as early pre-symptomatic markers for the 
development of atopic disorder. Reduced numbers of circulating regulatory T cells 
concomitant with increased numbers of circulating eosinophils is frequently cited 
(Fontenot et a l 2003; Godfrey et a l 2005; Liu et a l 2006). This is one of the first 
studies to investigate the impact of perinatal probiotic consumption on leukocyte 
counts at birth and 6 months of age.
Perinatal probiotic supplementation is postulated to stimulate development of the 
Thl cell repertoire (Eisenhofer et a l 1997; Backhed, Ding et a l 2004), mediate 
immune tolerance, and attenuate the development of Th2 mediated atopic disorder 
(Eckburg et a l 2005). Since the principle site of interaction of probiotic bacteria is 
the intestinal tract, it may appear unrelated that probiotics might exert a protective 
systemic effect against the development of atopic disorder at sites distal to the 
intestinal tract, such as the skin and respiratory tract. Nonetheless, propagation of an 
intestinal probiotic mediated Thl immunomodulatory signal is achievable 
systemically via the interaction of probiotic bacteria with (1) dendritic cells; (2) their 
transytocis via the intestinal epithelium M cells (Hathaway and Kraehenbuhl 2000); 
(3) and the re-circulatory nature of intestinal lymphocytes interactive with probiotic 
bacteria that home to other, mucosal sites and exert the effector function.
6.1.1 Aim of the study
The aim was to ascertain whether immunomodulatory signals provided by perinatal 
supplementation with the study consortium, altered lymphocyte and granulocyte 
population dynamics, away from a cellular phenotype pertinent to the inception of 
atopic disorder. This ex vivo study combined a flow cytometric and haematological 
analysis of neonatal whole blood from recruits on the PROBAT trial. Since 
automated haematology analysis of whole blood only provides information on total
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lymphocyte and granulocyte counts, the additional flow cytometric approach was 
required to analyse in more detail the effects of probiotic supplementation on key 
lymphocyte subsets, (T cell subsets, B cell subsets and dendritic cell subsets). We are 
currently one of the first groups to adopt this type of approach in any perinatal 
probiotic supplemental study for the prevention of atopy. Adopting this approach, 
umbilical cord blood samples at birth and peripheral blood at 6 months of age from 
recruits of the PROBAT trial were haematologically analysed using CellDyn and 
also immunophenotyped by flow cytometry to determine the percentages of key 
granulocytic and lymphocytic subpopulations involved in atopic disorder. Since 
lymphocytes continuously leave the blood, enter non-lymphoid and lymphoid organs 
and finally return to the blood again it is noteworthy that lymphocytes studied 
adopting this approach are predominantly recirculating in nature. The effects of 
perinatal probiotic supplementation on the proliferation of granulocytic (e.g. 
basophils and eosinophils) and lymphocytic subsets (e.g. gut homing lymphocytes, T 
regulatory cells and memory T cells) within neonatal whole blood was assessed in 
the context of the pathogenesis of atopic disorder (See Chapter 1, 1.3.4 to 1.3.5) in 
supplemented neonates.
A principal aim in any perinatal probiotic intervention is to manage the inherent Th2- 
mediated atopic predisposition in the presence of probiotic organisms capable of 
inducing Thl polarising cytokines that challenge the atopic predisposition (Furrie 
2005). To monitor this, ex vivo whole-blood cultures were established from birth to 6 
months of age from recruits on the PROBAT trial and stimulated with 
lipopolysaccharide (LPS) or peptidoglycan (PGN) which are ubiquitously occurring 
MAMP encountered by the newborn in the post utero environment, and act here as a 
measure of innate immune function. The application of the whole blood approach 
allowed for the contribution from multiple cell types (e.g. neutrophils, dendritic cells 
and monocytes) as well as soluble factors occurring in plasma (e.g. soluble CD 14, 
LPS binding protein) during microbial induction of the cytokine response. The 
application of LPS in this study was particularly useful since the allergen Der p 2 
functions as a ligand for TLR4, due to its structural homology to the mammalian 
TLR4 co-receptor MD-2 (Botos et a l 2011). These microbial stimulants served as a 
surrogate measure of granulocyte mediated innate immune function and allowed age 
related change in cytokine production to be measured ex vivo as a consequence of 
perinatal probiotic supplementation. The cytokines measured were TNF-a and IL-
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12p70, serving as a proxy for the Thl pro-inflammatory response and IL-10 serving 
as a proxy for the regulatory response. We therefore aimed to measure any 
underlying changes in the maturation of the innate cytokine immune response as a 
result of perinatal probiotic supplementation. We hypothesized that supplementation 
might augment granulocytic responses to microbial stimuli in a Thl dependent 
manner in the probiotic group compared to the placebo group.
Due to the ability of the study consortium to modulate induction of Thl inflammatory 
cytokines antagonistic to the expression of atopy supporting Th2 cytokines both in 
vitro, we hypothesize that there is a beneficial immunomodulatory role of perinatal 
probiotic supplementation occurring at the cellular immune level. We postulate that 
supplementation might contribute to the maturation of regulatory lymphocyte subsets 
necessary to control the maturation of Th2 dominated cellular immune responses that 
support the development of atopy in predisposed neonates. We also hypothesised that 
perinatal probiotic supplementation would accelerate the age related maturation of 
neonatal Thl immune responses at the cytokine level and reduce the circulating 
whole blood eosinophil and basophil counts in the probiotic group compared to the 
placebo group. We anticipate that the net clinical consequence of these responses 
would be a resistance of the atopic phenotype in consortium supplemented neonates.
6.2. Materials and Methods
6.2.1 Sample collection
All subjects were participants on the PROBAT trial. Umbilical cord blood was 
collected from the newborn immediately after birth by a qualified midwife and 
peripheral infant blood at 6 months of age. Blood collected into sodium heparin 
(Vacutainer, Greiner Bio-One); gel and clot activator tubes (Vacutainer) were used 
for all analyses presented in this chapter.
6.2.2 Automated haematology analysis
Full blood counts and differentials were generated using an automated haematology 
analyser (CellDyn Ruby; Abbott Diagnostics Maidenhead, UK). Total white blood 
cells, leukocyte populations and cytokine production were measured in umbilical 
cord blood collected at birth and venous blood collected at the 6 month follow-up.
6.2.3 Whole blood cultures
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Heparinised blood was diluted 1 in 4 in RPMI 1640/Glutamax (Invitrogen, Paisley, 
UK) in a total volume of 600 pi in culture tubes. Whole blood cultures were left 
untreated or treated with lOng/ml LPS and 3pg/ml PGN (Invivogen, California, 
USA). For IL-12p70, cultures were pre-treated for 90 minutes with 10 ng/ml; IFN-y 
(PeproTech EC Ltd, London, UK) prior to addition of LPS. After 24 hours 
incubation at 37°C in 5% C02-in-air cell free, culture supernatants were harvested by 
centrifugation. These were stored at -80°C until batch analysis of cytokines using 
specific ELIS As in accordance with the manufacturer’s instructions (TNFa, IL-10, 
IL-12p70; OptEIA, BD Biosciences, Oxford, UK).
6.2.4 Flow cytometry - staining
Antibodies were added at predetermined concentrations to FACS tubes and 50pl of 
whole blood added to each tube. Each tube was vortexed and incubated on ice for 30 
minutes in the dark. After this time 3 ml of FACS lyse (BD Biosciences) was added 
to each tube (except for tube 16 to which 3 mis of Easy Lyse (Dako) was added), the 
tubes were vortexed and then incubated in the dark at room temperature for a further 
10 minutes except for tube 16 which was incubated for 15 minutes. The cells were 
washed by centrifugation. The supernatant was discarded and the pellets were re­
suspended in FACS buffer prior to a further wash by centrifugation. After discarding 
the supernatant, the cells were re-suspended in 200 pi FACSFIX (BD Biosciences). 
Tubes were kept in the fridge and acquired on the flow cytometer (FACSAria; BD 
Biosciences) within 24 hours.
Difficulty arising in obtaining accurate absolute counts of lymphocytes 
subpopulations by flow cytometric immunophenotyping of neonatal cord blood is 
caused by erythroid cell contamination of the archetypal lymphocyte gate (Loken et 
al 1990). This was avoided by application of the reagent Easy Lyse which provides 
complete and gentle lysis of erythrocytes prior to FACs staining of whole blood.
6.2.5. Statistical analysis
Statistical analysis and p values were obtained to assess the maturation of total wbc,
neutrophils lymphocyte, monocytes eosinophils, basophils red blood cells and
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platelets and other haematological parameters from birth to 6 months of age. The 
effect of perinatal probiotic supplementation versus the placebo on hematopoietic 
ontogeny of the same cell types was determined as mean probiotic difference (as 
previously described see 5.2.3).
6.3. Results
6.3.1 Cell counts at birth and 6 months of age
As samples were being collected from a large number of newborns (umbilical cord 
blood n = 100) and 6 month old infants (peripheral blood n = 103) a comparison of 
changes in counts of various cell populations was undertaken. Automated 
haematology analysis yields data as total counts and, for leukocytes, percentage of 
total white blood cell counts. As leukocytes are the main interest of the study the 
data for these are shown graphically in Figure 6.1 with total counts (xl09/litre; Figure 
6.1a) and percentage of total leukocytes (Figure 6.1b).
For cell counts, there were significant differences between birth and 6 months of age 
for all cell types except red blood cells. Statistically significant higher levels were 
found in cord blood for total white blood cells, neutrophils, monocytes, eosinophils, 
basophils and platelets. Only lymphocytes were higher in the infant samples (p < 
0.0001). Similarly the percentages of each of the leukocyte subsets - neutrophils, 
monocytes, eosinophils and basophils - were significantly higher in cord blood; only 
lymphocytes were higher in the infant samples.
Among all the samples analysed there were 45 matched pairs for which data were 
available for the same infant at birth and 6 months of age (cell counts -  Figure 6.2; 
percentage of total leukocytes -  Figure 6.3). These data confirm the dramatic 
differences in lymphocyte and neutrophil counts/percentages in particular among the 
subsets studied.
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Figure 6.1. Automated haematology analysis of umbilical cord blood 
(orange) and peripheral blood from 6 month infants (green).
Summary o f (a) total counts (x 109/L), and percentages o f each major 
leukocyte population in blood collected at birth (n = 100) and at 6 months o f 
age (n = 103). There was a significant difference between the two age groups 
for all measurements. This was denoted by * P < 0.01 .Note that percentages 
are not available (N/A) for total white blood cells or platelets as this is 
calculated as percentage o f total white blood cells
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Figure 6 .2 .  mges in total and major leukocyte subset counts with age A utom ated  
haem atology analyses w as used to generate counts (x 10e9/L) o f (a) total w hite blood cells, (b) 
neutrophils, (c) lym phocytes, (d) m onocytes, (e) eosinophils, and (f) basophils from m atched  
samples of umbilical cord blood and peripheral blood collected at 6 m onths o f age from  
participants of PR O BA T study (n = 45)
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participants o f  P R O B A T  study (n =  45 )
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5.3.2 Cell counts in relation to probiotic versus placebo exposure
Counts o f total white blood cells, and counts and percentages o f  leukocyte 
subsets were compared at birth and 6 months o f age for infants recruited to 
the probiotic or placebo groups o f  the study (Figures 5.4 -  5.11). The only 
difference between the two study groups at the two age points was a 
decreased eosinophil counts at birth in infants whose mothers had taken the 
probiotic supplement over the last few weeks o f pregnancy (p = 0.0242). 
However there were no differences in the percentage o f  eosinophils at birth or 
the total counts or percentages o f eosinophils at 6 months o f age. Circulating 
platelet (Figure 6.10) and red blood cells (Figure 6.11) numbers and all other 
haematological parameters investigated did not differ with probiotic or 
placebo usage at any age.
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Figure 6.4 Total white blood cell counts from participants in the PRO BAT study.
Blood was collected at (a) birth (umbilical cord blood), and (b) 6 months o f age and used for 
automated haematology analysis to give total white blood cell counts (x lO^/litre). The box 
signifies the upper and lower quartiles (75% and 25% respectively), and the median is 
represented by the thick black line within the box. The whiskers represent the 5% and 95% 
percentile. Outliers are represented by. n Statistically significant results (P < 0  .05) were 
denoted by *
CD
probioticplaceboplacebo probiotic
placebo probiotic placebo probiotic
Figure 6.5 Neutrophil counts from participants in the PROBAT study.
Blood was collected at (a & b) birth (umbilical cord blood), and (c & d) 6 months o f age, and 
used for automated haematology analysis to give (a & c) total neutrophil counts (x 109/litre), 
and (b & d) percentage o f  neutrophils. The box signifies the upper and lower quartiles (75% 
and 25% respectively), and the median is represented by the thick black line within the box. 
The whiskers represent the 5% and 95% percentile. Outliers are represented b y .() Statistically 
significant results (P < 0.05) were denoted by *
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Figure 6.6 Lymphocyte counts from participants in the PROBAT study.
Blood was collected at (a & b) birth (umbilical cord blood), and (c & d) 6 
months o f age, and used for automated haematology analysis to give (a & c) 
total lymphocyte counts (x lO^/litre), and (b & d) percentage o f  lymphocytes. 
The box signifies the upper and lower quartiles (75% and 25% respectively), 
and the median is represented by the thick black line within the box. The 
whiskers represent the 5% and 95% percentile. Outliers are represented by. 0 
Statistically significant results (P < 0.05) were denoted by *
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Figure 6.7 Monocyte counts from participants in the PROBAT study.
Blood was collected at (a & b) birth (umbilical cord blood), and (c & d) 6 months o f age, 
and used for automated haematology analysis to give (a & c) monocyte counts (x 
109/litre), and (b & d) percentage o f monocytes. The box signifies the upper and lower 
quartiles (75% and 25% respectively), and the median is represented by the thick black 
line within the box. The whiskers represent the 5% and 95% percentile. Outliers are 
represented b y .(’ Statistically significant results (P <  0.05) were denoted by *
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Figure 6.8 Eosinophil counts from participants in the PROBAT study.
Blood was collected at (a & b) birth (umbilical cord blood), and (c & d) 6 months o f age, and 
used for automated haematology analysis to give (a & c) eosinophil counts (x 109/litre), and 
(b & d) percentage o f eosinophil. The box signifies the upper and lower quartiles (75% and 
25% respectively), and the median is represented by the thick black line within the box. The 
whiskers represent the 5% and 95% percentile. Outliers are represented by. n Statistically 
significant results (P < 0  .05) were denoted by *
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Figure 6.9 Basophil counts from participants in the PROBAT study.
Blood was collected at (a & b) birth (umbilical cord blood), and (c & d) 6 months o f age, and 
used for automated haematology analysis to give (a & c) basophil counts (x 109/litre), and (b 
& d) percentage o f basophil. The box signifies the upper and lower quartiles (75% and 25% 
respectively), and the median is represented by the thick black line within the box. The 
whiskers represent the 5% and 95% percentile. Outliers are represented by. n Statistically 
significant results (P <  0.05) were denoted by *
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Figure 6.10 Platelet counts from participants in the PROBAT study.
Blood was collected at (a & b) birth (umbilical cord blood), and (c & d) 6 months o f age, and 
used for automated haematology analysis to give (a & c) platelet counts (x 1 o Vlitre), and (b 
& d) percentage o f platelets. The box signifies the upper and lower quartiles (75% and 25% 
respectively), and the median is represented by the thick black line within the box. The 
whiskers represent the 5% and 95% percentile. Outliers are represented b y .(> Statistically 
significant results (P <  0.05) were denoted by *
201
(a) (b)
p lacebo  probiotic p lacebo probiotic
Figure 6.11 Red blood cell counts from participants in the PROBAT study.
Blood was collected at (a & b) birth (umbilical cord blood), and (c & d) 6 months o f age, 
and used for automated haematology analysis to give (a & c) red blood cell counts (x 
10 Vlitre), and (b & d) percentage o f red blood cells. The box signifies the upper and 
lower quartiles (75% and 25% respectively), and the median is represented by the thick 
black line within the box. The whiskers represent the 5% and 95% percentile. Outliers 
are represented by. ‘ ’ Statistically significant results (P < 0.05) were denoted by *
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6.3.3 Innate immune response at birth and 6 months of age
Assessment of age related changes in cytokine responses at birth and 6 months of 
age, employing the stimuli LPS and PGN, revealed statistically significant increases 
in IL-10 and TNF-a (Figure 6.12; all p < 0.0001) above the background level. For 
IL-12p70, a statistically significant increase above background was only see for 
LPS/IFN-y at birth (p = 0.032) and PGN at 6 months of age (p = 0.005) (Figure 
6.13). The IL-12p70 response to LPS/IFN-y at 6 months of age was near significant 
(p = 0.083).
Differences in the levels of these cytokines produced in response to LPS or PGN by 
cord blood versus infant peripheral blood were found: LPS-stimulated IL-10 was 
significantly higher at 6 months of age than at birth (p = 0.022); and PGN-stimulated 
TNF-a was significantly higher at 6 months of age (p = 0.013). As IFN-y pre­
treatment has been identified to maximise IL-12p70 output in response to either LPS 
or PGN, data for LPS and PGN alone (Figure 6.13a) and with IFN-y pre-treatment 
(Figure 6.13b) are shown. IL-12p70 responses were significantly elevated at 6 
months of age compared to birth in unstimulated (p < 0.0001), PGN (p < 0.0001), 
and unstimulated/IFN-y (p < 0.0001) whole blood cultures.
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Figure 6.12 IL-10 and TNF-a production by whole blood cultures
Whole blood cultures were prepared from n = 100 umbilical cord blood (orange) and n 
= 103 peripheral blood o f 6 month infants (green), and left unstimulated, or stimulated 
with LPS or PGN. The mean (a) IL-10 and (b) TNF-a levels ± SEM, in cell free 
culture supernatants harvested after 24 hour culture were measured using specific 
ELISA. The student T was used to compare LPS and PGN induced cytokine responses 
to the background level. P>0.05 was considered statistically significant and denoted 
with. * The student T was also used to determine whether there were differences 
between responses from birth to 6 months o f age, statistically significant differences 
(P>0.05) are indicated on the graph above the bracket.
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Figure 6.13 1L-I2p70 production by whole blood cultures
Whole blood cultures were prepared from n = 100 umbilical cord blood (orange) and n = 103 
peripheral blood o f 6 month infants (green), and left unstimulated, or stimulated with LPS or 
PGN. The mean IL-12p70 levels in cell free culture supernatants harvested after 24 hours o f 
culture ± SEM were measured using specific ELISA in samples that (a) had and (b) hadn't 
been pre-treated with lOng/ml IFN-y for 90 minutes. The student T was used to compare LPS 
and PGN induced cytokine responses to the background level. P>0.05 was considered 
statistically significant and denoted with. * The student T was also used to determine whether 
there were differences between responses from birth to 6 months o f age, statistically significant 
differences (P>0.05) are indicated on the graph above the bracket.
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6.3.4 Innate immune response in relation to probiotic versus placebo exposure
LPS- and PGN- induced IL-10 (graph not shown), IL-12p70 (Figure 6.14) and TNF- 
a (graph not shown) at birth and 6 months of age was investigated in PROBAT study 
participants. For IL-12p70, pre-treatment with IFN-y was also considered (Figure 
5.17)). IL-12p70 levels were significantly higher in the probiotic than the placebo 
group for the unstimulated samples at birth (p = 0.0221) and the LPS/IFN-y treated 
samples at 6 months of age (p = 0.0225). There were no differences associated with 
probiotic supplementation for IL-10 (graph not shown) and TNF-a level under any of 
the cell culture conditions used at either age.
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Figure 6.14 IL-12p70 response in whole blood cultures from participants in the 
PROBAT trial Whole blood cultures were prepared from (a,b, & c) umbilical cord 
blood and (d,e & f) peripheral blood o f 6 month infants and (a & d) left 
unstimulated, or stimulated with (b & e) LPS, or (c & f) PGN. IL-12p70 levels in 
cell free culture supernatants harvested after 24 hour culture were measured using a 
specific ELISA. The box signifies the upper and lower quartiles (75% and 25% 
respectively), and the median is represented by the thick black line within the box. 
The whiskers represent the 5% and 95% percentile. Outliers are represented b y .(’ 
Statistically significant results (P < 0.05) were denoted by *
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Figure 6.15 IL-12p70 response in whole blood cultures from participants in the 
PROBAT trial
Whole blood cultures were prepared from (a, b & c) umbilical cord blood and (d, e & f) 
peripheral blood o f 6 month infants and pre-treated with IFN-y (lOng/ml) for 90 
minutes prior to being (a & d) left unstimulated, or stimulated with (b & e) LPS, or (c 
& f) PGN. IL-12p70 levels in cell free culture supernatants harvested after 24 hour 
culture were measured using a specific ELISA. The box signifies the upper and lower 
quartiles (75% and 25% respectively), and the median is represented by the thick black 
line within the box. The whiskers represent the 5% and 95% percentile. Outliers are 
represented b y . () Statistically significant results (P < 0  .05) were denoted by *
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6.3.5 Whole blood flow cytometry on umbilical cord blood and 6 month infant 
blood from participant of the PROBAT trial
The presentation of results takes the following format for each series of FACs 
analysis: explanation of the gating strategy used including an example of the key 
analysis plots, graphical representation of results from probiotic versus placebo 
analysis for birth and infant samples, and summary table of statistical analysis.
6.3.6 Lymphocyte subsets -  T, B and NK cells
Lymphocytes were identified by their characteristic forward and side scatter profile 
(FSC and SSC, respectively) and then lineage specific antibodies -  CD3 for T cells, 
CD 19 for B cells and a combination of CD 16 and CD56 for NK cells -  used to 
identify the key lymphocyte subsets (Figure 6.18). A pan-leukocyte marker (CD45) 
was also included in the tube and could be incorporated into the subset identification 
strategy, if  required. The number of each of these populations, in each pi of blood, 
could be calculated from data available from automated haematology analysis. There 
were no differences between the study groups at birth or 6 months of age for the total 
counts of any of these populations (Figure 6.19). However, the percentage of 
lymphocytes that were NK cells was significantly lower in the probiotic versus 
placebo group at birth (p = 0.005) (Figure 6.20); and the percentage that were CD3+ T 
cells was significantly lower in the probiotic that placebo group at 6 months of age (p 
< 0 .0001)
6.3.7 CD4:CD8 T cell ratio
The two major subsets of CD3+ T cells are CD4+ T helper cells and CD8+ cytotoxic T 
cells. Typically, the CD4/CD8 ratio is considered by firstly identifying the total CD3+ 
subset and then the populations within this gate co-expressing either CD4 or CD8 
prior to calculation of the ratio (Figure 6.21). There were no differences between the 
probiotic and placebo group at either time point investigated (Figure 6.22).
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Figure 6.18: Gating strategy employed to identify key lymphocyte subsets.
F r o m  a  f o r w a r d  s c a t t e r  ( F S C )  v e r s u s  s i d e  s c a t t e r  ( S S C )  p l o t  t h e  ( a )  t o t a l  l y m p h o c y t e  
p o p u l a t i o n  i s  i d e n t i f i e d  b y  i t s  c h a r a c t e r i s t i c  p r o f i l e .  T h i s  g a t e  i s  t h e n  a n a l y s e d  in  
f u r t h e r  d e t a i l  b y  e i t h e r  ( b )  e x a m i n i n g  C D 4 5  e x p r e s s i o n  ( x - a x i s )  v e r s u s  a n y  o f  t h e  
l i n e a g e  m a r k e r s  u s e d  s u c h  a s  C D 3  a s  s h o w n  ( y - a x i s ) ,  o r  ( c )  e x a m i n i n g  e x p r e s s i o n  o f  
d i f f e r e n t  l i n e a g e  m a r k e r s  o n  t h e  x - a x i s  ( i n  t h i s  c a s e  C D 1 6 / C D 5 6 )  a n d  t h e  y - a x i s  ( i n  
t h i s  c a s e  C D 3 ) .  T h i s  g e n e r a t e d  d a t a  a b o u t  t h e  p e r c e n t a g e  o f  e a c h  k e y  p o p u l a t i o n  
w i t h i n  t h e  t o t a l  l y m p h o c y t e  g a t e .
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Figure 6.19: Key lymphocyte subsets by total counts at birth and 6 months of 
age in placebo (blue) versus probiotic (red) exposed participants of the 
PROBAT study.
A f t e r  g a t i n g  o n  l y m p h o c y t e s  t h e  c e l l u l a r  c o u n t  a t  e a c h  p o p u l a t i o n  ( x l 0 9/ L )  o f  b l o o d  
f o r  ( a  &  b )  T  c e l l s ,  ( c  &  d )  B  c e l l s ,  a n d  ( e  &  0  N K  c e l l s  w e r e  d e t e r m i n e d  a t  ( a ,  c  &  
e )  b i r t h  a n d  a t  ( b ,  d  &  1) 6  m o n t h s  o f  a g e .  T h e  b o x  s i g n i f i e s  t h e  u p p e r  a n d  l o w e r  
q u a r t i l e s  ( 7 5 %  a n d  2 5 %  r e s p e c t i v e l y ) ,  a n d  t h e  m e d i a n  i s  r e p r e s e n t e d  b y  t h e  t h i c k  
b l a c k  l i n e  w i t h i n  t h e  b o x .  T h e  w h i s k e r s  r e p r e s e n t  t h e  5 %  a n d  9 5 %  p e r c e n t i l e .  
O u t l i e r s  a r e  r e p r e s e n t e d  b y .  °  S t a t i s t i c a l l y  s i g n i f i c a n t  r e s u l t s  (P <  0 . 0 5 )  w e r e  d e n o t e d  
b y  *
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Figure 6.20: Key lymphocyte subsets by percentage at birth and 6 months of age 
in placebo (blue) versus probiotic (red) exposed participants of the PROBAT
study.
A f t e r  g a t i n g  o n  l y m p h o c y t e s  t h e  p e r c e n t a g e  o f  e a c h  p o p u l a t i o n  w a s  d e t e r m i n e d  f o r  ( a  
&  b )  T  c e l l s ,  ( c  &  d )  B  c e l l s ,  a n d  ( e  &  f )  N K  c e l l s  a t  ( a ,  c  &  e )  b i r t h  a n d  a t  ( b ,  d  &  f )
6  m o n t h s  o f  a g e .  T h e  b o x  s i g n i f i e s  t h e  u p p e r  a n d  l o w e r  q u a r t i l e s  ( 7 5 %  a n d  2 5 %  
r e s p e c t i v e l y ) ,  a n d  t h e  m e d i a n  i s  r e p r e s e n t e d  b y  t h e  t h i c k  b l a c k  l i n e  w i t h i n  t h e  b o x .  
T h e  w h i s k e r s  r e p r e s e n t  t h e  5 %  a n d  9 5 %  p e r c e n t i l e .  O u t l i e r s  a r e  r e p r e s e n t e d  b y .  °  
S t a t i s t i c a l l y  s i g n i f i c a n t  r e s u l t s  ( P < 0  . 0 5 )  w e r e  d e n o t e d  b y  *
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Figure 6.21: Gating strategy employed to identify CD4+ and CD8+ T cells.
S S C  v e r s u s  C D 3  w a s  u s e d  t o  ( a )  i d e n t i f y  t o t a l  C D 3  T  c e l l s .  T h i s  g a t e  i s  t h e n  
a n a l y s e d  i n  f u r t h e r  d e t a i l  b y  c o n s i d e r i n g  ( b )  C D 8  e x p r e s s i o n  ( x - a x i s )  v e r s u s  C D 4  
e x p r e s s i o n  ( y - a x i s ) .  T h i s  g e n e r a t e d  d a t a  a b o u t  t h e  r a t i o  o f  C D 4 : C D 8  c e l l s  w i t h i n  t h e  
t o t a l  T  c e l l  p o p u l a t i o n .
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Figure 6.22: CD4:CD8 T cell ratio at birth and 6 months of age in placebo (blue) 
versus probiotic (red) exposed participants of the PROBAT study.
A f t e r  g a t i n g  o n  t o t a l  C D 3  T  c e l l s  t h e  r a t i o  o f  C D 4 + a n d  C D 8  * C D 3 + T  c e l l s  a t  ( a )  
b i r t h ,  a n d  a t  ( b )  6  m o n t h s  o f  a g e  w a s  d e t e r m i n e d .  T h e  b o x  s i g n i f i e s  t h e  u p p e r  a n d  
l o w e r  q u a r t i l e s  ( 7 5 %  a n d  2 5 %  r e s p e c t i v e l y ) ,  a n d  t h e  m e d i a n  i s  r e p r e s e n t e d  b y  t h e  
t h i c k  b l a c k  l i n e  w i t h i n  t h e  b o x .  T h e  w h i s k e r s  r e p r e s e n t  t h e  5 %  a n d  9 5 %  p e r c e n t i l e .  
O u t l i e r s  a r e  r e p r e s e n t e d  b y . 11 S t a t i s t i c a l l y  s i g n i f i c a n t  r e s u l t s  ( P  <  0 . 0 5 )  w e r e  d e n o t e d  
b y  *
6.3.8 Naive and memory T cells
A n o t h e r  w a y  o f  a n a l y s i n g  T  c e l l s  i s  t o  c o n s i d e r  t h e  r e l a t i v e  a b u n d a n c e  o f  n a i v e  v e r s u s  
m e m o r y  c e l l s  i n  w h i c h  e x p r e s s i o n  o f  C D 4 5 R A  i s  c o n s i d e r e d  t o  i d e n t i f y  n a i v e  T  c e l l s  
c o n t r a s t i n g  t o  e x p r e s s i o n  o f  C D 4 5 R O  p r e d o m i n a n t l y  e x p r e s s e d  o n  t h e  m e m o r y  
s u b s e t .  In  t h e  n e o n a t e ,  n a i v e  C D 4 5 R A 4 T  c e l l s  d o m i n a t e  a n d  a r e  r e p e a t e d l y  r e p o r t e d  
t o  c o m p r i s e  > 9 0 %  o f  t h e  C D 4 4 T  c e l l  p o p u l a t i o n .  T h e r e f o r e  a f t e r  i d e n t i f y i n g  C D 4 + 
c e l l s  b y  c h a r a c t e r i s t i c  S S C  p r o f i l e  a n d  C D 4  e x p r e s s i o n  t h e  p e r c e n t a g e  o f  c e l l s  
e x p r e s s i n g  C D 4 5 R A  a n d / o r  C D 4 5 R O  w e r e  d e t e r m i n e d  ( F i g u r e  6 . 2 4 ) .  O n  c o m p a r i n g  
t h e  s t u d y  g r o u p s  t h e  p e r c e n t a g e  o f  C D 4 + T  c e l l s  b e a r i n g  a  n a i v e  p h e n o t y p e  
( C D 4 5 R A +/ C D 4 5 R A ~ )  w a s  s i g n i f i c a n t l y  e l e v a t e d  i n  t h e  p r o b i o t i c  g r o u p  a t  b i r t h  ( p  =
0 . 0 0 7 3 9 ;  F i g u r e  6 . 2 4  a ) .  T h i s  w a s  c o m p l e m e n t e d  b y  a  s i g n i f i c a n t l y  r e d u c e d  
p e r c e n t a g e  o f  C D 4 4 T  c e l l s  e x p r e s s i n g  a  m e m o r y  p h e n o t y p e  ( C D 4 5 R A 7 C D 4 5 R O )  in  
t h e  p r o b i o t i c  g r o u p  a t  b i r t h  ( p  =  0 . 0 0 8 7 5 ;  F i g u r e  6 . 2 4  c ) .  N o  s u c h  d i f f e r e n c e s  w e r e  
s e e n  a t  6  m o n t h s  o f  a g e  ( F i g u r e  6 . 2 4 ) .
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Figure 6.23: Gating strategy employed to identify CD45RA and CD45RO 
expressing CD4+ T cells.
S S C  v e r s u s  C D 4  w a s  u s e d  t o  ( a )  i d e n t i f y  t o t a l  C D 4 + T  c e l l s .  T h i s  g a t e  i s  t h e n  
a n a l y s e d  i n  f u r t h e r  d e t a i l  b y  c o n s i d e r i n g  ( b )  C D 4 5 R A  e x p r e s s i o n  ( x - a x i s )  v e r s u s  
C D 4 5 P v O  e x p r e s s i o n  ( y - a x i s ) .
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Figure 6.24: Naive and memory CD4^ T cells at birth and 6 months of age in 
placebo (blue) versus probiotic (red) exposed participants of the PROBAT 
study.
A f t e r  g a t i n g  o n  C D 4 + T  c e l l s  t h e  p e r c e n t a g e  o f  ( a  &  b )  C D 4 5 R A / C D 4 5 R O  p u t a t i v e  
n a i v e  a n d  ( c  &  d )  C D 4 5 R A ' / C D 4 5 R O +p u t a t i v e  m e m o r y  c e l l s  w e r e  d e t e r m i n e d  a t  ( a  
&  c )  b i r t h  a n d  a t  ( b  &  d )  6  m o n t h s  o f  a g e .  T h e  b o x  s i g n i f i e s  t h e  u p p e r  a n d  l o w e r  
q u a r t i l e s  ( 7 5 %  a n d  2 5 %  r e s p e c t i v e l y ) ,  a n d  t h e  m e d i a n  i s  r e p r e s e n t e d  b y  t h e  t h i c k  
b l a c k  l i n e  w i t h i n  t h e  b o x .  T h e  w h i s k e r s  r e p r e s e n t  t h e  5 %  a n d  9 5 %  p e r c e n t i l e .  O u t l i e r s  
a r e  r e p r e s e n t e d  b y . (} S t a t i s t i c a l l y  s i g n i f i c a n t  r e s u l t s  (P <  0 . 0 5 )  w e r e  d e n o t e d  b y  *
6.3.8 Regulatory T cells
P u t a t i v e  r e g u l a t o r y  T  c e l l s  w e r e  i d e n t i f i e d  a s  C D 4 + c e l l s  c o - e x p r e s s i n g  C D 2 5  ( F i g u r e  
6 . 2 5 ) .  T h e  p r o b i o t i c  g r o u p  a t  b i r t h  h a d  s i g n i f i c a n t l y  f e w e r  C D 4 C D 2 5  T  c e l l s  t h a n  
t h e  p l a c e b o  g r o u p  ( p  =  0 . 0 0 8 3 2 ;  F i g u r e  6 , 2 6 ) .
piaceoo prot»ot>c placebo probiotic
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Figure 6.25: Gating strategy employed to identify CD25+ CD4+ T cells.
S S C  v e r s u s  C D 4  w a s  u s e d  t o  i d e n t i f y  t o t a l  C D 4  T  c e l l s .  T h i s  g a t e  i s  t h e n  a n a l y s e d  in  
f u r t h e r  d e t a i l  b y  c o n s i d e r i n g  C D 2 5  e x p r e s s i o n  ( y - a x i s ) .
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Figure 6.26: CD25 expressing CD4+ T cells at birth and 6 months of age in 
placebo (blue) versus probiotic (red) exposed participants of the PROBAT 
study.
A f t e r  g a t i n g  o n  C D 4 + T  c e l l s  t h e  p e r c e n t a g e  o f  C D 2 5 "  c e l l s  a t  ( a )  b i r t h ,  a n d  a t  ( b )  6  
m o n t h s  o f  a g e  w a s  d e t e r m i n e d .  T h e  b o x  s i g n i f i e s  t h e  u p p e r  a n d  l o w e r  q u a r t i l e s  ( 7 5 %  
a n d  2 5 %  r e s p e c t i v e l y ) ,  a n d  t h e  m e d i a n  i s  r e p r e s e n t e d  b y  t h e  t h i c k  b l a c k  l i n e  w i t h i n  
t h e  b o x .  T h e  w h i s k e r s  r e p r e s e n t  t h e  5 %  a n d  9 5 %  p e r c e n t i l e .  O u t l i e r s  a r e  r e p r e s e n t e d  
b y . (} S t a t i s t i c a l l y  s i g n i f i c a n t  r e s u l t s  (P < 0  . 0 5 )  w e r e  d e n o t e d  b y  *
5.3.9 Gut homing T ceils
S i n c e  p r o b i o t i c  i m m u n o m o d u l a t o r y  e f f e c t s  a r e  p r o p a g a t e d  in  t h e  g u t ,  t h e  a n a l y s i s  o f  
p u t a t i v e  g u t  h o m i n g  T  c e l l s  i n  t h e  c i r c u l a t i o n  w a s  c o n s i d e r e d  a s  a  s u r r o g a t e  o f  
i m m u n o l o g i c a l  a c t i v i t y  i n  t h e  g u t .  E x p r e s s i o n  o f  t h e  i n t e g r i n s  a 4  ( C D 4 9 d )  a n d  p 7  
( C D 2 9 )  o n  b o t h  C D 4 4 a n d  C D 8 + T  c e l l s  w a s  e x a m i n e d  u s i n g  f l o w  c y t o m e t r y  ( F i g u r e  
6 . 2 7 ) .  P e r i n a t a l  p r o b i o t i c  s u p p l e m e n t a t i o n  w a s  a s s o c i a t e d  w i t h  r e d u c t i o n  o f  C D 8 + T  
c e l l s  e x p r e s s i n g  a t  b i r t h  ( p 7  a l o n e  — p  =  0 . 0 0 8 9 8 ,  F i g u r e  6 . 2 9  a )  a n d  b o t h  p 7 / C D 4 9 d  -  
p  =  0 . 0 0 5 0 1 ,  F i g u r e  6 . 2 8  c ) .
Figure 6.27: Gating strategy used to identify putative gut homing CD4* and 
CD8+ T cells.
C D 4 ^  a n d  C D 8 + T  c e l l s  w e r e  f i r s t  i d e n t i f i e d  a n d  e x p r e s s i o n  o f  C D 4 9 d  ( x - a x i s )  a n d  
p 7  i n t e g r i n  ( C D 2 9 ;  y - a x i s )  w a s  d e t e r m i n e d  f o r  ( a )  C D 4 ^  a n d  ( b )  C D 8 + T  c e l l s .
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Figure 6.28: 07 and CD49d expressing CD4+ T cells at birth and 6 months of age 
in placebo (blue) versus probiotic (red) exposed participants of the PROBAT 
study.
A f t e r  g a t i n g  o n  C D 4  o r  T  c e l l s  t h e  p e r c e n t a g e  o f  ( a  &  b )  0 7  e x p r e s s i n g ,  a n d  ( c  &  d )  
0 7 / C D 4 d  c o - e x p r e s s i n g  c e l l s  w e r e  d e t e r m i n e d  a t  ( a  &  c )  b i r t h  a n d  a t  ( b  &  d )  6  
m o n t h s  o f  a g e .  T h e  b o x  s i g n i f i e s  t h e  u p p e r  a n d  l o w e r  q u a r t i l e s  ( 7 5 %  a n d  2 5 %  
r e s p e c t i v e l y ) ,  a n d  t h e  m e d i a n  i s  r e p r e s e n t e d  b y  t h e  t h i c k  b l a c k  l i n e  w i t h i n  t h e  b o x .  
T h e  w h i s k e r s  r e p r e s e n t  t h e  5 %  a n d  9 5 %  p e r c e n t i l e .  O u t l i e r s  a r e  r e p r e s e n t e d  b y . ( ’ 
S t a t i s t i c a l l y  s i g n i f i c a n t  r e s u l t s  ( P  <  0 . 0 5 )  w e r e  d e n o t e d  b y  *
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Figure 6.29: p7 and CD49d expressing CD8+ T cells at birth and 6 months of age 
in placebo (blue) versus probiotic (red) exposed participants of the PROBAT 
study.
A f t e r  g a t i n g  o n  C D 8 + o r  T  c e l l s  t h e  p e r c e n t a g e  o f  ( a  &  b )  [37 e x p r e s s i n g ,  a n d  ( c  &  d )  
[ 3 7 / C D 4 9 d  c o - e x p r e s s i n g  c e l l s  w e r e  d e t e r m i n e d  a t  ( a  &  c )  b i r t h  a n d  a t  ( b  &  d )  6  
m o n t h s  o f  a g e .  T h e  b o x  s i g n i f i e s  t h e  u p p e r  a n d  l o w e r  q u a r t i l e s  ( 7 5 %  a n d  2 5 %  
r e s p e c t i v e l y ) ,  a n d  t h e  m e d i a n  i s  r e p r e s e n t e d  b y  t h e  t h i c k  b l a c k  l i n e  w i t h i n  t h e  b o x .  
T h e  w h i s k e r s  r e p r e s e n t  t h e  5 %  a n d  9 5 %  p e r c e n t i l e .  O u t l i e r s  a r e  r e p r e s e n t e d  b y . ( ’ 
S t a t i s t i c a l l y  s i g n i f i c a n t  r e s u l t s  ( P  <  0 . 0 5 )  w e r e  d e n o t e d  b y  *
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6.3.10 B cells
B  c e l l s  w e r e  i d e n t i f i e d  b y  t h e i r  t y p i c a l  S S C  a n d  e x p r e s s i o n  o f  t h e  B  l i n e a g e  m a r k e r  
C D  1 9  e x p r e s s i o n  o f  o t h e r  C D  a n t i g e n s  o f  i n t e r e s t  -  C D 2 1 , C D 2 3 ,  I g M ,  C D  1 c  a n d  
C D 5  -  w a s  d e t e r m i n e d  b y  g a t i n g  o n  t h i s  p o p u l a t i o n  a n d  d e t e r m i n i n g  t h e  p e r c e n t a g e  
p o s i t i v e  c e l l s  u s i n g  a  f l u o r o c h r o m e - c o n j u g a t e d  a n t i b o d y  t o  t h e  s u r f a c e  a n t i g e n  o f  
i n t e r e s t  v e r s u s  a n  i s o t y p e  c o n t r o l  ( F i g u r e  5 . 3 0 ) .  T h e  p e r c e n t a g e  o f  C D 1 9 + B  c e l l s  
e x p r e s s i n g  t h e  s u r f a c e  m a r k e r s  o f  i n t e r e s t  d i d  n o t  d i f f e r  b e t w e e n  t h e  t w o  s t u d y  g r o u p s  
a t  e i t h e r  b i r t h  o r  6  m o n t h s  o f  a g e  ( F i g u r e  6 . 3 1  a n d  6 . 3 2 ) .
®i
Figure: 6.30 Gating strategies employed to identify CD19+ B cells expressing 
CD21, CD23, IgM, CDlc or CD15.
T o t a l  B  c e l l s  w e r e  f i r s t  i d e n t i f i e d  b y  ( a )  S S C  v e r s u s  C D  1 9 .  A f t e r  g a t i n g  o n  t h e s e  c e l l s  
f u r t h e r  a n a l y s i s  f o r  e x p r e s s i o n  o f  o t h e r  m a r k e r s  o f  i n t e r e s t  s u c h  a s  ( b )  C D 2 1  ( y - a x i s )  
w a s  d e t e r m i n e d .
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Figure 6.31: CD19" B cells at birth and 6 months of age in placebo (blue) versus 
probiotic (red) exposed participants of the PROBAT study.
A f t e r  g a t i n g  o n  C D 1 9 + B  c e l l s  t h e  p e r c e n t a g e  o f  c e l l s  e x p r e s s i n g  ( a  &  b )  C D 2 1 , a n d  
( c  &  d )  C D 2 3  w a s  d e t e r m i n e d  a t  ( a  &  c )  b i r t h  a n d  a t  ( b  &  d )  6  m o n t h s  o f  a g e .  T h e  
b o x  s i g n i f i e s  t h e  u p p e r  a n d  l o w e r  q u a r t i l e s  ( 7 5 %  a n d  2 5 %  r e s p e c t i v e l y ) ,  a n d  t h e  
m e d i a n  i s  r e p r e s e n t e d  b y  t h e  t h i c k  b l a c k  l i n e  w i t h i n  t h e  b o x .  T h e  w h i s k e r s  r e p r e s e n t  
t h e  5 %  a n d  9 5 %  p e r c e n t i l e .  O u t l i e r s  a r e  r e p r e s e n t e d  b y .  °  S t a t i s t i c a l l y  s i g n i f i c a n t  
r e s u l t s  ( P <  0 . 0 5 )  w e r e  d e n o t e d  b y  *
placebo probioticplacebo
placeboplacebo probiotic
placebo probiotic placebo probiotic
Figure 6.32: CD19+ B cells at birth and 6 months of age in placebo (blue) versus 
probiotic (red) exposed participants of the PROBAT study.
A f t e r  g a t i n g  o n  C D 1 9 + B  c e l l s  t h e  p e r c e n t a g e  o f  c e l l s  e x p r e s s i n g  ( a  &  b )  I g M ,  ( c  &  d )  
C D 1  c ,  a n d  ( e  &  f )  C D 5  w a s  d e t e r m i n e d  a t  ( a ,  c  &  e )  b i r t h  a n d  a t  ( b ,  d  &  f )  6  m o n t h s  
o f  a g e .  T h e  b o x  s i g n i f i e s  t h e  u p p e r  a n d  l o w e r  q u a r t i l e s  ( 7 5 %  a n d  2 5 %  r e s p e c t i v e l y ) ,  
a n d  t h e  m e d i a n  i s  r e p r e s e n t e d  b y  t h e  t h i c k  b l a c k  l i n e  w i t h i n  t h e  b o x .  T h e  w h i s k e r s  
r e p r e s e n t  t h e  5 %  a n d  9 5 %  p e r c e n t i l e .  O u t l i e r s  a r e  r e p r e s e n t e d  b y .  (} S t a t i s t i c a l l y  
s i g n i f i c a n t  r e s u l t s  ( P  <  0 . 0 5 )  w e r e  d e n o t e d  b y  *
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6.3.11 Dendritic cells
D e n d r i t i c  c e l l s  w e r e  i d e n t i f i e d  b y  t h e i r  l a c k  o f  r a n g e  o f  l i n e a g e  m a r k e r s  ( i n c l u d i n g  
C D 3 ,  C D  1 4  a n d  C D  1 9 )  b u t  e x p r e s s i o n  o f  H L A - D R  ( F i g u r e  6 . 3 3 a ) .  T h i s  a l s o  a l l o w e d  
c a l c u l a t i o n  o f  t h e  p e r c e n t a g e  o f  l e u k o c y t e s  t h a t  w e r e  d e n d r i t i c  c e l l s  ( t o t a l  D C s ) .  T h e  
t w o  m a j o r  s u b s e t s  o f  D C s  c o u l d  t h e n  b e  i d e n t i f i e d  u s i n g  a n t i b o d i e s  t o  C D  1 2 3  ( I L -  
3 R a )  a n d  C D 1  l c .  T h i s  e n a b l e d  i d e n t i f i c a t i o n  o f  p l a s m a c y t o i d  D C s  ( p D C s ;
C D 1 2 3  / C D 1  l c  )  a n d  m y e l o i d  D C s  ( m D C s ;  C D 1 2 3 +/ C D 1  l c  ) ( F i g u r e  6 . 3 3 b )  a n d  
c a l c u l a t i o n  o f  e a c h  o f  t h e s e  p o p u l a t i o n s  a s  a  p e r c e n t a g e  t o t a l  D C s .  T h e r e  w e r e  n o  
d i f f e r e n c e s  i n  t o t a l  D C s  o r  e i t h e r  o f  t h e  s u b s e t s  a t  b i r t h  o r  6  m o n t h s  i n  t h o s e  t a k i n g  
p r o b i o t i c s  ( F i g u r e  6 . 3 4 ) .
( a ) ( b )
(MMXjM.**
i
<
i 10
Figure 6.33: Gating strategy for identification of dendritic cells subsets.
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Total dendritic cells were identified as (a) lineage-negative (x-axis) and HLA-DR- 
positive (y-axis). Further analysis of this gated population was undertaken with (b) 
anti-CD 123/IL-3R (x-axis) and CD1 lc (y-axis) to identify plasmacytoid dendritic 
cells (CD123+/CD1 lc ) and myeloid dendritic cells (CD1237CD1 lc+).
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Figure 6.34: Total and subsets of dendritic cells at birth and 6 months of age in 
placebo (blue) versus probiotic (red) exposed participants of the PROBAT 
study.
F l o w  c y t o m e t r y  w a s  u s e d  t o  i d e n t i f y  ( a  &  b )  t o t a l  D C s ,  ( c  &  d )  p D C s ,  a n d  ( e  &  f )  
m D C s  a t  ( a ,  c  &  e )  b i r t h  a n d  a t  ( b ,  d  &  f )  6  m o n t h s  o f  a g e .  T h e  b o x  s i g n i f i e s  t h e  
u p p e r  a n d  l o w e r  q u a r t i l e s  ( 7 5 %  a n d  2 5 %  r e s p e c t i v e l y ) ,  a n d  t h e  m e d i a n  i s  r e p r e s e n t e d  
b y  t h e  t h i c k  b l a c k  l i n e  w i t h i n  t h e  b o x .  T h e  w h i s k e r s  r e p r e s e n t  t h e  5 %  a n d  9 5 %  
p e r c e n t i l e .  O u t l i e r s  a r e  r e p r e s e n t e d  b y .  °  S t a t i s t i c a l l y  s i g n i f i c a n t  r e s u l t s  ( P  <  0 . 0 5 )  
w e r e  d e n o t e d  b y  *
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6.4. Discussion
6.4.1 Age dependent cellular maturation of neonatal immunity from birth to 6 
months of age
The in vivo immunomodulatory influence of perinatal probiotic supplementation 
during development of the newborn immune system from birth to 6 months of age 
was assessed during two fundamental aspects of neonatal immunity: (1) Cellular 
ontogeny of newborn haematopoiesis at the cell population level and (2) 
Augmentation of neonatal innate immune function towards microbial stimuli. In this 
discussion, special reference is given to how the observed effects of supplementation 
might relate to the onset of IgE mediated atopic disorder in the neonate.
Results of the current study highlighted statistically significant cellular differences 
between birth and 6 months of age in cord blood for total white blood cells, 
neutrophils, monocytes, eosinophils, basophils and platelets. With these cell types 
consistently more abundant in cord blood samples compared to infant blood samples, 
suggesting that granulopoesis is favoured in the neonate with a shift towards 
lymphopoiesis during infancy. These observations were supported by the fact that 
lymphocytes were significantly higher only in the 6 month infant samples. Matching 
of the birth and 6 month infant blood samples confirmed these dramatic differences 
in lymphocyte and granulocyte populations among the subsets studied (Figure 6.2; 
6.3). These observations were in line with observations by Pranke et al. (2001), 
Christensen et al. (2009) and Erkeller-Yuksel et a l (1992) who measured changes in 
major lymphocyte populations as a function of age and demonstrated that percentage 
lymphocyte counts increased from 41% at birth in cord blood to 47% between 2 
days to 11 months, only decrease by 1% during the period of 1 yr. to 6 yrs. and by 7% 
between 7 and 17 years.
From a qualitative standpoint, using the neutrophil as a characteristic example, 
although newborns have a reduced number of quiescent granulocyte and monocyte 
progenitor cells and a diminished precursor storage pool, neonatal neutrophils show 
impairment of multiple functional aspects, including chemotaxis, transmigration and 
rolling adhesion (Carr 2000; Henneke and Berner 2006). Such migratory defects 
correlate with the high proportion of immature neutrophils we have observed in the
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present study in umbilical cord blood. Furthermore functional deficits of neonatal 
neutrophils, such as diminished L-selectin expression and leukocyte migration into 
tissues, have been observed for neonatal eosinophils such that eosinophils are not 
normally resident in bodily tissues (Smith et a l 1992). Interestingly cord blood 
monocytes also exhibit chemotaxis defects (Holt et a l 2005; Tulic et a l 2011).
6.4.2 Cell counts in relation to probiotic versus placebo exposure
To date since 1997 over 30 randomised double-blind placebo-controlled clinical 
trials studying the efficacy of various probiotic combinations to prevent the induction 
of IgE-mediated allergy have been conducted. This is one of the first perinatal 
supplementation studies to assess the effects of a consortium of probiotic bacteria on 
the cellular context of granulopoesis. Interestingly, Allen et a l (2014) discovered a 
statistically significant reduction in eosinophil counts at birth in infants whose 
mothers had taken the probiotic supplement over the last few weeks of pregnancy. 
Since eosinophils mature only in the presence of the IL-5, IL-3 and GM-CSF this 
current observation is promising when reviewed in the light of clinical data that 
elevated eosinophil counts at birth and/or at 3 months are associated with early 
diagnosis of eczema and positive skin prick tests at 18 months of age (Borres et a l 
1995; Borres and Bjorksten 2004; Matsumoto et a l 2005). The current study 
suggests that perinatal probiotic supplementation might provide a Thl driven 
immunomodulatory signal capable of curtailing the differentiation of eosinophil. We 
hypothesised that this effect might require signals transmitted via gestation- 
associated tissues, such as the placenta (Conrad et a l 2009; Thornton et a l 2010).
These results were indirectly consistent with a probiotic treatment study conducted 
by Rosenfeldt et a l (2003), who administered (lyophilized) Lactobacilli rhamnosus 
19070-2 and Lactobacilli reuteri. DSM 122460) given in combination for 6 weeks to 
1- to 13-year-old children afflicted with Atopic dermatitis, and employed the use of 
eosinophil cationic protein (ECP), a cytotoxic protein released from activated 
eosinophils, as a proxy to monitor disease activity in AD. During active treatment, 
serum (ECP) levels significantly decreased as a result of supplementation, suggesting 
as in the current study that the immunomodulatory effect of probiotic bacteria 
impacts upon eosinophil activity. Another study conducted by Brouwer et al (2006) 
showed, during lactobacilli species supplementation, a moderate but significant 
reduction in soluble ECP levels was found.
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6.4.3 Innate immune response at birth and 6 months of age
The current study served to determine whether the immunological immaturity of 
newborn immunity marked by an innate immune bias towards upregulation of 
potentially atopic Th2 polarising cytokine responses (de Vries et a l 2000) can be 
reversed via perinatal probiotic supplementation. The principle observations were 
that LPS and PGN induced statistically significant age-dependent maturation of IL- 
10 and TNF-a response with age by whole blood cultures with these responses 
greater at 6 months of age. This age dependent maturation was consistent with 
results presented in the literature indicating that IL-10 induction during the neonatal 
period increases with age. Additionally, polarisation of TLR-Mediated IL-10 
responses of neonatal cord blood derived monocytes and APCs was increased during 
the neonatal period, with IL-10 production in the neonate three- to fivefold more than 
adults (De Wit et a l 2003; Chelvarajan et a l 2004).
Interestingly, the current study reported a statistically significant increase in TNF-a 
at 6 months of age in response to LPS and PGN at a time when induction of a TNF-a 
response is attenuated and tightly regulated.
Consistent with the age dependent increases in Thl pro-inflammatory cytokines 
between birth and 6 months of age, IL-12p70 levels in unstimulated, PGN and IFN-y 
stimulated whole blood cultures were significantly elevated at 6 months of age 
compared to birth, indicating an age dependent maturation of IL-12p70. This data 
was consistent with studies by Prescott et a l (2011) who sought to explore whether 
allergic children show differences in microbial TLR-mediated responses over their 
first 5 years of life. Interestingly they observed in non-allergic children a progressive 
and significant age-related increase in innate cytokine responses (IL-lp, IL-6, TNF- 
a, and IL-10) to virtually all TLR ligands corresponding with a parallel increase in 
adaptive Thl (IFN-y) responses to allergens and mitogens. Contrastingly, allergic 
children show exaggerated innate responses at birth but a relative decrease with age 
thereafter, so that by age 5 years, TLR responses are significantly attenuated 
compared to non-allergic subjects. It was concluded that early hyper-responsiveness 
in allergic subjects failed to translate to an equivalent maturation of Thl function,
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which remained attenuated relative to non-allergic subjects but associated with an 
aberrant age-dependent statistically significant increase in allergen-specific Th2 
responses.
6.4.4 Innate immune response in relation to probiotic versus placebo exposure
Probiotic bacteria augment maturational signals for development of the neonatal gut- 
associated lymphoid tissue in vivo (Hooper and Macpherson 2010). Additionally, 
their immunogenicity upon interaction with the cellular components of neonatal 
immunity renders them key contributors to the pro- and anti-inflammatory cytokine 
immune equilibrium within the neonatal gut. To test this hypothesis, we stimulated 
whole blood cultures at birth and 6 months of age from recruits on the PROBAT trial 
with the microbial stimuli LPS and PGN, and measured the ensuing innate and 
adaptive cytokine responses.
Perinatal probiotic supplementation significantly increased production of the Thl 
cytokine IL-12p70 in the probiotic group in unstimulated whole blood culture 
samples at birth. This type of response was indirectly consistent with the secondary 
outcomes of the trial of Allen et a l (2014) who reported that perinatal probiotic 
supplementation was synonymous with a reduction in IgE-mediated atopic 
sensitisation. This is because IgE-mediated atopic sensitisation cannot develop in an 
immunological microenvironment that is Thl orientated. Furthermore, LPS/IFN-y 
induced IL-12p70 responses by whole blood cultures were also significantly 
increased in the probiotic group at 6 months of age compared to the placebo group 
further supporting the notion that perinatal probiotic supplementation enhances 
maturation of the Thl immune response in vivo. These results were also in keeping 
with the notion that probiotic induction of a low-grade inflammatory response might 
contribute to their efficacy in preventing atopy (Marschan et al. 2008). To further 
explore this in the PROBAT trial cohort, in the future we aim to analyse faecal 
samples and plasma/serum samples to compare local gut and systemic inflammatory 
status as a consequence of perinatal probiotic supplementation.
The current results were in line with the results of West et al. (2009) from an 
immunological standpoint despite differences in their experimental approach. In a 
double-blind, placebo-controlled randomized intervention trial infants were fed
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cereals with (n: 89) or without Lactobacilli FI 9 (n: 90) from 4 to 13 months of age 
and the incidence of eczema and Thl/Th2 balance evaluated during weaning. At 13 
months of age, the authors demonstrated that IFN-y/ IL-4 mRNA ratio was 
significantly higher in the probiotic compared with the placebo group. The higher 
Thl/Th2 ratio in the probiotic compared to placebo group suggests enhancing effects 
of Lactobacilli FI 9 on the T cell-mediated immune response. Probiotics also 
increased Thl cytokines and inhibited allergen-induced IgE and Th2 cytokines in 
some atopic children. In another study Pohjavuori et a l (2004), showed an increase 
in IFN-y production in peripheral blood mononuclear cell in infants with Atopic 
dermatitis (AD) treated with the probiotic LGG instead of placebo concomitant with 
an improvement in AD severity associated with significant increases in the capacity 
for Thl IFN-y responses. This effect was still evident 2 months after the 
supplementation was ceased.
The results of the present study, support the ability of the study consortium to 
augment Thl responses in vivo and perhaps accelerate maturation of an otherwise 
attenuated Thl pro-inflammatory cytokine pathway during the neonatal period. 
Whether or not the observed Thl immune responses can be linked to protection 
against IgE-mediated atopic disorder will be reviewed in the light of the clinical 
outcomes of the PROBAT trial. Promisingly Thl polarising cytokine responses are 
antagonistic to the up-regulation of IgE mediated Th2 atopic responses in vivo and 
contribute to the polarisation of naive T cell towards the Thl phenotype.
In contrast to the results of the current study, in a randomized prenatal controlled trial 
by Boyle et a l LGG, treatment during pregnancy for the prevention of eczema was 
not associated with any change in the cord blood immune markers IL-10, IL-12, IFN- 
y and TNF-a selected. There observations may be in part due to the mode of 
probiotic supplemental scheme, suggesting that there may be differences in observed 
immunological outcomes between perinatal versus prenatal probiotic supplemental 
schemes
Data from the current study provided further support for the application of probiotic 
bacteria as a strategy to attenuate the risk of IgE-mediated atopic disorder 
(Kaliomaki et a l 2001, 2007; Niers et a l 2009) at both the cellular and innate 
immune level during early infancy. The application of haematological analyses to
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monitor alterations in both granulocytic and lymphocyte subsets from genetically 
predisposed atopic individuals combined with research into the underlying immune 
function of these subsets provided an in valuable diagnostic and prognostic research 
tool for further understanding the pathogenesis of atopic disorder; and the 
relationship between the microbial influence and the likelihood of immune 
dysregulated disorders in later life (Raes et a l 1993).
Despite the usefulness of data evaluating the cellular ontogeny of granulopoeisis and 
lymphopoiesis in the neonate compared to 6 month old infant, information on factors 
that affect these processes are limited. Since optimisation of the newborn intestinal 
microbiota via perinatal probiotic bacteria supplementation with intestinal bacteria of 
lactobacilli and bifidobacterial origin has been cited numerously as a method to both 
galvanise the integrity of newborn immunity and as a strategy to attenuate the risk of 
IgE-mediated atopic disorder; it seemed logical to determine whether probiotic 
bacteria forming an important constituent of the newborn microbiota might enhance 
process of granulopoeisis and lymphopoiesis in early life. The results of the current 
study indicate that the consortium plays an immunomodulatory role during age- 
dependent maturation of innate and adaptive cytokine responses from birth to 6 
months of age. However perinatal probiotic supplementation only had a transient 
effect on granulopoesis, effecting only the eosinophil population involved in the 
pathogenesis of atopic disorder at the blood circulation level at birth. Further analysis 
of the PROBAT study outcomes is required to determine whether this observation 
can be linked to a reduction in atopic disorders such as eczema, where eosinophilia at 
the sites of allergic inflammation is a hallmark component. Germ free animal models 
indicate that lymphocyte subset maturation during the neonatal period is influenced 
by the immunogenicity and/or types of probiotic organisms colonising the intestinal 
tract, upon interaction with the GALT. The key findings are now discussed:
6.4.5 Effects of perinatal probiotic supplementation on naive and memory T 
lymphocyte subsets
Flow cytometric analysis indicates that T cell compartments undergo dramatic 
compositional changes during childhood and that naive T cells are not generated 
exclusively by the thymus but also via cytokine-mediated proliferation of naive T 
cells within the periphery (van Gent et a l 2009). We considered the 
immunomodulatory role of perinatal probiotic supplementation in this process and
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discovered that the percentage of CD3+ T cells (employed as a surrogate marker for T 
cell activity) was significantly lower in the probiotic than placebo group at 6 months 
of age (p < 0.0001). This observation might imply that the immunomodulatory effect 
of perinatal probiotic supplementation renders the neonate less prone to antigenic 
challenge posed by allergic or infectious threats, therefore obviating the need for a 
robust adaptive immune response to less harmtul pathogenic or allergic challenge.
Although information regarding the CD4/CD8 ratio is not typically studied in atopic 
disorder, Joffe et a l (1983) demonstrated that the CD4/CD8 ratio increases in atopic 
dermatitis due to an increase of CD4+ T cells. Perinatal probiotic supplementation did 
not seem to have an effect on the CD4/CD8 ratio at either time point investigated in 
the current study.
At birth there is a natural predominance of CD45RA+/CD45RO' ‘naive’ T cells as the 
principal neonatal population (van Gent et a l 2009). On comparing the study groups, 
the percentage of CD4+ T cells bearing a naive phenotype (CD45RA+/CD45RO‘) was 
significantly elevated in the probiotic group at birth. This was complemented by a 
significantly reduced percentage of CD4+ T cells expressing a memory phenotype 
(CD45RA7CD45RO+) in the probiotic group at birth indicating a reduced level of 
antigen experience in the neonate at birth in probiotic exposed neonates compared to 
the placebo group. Perinatal probiotic supplementation might therefore reduce the 
risk of antigenic challenge at birth, while increasing the naive T cell pool on guard to 
respond to antigenic challenge. In the current study, perinatal probiotic 
supplementation appears to potentiate the naive T cell repertoire at birth.
Increases in allergen-induced Thl cytokine production by atopic children is 
associated with expansion of an allergen-specific memory CD45RO T cell 
population, since memory cells produce 10-fold more IFN-y than naive T cells (Smart 
and Kemp 2002). It was therefore noteworthy that the memory CD45RO T cell 
population was reduced at birth in probiotic exposed neonates compared to placebo 
group. Under appropriate stimulation, naive CD4+D45RA+ T cells can be 
phenotypically converted in vitro into memory type CD4+D45RO+ T cells (Early and 
Reen 1999) and acquires memory cell characteristics such as helper activity for B 
cells, and production of IL-4 and IFN-a (Akbar et a l 1988; Clement et a l 1988; 
Ferrer et al 1992). Furthermore, large pools of antigen-experienced effector memory
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CD4 and CD8 ( T r m  cells) with enhanced effector capabilities persist in uninflamed 
peripheral organs, such as the lung, skin and gut, providing a first line of defence 
against pathogens (Clark et a l 2006; Wakim et al. 2008; Vezys et al. 2009; Masopust 
et a l 2010; Purwar et a l 2011; Sheridan and Leffancois 201 l).Therefore, increases in 
the naive CD45RA pool in the probiotic group may reflect an immune signature in 
which atopic or infectious responses are reduced and the integrity of T cell immunity 
is strengthened in the neonate due to the increases in the naive T cell repertoire with 
potential effector memory cell capabilities. This result was further supported by the 
reduced CD45RO T cell pool in neonatal peripheral blood in the probiotic group 
suggesting a reduction in antigenic memory responses in the probiotic group 
compared to the placebo group. This result further supported the previous observation 
that CD3+ T cell activity in the neonate was reduced in the probiotic group at 6 
months compared to the placebo group.
6.4.6 Effects of perinatal probiotic supplementation on lymphocyte subsets
NK cells have a role in establishing blood supply to the fetoplacental unit (King and 
Loke 1991) and a key role of NK cells at this site is postulated to be the provision of 
necessary cytokines such as GM-CSF, TNF-a, IFN-y, TGF-p and LIF, with minimal 
impact on cytotoxicity. Interestingly, the percentage of lymphocytes that were NK 
cells was significantly lower in the probiotic versus placebo group at birth (p = 0.005) 
in the current study and may indicate a need to limit immune toxicity at the neonatal 
stage. However this result was somewhat unexpected since dietary probiotic 
supplementation has been linked to an enhancement of the peripheral blood 
circulating levels of NK cells and enhancement of tumouricidal NK cell activity in 
healthy elderly subjects (King and Loke 1991; Gill et a l 2001).
6.4.7 Regulatory T cells
CD4+ regulatory T cells are particularly abundant and potent at birth and there is 
much interest in their contribution to the etiology and onset of allergic disease, in 
early life (Fontenot et a l 2003; Godfrey et a l 2005; Liu et a l 2006). A functional 
analysis of this subset was beyond the scope of this study but a phenotypic analysis 
was included in the flow cytometry panel. The probiotic group at birth but not at 6 
months of age had significantly fewer CD4+CD25+ T cells than the placebo group.
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This result was unexpected because it is has been demonstrated that neonates at high 
atopic risk generated fewer CD4+CD25+ (Schaub et al. 2008).
Although the use of extracellular markers is commonly used to identify T reg 
phenotypes to characterize changes in Treg numbers during childhood caution must 
be warranted when identifying Tregs based on expression of only CD4 and CD25 as 
in some circumstances activated T cells adopt a similar phenotype. Therefore possible 
perturbations in the Treg repertoire should be confirmed by expression levels of the 
transcription factor foxP3
6.4.8 Gut homing T cells
Since immunological effects of probiotic bacteria are likely mediated via the gut; to 
determine whether perinatal probiotic supplementation reinforces the integrity of 
intestinal T cell immunity the analysis of putative gut homing T cells in the 
circulation was considered as a surrogate of gastrointestinal immunological activity. 
Maternal supplementation with probiotics was associated with reduction of CD8+ gut 
homing T cells at birth but not at 6 months of age. Therefore probiotics appeared to 
induce a reduction in the cytotoxic T cell response at birth but not at 6 months of age.
6.4.9 Dendritic cells
In studies of perinatal probiotic supplementation for the prevention of allergic disease 
little attention has been paid to the ratio of pDCs and mDCs and the subsequent risk 
of clinical atopic disease (Upham et a l 2004). We had hypothesized that perinatal 
probiotic supplementation might increase the circulating pDCs levels, an event cited 
as being protective against atopic outcomes. However, no significant differences in 
the total DCs or either of the DCs subsets (mDCs and pDCs) at birth or 6 months in 
those taking probiotics was observed. This result was unexpected especially in the 
light of the results of other authors, reporting that blood pDCs are less frequent in 
atopic or asthmatic children compared with healthy subjects (Hagendorens et a l 
2003). Similarly, in a large cohort of children with severe respiratory syncytial virus- 
induced bronchiolitis followed up until the age of 6 years who had asthma, the 
frequency of blood pDCs at 6 years was less than seen in children who did not (Silver 
et a l 2009). Furthermore, (Upham et al 2009) assessed the relationship between the 
relative frequencies of circulating DC subsets in early childhood by flow cytometry
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and discovered that pDCs were significantly less frequent in children who 
subsequently had an asthma diagnosis by age 5 years compared with children with no 
asthma diagnosis. They found that the frequency of circulating pDCs was inversely 
correlated to the cumulative rate of asthma diagnosed by a doctor. Although the 
frequency of pDCs appeared unrelated to the incidence of allergic sensitization, 
parent-reported asthma diagnosis by age 5 years was also associated with 
significantly fewer pDCs during infancy. The authors concluded that having fewer 
pDCs during infancy was a principal risk factor for asthma-related outcomes by the 
age of 5 years, whereas having more pDCs during infancy was associated with 
relative protection against asthma-related outcomes (Upham et a l 2009). In the light 
of the result of other authors it is plausible that the birth to 6 month time period may 
be too short to observe the immunological manifestation of atopic disorder at the 
level of the DC subsets.
6.4.10 Limitation of the current study
There are a number of mechanisms by which the frequency of lymphocyte subsets 
might be reduced in some children, including impaired differentiation from bone 
marrow precursors, poor cell survival, and increased infection related homing to 
peripheral tissues. However to our knowledge there were no adverse events as a 
consequence of probiotic supplementation (Allen et a l 2010).
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Chapter 7: In vitro effects of the study consortium on peripheral blood 
mononuclear cells from pregnant and non-pregnant female donors
7.1 Background
There are now a number of publications detailing the effects of probiotic 
supplementation in early life on the development of allergy and allergic disease. 
These fall broadly into two categories: those in which supplementation to the 
pregnant woman for the last few weeks of pregnancy and then to the child from birth 
sometime up to 2 years of age was made; and those in which supplementation of the 
infant only was made. Studies found to have a beneficial effect fall into the category 
in which supplementation of the pregnant woman, typically from around 36 weeks of 
gestation until birth, was included (Kim et a l 2009). This raises the possibility that it 
is supplementation of the pregnant woman and the downstream effects of this on 
maternal immune function and immune function at the matemo-fetal interface that 
are critical to any biological effect exerted by probiotics on the offspring. The impact 
of probiotic supplementation on the quality of passively transferred immunity in 
breast milk also needs to be taken into account.
To gain an appreciation for the likely immune responses elicited by probiotic 
exposure of pregnant women, understanding the nature of maternal immunity during 
pregnancy is paramount. Two unique immunological stories unfold during 
pregnancy. Firstly, a foetal allograft develops in an apparently sterile environment 
and acquires the essential framework of an immune system enabling it to mount an 
adequate, albeit immature, immune response. Secondly, a combination of foetal and 
maternal immunological factors conspires at the maternal-foetal interface to allow, 
and perhaps even encourage, growth of the semi-allogeneic foetus (Figure 6.1).
Indeed emerging evidence suggests that the immunological recognition of pregnancy 
is paramount to the maintenance and success of gestation (Aagaard-Tillery et a l 
2006).
A number of theories have been suggested to explain the immunological survival of 
the foetus within the self/non-self-paradigm encompassing notions of: (1) Anatomic 
separation of maternal and foetal tissues. (2) Antigenic immaturity of the foetus. (3) 
An attenuated maternal immune system and (4) the immune privileged site of the 
uterus. There is a vast literature relating to attempts by investigators to identify
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mechanisms explaining the ability of the immune-competent mother to tolerate the 
semi-allogeneic foetus within this conceptual framework. These strategies include:
1. Preferential expression of non-classical MHC Class I molecules HLA-E, F and G 
which are less polymorphic than the classical HLA class I molecules. All three of 
these are expressed on the extravillous trophoblast and have a role in modulating NK 
cell activity.
2. NK cells which have a role in controlling implantation and establishing blood 
supply to the fetoplacental unit (King and Loke 1991). There is an accumulation of 
NK cells in the maternal decidua in the first and second trimester with a reduction in 
the third trimester (Bulmer et al. 1991; Williams et a l 2009). A key role of NK cells 
at this site is postulated to be the provision of necessary cytokines such as GM-CSF, 
TNF-a, IFN-y, TGF-p and LIF, with minimal impact on cytotoxicity.
3. Indoleamine 2, 3,-dioxygenase (IDO) is the first and rate-limiting enzyme in 
tryptophan degradation. IDO degrades the indole moiety of tryptophan, serotonin and 
melatonin and initiates the production of neuroactive and immunoregulatory 
metabolites known as kynurenines. This leads to local depletion of tryptophan and 
increased kynurenines both of which affect T cell proliferation and survival (von 
Bubnoff et a l 2003; Temess et a l 2007; Curti et a l 2009). Treatment of pregnant 
mice with a pharmacologic inhibitor of IDO induced maternal T cell-mediated 
rejection of allogeneic but not syngeneic fetuses (Munn et a l 1998).
4. Complement regulation during pregnancy is critical to preventing matemal- 
mediated damage of the placenta and foetus. Regulators of complement activation - 
decay accelerating factor (DAF; CD55), CD59, and membrane co-factor protein 
(MCP; CD46) - are expressed extensively in the human placenta including the 
syncytiotrophoblast of the placenta that are in direct contact with maternal blood 
(Girardi et a l 2006).
However the strategies most relevant to the work presented in this thesis relate to 
changes in adaptive immunity reflected by variation in T cell populations and the 
cytokines they produce, and the innate immune response.
7.1.1 T cell subsets
Although relative deficiencies of Thl immune function in early life are reported as
an explanation for persistent Th2 allergic responses, the inhibition of Thl function is
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important for fetal survival in pregnancy (Prescott, S. and A. Nowak-Wegrzyn 2012). 
The fetus is a passive contributor to this process with weak Thl function caused by 
immaturity, principally imparted by epigenetic mechanisms that alter methylation 
patterns and gene expression at the IFN-y promoter in effector CD4+ T cells (North 
2011).
The concept of a Th2 biased immune response during pregnancy has dominated the 
reproductive immunology literature for around 20 years (Lin et a l  1993; Wegmann 
et a l 1993; Piccinni et a l 2000). However, mice lacking expression of the main Th2 
cytokines IL-4, IL-5, IL-9, and IL-13 (i.e. quadruple knockouts) do not have fertility 
problems (no differences in litter sizes and all offspring healthy) indicating that these 
cytokines are not essential for foetal survival even during allogeneic pregnancy 
(Fallon et a l 2002). Initial studies focused on the T cells themselves but there are 
very few T cells at the matemo-fetal interface and the paradigm has evolved to 
encompass type 1 and type 2 cytokines irrespective of their cell source which can 
include placenta and foetal membranes (Jones et a l  1997). Recognition of temporal 
and spatial differences in the dominance of either type 1 or type 2 cytokines has now 
emerged and there is now an appreciation of the need for balanced type 1/type 2 
responses depending on the tissue site and the stage of pregnancy. Other T cell 
subsets, namely regulatory T cells and Thl 7 cells are also of interest, and it has been 
suggested that homeostasis between regulatory and pro-inflammatory CD4+ T cell 
subsets might be pivotal for maternal immune tolerance of foetal antigen (Gustafsson 
et a l 2008).
7.1.2 Innate immunity
Innate immunity/inflammation is now considered to have a physiological role in 
implantation, the maintenance of pregnancy and parturition (Ashkar et a l 2000; Croy 
et a l 2002; Patni et a l 2007). There is extensive evidence of a heightened systemic 
inflammatory response in pregnant women (Sacks et a l 1999). For example, 
increased white blood cell count and increased levels of C-reactive protein and other 
acute phase proteins (Miller 2009). This might be balanced by increased circulating 
levels of anti-inflammatory molecules such as TGF-pi (Power et a l 2002) and IL-4 
(Zhao et a l 2009). The enhanced systemic inflammatory response during pregnancy 
has been postulated to be mediated by placenta-derived microparticles that get into 
the maternal circulation and are postulated to drive systemic inflammation in normal
healthy pregnant women (Sargent et a l 2006; Redman and Sargent 2008).
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Extravillous cytotrophoblasts
Villous syncytiotrophoblasts
Figure 7.1: Diagram of materno-fetal interface
T h e  p l a c e n t a  f o r m s  t h e  p r i n c i p a l  f o e t a l  t i s s u e  in  d i r e c t  c o n t a c t  w i t h  t h e  m a t e r n a l  
i m m u n e  s y s t e m .  T h e  p r i m a r y  c e l l  t y p e  i n f i l t r a t i n g  t h e  p l a c e n t a l  v i l l u s  w h i c h  i s  
b a t h e d  i n  c i r c u l a t i n g  m a t e r n a l  b l o o d  a n d  i t s  c o n s t i t u e n t  h a e m a t o p o i e t i c  c e l l s  a r e  t h e  
v i l l o u s  s y n c y t i o t r o p h o b l a s t  c e l l s  w h i c h  r e p r e s e n t s  t h e  c h i e f  c e l l u l a r  c o m p o n e n t  
i n t e r a c t i v e  w i t h  t h e  m a t e r n a l  i m m u n e  s y s t e m .  E x t r a v i l l o u s  c y t o t r o p h o b l a s t s  f o r m  
c o l u m n s  o f  c e l l s  t h a t  i n v a d e  i n t o  t h e  m a t e r n a l  d e c i d u a s .  D i a g r a m  r e d r a w n  a n d  
a d a p t e d  w i t h  p e r m i s s i o n  f r o m  ( A a g a a r d - T i l l e r y  et al. 2 0 0 6 ) .
7.1.3 Breast milk
P r o g r e s s  i n  r e s e a r c h  o n  h u m a n  l a c t a t i o n  a n d  b r e a s t  m i l k  h a s  a d v a n c e d  o u r  k n o w l e d g e  
a b o u t  t h e  s i g n i f i c a n c e  o f  b r e a s t  m i l k  f o r  t h e  i n f a n t  ( L e v y  2 0 0 7 ;  L o n n e r d a l  2 0 1 0 ) .  
S e v e r a l  g r o w t h  f a c t o r s  a n d  c y t o k i n e s  s u c h  a s  T G F - ( 3 1  a n d  I L - 1 0  a r e  p r e s e n t  i n  b r e a s t  
m i l k  a n d  t h e i r  c a p a c i t y  t o  p e r s i s t  i n  t h e  i n f a n t  g u t  a n d  e x e r t  t h e i r  a c t i v i t i e s  i s  
p o s t u l a t e d  t o  i n f l u e n c e  m a t u r a t i o n  o f  i m m u n e  f u n c t i o n  a n d  t h e  d e v e l o p m e n t  o f  o r a l  
t o l e r a n c e  ( P e r o n i  et al. 2 0 1 0 ) .  R e c e n t  f i n d i n g s  s h o w  t h a t  s p e c i f i c  s t r a i n s  o f  b a c t e r i a  
a r e  p r e s e n t  in  b r e a s t  m i l k  a n d  a c t  a s  p r o b i o t i c s  d u r i n g  e a r l y  c o l o n i s a t i o n  o f  t h e
2 4 0
infant’s intestine and that human milk oligosaccharides (prebiotics) are specific 
substrates for probiotic strains. Amongst the bacterial groups found in breast milk, 
lactobacilli constitute an important group. One of the Lactobacillus strains isolated 
from breast milk with an important probiotic potential is Lactobacillus salivarius 
CECT5713 (Martin et al. 2006) this strain is endowed with a powerful anti-bacterial 
properties able to strongly protect mice from Salmonella infection (Olivares et a l 
2006). Moreover, Lactobacillus salivarius modulates the immune response in 
animal models showing an anti-inflammatory character able to prevent colonic 
inflammation in a rat model of colitis (Peran et a l 2005; Diaz-Ropero et a l 2007).
7.1.4 Need for the study
Perinatal probiotic supplementation, which includes supplementation of the pregnant 
woman, is an emerging therapeutic feature in contemporary paediatric immunology 
to strategically facilitate improvement in the quality of passively transferred 
immunity and newborn microbial populations. Although probiotics have a long 
record of safe use (Allen et a l 2010) and have been administered widely to pregnant 
women in probiotic birth cohort supplemental studies, there is a paucity of research 
both in vitro and in vivo characterising the immunomodulatory effects of probiotic 
supplementation on immune parameters during pregnancy. Probiotic 
supplementation of the pregnant woman is postulated to induce beneficial gastro- 
immune equilibrium within the offspring; characterised by establishment of a 
favourable microfloral foundation in the neonatal gut ultimately offering protection 
against intestinal barrier microbial aberrancies and immune dysfunctions by 
attenuating the detrimental effects of a microbiota lacking in beneficial 
microorganisms (Barouei et a l 2009). While research suggests that such a pathway 
may exist, no studies have directly investigated this relationship in terms of the 
immunomodulatory role of probiotics during pregnancy.
This in vitro study attempts to link probiotic supplemental approaches and their 
possible prophylactic outcomes on reproductive immunology. Using a similar in 
vitro model as in chapter 3, the effects of the study consortium on cytokine responses 
in peripheral blood mononuclear cells prepared from pregnant and non-pregnant 
women was investigated.
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Hypothesis:
The Thl response to the consortium will be attenuated in pregnant woman compared 
to the non-pregnant woman, while the IL-10 immunosupressive response will be 
upregaluated in the pregnant woman.
7.2 Rationale and experimental approach
7.2.1 Samples and subjects
Peripheral blood (10 -  15ml) from healthy pregnant women undergoing pre­
anaesthetic check prior to elective caesarean section at term and healthy non­
pregnant women was collected into sodium heparin as anticoagulant. For ease and 
clarity, unless stated otherwise, the prefix pPBMCs indicates mononuclear cells 
obtained from peripheral blood of pregnant women and nPBMCs mononuclear cells 
from peripheral blood of non-pregnant women.
7.2.2 Co-culture of pPBMCs and nPBMCs with the study consortium
PBMCs were isolated by density gradient centrifugation and used as follows:
1. Cells (1 x 106/ml) were co-cultured alone or in the presence of a dose course of 
106, 105,104,103 and 102 CFUs/ml of the study consortium, as described in section
2.1.4 Cell/bacteria free supernatants were harvested and stored at -20° C until 
analysis using ELISAs.
2. Cells (1 x l06/ml) were co-cultured with 106 CFUs/ml of the study consortium for 
24 hours and then cultures left untreated or treated with PHA (1 pg/ml) or SEB 
(200ng/ml) for a further 24 hours. Cell/bacteria free supernatants were harvested by 
centrifugation and stored at -20°C until analysis using ELISAs.
7.2.3 Baseline levels of mononuclear leukocyte subpopulations in pPBMCs and 
nPBMCs
PBMCs prepared from blood of pregnant and non-pregnant donors were subject to 
flow cytometry to compare the leukocyte composition. This was intended to provide 
insight into any differences in cytokine responses seen between the two groups. The 
cell types studied were: CD14+ monocytes, CD19+ B cells, CD16/CD56 expressing
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NK cells, CD3+/CD4+ T helper cells and CD3+/CD8+ cytotoxic T cells. After 
preparation of MNCs by density gradient centrifugation, 0.5 x 106 cells were 
incubated with fluorochrome conjugated antibodies for 30 minutes on ice in the dark. 
Cells were then washed by centrifugation in FACS buffer, supernatants discarded 
and the cell pellet re-suspended in 200pl FACS fix prior to acquisition within 24 
hours.
7.2.4 Statistical analysis
The student’s t test was employed to determine whether: (1) cytokine responses from 
pPBMCs and nPBMCs in response to a dose course of the study consortium were 
different when compared to the unstimulated mononuclear control; and (2) if 
consortium induced TNF-a, IL-12p70, IL-10 and TGF-pl responses differed 
beteween pPBMC compared to nPBMCs.
7.3 Results
7.3.1 Effects of the study consortium on cytokine responses from PBMCs 
isolated from pregnant and non-pregnant women
Consistent with the data shown in chapter 3, TNF-a, IL-12p70 and IL-10 were 
produced in response to all doses of the study consortium by all women (Figure 7.2). 
This response was statistically significant at 106 and 105 CFUs/ml compared with no 
bacteria for all three cytokines in both groups of women. Persistence of a significant 
effect at lower doses differed for each of the cytokines with a significant effect on 
TNFa persisting even at the lowest dose studied (10 CFUs/ml) whereas a 
significant
effect on IL-10 was lost by 104 CFUs/ml for non-pregnant women but not until 103 
CFUs/ml for pregnant women. Other than the IL-10 response at 105 CFUs/ml (p = 
0.04) and 104 CFUs/ml (p = 0.03) in which PBMCs from pregnant women gave the 
higher response, and the higher IL-12p70 response by PBMCs of pregnant women at 
102 CFUs/ml (p = 0.03), there were no differences between the responses by cells 
from pregnant and non-pregnant donors. TGF-pl occurs in a latent form and 
requires activation by acidification and then neutralisation to measure total TGF-pi. 
TGF-pl levels after activation did not show any association with the dose of the 
study consortium used (Figure 7.3).
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Figure 7.2: Cytokines produced by peripheral blood mononuclear cells of 
pregnant (pPBMCs; n = 10 -12 ) and non-pregnant (nPBMCs; n = 7 -  8) w o m e n  
in  r e s p o n s e  t o  a  d o s e  c o u r s e  o f  t h e  s t u d y  c o n s o r t i u m .  C e l l / b a c t e r i a  f r e e  c u l t u r e  
s u p e r n a t a n t s  w e r e  p r e p a r e d  a f t e r  2 4  h o u r s  i n c u b a t i o n  f o r  m e a s u r e m e n t  o f  ( a )  T N F - a ,  
( b )  I L - 1 2 p 7 0 ,  a n d  ( c )  I L - 1 0  p r o d u c t i o n  ( a l l  p g / m l )  u s i n g  s p e c i f i c  E L I S A s .  R e s u l t s  
a r e  s h o w n  a s  m e a n  ±  S E M .  S i g n i f i c a n t  d i f f e r e n c e s  ( p  <  0 . 0 5 )  b e t w e e n  t h e  r e s p o n s e  
b y  p P B M C s  a n d  n P B M C s  c o m p a r e d  t o  t h e  u n - s t i m u l a t e d  m o n o n u c l e a r  c e l l  c o n t r o l  
i s  d e n o t e d  b y  * .
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Figure 7.3: TGF-pi produced by peripheral blood mononuclear cells of 
pregnant (pPBMCs; n = 12) and non-pregnant (nPBMCs; n = 7) women in 
response to a dose course of the study consortium.
C e l l / b a c t e r i a  f r e e  c u l t u r e  s u p e r n a t a n t s  w e r e  p r e p a r e d  a f t e r  2 4  h o u r s  i n c u b a t i o n  f o r  
m e a s u r e m e n t  o f  T G F - ( 3 1  a f t e r  a c t i v a t i o n  ( a c i d i f i c a t i o n / n e u t r a l i s a t i o n )  u s i n g  a  
s p e c i f i c  E L I S A .  R e s u l t s  a r e  s h o w n  a s  m e a n  ±  S E M .  S i g n i f i c a n t  d i f f e r e n c e s  ( p  <  
0 . 0 5 )  b e t w e e n  t h e  r e s p o n s e  b y  p P B M C s  a n d  n P B M C s  c o m p a r e d  t o  t h e  u n ­
s t i m u l a t e d  m o n o n u c l e a r  c e l l  c o n t r o l  i s  d e n o t e d  b y  * .
7.3.2 Immunomodulatory effects of the study consortium upon polyclonally 
stimulated mononuclear cells isolated from pregnant and non-pregnant women.
F o r  t h e s e  e x p e r i m e n t s ,  P B M C s  w e r e  c u l t u r e d  w i t h  1 0 6 C F U s / m l  o f  t h e  s t u d y
c o n s o r t i u m  ( d e n o t e d  w i t h  t h e  p r e f i x  ( + ) )  f o r  2 4  h o u r s  p r i o r  t o  s t i m u l a t i o n  w i t h  P H A  
o r  S E B  f o r  a  f u r t h e r  2 4  h o u r s .  B o t h  P H A  a n d  S E B  i n c r e a s e d  I L - 1 7  l e v e l s  in  
s u p e r n a t a n t s  o f  n P B M C s  a n d  p P B M C s .  P H A - s t i m u l a t e d  I L - 1 7  w a s  r e d u c e d  in  
P B M C s  f r o m  p r e g n a n t  v e r s u s  n o n  p r e g n a n t  w o m e n  ( p  =  0 . 0 4 6 )  a n d  p r o b i o t i c s  
i n d u c e d  a  s i g n i f i c a n t  i n c r e a s e  i n  P H A - i n d u c e d  I L - 1 7  i n  P B M C s  f r o m  p r e g n a n t  b u t  
n o t  n o n  p r e g n a n t  w o m e n  ( p  =  0 . 0 0 2 ) .
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Figure 7.4: Cytokines produced by peripheral blood mononuclear cells of 
pregnant (pPBMCs) n  =  1 0  a n d  n o n - p r e g n a n t  ( n P B M C s )  n  =  8  w o m e n  in  r e s p o n s e  
t o  1 0 6 C F U s  o f  t h e  s t u d y  c o n s o r t i u m  a l o n e  o r  a f t e r  a d d i t i o n  o f  P H A  o r  S E B .  
C e l l / b a c t e r i a  f r e e  c u l t u r e  s u p e r n a t a n t s  w e r e  p r e p a r e d  a f t e r  2 4  h o u r s  i n c u b a t i o n  
w i t h / w i t h o u t  p r o b i o t i c  a n d  a  f u r t h e r  2 4  h o u r s  w i t h / w i t h o u t  P H A  o r  S E B  f o r  
m e a s u r e m e n t  o f  ( a )  I F N y ,  a n d  ( b )  I L - 1 7  ( a l l  p g / m l )  u s i n g  s p e c i f i c  E L I S A s .  T h e  
s t u d e n t  t t e s t  w a s  e m p l o y e d  t o  d e t e r m i n e  w h e t h e r  t h e r e  w a s  a  s t a t i s t i c a l l y  s i g n i f i c a n t  
d i f f e r e n c e  in  m o n o n u c l e a r  c e l l  r e s p o n s e  b e t w e e n  ( 1 )  c o n s o r t i u m  a n d  t h e  c o n t r o l .  ( 2 )  
S E B  o r  P H A  s t i m u l a t e d  m o n o n u c l e a r  c e l l s  v e r s u s  t h e  c o n t r o l  a n d  ( 3 )  S E B  o r  P H A  
s t i m u l a t e d  m o n o n u c l e a r  c e l l s  a l o n e  v e r s u s  S E B  o r  P H A  s t i m u l a t e d  m o n o n u c l e a r  c e l l s  
in  t h e  p r e s e n c e  o f  t h e  c o n s o r t i u m .  D e t a i l s  o f  p - v a l u e s  <  0 . 0 5  a r e  d e n o t e d  o n  t h e  
g r a p h s  w i t h  a n  *
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7.3.3 Basal levels of mononuclear leukocyte subpopulations in healthy 
pregnant and non-pregnant women
The cellular content of PBMC preparations from pregnant and non-pregnant women 
was monitored. The gating strategy used is shown in Figure 7.5. A gate was first 
drawn around mononuclear cells based on their characteristic forward and side 
scatter profiles (Figure 7.5a). Events within this gate were re-drawn on the basis of 
CD 19 versus CD 14 expression to identify B cells and monocytes, respectively 
(Figure 7.5b), and again on the basis of CD3 and CD16/56 expression to identify T 
cells and NK cells, respectively (Figure 7.5c). The isotype control is also shown and 
this facilitated the placing of quadrants on the dot plots (Figure 6.5d).
Pregnant women were found to have significantly fewer total CD3+ T cells in the 
PBMC preparation than non-pregnant women (p = 0.00027; Figure 6.6), but they had 
higher proportion of B cells (p = 0.023). Monocytes tended to be more abundant in 
PBMCs from pregnant women but this did not reach significance (p = 0.0892); NK 
cells tended to be lower in PBMCs prepared from peripheral blood of pregnant 
women but this did not reach statistical significance. On combining CD3+ T cells, 
CD19+ B cells and CD16+CD56+ NK cells as total lymphocytes, and comparing to 
whole blood available for these women (Figure 7.7), lymphocytes were less abundant 
in samples from pregnant women in both MNC preparations and whole blood (p = 
0.00003 and 0.07741, respectively).
Consideration of the relative abundance of the two main T cell subsets was then 
made in the mononuclear cell preparations. To identify these subsets -  CD3+CD4+ T 
helper cells and CD3+CD8+ cytotoxic T cells -  a gate was drawn around CD3+ cells 
(Figure 7.8a) and expression of CD4 of CD8 by these CD3+ cells then investigated 
(Figure 7.8b). There was no difference between the relative abundance of 
CD3+CD4+ and CD3+CD8+ T cells in pregnant and non-pregnant donors (Figure 
7.9).
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Figure 7.5: Gating strategy for identification of mononuclear leukocyte subsets
M o n o n u c l e a r  c e l l s  w e r e  f i r s t  i d e n t i f i e d  b y  t h e i r  c h a r a c t e r i s t i c  s i d e  s c a t t e r  ( S S C )  a n d  
f o r w a r d  s c a t t e r  ( F S C )  p r o f i l e s  a n d  a  g a t e  d r a w n  a r o u n d  t h e s e  c e l l s  ( a ) .  E x p r e s s i o n  o f  
( b )  C D 1 4  ( a n t i - C D 1 4 : P E - C y 5 . 5 )  a n d  C D 1 9  ( a n t i - C D  1 9 : A P C ) ,  a n d  ( c )  C D 3  ( a n t i -  
C D 3 : P E - C y 5 . 5 )  a n d  C D  1 6 / 5 6  ( b o t h  a n t i b o d i e s  c o n j u g a t e d  t o  A P C )  w e r e  d e t e r m i n e d  
in  s e p a r a t e  t u b e s .  A n  i s o t y p e  c o n t r o l  i s  s h o w n  i n  ( d ) .
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Figure 7.6: Basal levels of CD3+ T cell, CD16+/CD56+ NK cells, CD19+ B cells 
and monocytes T cell, B cell and NK cell population levels present in 
peripheral blood mononuclear cells from pregnant (n = 5) and non-pregnant (n 
= 4) women.
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Figure 7.7: Relative abundance of lymphocytes in (a) mononuclear cells, and (b) 
whole blood from pregnant (n = 5) versus non-pregnant (n = 4) women.
L y m p h o c y t e s  i n  P B M C  p r e p a r a t i o n s  w e r e  d e t e r m i n e d  u s i n g  f l o w  c y t o m e t r y  a n d  in  
w h o l e  b l o o d  u s i n g  a u t o m a t e d  h a e m a t o l o g y  a n a l y s i s .
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Figure 7.8: Gating strategy used to identify the two major subsets of T cells.
A  g a t e  w a s  d r a w n  a r o u n d  C D 3  c e l l s ,  a n d  t h e n  e x p r e s s i o n  o f  ( a )  C D 4  ( a n t i -  
C D 4 : F I T C )  a n d  C D 8  ( a n t i - C D 8 : P E )  b y  t h e s e  c e l l s  i n v e s t i g a t e d .
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Figure 7.9: Relative abundance of CD3+CD4+ and CD3+CD8+ T cells in total 
CD3+ population in PBMCs of pregnant versus non-pregnant donors.
C D 3 4 c e l l s  w e r e  i d e n t i f i e d  u s i n g  f l o w  c y t o m e t r y ,  a  g a t e  w a s  d r a w n  a r o u n d  t h e s e  a n d  
t h e n  t h e  c e l l s  p o s i t i v e  f o r  C D 4  o r  C D 8  i d e n t i f i e d
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7.4 Discussion
7.4.1 Role of the study consortium on the induction of inflammatory responses 
from mononuclear cells extracted from both pregnant and non-pregnant 
women
This in vitro study served to determine whether the immunomodulatory roles of 
probiotic supplementation during pregnancy could potentially impact positively on 
foetal immunology. While it remains controversial whether true suppression of the 
maternal immune response exists, multiple lines of evidence suggest that soluble 
secreted factors in the form of cytokines having immunosuppressive or 
immunomodulatory capacity are associated with implantation and foetal survival. 
Focus on the enigma of how the foetal semi-allograft avoids immunological attack 
by the immune system of the pregnant mother has led investigators to assume that a 
maternal response to foetal antigens will be harmful to the foetus. This paradigm is 
known as immunodystrophism. Moreover inhibitory effects of the maternal immune 
system need not be deleterious to the foetus and may serve to limit the extent of 
trophoblast invasion which occurs during the first 20 weeks of normal pregnancy 
(Whitley et al. 2007). A range of cytokines appear to be involved during pregnancy, 
collectively having roles at the matemal-foetal interface.
Consistent with results in Chapter 3, production of the pro-inflammatory cytokines 
IL-12p70 and TNF-a by mononuclear cells occurred in a dose dependent manner in 
response to the consortium and was greatest at the highest consortium doses of 106 
and 105 CFUs/ml, for both study groups. An attenuation of the IL-12p70 response 
occurred on decreasing consortium concentration. Interestingly consortium 
concentrations ranging from 10 CFUs to 10 CFUs induced greater IL-12p70 
responses from pPBMCs compared to nPBMCs and this was most apparent at the 
lower consortium concentrations and the difference was statistically significant at a 
doses of 102 CFUs/ml (p value =0.03) suggesting that pPBMCs at lower consortium 
doses have a greater capacity than nPBMCs to produce the inflammatory cytokine 
IL-12p70. Whether the consortium can induce low or high concentrations of IL- 
12p70 during pregnancy in vivo and whether this places immunological constraints 
or benefits on reproductive immunology still needs further clarification.
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Interestingly, TNF-a production by pPBMCs in response to the consortium at all 
doses analysed compared to nPBMCs was superior although not statistically 
significant. Since TNF-a is a marker of heightened immunological activity and a 
cytokine that induces growth and differentiation it seems reasonable that its 
production in response to the consortium would be greater in pregnant versus non 
pregnant women to reflect the heightened state of growth and development occurring 
during pregnancy to perhaps regulate excessive trophblast cellular invasion. 
Trophoblast cells display a unique capability marked by a physiological invasion of 
the surrounding tissue. Although their invasive nature bears resemblance to the 
behaviour of tumors the imposing difference is that under normal physiological 
conditions trophoblast invasion is temporally and spatially controlled in contrast to 
the unlimited invasive nature of tumors and initiates immediately after embryo 
implantation into the endometrium (Fitzgerald et a l 2008). Parallel to tumours, 
trophoblasts secrete proteases, such as matrix metalloproteinases, which dissolve the 
extracellular matrix and the surrounding tissue thereby facilitating trophoblasts 
invasion. The invasive capacities of trophoblasts are positively and negatively 
regulated by numerous cytokines including leukaemia inhibitory factor, IL-6 
however their roles are beyond the scope of this discussion; for a good review see 
Fitzgerald et a l (2008). The role of TNF-a will be particularly considered for the 
benefit of the discussion. A commonly appreciated notion is the paradigm of 
immunodystrophism which suggests that the maternal immune response to foetal 
antigens is harmful to the foetus (Anderson et a l 1991). However, inhibitory effects 
of the immune system need not be deleterious to the foetus and TNF-a induction has 
been demonstrated to limit the extent of trophoblast invasion during normal 
pregnancy. Histological evaluation of ectopic pregnancies (Paterson and Grant 1975) 
in which trophoblast is dramatically more invasive and destructive, suggests that 
local factors in the decidua and/or endometrium inhibit trophoblast invasiveness. 
While it remains controversial whether immunological suppression of the maternal 
immune response occurs in vivo, multiple lines of evidence suggest that soluble 
factors associated with implantation and foetal survival are secreted and collectively 
have immunosuppressive or immunomodulatory capacity.
The soluble factors TNF-a, IFN-y and IFN-a/p can inhibit in vitro rodent 
trophoblast cultures (Hunt et a l 1990) and similar cytokines, including granulocyte 
colony stimulating factor ., can restrict the growth of the human choriocarcinoma cell 
line, JEG-3 (Berkowitz et a l 1988). This restriction may be due to an inhibition of
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trophoblast cell DNA synthesis by the cytokines (Hunt, Lessin et a l 1989) It is 
uncertain whether cytokines have direct toxicity against trophoblasts. Although one 
group demonstrated that trophoblast monolayers can be disrupted by TNF-a or IFN-y 
(Yui J et al 1993), another found that TNF-a did not kill trophoblast cells in vitro 
(Drake and JR 1990). Additionally the study consortium alone was able to stimulate 
significant amounts of IFN-y production from pPBMCs and nPBMCs in comparison 
to the un-stimulated controls. IFN-y production from pPBMCs in response to the 
consortium was statistically significant. Although the consortium also stimulated 
IFN-y production from nPBMCs, the result was not statistically significant, and there 
were no significant differences between IFN-y responses of pPBMCs and nPBMCs.
Although physiological levels of these cytokines are present during normal 
pregnancy, harmful levels may be produced in certain pathological conditions such 
as infection and hypoxia and it is important to monitor whether probiotic 
supplementation during pregnancy alters physiologically levels of TNF-a and IFN-y 
in vivo. A point of note is that systemic administration of TNF-a (Silen et a l 1989; 
Chaouat et a l 1990; Silver et a l 1994) and IFN-y all result in pregnancy loss in 
murine models (Chaouat et a l 1990).
7.4.2 Role of the study consortium on the induction of anti-inflammatory 
responses from mononuclear cells extracted from both pregnant and non­
pregnant women
The anti-inflammatory cytokine, IL-10 included in this study represented a cytokine 
that supports suppressive and regulatory immune responses during normal pregnancy 
(Thaxton and Sharma 2010). In the present study, it was discovered that the strongest 
consortium dose of 106 CFUs induce the greatest IL-10 response from PBMCs 
isolated from both healthy pregnant and non-pregnant women. A dilution of this 
effect was observed with decreasing consortium concentration and the IL-10 
response appeared to plateau at doses between 104 and 102 CFUs in both pregnant 
and non-pregnant women.
In marked contrast, the IL-10 response by PBMCs from pregnant women was 
significantly stronger in comparison to responses observed by PBMCs from healthy 
women and this was apparent at consortium does of 105 and 104. In this scenario 
consortium concentrations of 106, 105 and 104 induced the greatest IL-10 responses (P
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= 0.026, 0.07 and 0.013 respectively) although the response began to decline at the 
lower doses of 103 and 102 this decline was not statistically significant. The 
immunological significance of this result is exemplified when considered in the 
context of the physiological role of IL-10 during pregnancy.
IL-10 is a facilitator of successful pregnancy, both as an immune suppressive agent 
and a mediator of cross talk between the placenta and the decidua. The role of IL-10 
during pregnancy as a suppressor of active maternal immunity to allow acceptance of 
the foetal allograft is a widely accepted paradigm. For instance IL-10 levels increase 
markedly in women during early pregnancy and remain elevated well into the third 
trimester immediately prior to onset of labour (Thaxton and Sharma 2010).
Moreover, secretion of IL-10 by a diverse set of maternal and foetal cells inclusive of 
Trophoblasts, Uterine NK cells, monocytes and Treg has proven to aid in the 
orchestration of normal processes of pregnancy. However it is unknown whether 
probiotic bacteria and/or their DNA transcripts occurring within the placenta are 
interactive with maternal and foetal cells to influence IL-10 production. The 
observation that IL-10 was increased more preferentially in pregnant women 
compared to non-pregnant women correlates with the necessity for regulated IL-10 
producing during normal pregnancy.
7.4.3 The immunomodulatory effect of a consortium of potential probiotics on 
Thl and Thl7 cytokine production as represented by IFN-y and IL-17 
production from
As for IFN-y, the study consortium alone induced more IL-17 from both pPBMCs 
and nPBMCs in comparison to the unstimulated controls. Additionally, the 
consortium potentiated PHA-induced IL-17 production by pPBMCs but otherwise 
had no effect on induced IL-17 production. The apparent lack of Thl cytokine 
production in the form of IFN-y production from pPBMCs compared to nPBMCs in 
response to the consortium could be in part explained by a reduced CD3 positive T 
cell repertoire in pregnant women compared to non-pregnant women. One of the 
major sources of both IFN-y in the PBMC preparations used is T cells and these 
were significantly reduced in the preparation from pregnant subjects. This possibility 
could be considered in future studies using intra-cellular flow cytometry or 
ELISPOT. The observation that T cells are reduced in the PBMC preparations was 
supported by decreased lymphocyte numbers in whole blood from the same donors
although in the small number analysed this did not achieve significance.
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The maternal immune response changes dramatically during pregnancy along with 
dimensions of the T cell compartment (Koch and Platt 2007). A number of authors 
have described declines in both the CD4+ and CD8+ peripheral blood T cell subsets 
over pregnancy: CD4+ T cells decrease in the 2nd and 3rd trimesters while CD8+ T 
cells decreased during the third trimester (Tallon et a l 1984); CD8+ T cells 
decreased during the 1st trimester while CD4+T cells decreased in the 3rd trimester 
with both populations increasing to baseline levels four months postpartum 
(Watanabe et a l 1997). Current results indicate a statistically significant increase in 
B cells during pregnancy. This could be explained by oestrogen stimulatory effect on 
humoral immunity which acts on B cells, thereby increasing IgG and IgA synthesises 
during pregnancy.
Chapter 8: General discussion
8.1 Role of the study consortium during infancy and pregnancy
Inadequate microbial colonisation of the gut is a key environmental determinant
contributing to the expression of IgE-mediated atopic disease. Perinatal probiotic 
supplementation is therefore postulated to contribute to microbiota mediated 
immunomodulatory responses, critical in shaping development ofhypo- 
responsiveness to allergens (Isolauri 2004).
In the present study mononuclear cells prepared from umbilical cord blood or adult
peripheral blood, co-cultured in the presence of the study consortium in vitro, were
induced to generate a dose dependent, monocyte mediated release of the pro-
inflammatory cytokines TNF-a, IL-6, IL-lp, IL-17, IL-12p70, IFN-y and the
immunosuppressive cytokines IL-10 and TGF-pi. Interestingly CBMCs were
significantly impaired in their ability to produce IL-12p70 and IL-10 following
incubation with the consortium compared to PBMCs, an observation likely
attributable to under-developed mechanisms of Thl immunity in the newborn
(Siegrist 2001; Adkins et a l 2004; Marchant and Goldman 2005) and the newborn
propensity to respond to antigenic stimuli with a Th2 biased scheme of immunity
reminiscent of the in utero environment. Data from the present study indicated that
the consortium induced a subtle mode of inflammation likely necessary to circumvent
over-excessive and deleterious Thl responses during the early stages of life.
Furthermore, the consortium down regulated PHA and SEB induced IL-13 (a key
allergy orchestrating cytokine) while potentiating IFN-y (a key Thl driving cytokine)
responses from both PBMCs and CBMCs. Further interrogation of the study
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consortium is necessary to determine whether the consortium induces soluble 
mediators within the cell culture media also capable of inducing cytokine responses 
from umbilical mononuclear cells. Furthermore whether the consortium induces 
monocyte maturation marked by the upregulation of co-stimulatory molecules 
remains to be resolved in the current study
At the maternal-foetal interface, a range of cytokines are involved during pregnancy. 
It was therefore imperative to gain an insight into the immunomodulatory roles of 
probiotic supplementation during pregnancy and the downstream impact on foetal 
immunology. The current study indicated that production of the pro-inflammatory 
cytokines IFN-y, IL-12p70 IL-17, TNF-a and the suppressive cytokine IL-10 by 
mononuclear cells extracted from both pregnant (pPBMCs) and non-pregnant 
(nPBMCs) women occurred in a dose dependent manner in response to the study 
consortium. pPBMCs at lower consortium doses had a significantly greater capacity 
than nPBMCs to produce the inflammatory cytokine IL-12p70. Interestingly there 
was a lack IFN-y production from pPBMCs compared to nPBMCs in response to the 
consortium, likely attributable to the reduced CD3+ T cell repertoire in pregnant 
women compared to non-pregnant women.
Although physiological levels of the pro-inflammatory cytokines are present during 
normal pregnancy, harmful levels occur in pathological conditions such as infection 
or hypoxia. Under normal conditions the induction of the pro-inflammatory 
cytokines need not be deleterious to the foetus (Hunt et a l 1989). In the present 
study no adverse effects as a result of perinatal probiotic supplementation were 
reported (Allen et a l 2010). Interestingly, the IL-10 response by PBMCs from 
pregnant women was significantly stronger in comparison to responses observed by 
PBMCs from healthy women. The immunological significance of this result is 
exemplified when considered in the context of a physiological role of IL-10 as a 
facilitator of a successful pregnancy. Furthermore, maternal immune response 
changes dramatically during pregnancy along with dimensions of the T and B cell 
compartments (Koch and Platt 2007). Current results indicated a statistically 
significant increase in B cells during pregnancy. This could be explained by the 
oestrogenic effect on humoral immunity which acts on B cells, increasing humoral 
immunity during pregnancy.
8.2 Probiotics in the prevention of atopic disorder: a randomised controlled trial
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Administration of a multi-strain, high-dose probiotic to mothers during late 
pregnancy and their infants from birth to 6 months of age was not significantly 
effective as a pre-emptive strategy to prevent eczema in infants predisposed to a 
sentence of atopic eczema in later life during the PROBAT trial (Allen et a l 2014). 
However probiotic administration was associated with a reduced frequency in 
sensitivity to food antigens, concomitant with a reduced risk of atopic sensitisation 
by 2 years of age.
8.3 Ex vivo Imunomodulatory role of probiotics during infancy
Whether perinatal probiotic supplementation boosts cytokine function in a way that 
might represent an attenuation of the symptoms of atopy was studied ex vivo by 
studying the down regulation of the Th2 allergy orchestrating cytokines and the up 
regulation of the Thl cytokines by mitogen stimulated mononuclear cells isolated 
from the blood of atopy predisposed neonates recruited to the PROBAT trial at birth 
and at 6 months of age. Surprisingly, no statistically significant effect of 
supplementation on IL-4, IL-10, and IL-13 or IFN-y production by mitogen 
stimulated neonatal mononuclear cells was observed. Interestingly, PHA induced ex 
vivo IL-13 responses showed an inverse association with age suggesting a reduction 
in a key allergy exacerbating cytokine in the PROBAT cohort with age. Whether this 
observation was dependent or independent of perinatal probiotic supplementation 
remains unresolved.
8.4 Innate immune response in relation to probiotic versus placebo exposure
The immunogenicity of probiotic bacteria upon interaction with the whole blood 
cellular components of neonatal immunity (such as the granulocytes) renders them 
key contributors to the pro- and anti-inflammatory cytokine tone within the neonatal 
gut and the periphery. To test this hypothesis whole blood cultures were stimulated at 
birth and 6 months of age from recruits on the PROBAT trial with 
lipopolysaccharide or peptidoglycan, the ensuing cytokine responses were measured. 
Perinatal probiotic supplementation significantly increased Thl IL-12p70 cytokine 
capacity in the probiotic group in unstimulated samples at birth. Additionally 
LPS/IFNy induced IL-12p70 responses by whole blood cultures were also 
significantly increased in the probiotic group at 6 months of age. Further supporting 
the notion perinatal probiotic supplementation may enhance maturation of in vivo
257
Thl responses in probiotic treated groups compared to placebo group, and accelerate 
maturation of an otherwise attenuated Thl pro-inflammatory cytokine pathway 
during the neonatal period. Whether or not the observed Thl immune responses can 
be linked to protection against IgE-mediated atopic disorder will be reviewed in the 
light of the clinical outcomes of the PROBAT trial for future studies. Promisingly 
Thl polarising cytokine responses are antagonistic to the up-regulation of IgE 
mediated Th2 atopic responses in vivo and contribute to the polarisation of naive T 
cell towards the Thl phenotype. These results provide further support for the 
application of probiotic bacteria as a strategy to attenuate the risk of IgE-mediated 
atopic disorder at both the cellular and innate immune level during early infancy.
8.5 Cell counts in relation to probiotic versus placebo exposure employing 
haematological analysis
Hematopoietic myeloid progenitors are postulated to support recruitment of pro- 
inflammatory cells to tissues sites prominent in atopic diseases (Gauvreau et a l 
2009). Furthermore hematopoietic progenitors from umbilical cord blood of high risk 
genetically predisposed neonates give rise to more eosinophil and basophil 
progenitors involved in the pathogenesis of atopic disorder (Reece et a l 2011). 
Interestingly perinatal probiotic supplementation only had a transient effect on 
granulopoesis, affecting only the cord blood eosinophil count, which was reduced at 
birth. Although this result was indirectly linked with the results of Allen et a l (2014) 
highlighting that perinatal probiotic supplementation is associated with a reduction in 
atopic sensitisation. Future analysis of the PROBAT study outcomes is required to 
determine whether this observation correlates to a reduction in atopic disorders in 
later life, where eosinophilia at the sites of allergic inflammation is a hallmark 
component. Long-term follow-up to determine the effect of probiotic administration 
on the allergic march is therefore of utmost importance (Ker et a l 2009).
8.6 Cell counts in relation to probiotic versus placebo exposure employing 
immunophenotypic analysis
A flow cytometric approach was employed to consider in more detail the effects of 
perinatal probiotic supplementation on key lymphocyte subsets, T cell subsets, B cell 
subsets and dendritic cell subsets on percentages of key lymphocytic subpopulations 
involved in atopic disorder. On comparing the probiotic and placebo groups the 
percentage of CD4+ T cells bearing a naive phenotype (CD45RA+/CD45RO') was
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significantly elevated in the probiotic group at birth. This was complemented by a 
significantly reduced percentage of CD4+ T cells expressing a memory phenotype 
(CD45RA7CD45RO+) in the probiotic group at birth suggesting that perinatal 
probiotic supplementation was able to potentiate the naive T cell repertoire during the 
neonatal period. This observation may be reflective of a general probiotic mediated 
reduction of atopic or infectious responses in vivo due to a strengthening of adaptive 
immunity at the cellular level in the neonate. The reduced CD45RO T cell pool in 
neonatal peripheral blood in the probiotic group could also be indicative of a 
reduction in antigenic memory responses in the probiotic group compared to the 
placebo group imparted by a greater proportion of naive T lymphocytes with the 
capacity to differentiate to T lymphocytes with effector function against atopic or 
infectious responses.
8.7 Further work
Further exploration of the current cohort with analysis of faecal samples and 
plasma/serum to compare local gastrointestinal and systemic inflammatory responses 
is necessary to gain further insight into the immunomodulatory role of probiotics in 
infancy. For instance the specificity of human immune responses to common 
environmental allergens in plasma samples from recruits in the PROBAT trial for the 
presence of allergen specific IgE antibodies (Batard et a l 1993; Batard et a l 1993; 
Possin et a l 2010) is currently being analysed for future work.
Gene expression analysis by quantitative reverse transcriptase PCR of neonatal blood 
is also necessary for future studies into the role of perinatal probiotic 
supplementation to determine whether probiotic supplementation effects the gene 
expression levels of gene transcripts such Epsilon (e) germline gene transcripts Ie+, 
Ce+ mRNA which precedes class switch recombination to IgE via IL-4 and/or IL-13 
(Cameron et a l 2000).This would have provided further information of the role of 
probiotics during infancy at the molecular level.
Furthermore since horizontal transfer of bacterial DNA from mother to foetus via 
the placenta has been reported and Bifidobacterium and Lactobacillus and their DNA 
transcripts have been detected in the human placenta irrespective of mode of 
delivery: (Satokari et a l 2009). It would have been interesting to determine whether
259
there is a difference in consortium mediated mRNA transcripts in the placenta as a 
result of perinatal probiotic supplementation.
Additionally the effects of perinatal probiotic supplementation on the immunology of 
breast milk might also provide some insightful information on the 
immunomodulatory effects of probiotics in infancy. Since we have archived 
placental biopsies and milk samples from recruits on the PROBAT trial, such studies 
can still be initiated.
8.8 Final Conclusion
Thl responses antagonise the differentiative signature imposed by the upregulation of 
Th2 responses that support the development of allergy accelerating cytokines such as 
IL-13. Equally subsequent differentiation of the allergen receptive granulocytes such 
as the eosinophils and basophils also involved in orchestrating the allergic response is 
also a consequence. In conclusion the immunomodulatory effect of perinatal 
administration of a multi-strain probiotic during infancy is marked by a significant 
reduction in eosinophil counts at birth in the probiotic group, along with a marked 
reduction in atopic sensitisation and skin prick positivity to common food allergens. 
Interestingly whole blood cultures from the PROBAT trial recruits stimulated with 
LPS and IFN-y induced significantly increased IL-12p70 Thl immune responses in 
the probiotic group at 6 months of age. This observation further supports the notion 
that perinatal probiotic supplementation enhances innate immune function and 
promotes induction of low grade Thl mediated inflammation postulated to contribute 
to the attenuation of the expression of the atopic phenotype in later life. These 
observations are also indirectly linked to the capacity of the study consortium to 
down regulates in vitro PHA and SEB induced IL-13 (a key allergy orchestrating 
cytokine) while potentiating IFN-y (a key Thl driving cytokine) responses from both 
PBMCs and CBMCs.
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